Document:

Asset Purchase Agreement

 Exhibit 10.1 
 ASSET PURCHASE AGREEMENT 
 BY AND AMONG 

TO GO BRANDS, INC. 
 Seller, 
 MEDPODIUM HEALTH PRODUCTS, INC., 

Buyer, 

AND 

CARDIUM THERAPEUTICS, INC., 
 Owner of Buyer. 
 Dated as of September 28, 2012 

 TABLE OF CONTENTS 

 

							
	  	  	Page	 
		
	 ARTICLE I PURCHASE AND SALE OF ASSETS
	  	 	1	  
	 1.1
	 	 Purchase and Sale of Assets
	  	 	1	  
	 1.2
	 	 Excluded Assets
	  	 	4	  
	 1.3
	 	 Assumption of Liabilities
	  	 	4	  
	 1.4
	 	 Excluded Liabilities
	  	 	5	  
	 1.5
	 	 Closing
	  	 	6	  
	 1.6
	 	 Transfer Documents
	  	 	7	  
	 1.7
	 	 Consents of Third Parties
	  	 	8	  
	 1.8
	 	 Further Assurances
	  	 	8	  
	 1.9
	 	 Transfer Taxes
	  	 	9	  
		
	 ARTICLE II PURCHASE PRICE
	  	 	9	  
	 2.1
	 	 Purchase Price
	  	 	9	  
	 2.2
	 	 Delivery of Shares
	  	 	9	  
	 2.3
	 	 Working Capital
	  	 	9	  
	 2.4
	 	 Allocation of Purchase Price
	  	 	10	  
	 2.5
	 	 Seller’s Responsibility for Seller Liabilities
	  	 	10	  
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER
	  	 	10	  
	 3.1
	 	 Organization, Good Standing and Qualification of the Seller
	  	 	10	  
	 3.2
	 	 Ownership of the Seller; Subsidiaries
	  	 	11	  
	 3.3
	 	 Authorization; Binding Obligation
	  	 	11	  
	 3.4
	 	 Consents and Approvals
	  	 	11	  
	 3.5
	 	 No Violation
	  	 	12	  
	 3.6
	 	 Regulatory Matters; Licenses and Permits
	  	 	12	  
	 3.7
	 	 Title to and Condition of Properties; Sufficiency of Assets
	  	 	12	  
	 3.8
	 	 Real Property
	  	 	13	  
	 3.9
	 	 Personal Property Leases
	  	 	14	  
	 3.10
	 	 Environmental Matters
	  	 	14	  
	 3.11
	 	 Financial Statements; No Undisclosed Liabilities
	  	 	15	  
	 3.12
	 	 Absence of Certain Events
	  	 	16	  
	 3.13
	 	 Legal Proceedings
	  	 	18	  
	 3.14
	 	 Compliance with Laws
	  	 	19	  
	 3.15
	 	 Employment Matters
	  	 	19	  
	 3.16
	 	 Taxes
	  	 	22	  
	 3.17
	 	 Contracts
	  	 	23	  
	 3.18
	 	 Transactions With Affiliates
	  	 	25	  
	 3.19
	 	 Insurance
	  	 	26	  
	 3.20
	 	 Intellectual Property
	  	 	26	  
	 3.21
	 	 Accounts Receivable; Accounts Payable
	  	 	29	  
	 3.22
	 	 Absence of Restrictions on Business Activities
	  	 	30	  
	 3.23
	 	 Payments: Foreign Corrupt Practices Act: U.S. Export and Sanctions Laws
	  	 	30	  
	 3.24
	 	 Books and Records
	  	 	31	  
	 3.25
	 	 Inventory
	  	 	31	  
	 3.26
	 	 Internal Controls
	  	 	31	  

  
 -i-

 TABLE OF CONTENTS CONTINUED 

 

							
	  	 	 	  	Page	 
	 3.27
	 	 Solvency
	  	 	31	  
	 3.28
	 	 Relationships with Customers and Suppliers
	  	 	32	  
	 3.29
	 	 Seller Products
	  	 	32	  
	 3.30
	 	 No Brokers
	  	 	33	  
	 3.31
	 	 FDA Compliance; Compliance with Healthcare Laws
	  	 	33	  
	 3.32
	 	 Investment Representations
	  	 	35	  
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE BUYER AND THE PARENT
	  	 	37	  
	 4.1
	 	 Organization and Good Standing
	  	 	37	  
	 4.2
	 	 Authorization; Binding Obligation
	  	 	37	  
	 4.3
	 	 Consents and Approvals
	  	 	37	  
	 4.4
	 	 No Violation
	  	 	38	  
	 4.5
	 	 Legal Proceedings
	  	 	38	  
	 4.6
	 	 Status of Shares
	  	 	38	  
	 4.7
	 	 Public Company Financial Reporting
	  	 	38	  
		
	 ARTICLE V COVENANTS
	  	 	39	  
	 5.1
	 	 Conduct of Business Pending Closing
	  	 	39	  
	 5.2
	 	 Cooperation; Approvals, Filings and Consents
	  	 	41	  
	 5.3
	 	 Access to Information; Updated Financial Information
	  	 	41	  
	 5.4
	 	 Notice of Certain Events
	  	 	42	  
	 5.5
	 	 Public Announcements
	  	 	43	  
	 5.6
	 	 No Solicitation of Other Proposals
	  	 	43	  
	 5.7
	 	 Employment Matters
	  	 	44	  
	 5.8
	 	 Use of Names
	  	 	46	  
	 5.9
	 	 Accounts Receivable/Collections
	  	 	46	  
	 5.10
	 	 Transition Matters
	  	 	46	  
	 5.11
	 	 Mutual Cooperation
	  	 	46	  
	 5.12
	 	 Transfer Restrictions
	  	 	47	  
		
	 ARTICLE VI CONDITIONS PRECEDENT TO CLOSING
	  	 	47	  
	 6.1
	 	 Conditions to Obligation of Each Party
	  	 	47	  
	 6.2
	 	 Additional Conditions to Obligations of the Buyer
	  	 	48	  
	 6.3
	 	 Additional Conditions to Obligations of the Seller
	  	 	50	  
		
	 ARTICLE VII SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION
	  	 	51	  
	 7.1
	 	 Survival of Representations, Warranties and Covenants
	  	 	51	  
	 7.2
	 	 Indemnification
	  	 	51	  
	 7.3
	 	 Limitations on Indemnification
	  	 	52	  
	 7.4
	 	 Indemnification Process
	  	 	53	  
	 7.5
	 	 Fraud and Related Claims; Characterization of Payments
	  	 	54	  
	 7.6
	 	 Insurance Claims
	  	 	55	  
		
	 ARTICLE VIII TERMINATION, AMENDMENT, WAIVER AND EXPENSES
	  	 	55	  
	 8.1
	 	 Termination
	  	 	55	  

  
 -ii-

 TABLE OF CONTENTS CONTINUED 

 

							
	  	 	 	  	Page	 
	 8.2
	 	 Effect of Termination
	  	 	55	  
	 8.3
	 	 Expenses
	  	 	56	  
	 8.4
	 	 Amendment and Waiver
	  	 	56	  
		
	 ARTICLE IX MISCELLANEOUS
	  	 	56	  
	 9.1
	 	 Entire Agreement
	  	 	56	  
	 9.2
	 	 Assignment
	  	 	57	  
	 9.3
	 	 Counterparts
	  	 	57	  
	 9.4
	 	 Governing Law; Venue; Waiver of Jury Trial
	  	 	57	  
	 9.5
	 	 Specific Performance
	  	 	57	  
	 9.6
	 	 Interpretation
	  	 	57	  
	 9.7
	 	 Severability
	  	 	58	  
	 9.8
	 	 Notices
	  	 	58	  
	 9.9
	 	 Representation by Counsel
	  	 	59	  
	 9.10
	 	 Construction
	  	 	59	  
	 9.11
	 	 Waivers
	  	 	59	  
	 9.12
	 	 Third Party Beneficiaries
	  	 	59	  
	 9.13
	 	 Bulk Sales Law
	  	 	60	  
	 9.14
	 	 Waiver of Jury Trial
	  	 	60	  

  
 -iii-

 EXHIBITS AND SCHEDULES 
 EXHIBITS: 
  

			
	 Exhibit A
	  	Form of Bill of Sale and Assignment Agreement
	 Exhibit B
	  	Form of Assumption Agreement
	 Exhibit C
	  	Form of Copyright Assignment
	 Exhibit D
	  	Form of Trademark Assignment
	 Exhibit E
	  	Form of Patent Assignment
	 Exhibit F
	  	Escrow Agreement
	 Exhibit G
	  	Voting Agreement

 SCHEDULES: 
  

			
	 Schedule I
	  	Index of Defined Terms; Table of Definitions
	 Schedule 1.1(a)(i)
	  	Assigned Contracts
	 Schedule 1.1(b)
	  	Tangible Personal Property
	 Schedule 1.1(d)
	  	Credits, Refunds, Prepaid Expenses, Etc.
	 Schedule 1.1(e)
	  	Approvals and Orders
	 Schedule 1.1(j)
	  	Telephone Numbers, Domain Names, E-mail Addresses, Etc.
	 Schedule 1.1(k)
	  	Inventory
	 Schedule 1.2(i)
	  	Certain Excluded Assets
	 Schedule 1.3(a)
	  	Certain Assumed Obligations
	 Schedule 1.3(b)
	  	Trade Payables
	 Schedule 1.4(a)
	  	Certain Excluded Contracts
	 Schedule 1.4(p)
	  	Certain Excluded Liabilities
	 Schedule 2.3(a)
	  	Working Capital
	 Schedule 3.2
	  	Ownership of the Seller
	 Schedule 3.16(a)
	  	Beneficiary of any extension to file tax return
	 Schedule 3.16(b)
	  	Audits
	 Schedule 5.2(c)
	  	Certain Third Party Consents
	 Schedule 5.7(a)
	  	Business Employees Who May Be Offered Employment by Buyer
	 Schedule 5.7(b)
	  	Assumed Pre-Existing Employee Obligations
	 Schedule 7.2(a)
	  	Certain Indemnification Matters

  
 -iv-

 ASSET PURCHASE AGREEMENT 

THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of September 28, 2012 (the “Effective Date”),
is made by and among To Go Brands, Inc., a Nevada corporation (the “Seller”) and Cardium Therapeutics, Inc., a Delaware corporation (the “Parent”), and Parent’s wholly-owned subsidiary MedPodium Health
Products, Inc., a Delaware corporation (the “Buyer”). 
 WHEREAS, the Seller is engaged in the business of
developing and marketing branded dietary supplements, natural foods and other products being developed by Seller (individually and collectively the “Business”), and owns substantially all of the goodwill and other assets used in
connection with the operation of the Business; 
 WHEREAS, subject to the terms and conditions set forth in this Agreement, the
Seller wishes to sell, assign and transfer to the Buyer, and the Buyer wishes to purchase from the Seller all of the Seller’s right, title and interest in and to the Acquired Assets (as defined below) and the Buyer is willing to assume from the
Seller the Assumed Liabilities (as defined below), all as set forth herein; 
 WHEREAS, as a condition and an inducement to the
Buyer entering into this Agreement, concurrently with the execution and delivery of this Agreement, the Seller and its officers have entered into non-competition agreements with the Buyer, dated as of the date hereof, which agreements shall become
effective at and contingent upon the Closing (each, a “Post-Closing Non-Competition Agreement”), and its directors have entered into non-disclosure agreements with the Buyer, dated as of the date hereof, which agreements shall
become effective at and contingent upon the Closing (each, a “Post-Closing Non-Disclosure Agreement”) and Messrs. Derek Howe, Bruce Howe, Mindy Paris, Ken Shield and John Moore (the “Designated Employees”) have entered (or
will enter) into employment or consulting agreements with the Buyer, dated as of the date hereof, which agreements shall become effective at and contingent upon the Closing (each, a “Post-Closing Employment Agreement”); and

 WHEREAS, capitalized terms used and not otherwise defined herein shall have the meanings set forth on Schedule I
attached hereto. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and
agreements herein contained, and intending to be legally bound hereby, the parties hereto agree as follows: 
 ARTICLE I

 PURCHASE AND SALE OF ASSETS 
 1.1 Purchase and Sale of Assets. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, the Seller shall sell, transfer, assign and deliver to the Buyer, and
relinquish to the Buyer in perpetuity, free and clear of all Liens, all of its right, title and interest in and to the Acquired Assets. As used in this Agreement, the term “Acquired Assets” means all of the assets, 

  
 -1-

 
properties, rights, interests and goodwill related to the Business of every kind, nature, character and description whatsoever, whether real, personal or mixed, tangible or intangible, wherever
located, owned, used or held for use by the Seller, whether now owned, used or held or acquired prior to the Closing, including the following, but excluding the Excluded Assets: 

(a) all right, title and interest in, to and under (i) all Contracts listed on Schedule 1.1(a)(i) attached hereto;
(ii) all non-competition, non-solicitation, confidentiality, assignment of invention and similar Contracts to which the Seller is a party or is entitled to rights thereunder, the primary purpose of which are to provide for non-competition,
non-solicitation, confidentiality, assignment of invention or similar covenants running in favor of the Seller; (iii) all customer Contracts entered into by the Seller between the date of this Agreement and the Closing; and (iv) any other
Contract entered into by the Seller between the date of this Agreement and the Closing which the Buyer, in its sole discretion, agrees in writing prior to the Closing shall constitute an “Assigned Contract” pursuant to this
Section 1.1(a) (the “Assigned Contracts”); 
 (b) all tangible personal property wherever located,
including all equipment, machinery, tools, dies, molds, furniture, fixtures, office equipment, computers, communications equipment, supplies, spare and replacement parts and other physical assets of the Seller, including the items listed on
Schedule 1.1(b) attached hereto; 
 (c) all accounts receivable, notes receivable and other rights to receive
payment from any Person outstanding on the Closing Date; 
 (d) all deposits (including vendor and customer deposits), rights to
credits, refunds, prepaid expenses, deferred charges, advance payments, security deposits and prepaid items, including those listed on Schedule 1.1(d) attached hereto; provided, however, that notwithstanding anything contained herein to
the contrary Seller shall retain up to One Hundred Thousand Dollars ($100,000) of cash on hand and in banks held by the Seller as of the Closing in an amount sufficient to satisfy certain Working Capital Liabilities of the Seller outstanding as of
the Closing and not expressly assumed by the Buyer hereunder (the “Retained Cash”), including, without limitation, legal fees and costs, accounting fees and costs, Taxes, costs related to shareholder communications, any and all tail
coverages for insurance required to be purchased hereunder or otherwise, corporate fees, banking fees, stock transfer fees and administrative fees (individually and collectively the “Seller Expenses”), all of which will be set forth
in the Updated Working Capital Statement; provided, further, that the Retained Cash shall be an adjustment to Purchase Price, by reducing the Shares to be provided in accordance with Section 2.1(a) by an amount necessary to offset the value of
the Retained Cash (for purposes of illustration, if the Seller retained $100,000 as Retained Cash, the value to be paid in Shares pursuant to Section 2.1(a) would be reduced by $100,000, or by 400,000 shares priced at $0.25 per share).

 (e) all Approvals and Orders, to the extent their transfer is permitted by Law, including those listed on Schedule
1.1(e) attached hereto; 
 (f) all Seller Intellectual Property, and the goodwill associated therewith, licenses and
sublicenses granted in respect thereto and rights thereunder, together with all claims 

  
 -2-

 
against third parties for profits and all costs, losses, claims, liabilities, fines, penalties, damages and expenses (including interest which may be imposed in connection therewith), court costs
and reasonable fees and disbursements of counsel, consultants and expert witnesses incurred by reason of the past infringement, alleged infringement, unauthorized use or disclosure or alleged unauthorized use or disclosure of any Seller Intellectual
Property, together with the right to sue for, and collect the same, or to sue for injunctive relief, for the Buyer’s own use and benefit, and for the use and benefit of its successors, assigns or other legal representatives; 

(g) all claims, demands, causes of action, choses in action, rights of recovery, rights of set off, rights of recoupment (including any
such item relating to the payment of Taxes), rights to payment or to enforce payment and rights to insurance proceeds, whether choate or inchoate, known or unknown, or contingent or non-contingent and whether or not liquidated, except to the extent
related to the Excluded Assets; 
 (h) all guarantees, warranties, indemnities and similar rights in favor of the Seller, except
to the extent related to the Excluded Assets; 
 (i) all books, records, information, files, manuals, databases and other
materials maintained by or on behalf of the Seller in any medium (including, where available, digital media), including all customer, supplier and mailing lists and databases, advertising materials, research files and correspondence, market research
studies and surveys, operating data and plans, production data, technical documentation (design specifications, functional requirements, operating instructions, logic manuals, flow charts, etc.), user documentation (installation guides, user
manuals, training materials, release notes, working papers, etc.), equipment repair, maintenance and service records, sales and promotional materials and records, purchasing and billing records, research and development files, data, intellectual
property disclosures, media materials, accounting files and records, sales order files and non-medical personnel files for all Transferred Employees, and all lists of and all rights in and to the information contained therein; 

(j) all telephone and facsimile numbers, websites (including the content thereof), e-mail addresses, Internet domain names and business
and trade names of the Seller, including those listed on Schedule 1.1(j) attached hereto; 
 (k) all Inventory of the
Seller, including all Inventory set forth on Schedule 1.1(k) attached hereto (other than Inventory that is sold in the ordinary course of business prior to Closing); 

(l) all goodwill of the Business; and 
 (m) all of the assets, properties, rights, interests, intellectual property and goodwill of Seller of every kind and nature whatsoever, whether real, personal or mixed, tangible or intangible, wherever
located, owned, used or held for use by Seller and used in connection with the operation of the Business, whether now owned, used or held or acquired prior to the Closing, including all of Seller’s right, title and interest in, to and under all
Contracts listed on Schedule 1.1(a)(i) attached hereto, but excluding the Excluded Assets. 

  
 -3-

 1.2 Excluded Assets. Notwithstanding the provisions of Section 1.1, the
following assets and properties are to be retained by the Seller and shall not constitute Acquired Assets (collectively, the “Excluded Assets”): 
 (a) all right, title and interest in, to and under all Contracts to which the Seller is a party or by which the Seller or any of its assets or properties is otherwise subject to or bound other than the
Assigned Contracts (collectively, the “Excluded Contracts”); 
 (b) any capital stock or other equity interest
in any Subsidiary, Affiliate or other Person, and all options, warrants or other rights to acquire such capital stock or other equity interest; 
 (c) subject to Section 1.1(g), all right, title and interest to all insurance policies of the Seller; 
 (d) all minute books and stock records of Seller; 
 (e) all personnel records of
all Business Employees other than Transferred Employees and all medical records and other medical information of Transferred Employees that the Seller is required by Law to retain in its possession; 

(f) all rights of the Seller under this Agreement and the Related Agreements; 

(g) all Employee Benefit Plans of the Seller and all assets related thereto; 

(h) the Retained Cash; and 
 (i) those assets specifically set forth on Schedule 1.2(i) attached hereto. 

1.3 Assumption of Liabilities Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, the Buyer
shall assume from the Seller only the following Liabilities (the “Assumed Liabilities”): 
 (a) obligations of
the Seller for performance arising after the Closing under the Assigned Contracts to the extent that the Seller’s rights thereunder are actually (with consent where required) assigned to the Buyer, including those certain obligations set forth
in Schedule 1.3(a); provided, that, the Buyer shall not assume, and does not hereby agree to pay, discharge or perform, (i) any Losses relating in any manner to or arising from any breach or default of the Seller of any
Assigned Contract occurring prior to the Closing Date regardless of whether such breach or default is disclosed pursuant to this Agreement or (ii) any Liability to indemnify any Person under such Assigned Contract arising from or relating to
any act or omission occurring prior to the Closing; and 
 (b) those trade payables of the Seller specifically set forth in
Schedule 1.3(b) and those incurred by the Seller between the date of this Agreement and the Closing in the ordinary course of business and in compliance with Section 5.1 of this Agreement; and 

  
 -4-

 (c) certain assumed employee-related obligations (the “Assumed Pre-existing Employee
Obligations” as defined in Section 5.7(b) and set forth in Schedule 5.7(b)). 
 1.4 Excluded Liabilities.
Except as expressly assumed pursuant to Section 1.3, the Buyer is not assuming and shall not have any liability or obligation whatsoever for any Liabilities of the Seller or any of its predecessors or Affiliates whatsoever, whether or not
arising out of the ownership or operation of the Business or the Acquired Assets, all of which will be retained and satisfied by the Seller (the “Excluded Liabilities”). Without limiting the generality of the foregoing, Buyer shall
not assume or be deemed to assume any of the following Liabilities, all of which shall constitute Excluded Liabilities: 
 (a)
Liabilities arising under or relating to any written or oral Contract to which the Seller is a party or by which the Seller, or any of its assets or properties is otherwise subject or bound, other than Liabilities arising under the Assigned
Contracts to the extent specifically set forth in Section 1.3(a), including those Contracts set forth on Schedule 1.4(a) attached hereto; 
 (b) Liabilities of the Seller or any of its predecessors or Affiliates in respect of any Indebtedness; 
 (c) Liabilities of the Seller or any of its predecessors or Affiliates in respect of any Transaction Expenses; 
 (d) Liabilities of the Seller or any of its predecessors or Affiliates to any Affiliate or current or former stockholder, convertible debt holder or option or warrant holder (or any of their successors,
assigns, heirs or legal representatives) of the Seller or any of its predecessors or Affiliates; 
 (e) Liabilities of the
Seller or any of its predecessors or Affiliates for or in respect of Taxes and any Taxes resulting from or relating to the consummation of the transactions contemplated hereby (including any Taxes that may become due as a result of any bulk sales or
similar tax that may be assessed against the Seller or any of its Affiliates following the Closing); 
 (f) Liabilities of the
Seller or any of its predecessors or Affiliates to any present or former director, officer, employee, consultant or independent contractor of the Seller or its predecessors or Affiliates, including Liabilities arising under any federal, state, local
or foreign Laws, Approvals or Orders and including any Liability for transaction or retention bonuses payable by the Seller to any such person; 
 (g) Liabilities of the Seller or any of its predecessors or Affiliates for any Actions against the Seller or any of its predecessors or Affiliates, including any Actions pending or threatened against the
Seller or any of its predecessors or Affiliates as of the Closing Date; 
 (h) Liabilities of the Seller or any of its
predecessors or Affiliates arising out of or resulting from any violation of or non-compliance with any federal, state, local or foreign Approvals, Laws or Orders; 

  
 -5-

 (i) Liabilities of the Seller or any of its predecessors or Affiliates arising out of,
relating to or resulting from any obligation to indemnify any Person (other than pursuant to an Assigned Contract to the extent assumed pursuant to Section 1.3(a)); 
 (j) Liabilities of the Seller arising under this Agreement or any of the Related Agreements; 
 (k) Liabilities resulting from or relating to products sold or services performed by the Seller or any of its predecessors or Affiliates, including any Liabilities resulting from or relating to any
product liability claims with respect to any Seller Products; 
 (l) Liabilities of the Seller or any of its predecessors or
Affiliates based upon such Person’s acts or omissions; 
 (m) Liabilities arising under any Employee Benefit Plan or any
benefit, tax or compensation Liability of any ERISA Affiliate; 
 (n) Liabilities arising in connection with or in any way
relating to the Business, any Acquired Assets, any property now or previously owned, leased or operated by the Seller or any of its predecessors or Affiliates, or any activities or operations occurring or conducted at any property now or previously
owned, operated or leased by the Seller or any of its predecessors or Affiliates (including offsite disposal), which arise under or relate to any Environmental Laws; 
 (o) Liabilities attributable in any manner to the Excluded Assets; and 
 (p)
Liabilities set forth in Schedule 1.4(p) attached hereto. 
 The disclosure of any Liability on any schedule to this Agreement shall not
create an Assumed Liability or other Liability of the Buyer, except where such disclosed Liability has been expressly assumed by the Buyer as an Assumed Liability pursuant to Section 1.3. 

1.5 Closing Subject to the terms and conditions hereof, the closing of the transactions contemplated by this
Agreement (the “Closing”) will take place at 11:00 a.m. (PST) on the third (3rd) Business Day following the date on which all of the conditions set forth in ARTICLE VI have been satisfied or waived (other than any such conditions that by their terms cannot be satisfied until
the Closing Date, which conditions shall be required to be so satisfied or waived on the Closing Date), unless another time or date is agreed to in writing by the Seller and the Buyer (the “Closing Date”). The Closing shall be held
at the offices of Sheppard Mullin Richter & Hampton, 12275 El Camino Real, Suite 200, San Diego CA 92130, unless another place is agreed to in writing by the parties hereto (it being understood that the Closing may be affected by the
delivery of documents via e-mail, facsimile or overnight courier). The consummation of the transactions contemplated by this Agreement to occur at the Closing shall be deemed to occur at 12:01 a.m. (PST) on the Closing Date. 

  
 -6-

 1.6 Transfer Documents At the Closing, in addition to the other Closing deliverables
contemplated by ARTICLE VI, the parties shall execute and deliver to each other, or cause to be executed and delivered to each other, the following documents (collectively, the “Transfer Documents”): 

(a) the Seller shall execute and deliver to the Buyer one or more bills of sale and assignment agreements in substantially the form of
Exhibit A attached hereto (each, a “Bill of Sale and Assignment Agreement”) pursuant to which the Seller will transfer and assign to the Buyer the Acquired Assets; 

(b) the Buyer shall execute and deliver to the Seller one or more assumption agreements in substantially the form of
Exhibit B attached hereto (each, an “Assumption Agreement”) pursuant to which the Buyer will assume from the Seller the Assumed Liabilities; 
 (c) the Seller will execute and deliver to the Buyer one or more copyright assignments in substantially the form of Exhibit C attached hereto (the “Copyright Assignment”)
pursuant to which the Seller will transfer and assign to the Buyer the Copyrights being acquired by the Buyer pursuant to this Agreement, if any; 
 (d) the Seller will execute and deliver one or more trademark and domain assignments in substantially the form of Exhibit D attached hereto (the “Assignment of Trademarks and
Domains”) pursuant to which the Seller will transfer and assign to the Buyer the Trademarks and internet domains being acquired by the Buyer pursuant to this Agreement, if any; 

(e) the Seller will execute and deliver one or more patent assignments in substantially the form of Exhibit E attached hereto (the
“Patent Assignment”) pursuant to which the Seller will transfer and assign to the Buyer the Patents being acquired by the Buyer pursuant to this Agreement, if any; 

(f) the Parent and the Seller will execute and deliver one or more escrow agreements in substantially the form of Exhibit F
attached hereto (the “Escrow Agreement”) pursuant to which the Shares and the Claim Shares will be deposited with the Escrow Agent subject to the provisions therein; 

(g) stockholders of the Seller, collectively holding at least Ninety percent (90%) of the outstanding common stock of the Seller and
Sixty-Six and Two Thirds percent (66 2/3%) of the outstanding preferred stock of the Seller, will enter into one or more voting agreements with Parent in substantially the form of Exhibit G attached hereto (the “Voting
Agreement”) pursuant to which such stockholders of Seller will agree to vote their shares of Seller as set forth and subject to the provisions therein; and 
 (h) the Seller will execute and deliver all such other bills of sale, assignments, endorsements, intellectual property right assignments, trade name assignments, domain name assignments, certificates of
title, consents and other good and sufficient instruments and documents of conveyance and transfer in form and substance satisfactory to the Buyer, as the Buyer reasonably shall deem necessary or appropriate to vest in or confirm to the Buyer all of
the Seller’s right, title and interest in and to all of the Acquired Assets. 

  
 -7-

 1.7 Consents of Third Parties. 

(a) Notwithstanding anything in this Agreement or in any Related Agreement to the contrary, neither this Agreement nor any such Related
Agreement shall constitute an agreement to assign or otherwise transfer, or require the Buyer to assume any obligations under, any Assigned Contract if an attempted assignment or transfer thereof would, without the consent of a third party to such
assignment or transfer, constitute a breach thereof, would be ineffective, would affect adversely the rights of the Buyer thereunder or would violate any applicable Law. If any such consent has not been obtained as of the Closing Date and the Buyer
nevertheless determines to proceed with the Closing, the Seller shall use its best efforts to obtain such consent following the Closing, and the Buyer will provide reasonable cooperation to the Seller in seeking to obtain any such consent. The
Seller shall pay and discharge any and all out-of-pocket costs or expenses of seeking to obtain or obtaining any such consent or approval before the Closing Date. 
 (b) If any Assigned Contract is not transferred to the Buyer at the Closing pursuant to this Agreement, the Seller shall cooperate with the Buyer in any reasonable arrangement designed to provide for the
Buyer all of the benefits of, and to have the Buyer assume the obligations to the extent set forth in Section 1.3 with respect to, such Assigned Contract. In such event, until such consent has been obtained, (i) the Buyer shall use
commercially reasonable efforts to perform in the Seller’s name (as applicable) all of such obligations; provided, however, that the Buyer shall not be required to take any action in performing such obligations which, in the
Buyer’s reasonable judgment, would subject the Buyer to an unreasonable risk of incurring a Liability and (ii) the Seller shall take all actions reasonably requested by the Buyer to enforce for the benefit of the Buyer any and all rights
of the Seller with respect to any such Assigned Contract. 
 (c) The Seller hereby authorizes the Buyer to perform all of its
obligations after the Closing with respect to all Assigned Contracts that are not assigned to the Buyer at the Closing. The Seller agrees to remit promptly to the Buyer all collections or payments received by the Seller in respect of all such
Assigned Contracts, and shall hold all such collections or payments in trust for the benefit of, and promptly pay the same over to, the Buyer; provided, however, that nothing herein shall create or provide any rights or benefits in or
to third parties. 
 (d) Nothing in this Section 1.7 shall be deemed to modify in any respect any of the Seller’s
representations or warranties set forth herein or the conditions to the Buyer’s obligations contained in ARTICLE VI hereof, be deemed a waiver by the Buyer of its right to have received on or before the Closing Date an effective assignment of
all of the Acquired Assets or be deemed to constitute an agreement to exclude from the Acquired Assets any assets described under Section 1.1. 
 1.8 Further Assurances At any time and from time to time after the Closing, at the request of the Buyer and without further consideration, the Seller will execute and deliver such other instruments
of sale, transfer, conveyance, assignment and confirmation, and will take such further action, as may be 

  
 -8-

 
reasonably requested in order to more effectively transfer, convey and assign to the Buyer, and to confirm the Buyer’s title in and to, all of the Seller’s right, title and interest in
and to the Acquired Assets, and each of the parties shall execute such other documents and take such further action as may be reasonably required or desirable to carry out the provisions of this Agreement and the transactions contemplated hereby.

 1.9 Transfer Taxes Any Transfer Taxes and corresponding Tax Returns required to be filed in connection with the
transaction contemplated by this Agreement and associated matters shall be prepared and filed when due by the party responsible under applicable Law for filing such Tax Returns. The party filing any such Transfer Tax Return shall provide the other
parties with a copy of such return for review and comment at least twenty (20) days prior to such filing. 
 ARTICLE II

 PURCHASE PRICE 
 2.1 Purchase Price The purchase price for the Acquired Assets (the “Purchase Price”) shall be the following: 

(a) Up to Ten Million (10,000,000) shares of Parent Common Stock (the “Shares”), representing an aggregate value of
up to Two Million Five Hundred Thousand Dollars ($2,500,000) (based on a per share value equal to the greater of Twenty-Five cents ($0.25) per share or the Fifteen Day VWAP as of the Trading Day immediately preceding the Closing Date) less an
adjustment to account for Retained Cash as provided under Section 1.1(d); and 
 (b) the value of the Assumed Liabilities.

 2.2 Delivery of Shares. At the Closing: 
 (a) The Parent shall deposit or cause to be deposited with the Escrow Agent (i) twelve and one half percent (12.5%) of the number of Shares (the “Claim Shares”) to be held as a
reserve for a period of eighteen (18) months following the Closing in accordance with the terms of the Escrow Agreement to secure payment of Buyer’s right to indemnification under Article VII of this Agreement. 

(b) The Parent shall deposit or cause to be deposited with the Escrow Agent the remaining eighty seven and one half percent
(87.5%) of the Shares, which shall be held in escrow and released to Seller in a series of 12 equal monthly installments beginning six months following the Closing in accordance with the terms of the Escrow Agreement. 

2.3 Working Capital. 
 (a) Schedule 2.3(a) reflects the Working Capital of the Seller, as set forth in reasonable detail by the Seller’s Chief Financial Officer (the “Current Working Capital”). 

  
 -9-

 (b) Four (4) Business Days prior to the Closing, the Seller shall deliver to the Buyer
a certificate (the “Updated Working Capital Statement”) certified by the Seller’s Chief Financial Officer setting forth in reasonable detail an updated calculation of the Working Capital of the Seller which shall include an
accounting of the Retained Cash and itemized Seller Expenses as described in Section 1.1(d). 
 2.4 Allocation of
Purchase Price. The Purchase Price shall be allocated among the Acquired Assets as determined by the Buyer in good faith and shall be set forth in a schedule produced by the Buyer within one hundred twenty (120) days following the Closing
Date (the “Allocation Schedule”). The parties shall, and shall cause their respective Affiliates to, make consistent use of the allocations set forth in the Allocation Schedule (as reasonably adjusted to account for events occurring
after the determination of the Allocation Schedule) for all Tax purposes, file all Tax Returns in a manner consistent with the Allocation Schedule (as adjusted) and take no tax position contrary thereto unless required to do so by a change in
applicable Laws or a good faith resolution of a Tax contest 
 2.5 Seller’s Responsibility for Seller Liabilities.
Following deposit by Parent of the Shares with the Escrow Agent, as set forth above, and other than as to the Assumed Liabilities, Seller shall in all events be solely responsible for any and all further distribution of proceeds to its creditors and
shareholders, as appropriate, and neither Buyer nor Parent shall in any way be liable or responsible for distribution of any portion of the Purchase Price directly to any of Seller’s creditors or shareholders. 

ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE SELLER 
 Except as disclosed by the
Seller in a writing dated as of the date of this Agreement and delivered by the Seller to the Buyer (a “Written Schedule of Exceptions”), the Seller hereby represents and warrants to the Buyer that the representations and warranties
contained in this ARTICLE III are true, complete and correct. The Written Schedule of Exceptions shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this ARTICLE III, and the disclosures in
any section or subsection of the Written Schedule of Exceptions shall qualify only the corresponding section or subsection of this ARTICLE III. 
 3.1 Organization, Good Standing and Qualification of the Seller The Seller is duly incorporated and validly existing and in corporate and tax good standing under the Laws of the State of Nevada.
The Seller is duly qualified or licensed as a foreign corporation to do business and is in corporate and tax good standing under the Laws of each jurisdiction where the character of the Acquired Assets or the nature of the Business makes such
qualification or licensing necessary, except where the failure to be so qualified or licensed and in good standing would not, individually or in the aggregate, be reasonably likely to have a Business Material Adverse Effect. The Seller has all
requisite power and authority, and is in possession of all Approvals necessary, to own, lease and operate the Acquired Assets and to carry on the Business as it is now being conducted. The Seller has delivered to the Buyer complete and accurate
copies of its Organizational Documents, in each case as amended (if 

  
 -10-

 
applicable) and in effect as of the date hereof. Set forth in Section 3.1 of the Written Schedule of Exceptions is a list of (i) the jurisdictions in which the Seller is qualified or
licensed to transact business, (ii) every state or foreign jurisdiction in which the Seller has employees or facilities and (iii) the directors and officers of the Seller. 

3.2 Ownership of the Seller; Subsidiaries All outstanding shares of the Seller are owned solely by individuals and entities set
forth in Schedule 3.2. Each person listed on Schedule 3.2 is an “accredited investor” as that term is defined under Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”)
and the California Corporate Securities Law of 1968, as amended. There are no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind (contingent or otherwise) obligating the Seller
to issue, deliver or sell, or cause to be issued, delivered or sold, any shares of capital stock of the Seller, other than those set forth in Section 3.2 of the Written Schedule of Exceptions. The Seller has not had, nor does it currently have,
any Subsidiaries, nor has it ever owned, nor does it currently own, any capital stock or other proprietary interest, directly or indirectly, in any other Person. 
 3.3 Authorization; Binding Obligation The Seller has all necessary power and authority to execute and deliver this Agreement, each Related Agreement to which it is a party and each other instrument
or document required to be executed and delivered by it pursuant to this Agreement or any such Related Agreement, and to perform each of its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The
execution and delivery by the Seller of this Agreement and each Related Agreement to which it is a party, the performance of its obligations hereunder and thereunder, and the consummation of the transactions contemplated hereby and thereby, have
been duly and validly authorized by all requisite actions on the part of the Seller and no other corporate proceedings on its part are necessary to authorize this Agreement or any Related Agreement to which it is a party or to consummate the
transactions so contemplated herein and therein. This Agreement has been, and each of the Related Agreements to which the Seller is a party, when executed and delivered by the Seller, will be, duly and validly executed and delivered by the Seller
and this Agreement constitutes, and each Related Agreement to which the Seller is a party, when executed and delivered by the Seller, and each other party hereto and thereto, will constitute, a legal, valid and binding obligation of the Seller
enforceable against the Seller in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors’ rights generally
and (ii) as limited by Laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 3.4 Consents and Approvals The execution and delivery by the Seller of this Agreement, the Related Agreements to which the Seller is a party or any other instrument or document required by this
Agreement or any Related Agreement to be executed and delivered by the Seller do not, and the performance of this Agreement, the Related Agreements to which the Seller is a party and any other instrument or document required by this Agreement or any
Related Agreement to be executed and delivered by the Seller shall not, require the Seller to obtain any Approval of any Person or Approval of, observe any waiting period imposed by, or make any filing with or notification to, any Governmental
Authority. 

  
 -11-

 3.5 No Violation The execution and delivery by the Seller of this Agreement, the
Related Agreements to which the Seller is a party or any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Seller do not, and the performance of this Agreement, the Related
Agreements to which the Seller is a party or any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Seller, will not, (a) conflict with or violate the Organizational Documents of
the Seller, (b) conflict with or violate any Law or Order applicable to the Seller or by which Seller or any of the Acquired Assets are bound or affected, or (c) result in any breach or violation of or constitute a default (or an event
that with notice or lapse of time or both would become a breach, violation or default) under, or result in the creation of a Lien on any of the Acquired Assets pursuant to, any Assigned Contract or any other material Contract to which the Seller is
a party or is otherwise bound, or any Approval to which the Seller is a party or by which the Seller is bound or affected. 

3.6 Regulatory Matters; Licenses and Permits Section 3.6 of the Written Schedule of Exceptions contains a correct and
complete list of all Approvals and Orders that have been issued, granted or otherwise made available to the Seller with respect to the Business (the “Business Licenses”). Each Business License is valid and in full force and effect,
no Business License is subject to any Lien, limitation, restriction, probation or other qualification, and there is no default under any Business License or, to the Knowledge of the Seller, any basis for the assertion of any default thereunder.
There is no Action pending or, to the Knowledge of the Seller, threatened that would reasonably be expected to result in the termination, revocation, limitation, suspension, restriction or impairment of any Business License or the imposition of any
fine, penalty or other sanctions for violation of any legal or regulatory requirements relating to any Business License or, to the Knowledge of the Seller, any basis therefore. The Seller has, and has had at all relevant times, all Approvals that
are or were necessary in order to enable the Seller to own and operate the Acquired Assets and to conduct the Business, including all necessary Approvals from the U.S. Food and Drug Administration (the “FDA”) or any foreign
regulatory agency with a similar regulatory purpose. None of the Business Licenses will be adversely affected by the consummation of the transactions contemplated hereby. The Seller is in compliance in all material respects with the terms and
conditions of each Business License held by it and the Seller has not received notice of any Action, and no such Action is pending, relating to the cancellation, suspension, revocation, modification or non-renewal of any Business License.

 3.7 Title to and Condition of Properties; Sufficiency of Assets. 

(a) The Seller is the sole and exclusive legal and equitable owner of all right, title and interest in, and has good, valid and marketable
title to, all of the Acquired Assets purported to be owned by the Seller and the legal and valid right to use all other Acquired Assets used or held for use by the Seller including all Acquired Assets held under Personal Property Leases, the Office
Lease or License Agreements, in any case, free and clear of all Liens, other than Permitted Liens. The Seller has the power and the right to sell, assign and transfer good, 

  
 -12-

 
valid and marketable title to all of the Acquired Assets purported to be owned by the Seller and the valid, enforceable and sufficient right to use all of the other Acquired Assets, free and
clear of all Liens other than Permitted Liens. 
 (b) All tangible assets and personal property included in the Acquired Assets
have been maintained in accordance with normal industry practice and are in good operating condition and repair, subject to ordinary wear and tear, and there has not been any interruption of the operations of the Business due to the condition of any
such assets or properties. 
 (c) The Acquired Assets, including all assets and properties held under the Personal Property
Leases, the Office Lease and License Agreements, comprise all assets, properties, rights and Contracts used in connection with the operation of the Business except for the Excluded Assets set forth in Section 1.2 hereto (which are not being
acquired by the Buyer), which Acquired Assets are all of the assets, properties, rights and Contracts necessary for Buyer to operate the Business following the Closing in the manner in which the Business is currently conducted. All operations of the
Business are conducted by the Seller. 
 3.8 Real Property. 

(a) The Seller does not own, nor has it ever owned, any real property. Section 3.8 of the Written Schedule of Exceptions sets forth a
complete and accurate list of all real property that is leased by the Seller and used in connection with the operation of the Business, including all real property subject to the Office Lease (the “Leased Real Property”). The Office
Lease is in full force and effect and is the legal, valid and binding obligation of the Seller and, to the Knowledge of the Seller, of the other parties thereto in accordance with its terms, and neither the Seller nor, to the Knowledge of the
Seller, the other parties thereto is in breach or default thereunder and there exists no event, condition or occurrence which (with or without due notice or lapse of time, or both) would constitute such a breach, default or alleged breach or default
by the Seller or, to the Knowledge of the Seller, the other parties thereto of any of the foregoing. Other than consent of the Landlord to the Office Lease, no consent of, or notice to, any third party is required under the Office Lease as a result
of or in connection with, and the enforceability of the Office Lease will not be affected in any manner by, the execution, delivery and performance of this Agreement or the transactions contemplated hereby. Seller has obtained all consent necessary
from the Landlord for the transfer of the Office Lease from the Seller to the Buyer and the Seller has paid all fees or costs associated therewith. The Seller has delivered to the Buyer a true and complete copy of the Office Lease, including all
amendments thereto. 
 (b) The Seller holds the property leased to it under the Office Lease free and clear of all Liens, claims
or rights of any third parties, other than Permitted Liens, and the possession of the Leased Real Property (the “Premises”) by the Seller has not been disturbed and no claim has been asserted against the Seller adverse to its rights
in such Premises. All improvements, fixtures and structures on the Premises and the current uses of the Premises conform in all material respects to all applicable Laws, including building, zoning, health, safety and other Laws, and applicable
zoning Laws permit the presently existing improvements and the conduct of the Business as being conducted on the Premises. All improvements, mechanical equipment, fixtures and operating systems included in the Premises are in good operating
condition and repair (ordinary wear and tear excepted) and there does not exist any condition which materially interferes with the economic value or use of such property and improvements. 

  
 -13-

 (c) The Seller has not granted any leases or licenses, or created any tenancies, affecting
the Premises. Except as disclosed in Section 3.8(c) of the Written Schedule of Exceptions, there are no other parties in possession of any portion of the Premises as trespassers or otherwise. 

(d) The Seller is not a party to or is otherwise bound by, nor is any of the Premises subject to, any Contract requiring it to pay any
commissions or other compensation to any brokers or agents in connection with any of the Premises, and has had no dealings with any broker or agent with respect to the Premises upon which any such broker or agent would be entitled to a commission or
other compensation. 
 (e) To the Knowledge of the Seller, (i) there are no Laws or Orders now in existence or under active
consideration by any Governmental Authority which could require the tenant of any Leased Real Property to make any expenditure in excess of $10,000 to modify or improve such Leased Real Property to bring it into compliance therewith and
(ii) the Seller is not required to expend more than $10,000 in the aggregate under the Office Lease to restore the Leased Real Property at the end of the term of the Office Lease to the condition required under the Office Lease (assuming the
conditions existing in such Leased Real Property as of the date hereof). 
 3.9 Personal Property Leases Section 3.9
of the Written Schedule of Exceptions sets forth a complete and accurate list of all personal property that is leased by the Seller (the “Leased Personal Property” and, the leases covering the Leased Personal Property, collectively,
the “Personal Property Leases”). The Seller is the owner and holder of the leasehold interests purported to be granted by each Personal Property Lease, and all Personal Property Leases are in full force and effect in accordance with
the terms thereof and are the legal, valid and binding obligations of the Seller and, to the Knowledge of the Seller, of each other party thereto enforceable in accordance with their respective terms, and neither the Seller nor, to the Knowledge of
the Seller, the other party or parties thereto is or are in material breach or default thereunder and there exists no event, condition or occurrence which (with or without due notice or lapse of time, or both) would constitute such a material
breach, default or alleged breach or default by the Seller or, to the Knowledge of the Seller, the other party or parties thereto of any of the foregoing. No consent of, or notice to, any third party is required under any Personal Property Lease as
a result of or in connection with, and the enforceability of any such Personal Property Lease will not be affected by, the execution, delivery and performance of this Agreement or any Related Agreement, or the transactions contemplated hereby or
thereby. The Seller has delivered to the Buyer complete and accurate copies of all Personal Property Leases, including all amendments thereto. 
 3.10 Environmental Matters. 
 (a) Except as set forth in
Section 3.10(a) of the Written Schedule of Exceptions, the Seller has complied and is in compliance in all material respects with all 

  
 -14-

 
Environmental Laws, which compliance includes the possession by the Seller of all Approvals required under applicable Laws and compliance with the terms and conditions thereof.
Section 3.10(a) of the Written Schedule of Exceptions includes a list of all of the Approvals required under Environmental Laws necessary to own and operate the Acquired Assets or the Business as currently conducted. There are no past or
present facts, circumstances, conditions, activities or incidents which could give rise to any Liability or result in a claim against the Seller or the Buyer under any Environmental Law. There have been no releases by the Seller or any of its
Affiliates of any Materials of Environmental Concern into the environment at any real property or facility formerly or currently owned or operated by the Seller or any of its Affiliates that is or was ever used by the Seller or any of its
Affiliates. The Seller has no Knowledge of any release by any other Person of any Materials of Environmental Concern into the environment at any parcel of real property or any facility formerly or currently operated by the Seller that is or was ever
used by the Seller or any of its Affiliates. There is no Action pending or, to the Knowledge of the Seller, threatened or other notice of violation, formal administrative proceeding or written information request by any Governmental Authority, nor
has the Seller received notice of any investigation by any Governmental Authority relating to any Environmental Law nor any other notice from a Governmental Authority or any Person alleging that the Seller is not in compliance with any Environmental
Law or Approval required under any Environmental Law or has any Liability under any Environmental Law or for the remediation of any Materials of Environmental Concern at any property. 

(b) There are no facts, circumstances or conditions existing at any facilities owned or operated by the Seller or any of its Affiliates,
including the release of any Materials of Environmental Concern, that would reasonably be expected to give rise to any material Liability or result in a claim against the Seller or any of its Affiliates, under any Environmental Law. 

(c) Set forth in Section 3.10(c) of the Written Schedule of Exceptions is a complete and accurate list of all environmental reports,
investigations or audits (whether in hard copy or electronic form) relating to premises currently or previously leased, owned or operated by the Seller or any of its Affiliates (whether conducted by or on behalf of the Seller or any of its
Affiliates or a third party, and whether done at the initiative of the Seller or an Affiliate or directed by a Governmental Authority or other third party) of which the Seller is aware. A complete and accurate copy of each such document has been
provided to the Buyer. 
 3.11 Financial Statements; No Undisclosed Liabilities. 

(a) Section 3.11 of the Written Schedule of Exceptions contains the following financial statements (collectively, the
“Financial Statements”): 
 (i) the unaudited balance sheet of the Seller as of August 30, 2012 (the
“Interim Balance Sheet”) and the related statements of income, cash flow and stockholders’ equity for the eight-month period then ended (the “Interim Financial Statements”); and 

(ii) the unaudited balance sheets of the Seller as of December 31, 2011 and December 31, 2010 and the related statements of
income, cash flow and stockholders’ equity for the respective twelve-month periods then ended. 

  
 -15-

 The Financial Statements were prepared in accordance with the books and records of the Seller, are complete
and correct and fairly and accurately present in all material respects the financial condition of the Seller and the Business as of the dates indicated and the results of operations of the Seller and the Business for the respective periods
indicated, and have been prepared in accordance with GAAP, consistently applied, except for the absence of complete footnote disclosure as required by GAAP and subject to changes resulting from normal, recurring period-end audit adjustments. The
Financial Statements reflect the consistent application of GAAP throughout the periods involved. 
 (b) Except as and to the
extent the amounts are specifically accrued or disclosed in the Interim Balance Sheet, the Seller does not have any material Liabilities, whether or not required by GAAP to be reflected in the Interim Balance Sheet, except for Liabilities that were
incurred in the ordinary course of business consistent with past practice since the date of the Interim Balance Sheet. 
 3.12
Absence of Certain Events Since December 31, 2011, the Business has been conducted only in the ordinary and usual course and in a manner consistent with past practice and there has not been any change, event, loss, development, damage or
circumstance affecting the Acquired Assets or the Business which, individually or in the aggregate, has had or could reasonably be expected to have a Business Material Adverse Effect (a “Business Material Adverse Change”). As
amplification and not in limitation of the foregoing, since December 31, 2011, there has not been: 
 (a) any material
decrease in the value of any of the Acquired Assets, other than ordinary depreciation consistent with past practices; 
 (b) any
voluntary or involuntary sale, assignment, license or other disposition of any kind of any material asset or property of the Seller used in connection with the operation of the Business, except the sale of inventory in the ordinary course of
business; 
 (c) any Lien imposed or created on any of the Acquired Assets; 

(d) any damage, destruction or loss of any material asset or property of the Seller used in connection with or relating to the operation
of the Business, by fire or other casualty, whether or not covered by insurance; 
 (e) any capital expenditure or commitment by
the Seller in excess of $5,000 or series of capital expenditures or commitment in excess of $10,000 in the aggregate; 
 (f) any
payment, discharge or satisfaction of any material Liability of the Seller or the Business other than payments made in the ordinary course of business of Liabilities reflected or reserved against in the Interim Balance Sheet or Liabilities incurred
since that date in the ordinary course of business consistent with past practice; 
 (g) any assignment, termination,
modification or amendment of any material Contract to which the Seller was or is a party or which is otherwise related to the Business, except for terminations, modifications or amendments made in the ordinary course of business consistent with past
practice and which would not, either individually or in the aggregate, have a Business Material Adverse Effect; 

  
 -16-

 (h) any notice to the Seller that any Assigned Contract or other material Contract to which
the Seller was or is a party that relates to the Business or the operation thereof has been breached, repudiated or terminated or will be breached, repudiated or terminated; 
 (i) any change in the rate of compensation, commission, bonus or other direct or indirect remuneration payable or to become payable to any Business Employee, or any agreement to pay any bonus or extra
compensation or other employee benefit to any Business Employee; 
 (j) any failure to pay or discharge when due (after the
application of any applicable grace periods) any material Liabilities of the Seller arising from the operation of the Business, except for Liabilities contested in good faith by the Seller and for accounts payable of the Seller which are paid in
accordance with the historical practices of the Seller, provided that, such Liabilities and accounts payable have been fully reflected and reserved for in the Interim Balance Sheet; 

(k) any change in any of the accounting principles adopted by the Seller or any change in the Seller’s accounting policies,
procedures, practices or methods with respect to applying such principles, other than as required by GAAP; 
 (l) any material
transaction or Contract entered into, or Liability created, assumed, guarantied or incurred, by the Seller outside the ordinary course of business; 
 (m) any amendment to the Organizational Documents of the Seller; 
 (n) any Tax
election made by the Seller, or any change of any annual Tax accounting period, amendment of any Tax Return, settlement of any income Tax Liability, entry into any closing agreement, settlement of any Tax claim or assessment, surrender of any right
to claim a Tax refund or consent to any extension or waiver of the limitations period applicable to any Tax claim or assessment; 
 (o) any acquisition of or agreement to acquire by merging or consolidating with, or by purchasing a substantial portion of the capital stock or assets of, or by any other manner, any business or any
corporation, partnership, limited liability entity, joint venture, association or other business organization; 
 (p) any
termination of employment (or other form of engagement) of any Business Employee or any expression of intention by the Seller or by any such Business Employee to terminate employment (or other engagement); 

(q) any cancellation or forfeiture of any material debts or claims of the Seller or any waiver of any material rights of material value
to the Seller or the Business or settlement of any Action; 

  
 -17-

 (r) any write-off of any accounts receivable or notes receivable of the Seller or any
portion thereof in excess of $10,000 individually or $20,000 in the aggregate, or any sale, assignment or disposition of any such account or note receivable (including by means of any factoring agreement); 

(s) any incurrence, assumption or creation of any Indebtedness or guarantee of any Indebtedness of any other Person, or making,
incurrence, assumption, creation or guarantee of any loan, or making of any advance or capital contribution to or investment in any Person by the Seller; 
 (t) any engagement by the Seller in any transaction with any Affiliate, employee, officer, director or security holder thereof, other than the payment of normal wages and salaries to employees in the
ordinary course of business and consistent with past practice and advances to employees in the ordinary course of business for travel and similar business expenses and consistent with past practice; 

(u) any grant of any license or sublicense of any rights under or with respect to, or sale, transfer or permission to lapse, of any
Seller Intellectual Property; or 
 (v) any agreement, understanding, authorization or proposal, whether in writing or
otherwise, for the Seller to take any of the actions specified in this Section 3.12. 
 3.13 Legal Proceedings.

 (a) Section 3.13(a) of the Written Schedule of Exceptions sets forth all Actions pending or, to the Knowledge of the
Seller, threatened against the Seller or any of its officers or directors (in their capacities as such) or otherwise relating to the Business, and the Seller has not received any claim, complaint, incident, report, threat or notice of any such
Action. There is no Action pending or threatened against any other Person by the Seller. 
 (b) Section 3.13(b) of the
Written Schedule of Exceptions sets forth all Actions that (i) involved the Seller at any time during the past three (3) years and (ii) are no longer pending (the “Prior Actions”). All of the Prior Actions have been
concluded in their entirety and the Seller does not have any Liability with respect to the Prior Actions. The Seller has provided the Buyer with all formal written communications relating to the Prior Actions between the Seller and a Governmental
Authority and any Orders related thereto. 
 (c) The Seller has no Knowledge as to any Liability relating to the Seller’s
ownership or operation of the Acquired Assets or the Business. 
 (d) There are no outstanding Orders against, involving or
affecting the Seller, the Business or the Acquired Assets, and the Seller is not in default with respect to any such Order of which it has Knowledge or was served upon it. 
 (e) There is no Action pending or, to the Knowledge of the Seller, threatened by or against the Seller that (a) relates to the Business, the Acquired Assets or the Assumed Liabilities, (b) would
give any Person the right to enjoin or rescind the transactions contemplated 

  
 -18-

 
by this Agreement, or (c) would otherwise prevent the Seller from (i) executing and delivering this Agreement or the Related Agreements to which it is a party or (ii) performing
the Seller’s obligations pursuant to, or observing any of the terms and provisions of, this Agreement or the Related Agreements to which it is a party. 
 3.14 Compliance with Laws. 
 (a) The Seller has complied and is in
compliance in all material respects with all Laws applicable to (i) the Seller, (ii) the Acquired Assets and (iii) the Seller’s ownership, use or operation thereof, and the operation of the Business. The Seller has not received
any notice to the effect that, or otherwise been advised that, the Seller is not in compliance with any such Laws, and the Seller does not have any reason to anticipate that any existing circumstances are likely to result in an Action or a violation
of any such Law. No investigation or review by any Governmental Authority with respect to the Seller or the Business is pending or, to the Knowledge of the Seller, threatened, nor has any Governmental Authority indicated an intention to conduct the
same. 
 (b) The Seller has complied and is in compliance in all material respects with all applicable security and privacy
standards regarding protected health information under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the Regulations promulgated thereunder and all applicable state privacy Laws in connection with the
operation of the Business. The Seller has not received from any Person, nor have been made aware of, any written complaints or concerns regarding the Seller’s or any Seller Product’s noncompliance with HIPAA, any regulations promulgated
thereunder, or any applicable state privacy Laws. To the extent that the Seller has represented to a customer of the Business that Business’ products or services comply with any privacy or security Laws or standards, the Seller has undertaken
all activities reasonably necessary to comply with such Laws or standards. 
 3.15 Employment Matters. 

(a) Section 3.15(a) of the Written Schedule of Exceptions sets forth a complete and accurate list of all current Business Employees
as of the date hereof and each such Business Employee’s (i) rate of pay or annual compensation (including actual or potential annual, incentive, retention, change-of-control or other bonus or similar payments and the terms of any
commission payments or programs) as of the date hereof, (ii) title(s), (iii) status of employment or engagement, (iv) date of hire or engagement, (v) annual vacation, sick and other paid time off allowance, (vi) amount of
accrued vacation, sick and other paid time off and the economic value thereof, (vii) description of other fringe benefits and (viii) terms of severance benefits. Section 3.15(a) of the Written Schedule of Exceptions also identifies
each Business Employee who is not fully available to perform his or her duties as a result of disability or other leave and sets forth the basis of such leave and the anticipated date of return to full service. Section 3.15(a) of the Written
Schedule of Exceptions sets forth all employment, consulting, independent contractor, severance pay, continuation pay, termination or indemnification Contracts between the Seller or any of its Affiliates and any current or former Business Employee.

  
 -19-

 (b) Except as listed in Section 3.15(a) of the Written Schedule of Exceptions, neither
the Seller nor any of its Affiliates are, and, as of the Closing Date, will be delinquent in payments to any Business Employee for any wages, salaries, commissions, bonuses, benefits or other compensation, including vacation time and sick leave, for
any services performed by them to date or through the Closing Date or any amounts required to be reimbursed to any Business Employee or any post-employment or post-engagement obligations of any type. Upon termination of employment or engagement of
any Business Employee, neither the Buyer nor any of its Affiliates will, by reason of anything done prior to the Closing, be liable to any Business Employee for so-called “severance pay” or any other similar payments, and to the
Seller’s Knowledge, there are no circumstances whereby any current or former Business Employee may demand payment or compensation in connection with the termination of his or her employment. No current Business Employee has informed the Seller
that such individual intends to terminate his or her employment or engagement with the Seller. 
 (c) Neither the Seller or any
of its Affiliates nor, to the Knowledge of the Seller, any Business Employee is in violation of any term of any employment, consulting, independent contractor, non-disclosure, non-competition, inventions assignment or any other Contract (or any
other legal obligation such as a trade secrets statute or common law duty of loyalty) relating to the relationship of such Business Employee with the Seller or any of its Affiliates or any other Person or has been notified that such Business
Employee may be in violation of any such Contract or other legal obligation. Each current Business Employee who is required to be licensed by applicable Law is so licensed, and complete and accurate copies of such Licenses have previously been
delivered to the Buyer. 
 (d) During the preceding twelve (12) months, the Seller has had adequate levels of staffing to
conduct the Business in a commercially reasonable manner. 
 (e) Neither the Seller nor any of its Affiliates is a party to any
collective bargaining Contracts or other Contracts with any labor unions or other representatives of the Business Employees nor is it under any obligation to bargain with any bargaining agent on behalf of any Business Employees. To the Knowledge of
the Seller, there have not been any organization campaigns, petitions or other unionization activities seeking recognition of a collective bargaining unit which could affect the Business. There are no existing or threatened labor strikes, work
stoppages or organized slowdowns affecting the Business. 
 (f) There are no unfair labor practice complaints or other Actions
pending or, to the Knowledge of the Seller, threatened against the Seller before the National Labor Relations Board, any Court or any Governmental Authority concerning any Business Employee. There are no complaints or other Actions pending or, to
the Knowledge of the Seller, threatened by or on behalf of any Business Employee alleging breach of any express or implied Contract. 
 (g) Section 3.15(g) of the Written Schedule of Exceptions sets forth all Employee Benefit Plans under which current or former Business Employees (or their beneficiaries) are eligible to participate
or derive a benefit or for which the Acquired Assets may be subject to any Liability. The Seller has delivered to the Buyer correct and complete copies of all Employee Benefit Plans listed in Section 3.15(g) of the Written Schedule of
Exceptions. Each Employee Benefit Plan intended to be qualified under section 401(a) of the Code, and the 

  
 -20-

 
trust (if any) forming a part thereof, is so qualified and has received a favorable determination letter from the IRS. Each Employee Benefit Plan has been operated in accordance with applicable
Law in all material respects. 
 (h) The Seller and its Affiliates have complied in all material respects with all its
obligations under the Law with respect to any aspect of the employment or engagement of all Business Employees, including with respect to employment practices, terms and conditions of employment, wage and hours, and the health and safety at work of
their employees, and there are no claims pending or, to the Knowledge of the Seller, threatened by any person in respect of employment or engagement or any accident or injury. Neither the Seller nor any ERISA Affiliate has maintained a
“multiemployer plan” (as defined in Section 3(37) of ERISA) or an arrangement subject to Section 501(c)(9), 419 or 419A of the Code, or a “pension plan” (as defined in Section 3(2) of ERISA) subject to Title IV of
ERISA, a self-insured plan providing medical benefits or a plan providing for medical or life insurance coverage beyond termination of employment (other than COBRA Coverage or under similar state Laws). 

(i) Each current Business Employee who is located in the United States and is not a United States citizen has all Approvals necessary to
work in the United States in accordance with applicable Law. 
 (j) There is no charge or proceeding with respect to a violation
of any occupational safety or health standards that has been asserted or is now pending or, to the Knowledge of the Seller, threatened with respect to the Seller or the Business. 

(k) There is no charge of discrimination in employment or employment practices, for any reason, including age, gender, race, religion or
other legally protected category, or any alleged violation of any privacy Laws, which has been asserted or, to the Knowledge of the Seller, is now pending or threatened before the United States Equal Employment Opportunity Commission, or any other
Governmental Authority in any jurisdiction in which the Seller has employed or currently employs any person. 
 (l) Neither the
execution and delivery of this Agreement nor consummation of the transactions contemplated hereby (or such transactions in combination with any prior or subsequent transactions or events) will (i) result in any current or former employee,
director or consultant of the Business becoming entitled to any unemployment compensation, deferred compensation, bonus or severance pay, materially increase or otherwise enhance any benefits otherwise payable by Seller, (ii) result in the
acceleration of time of payment or vesting. or an increase in the amount of any compensation due to any current or former employee, director or consultant of the Business, (iii) result in forgiveness, in whole or in part, of any outstanding
loans made by Seller to any current or former employees, directors or consultants of the Business, or (iv) result in a payment that would be considered a “parachute payment” within the meaning of Section 280G of the Code.

 (m) Seller has maintained. operated and administered each nonqualified deferred compensation plans (within the meaning of
either Section 409A or Section 457A of the Code) (each, a “Nonqualified Deferred Compensation Plan”) in full compliance with the requirements of Sections 409A and 457A of the Code and the regulations and guidance

  
 -21-

 
promulgated thereunder. No payment made or to be made under a Nonqualified Deferred Compensation Plan is or will be subject to taxation pursuant to, or any Taxes, interest or penalties imposed
by, Section 409A or 457A of the Code. All Nonqualified Deferred Compensation Plan documents are in full compliance with the requirements of Code Sections 409A and 457A and do not require any amendments or modifications to achieve such
compliance. 
 3.16 Taxes. For purposes of the following representations, the term “Seller” shall be construed
to refer also to each predecessor-in-interest of Seller and each other entity or person for whose liability for Taxes Seller has or may have liability or responsibility. 
 (a) All Taxes payable by the Seller have been timely paid, or, to the extent not required to have been paid, have been accrued in the Interim Balance Sheet; all federal, state, local and foreign Tax
Returns required to be filed by or on behalf of the Seller with respect to any such Taxes have been timely filed, and all such Tax Returns are complete and correct in all material respects and have been filed in accordance with all applicable Law;
all Taxes that the Seller is or was required by Law to have withheld have been duly withheld or collected and, to the extent required, have been paid to the proper Governmental Authority; no unpaid Tax deficiency has been asserted against or with
respect to the Seller and the Seller has not received notice of any such assertion. The Seller has not executed or entered into any ruling or agreement with any Governmental Authority regarding Taxes or has agreed to make any adjustment to its
income or deductions pursuant to a change in its method of accounting. Except as provided in Schedule 3.16(a), Seller currently is not the beneficiary of any extension of time within which to file any Tax Return related to the Business or
Assets. The Seller has not been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, and no withholding
pursuant to Section 1445 of the Code will be required in connection with this Agreement or the transactions contemplated hereby. There are no Liens with respect to Taxes upon any of the Acquired Assets other than Permitted Liens. 

(b) No claim has ever been made or is expected to be made by any Governmental Authority in a jurisdiction where Seller does not file Tax
Returns that Seller is or may be subject to taxation by that jurisdiction. Schedule 3.16(b) contains a complete list of all audits, examinations and investigations with respect to Taxes or Tax Returns of Seller or related to the Business or
Assets that have been audited or currently are under audit and a complete description of any and all deficiencies or other amounts that were paid or are currently being contested. All such deficiencies or other amounts proposed as a result of such
audits have been paid, reserved against, or settled without further liability (or are being contested in good faith by appropriate proceedings as described in Schedule 3.16(b)). Except as provided in Schedule 3.16(b), there is no dispute
or claim concerning any Taxes related to the Business or Assets either (i) claimed or raised by any Governmental Authority in writing or (ii) as to which Seller has Knowledge. Except as described in Schedule 3.16(b), Seller has not
given or been requested to give waivers or extensions (or is or would be subject to a waiver or extension given by any other Person) of any statute of limitations relating to the assessment or payment of Taxes with respect to the Business or
Acquired Assets. 

  
 -22-

 (c) Seller (i) has not been a member of an Affiliated Group filing a consolidated
federal income Tax Return and (ii) does not have any Liability for the Taxes of any Person under Treasury Regulation § 1.1502-6 or similar Law, as a transferee or successor, by Contract, or otherwise. 

(d) No power of attorney with respect to Taxes has been executed by Seller or filed with any Governmental Authority with respect to
Seller. 
 (e) Seller has complied in all material respects with all provisions of Tax law relating to withholding, payment and
remittance of Taxes and information reporting with respect thereto, and Seller has, within the time and in the manner prescribed by Tax law, paid over to the proper Governmental Authorities all amounts required. 

(f) There is no Tax ruling, request for ruling or settlement, compromise, closing or Tax collection agreement in effect or pending, which
does or could affect the liability of Seller or Buyer for Taxes with respect to the Acquired Assets or Business for any period after the Closing Date. 
 (g) Seller has never claimed a credit for research and experimentation expenditures under Section 41 of the Code, any predecessor provision, or any corresponding or similar provision of state, local
or foreign law. 
 (h) No provisions of any Assigned Contracts are properly treated for United States federal income tax
purposes as an entity (including without limitation a partnership) or as indebtedness. 
 (i) No Asset is (i) “tax
exempt use property” within the meaning of Section 168(h)(1) of the Code or Section 470(c)(2) of the Code, (ii) tax-exempt bond financed property within the meaning of Section 168(g) of the Code, or (iii) subject to a
lease under IRC Section 7701(h) or any predecessor provision. 
 3.17 Contracts. 

(a) Section 3.17(a)(i) of the Written Schedule of Exceptions sets forth a complete and accurate list of all of the following
Contracts to which the Seller is a party or is otherwise bound or by which any of the Acquired Assets are subject (and with respect to any oral Contract provides a complete description of the terms of such Contract) (the “Scheduled
Contracts”): 
 (i) all notes, loans, credit agreements, mortgages, indentures, security agreements, operating leases,
capital leases and other Contracts relating to Indebtedness and any Contract of suretyship or guaranty; 
 (ii) all employment,
consulting and independent contractor Contracts, and all bonus, commission, compensation, pension, insurance, retirement, deferred compensation and other plans, Contracts and other arrangements for the benefit of any Business Employee; 

  
 -23-

 (iii) all Contracts involving an annual payment to or by the Seller from or to any Person
in excess of $25,000 individually or $50,000 in the aggregate with respect to all Contracts with such Person; 
 (iv) all
Contracts for capital expenditures or the purchase or sale of any asset or property of the Seller in excess of $25,000 individually for any Person or $50,000 in the aggregate for all Contracts with such Person; 

(v) all customer Contracts for the purchase of products or services from the Seller other than purchase orders received in the ordinary
course of business in an amount not greater than $50,000; 
 (vi) all joint venture, partnership or other Contracts involving a
share of profits or losses with another Person; 
 (vii) all Contracts with any Affiliate of the Seller; 

(viii) all Contracts restricting competition, solicitation or the business activities of the Seller; 

(ix) all Contracts pursuant to which the Seller has granted or received manufacturing rights, most favored nation pricing provisions or
exclusive marketing, sales or other similar rights relating to any product, service, technology, asset or territory; 
 (x) all
Government Contracts and Government Bids outstanding; 
 (xi) all sales, agency, representative, distributor, franchise or
similar Contracts in excess of $25,000 individually or $50,000 in the aggregate with respect to all Contracts with such Person ; 
 (xii) all Contracts under which the Seller subcontracts services to a third party in excess of $25,000 individually or $50,000 in the aggregate with respect to all Contracts with such Person; 

(xiii) any material Contract which is terminable upon or prohibits a sale of substantially all of the assets of Seller; 

(xiv) all Contracts granting or permitting any Lien on any of the Acquired Assets; 

(xv) all Contracts with any vendors, suppliers or contractors in excess of $25,000 individually or $50,000 in the aggregate with respect
to all Contracts with such Person; and 
 (xvi) any other Contracts that are material to the Seller or the Business and have
not been previously disclosed pursuant to this Section 3.17. 

  
 -24-

 (b) The Seller has delivered to the Buyer complete and accurate copies of all Assigned
Contracts and Scheduled Contracts, including all amendments thereto. The Seller is not in breach or default in any material respects under the terms of any Assigned Contract and, there exists no event, condition or occurrence which (with or without
due notice or lapse of time, or both) would constitute such a breach or default by the Seller nor has the Seller received any notice of any breach or default or alleged breach or default under any Assigned Contract. To the Knowledge of the Seller,
no other party to any Assigned Contract is in default under the terms thereof, and, to the Knowledge of the Seller, there exists no event, condition or occurrence which (with or without due notice or lapse of time, or both) would constitute such a
breach or default by any such party, nor has the Seller received any notice of any breach or default by any such party. 
 (c)
The Assigned Contracts are in full force and effect and are valid and binding obligations of the Seller and, to the Knowledge of the Seller, the other parties thereto. The Seller has not received any notice from any other party to an Assigned
Contract of the termination or threatened termination thereof, nor of any claim, dispute or controversy with respect thereto, nor, to the Knowledge of the Seller, is there any basis therefor. 

(d) No consent of, or notice to, any third party is required under any Assigned Contract as a result of or in connection with, and
neither the enforceability nor any of the terms or provisions of any Assigned Contract will be affected in any manner by, the execution, delivery and performance of this Agreement or any Related Agreement, or the transactions contemplated hereby or
thereby, other than as disclosed in Section 3.17(a)(i) of the Written Schedule of Exceptions. 
 (e) Except as set forth in
Section 3.17(e) of the Written Schedule of Exceptions, (i) there are no non-United States citizens employed by the Seller or any of its Affiliates actively working on any Government Contract nor are there any employees or contractors
working on Government Contracts outside of the United States, (ii) the final indirect rate submissions, including all support schedules, submitted to any Governmental Authority with respect to Government Contracts have been approved and
(iii) to the extent required by Law, all Government Contracts have been awarded, and all Government Bids have been submitted, under a full and open procurement process without preferential treatment of any kind. To the Knowledge of the Seller,
there exists no basis for a claim of any liability by any Governmental Authority as a result of defective cost and pricing data submitted to such Governmental Authority, including any such data relating to liabilities accrued on the Seller’s
books or in its financial accounts for deferred compensation to any Business Employee. To the Knowledge of the Seller, no audit or review of any Government Contract will likely result in the disallowance of, or claim for, any amount paid or payable
to the Seller under such Government Contract, whether as a result of excess payments, excess profit recapture or otherwise. 

3.18 Transactions With Affiliates. Section 3.18 of the Written Schedule of Exceptions lists all Contracts or transactions to
or by which the Seller, on the one hand, and any of its Affiliates, officers, directors or employees or, to the Knowledge of the Seller, any family member, relative or Affiliate of any such officer, director or employee, on the other hand, are or
have been a party or otherwise bound or affected and that (i) were entered into since January 1, 2008, (ii) are currently pending or in effect or (iii)

  
 -25-

 
involve continuing Liabilities that, individually or in the aggregate, have been or will be material to the Seller (each an “Affiliate Transaction”). Each Affiliate Transaction
was on terms and conditions as favorable to the Seller as would have been obtainable by it at the time in a comparable arm’s-length transaction with a Person other than such Person. No officer, director or employee of the Seller, or, to the
Knowledge of the Seller, any family member, relative or Affiliate of any such officer, director or employee, (i) owns, directly or indirectly, any interest in (x) any asset or other property used in or held for use by the Seller in
connection with the operation of the Business or (y) any Person that is a supplier, customer, vendor or competitor of the Seller, (ii) serves as an officer, director or employee of any Person that is a supplier, customer, vendor or
competitor of the Seller or (iii) is a debtor or creditor of the Seller. 
 3.19 Insurance. The Seller, the Business
and the Acquired Assets are, and will through the Closing Date be, insured with reputable insurers against risks normally insured against by similar businesses under similar circumstances. Section 3.19 of the Written Schedule of Exceptions
lists, by type, carrier, policy number, limits, premium and expiration date, all insurance coverage carried by the Seller (with respect to the Business or the Acquired Assets), together with a history of all claims made by the Seller thereunder
since October 28, 2004, which insurance will remain in full force and effect in accordance with policy terms, with respect to all events occurring prior to the Closing Date. Section 3.19 of the Written Schedule of Exceptions also states
whether each such policy is carried on a “claims made” or “occurrence” basis. All such insurance policies are owned by and payable solely to the Seller and all premiums with respect thereto are currently paid and will be paid
through the Closing Date. The Seller has not failed to give any notice of any claim under any such policy in due and timely fashion, has not received notice of cancellation or non-renewal of any such policy and has no Knowledge of any threatened or
proposed cancellation or non-renewal of any such policy, and the Seller is otherwise in compliance with the terms of such policies. The Seller has never maintained, established, sponsored, participated in or contributed to any self-insurance plan.
There are no outstanding claims under any such policy which have gone unpaid for more than thirty (30) days, or as to which the insurer has disclaimed liability. Since October 28, 2004, the Seller has not been denied or had revoked,
cancelled, non-renewed or rescinded any policy of insurance. 
 3.20 Intellectual Property. 

(a) Section 3.20(a) of the Written Schedule of Exceptions sets forth a complete and accurate list of all United States and foreign
Patents, Trademarks (including unregistered Trademarks), Internet domain names and registered Copyrights comprising Seller Intellectual Property, indicating for each, the applicable jurisdiction, registration number (or application number), date
issued (or date filed), and status (including the next action or payment and date due). All registered and applied for Trademarks, Patents and Copyrights included in the Seller Intellectual Property are currently pending, in compliance in all
material respects with all legal requirements (including the timely filing of responses, statements or affidavits of use and incontestability and renewal applications and required fees with respect to Trademarks, and the payment of filing,
examination, maintenance and other fees and the filing of responses, declarations and affidavits with respect to Patents), to the Seller’s Knowledge are valid and enforceable, and are subject to those fees, responses or actions falling due
within sixty (60) days 

  
 -26-

 
after the Closing Date as shown in Section 3.20 of the Written Schedule of Exceptions. No such Trademark has been or is now involved in any cancellation proceeding and, to the Knowledge of
the Seller, no such Action is threatened with respect to any of such Trademarks. All Trademarks included in the Seller Intellectual Property have been in continuous use by the Seller since they were first used by the Seller. To the Knowledge of the
Seller, there has been no prior use of such Trademarks by any Person which would confer upon such Person superior rights in such Trademarks; and the registered Trademarks have been continuously used in the form appearing in, and in connection with
the goods and services listed in their respective registration certificates or identified in their respective pending applications. No Patent included in the Seller Intellectual Property has been or is now involved in any litigation, infringement,
interference, reissue, re-examination, opposition, invalidity or nullity proceeding. No Copyright registration or copyrightable work included in the Seller Intellectual Property has been or is now involved in any litigation. To the Knowledge of the
Seller, there are no Trademarks of any third party potentially conflicting with the Trademarks included in the Seller Intellectual Property or Patents of any third parties potentially interfering with the Patents included in the Seller Intellectual
Property. 
 (b) Section 3.20(b) of the Written Schedule of Exceptions sets forth a complete and accurate list of all
license agreements granting any right to use or practice any rights under any Seller Intellectual Property (“Licensed Intellectual Property”), whether the Seller is the licensee or licensor thereunder, and any assignments, consents,
forbearances to sue, judgments, orders, settlements, indemnification or similar obligations relating to any Licensed Intellectual Property to which the Seller is a party or otherwise bound (excluding employee and consulting agreements and
assignments filed with the United States Patent and Trademark Office) (collectively, the “License Agreements”), indicating for each the title, the parties, date executed, whether or not it is exclusive and the Licensed Intellectual
Property covered thereby. The License Agreements are valid and binding obligations of the Seller, and to the Seller’s Knowledge, of each other party thereto enforceable in accordance with their respective terms, and neither the Seller nor, to
the Knowledge of the Seller, the other party or parties thereto is or are in breach or default thereunder in any material respect, and there exists no event, condition or occurrence which (with or without due notice or lapse of time, or both) would
constitute such a breach or default or alleged breach or default by the Seller or, to the Knowledge of the Seller, the other party or parties thereto of any of the foregoing. No consent of, or notice to, any Person is required under any License
Agreement as a result of or in connection with, and the terms or enforceability of any License Agreement will not be affected in any manner by, the execution, delivery and performance of this Agreement or any Related Agreement, or the transactions
contemplated hereby or thereby. The Seller has not received any notice of termination or cancellation under any material License Agreements. 
 (c) The Seller Intellectual Property constitutes all of the Intellectual Property used in or necessary for the conduct of the Business as currently conducted, including all Intellectual Property necessary
to use, manufacture, market and distribute the Seller Products, in each case to the extent the Seller uses, manufactures, markets or distributes the Seller Products. 
 (d) No royalties, honoraria or other fees are payable to any third parties for the use of or right to use any Seller Intellectual Property other than as set forth in the License Agreements. All
inventions, discoveries, Trade Secrets and works, whether or not patented or 

  
 -27-

 
patentable or otherwise protectable under Law, created, prepared, developed or conceived by Business Employees are the exclusive property of the Seller and were either created, prepared,
developed or conceived by (i) Business Employees within the scope of their employment or (ii) by independent contractors who have duly assigned their rights to the Seller pursuant to enforceable written agreements. 

(e) The Seller owns exclusively all Seller Intellectual Property purported to be owned by the Seller, and has a valid, enforceable,
freely transferable and sufficient right to use for the purposes the Seller has previously used, all Seller Intellectual Property licensed by the Seller, free and clear of all Liens, other than Permitted Liens. 

(f) The operation of the Business as currently conducted, the sale or use of the Seller Products or services of the Seller, and the use
of the Seller Intellectual Property in connection therewith has not and does not or will not, when conducted in substantially the same manner following the Closing, infringe upon, violate, misappropriate or make unlawful use of any Intellectual
Property or other rights of any other Person or constitute unfair trade practices. The Seller has not received notice of any allegation that the use of any Seller Intellectual Property or the conduct of the Business as currently conducted or
proposed to be conducted would infringe upon, violate, misappropriate or make unlawful use of any Intellectual Property or other rights of any other Person, nor is the Seller aware of any basis for such a claim. To the Knowledge of the Seller, no
Person is misappropriating, infringing, violating or making unlawful use of any Seller Intellectual Property. There is no Action pending or, to the Knowledge of the Seller, threatened alleging that the conduct of the Business infringes upon,
violates or constitutes the unauthorized use of the Intellectual Property or other rights of any other Person, nor is the Seller aware of any basis for such a claim. The Seller has not threatened to bring and the Seller has not brought any Action
regarding the ownership, use, validity or enforceability of any Seller Intellectual Property. 
 (g) The consummation of the
transactions contemplated hereby will not result in the loss or impairment of the Seller’s ownership or other rights in and to any of the Seller Intellectual Property or under any of the License Agreements, require the Seller to grant to any
third party any right to any Seller Intellectual Property or obligate the Seller to pay any royalties or other amounts to any third party in excess of any obligations to pay amounts to such third parties pursuant to Contracts existing prior to the
Closing, nor will the consummation of the transactions contemplated hereby require the approval or consent of any Governmental Authority or other Person in respect of any Seller Intellectual Property. 

(h) Section 3.20(h) of the Written Schedule of Exceptions lists all Software (including Software being developed) which is owned,
licensed or otherwise used (or intended to be used) by the Seller or provided (or intended to be provided) by the Seller to the Seller’s customers and indicates whether the Software is subject to an escrow agreement or a license agreement (and,
if so, indicates where the Software is held in escrow and identifies such license agreement), any software programs or platforms that the Software is based upon, built upon or otherwise needed to use the Software, the developer of the Software, any
developers that modified the Software and how the Software is used (i.e., whether it is used only by the Seller, only by the Seller’s customers or both). The Seller has not sold or licensed any such Software to a third party. All Software owned
by the Seller, and to the Knowledge of the Seller, all Software 

  
 -28-

 
licensed from third parties by the Seller, is free from any significant software defect or programming or documentation error, operates and runs in a reasonable and efficient business manner,
conforms to the specifications thereof, if applicable, and, with respect to the Software owned by the Seller, the applications can be compiled from their associated source code without undue burden. The Seller has delivered to the Buyer all required
documentation relating to the compilation and linking, use, maintenance and operation of the Software described herein. 
 (i)
All of the copyrightable materials incorporated in, underlying or used with the Seller Products have been created by employees of the Seller within the scope of their employment by the Seller or by independent contractors of the Seller who have
executed agreements expressly assigning all right, title and interest in such copyrightable materials to the Seller. No portion of such copyrightable material was jointly developed with any third party. 

(j) The Seller has taken all reasonable steps in accordance with normal industry practice to protect the Seller Intellectual Property,
including all rights in confidential information and Trade Secrets included in the Seller Intellectual Property. Except pursuant to enforceable confidentiality obligations in favor of the Seller, there has been no disclosure of any the confidential
information or Trade Secrets included in the Seller Intellectual Property. To the Knowledge of the Seller, no current or former employee, consultant, contractor or potential partner or investor of the Seller is in unauthorized possession of any of
the confidential information, Trade Secrets or Software included in the Seller Intellectual Property. 
 (k)
Section 3.20(k) of the Written Schedule of Exceptions describes all databases and organized or structured collections of data used by the Seller (the “Databases”). Following the Closing, the Databases will have at least the
same information and functionality as exists prior to the Closing. No Person (other than the Seller) has any right, title or interest in or to any of the information contained in any of the Databases and the Seller has not sold, assigned, leased,
transferred, permitted the use of or otherwise disclosed to any Person any information contained in any of the Databases, including any Personally Identifiable Information. The Seller has complied and is in compliance with all applicable privacy
Laws, and all information contained in the Databases has been collected, used and maintained in accordance with all applicable privacy Laws. The Seller has the right to sell and assign all of its rights in and to the Databases and all information
contained therein, and any such sale and assignment will not violate any privacy policy applicable to any Personally Identifiable Information contained therein at the time it was collected. 

3.21 Accounts Receivable; Accounts Payable 
 (a) All accounts receivable included in the Acquired Assets (i) have arisen from bona fide transactions in the ordinary course of business consistent with past practice, (ii) represent valid and
enforceable obligations, and (iii) are owned exclusively by the Seller free and clear of all Liens. No discount or allowance from any such receivable has been made or agreed to and none represents billings prior to actual sale of goods or
provision of services, other than those discounts and allowances provided in the ordinary course of business. There is no obligor of any such account receivable that has refused or threatened to refuse to pay its obligations for any reason and, to
the Knowledge of the Seller, no such obligor has been declared bankrupt by a 

  
 -29-

 
court of competent jurisdiction or that is subject to any bankruptcy proceeding. Attached hereto as Section 3.21(a) of the Written Schedule of Exceptions is a complete and accurate accounts
receivable aging report as of the date hereof. 
 (b) All accounts payable and accrued expenses of the Seller have arisen only
from bona fide transaction in the ordinary course of business consistent with past practice. Section 3.21(b) of the Written Schedule of Exceptions is a complete and accurate accounts payable aging report as of the date hereof, which report
include the name, address, account number and other information and contact information for each creditor listed therein. 

3.22 Absence of Restrictions on Business Activities Except as described in Section 3.22 of the Written Schedule of
Exceptions, there is no Contract or Order binding upon the Seller, or any of the Acquired Assets which has had or could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Seller, any
acquisition of property (tangible or intangible) by the Seller, the conduct of the Business or otherwise limiting the freedom of the Seller to engage in any line of business or to compete with any Person. Without limiting the generality of the
foregoing, the Seller has not entered into any agreement under which it is restricted from selling, licensing, manufacturing or otherwise distributing any of its technology or from providing services to customers or potential customers or any class
of customers, in any geographic area, during any period of time, or in any segment of the market in connection with the Business. 
 3.23 Payments: Foreign Corrupt Practices Act: U.S. Export and Sanctions Laws. 
 (a) Neither the Seller, nor any director, officer, agent, employee or other Person associated with or acting on behalf of the Seller has, directly or indirectly (i) paid or delivered or agreed to pay
or deliver any fee, commission or other sum of money or item of property, however characterized, to any Person, government official or other party that is illegal or improper under any applicable Law, (ii) used any funds for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity, (iii) made any unlawful payment or offered anything of value to any foreign or domestic government official or employee or to any foreign or domestic
political parties or campaigns, (iv) violated or is in violation of any provision of the United States Foreign Corrupt Practices Act of 1977 (15 United States Code Section 78dd-1, et seq.), as amended, or any applicable Law of similar
effect, (v) made any unlawful bribe, rebate, payoff, influence payment, kickback or transfer of value to any other Person or (vi) established or maintained any fund that has not been recorded in the books and records of the Seller.

 (b) The Seller has complied and is in compliance with applicable provisions of the United States export and sanctions laws,
and regulations implemented thereunder, including the Arms Export Control Act (22 United States Code Section 2751 et seq.), as amended, the Export Administration Act (50 United States Code Section 2401 et seq.), as amended, the
International Emergency Economic Powers Act (50 United States Code Section 17091 et seq.), as amended, and the various sanctions regulations administered by the Office of Foreign Assets Control of the Department of the Treasury of the United
States, as amended. 

  
 -30-

 3.24 Books and Records The books and records of the Seller delivered or made
available to the Buyer are complete and accurate in all material respects and reflect the assets, liabilities, prospects, business, financial condition and results of operations of the Business in all material respects and have been maintained in
accordance with prudent business practices. The minute books of the Seller contain materially accurate and complete records of all meetings held by, and corporate action taken by, the stockholders, the board of directors and committees of the board
of directors of the Seller, and no meeting of any stockholders, board of directors or committee has been held where material matters were approved, voted upon or acted upon for which minutes have not been prepared and are not contained in such
minute books. 
 3.25 Inventory All raw materials, supplies, manufactured and processed parts, work-in-progress,
packaging and finished goods and other items of the Business (“Inventory”) are and as of the Closing will be of a quality that is suitable, usable or (in the case of finished goods and products) saleable in the ordinary course of
its business. The Seller is not presently, and at the time of the Closing will not be, in possession of any Inventory that is not owned by the Seller. The quantity of the Inventory on hand or in transit is, and at the Closing will be, at levels
substantially customary for the Business. 
 3.26 Internal Controls The Seller maintains a system of internal control
over financial reporting, its system of internal control being designed to be essentially equivalent to the system it maintained during its most recent two annual periods as an audited corporation, and sufficient to provide reasonable assurance
(a) that the Seller maintains records that in reasonable detail accurately and fairly reflect their respective transactions and dispositions of assets, (b) that transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (c) that transactions, receipts and expenditures are executed only in accordance with authorizations of management and the Seller’s Board of Directors and
(d) regarding prevention or timely detection of the unauthorized access, acquisition, use or disposition of the Seller’s assets. The Seller has disclosed to the Buyer any and all material fraud committed by management or other Business
Employees who have a significant role in the Seller’s internal control over financial reporting. 
 3.27 Solvency.

 (a) The Seller has not (i) made a general assignment for the benefit of creditors, (ii) filed any voluntary petition
in bankruptcy or suffered the filing of an involuntary petition by any creditor, (iii) suffered the appointment of a receiver to take possession of all or any portion of its assets, (iv) suffered the attachment or judicial seizure of all
or any portion of its assets, (v) admitted in writing its inability to pay its debts as they come due or (vi) made an offer of settlement, extension or composition to its creditors generally. 

(b) The Purchase Price and other terms and provisions of this Agreement and of the Related Agreements were negotiated at arm’s
length and are fair, reasonable and consistent with existing market conditions. The Seller has undertaken discussions with other 

  
 -31-

 
potential purchasers of the Acquired Assets and, based on those discussions and the Seller’s own Knowledge of market conditions, believes that the terms provided for in this Agreement and
the Related Agreements, including price, represent in their totality the most favorable terms available to the Seller. The transactions contemplated by this Agreement and the Related Agreements are not being entered into by the Seller with the
intention of hindering, delaying or defrauding any of the Seller’s current or future creditors. 
 3.28 Relationships
with Customers and Suppliers Section 3.28 of the Written Schedule of Exceptions includes a list of the Seller’s top ten (10) customers (collectively, the “Customers”) by net revenue for the each of the years ended
December 31, 2010 and December 31, 2011 and for the eight-month period ended August 30, 2012. There are not, and have not been during the two (2) year period preceding the date hereof, any material disputes with any Customer.
During the past two (2) years, no Customer has cancelled or otherwise terminated any Contract with the Seller prior to the expiration of such Contract’s term, or has threatened to cancel or otherwise terminate its relationship with the
Seller or to substantially reduce its sales to or purchases from the Seller of any products, equipment, goods or services. The Seller has not (i) breached in any material respect any agreement with or (ii) engaged in any fraudulent conduct
with respect to any customer of the Seller. The Seller does not have any single source suppliers. There are not, and have not been during the two (2) year period preceding the date hereof, any material disputes with any material supplier of the
Seller. During the past two (2) years, no material supplier has cancelled, terminated, or otherwise altered its relationship with the Seller nor has any current material supplier of the Seller notified the Seller of any intention to do so or
otherwise threatened to cancel, terminate or materially alter its relationship with the Seller. 
 3.29 Seller Products.
Section 3.29 of the Written Schedule of Exceptions sets forth all warranties, express or implied, written or oral, with respect to the Seller Products. As of the date hereof there are no pending, or to the Knowledge of the Seller, threatened
Actions with respect to any such warranties, nor, to the Knowledge of the Seller, is there any fact or circumstance which could be a basis for such an Action; there are no statements, citations or decisions by any Governmental Authority declaring
any Seller Product defective or unsafe, nor, to the Knowledge of the Seller, is there any fact or circumstance which could be a basis for such a statement, citation or decision; no Seller Product fails to meet any standards in any material respect
promulgated by any applicable Governmental Authority; there have been no recalls ordered by any Governmental Authority with respect to any Seller Product, nor, to the Knowledge of the Seller, is there any fact or circumstance which could be a basis
for such a recall; and there are no pending or, to the Seller’s Knowledge, threatened product liability Actions against or involving the Seller or any Seller Product, nor, to the Seller’s Knowledge, is there any fact or circumstance which
could be a basis for such Action, nor have any such Actions been settled or adjudicated by Seller. To the Knowledge of the Seller, there is no design defect with respect to any Seller Product. The Seller is not aware of any allegation that a defect
in any Seller Product has been the cause of an injury to a consumer. The Seller Products contain adequate warnings, presented in a reasonably prominent manner, in accordance with applicable Laws, Orders or requirements of any Governmental Authority
and current industry practice with respect to their contents and use. Section 3.29 of the Written Schedule of Exceptions sets forth a list of all guaranty, warranty, right of return or indemnity claims made with respect to any of the Seller
Products during the last three (3) years together with the costs or expenses incurred by the Seller in satisfying any such claims. 

  
 -32-

 3.30 No Brokers Except as set forth in Section 3.30 of the Written Schedule of
Exceptions, neither the Seller, nor any of its Representatives, has employed or engaged, either directly or indirectly, or incurred or will incur any Liability to, any broker, finder, investment banker or other agent in connection with the
transactions contemplated by this Agreement. 
 3.31 FDA Compliance; Compliance with Healthcare Laws. 

(a) The operations of the Business and, to the Knowledge of the Seller, any third party acting on the Business’ behalf, including the
manufacture, import, export, testing, development, processing, packaging, labeling, storage, marketing, and distribution of all products, are in compliance in all material respects with all applicable laws and regulations of the United States and
any state, local, or foreign government or agency with regulatory jurisdiction over the Business. There are no pending or, to the Knowledge of the Seller, threatened Actions by the FDA or any other similar foreign or domestic regulatory agency
against the Seller. The Seller has not received notice of any pending or threatened claim related to a violation of any Law within the FDA’s regulatory jurisdiction (or any similar foreign or state law, rule regulation or policy) or has any
Knowledge or reason to believe that any foreign or state regulatory agency is considering such action. 
 (b) Except as set
forth on Section 3.31(b) of the Written Schedule of Exceptions, since October 28, 2004, the Seller has not received any FDA Form 483 notice of adverse findings, warning letters, or other correspondence or notice from the FDA, or other
similar regulatory agency alleging or asserting the Seller’s noncompliance with any applicable Laws enforced by the FDA or such similar foreign regulatory agency, and the Seller does not have any Knowledge or reason to believe that the FDA or
any similar regulatory agency is considering such action. 
 (c) The manufacture of Seller Products by or on behalf of, the
Seller is being conducted in compliance in all material respects with all Laws including FDA’s Quality Systems Regulation. In addition, the Seller, and to the Knowledge of the Seller, any third-party manufacturer of products on the
Seller’s behalf, are in compliance in all material respects with all applicable FDA requirements, including registration, listing and premarket notification requirements set forth in 21 U.S.C. § 360, the investigational device
exemption set forth in 21 U.S.C. § 360j(g) and all other similar laws applicable in any foreign jurisdiction. 
 (d)
The Seller is not subject to any determination by a Governmental Authority excluding, suspending, debarring or otherwise restricting, or proposing to so restrict the Seller, or any director, officer, employee, contractor, or agent of the Seller from
participation in any government health care program, whether pursuant to 42 U.S.C. § 1320a-7(a) or other applicable law. 

  
 -33-

 (e) The Seller is not the subject of any pending or, to the Knowledge of the Seller ,
threatened investigation by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991), or any similar investigation by a foreign
regulatory agency. The Seller has not committed any act, made any statement, or failed to make any statement that would provide a basis for the FDA to act adversely against the Seller under the foregoing Final Policy, and has not committed any act,
made any statement or failed to make any statement that would provide a basis for a foreign regulatory agency to act adversely against the Seller under a similar policy. The Seller has not employed in any capacity any individual who has been
debarred or excluded pursuant to the FD&C Act or 42 U.S.C. § 1320a-7(a), nor has the Seller used, employed, hired or contracted with any clinical investigator who has been disqualified under 21 C.F.R. § 812.119 or who has
engaged in any conduct that would reasonably be expected to result in disqualification as a clinical investigator under 21 C.F.R. § 812.119. The Seller has not used in connection with clinical investigation conducted by or on behalf of the
Seller an institutional review board or institution that has been disqualified under 21 C.F.R. § 56.121 or that has engaged in conduct that would reasonably be expected to result in disqualification under 21 C.F.R. § 56.121.

 (f) Any clinical trials or human and animal studies described in Section 3.31(e) of the Written Schedule of Exceptions
were and, if still pending, are being conducted (to the Seller’s Knowledge with respect to such studies conducted by third parties) in all material respects in accordance with standard medical and scientific research procedures and all
applicable rules, regulations and policies of the FDA, including current Good Clinical Practices and Good Laboratory Practices, and all applicable state and foreign regulatory requirements and standards. 

(g) Section 3.31(g) of the Written Schedule of Exceptions lists all claims, statements, and other matters (including all
correspondence or communications with Governmental Authorities, intermediaries or carriers) concerning or relating to any federal or state government funded health care program that involves, relates to or alleges: (i) any violation of any
applicable rule, regulation, policy or requirement of any such program or any irregularity with respect to any activity, practice or policy of the Seller; or (ii) any violation of any applicable rule, regulation, policy or requirement of any
such program or any irregularity with respect to any claim for payment or reimbursement made by the Seller or any payment or reimbursement paid to the Seller. Except as set forth in Section 3.31(f) of the Written Schedule of Exceptions, there
are no such violations or irregularities nor are there any grounds to anticipate the commencement of any investigation or inquiry, or the assertion of any claim or demand by any Government Authority, intermediary or carrier with respect to any of
the activities, practices, policies or claims of the Seller, or any payments or reimbursements claimed by the Seller. The Seller is not currently subject to any outstanding audit by any such Government Authority, intermediary or carrier, and there
are no grounds to anticipate any such audit in the foreseeable future. 
 (h) The Seller has not submitted any claim to any
Payment Program in connection with any referrals that violated any applicable self-referral Law, including the Federal Ethics in Patient Referrals Act, 42 U.S.C. § 1395nn (known as the “Stark Law”), or any applicable state
self-referral Law. 

  
 -34-

 (i) The Seller has complied in all material respects with all disclosure requirements of all
applicable self-referral Laws, including the Stark Law and any applicable state self-referral Law. 
 (j) The Seller has not
knowingly or willfully solicited, received, paid or offered to pay any remuneration, directly or indirectly, overtly or covertly, in cash or kind for the purpose of making or receiving any referral which violated any applicable anti-kickback Law,
including the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b) (known as the “Anti-Kickback Statute”), or any applicable state anti-kickback Law. 

(k) The Seller has not submitted any claim for payment to any Payment Program in violation of any Laws relating to false claim or fraud,
including the Federal False Claim Act, 31 U.S.C. § 3729, or any applicable state false claim or fraud Law. 
 (l) Neither
the Seller nor any of its officers, directors or employees, acting in their capacities as such, is or has been involved in any activities which are, or are alleged in writing by an qui tam relator or regulatory agency to be, prohibited under the
federal Medicare and Medicaid statutes, which are specifically defined as 42 U.S.C. §§ 1320a-7, 1320(a)-7a, 1320a-7b. 1395nn, 18 U.S.C. § 1347, § 287, § 1001 and § 1035, or the federal CHAMPUS/TRICARE statute, or the
regulations promulgated pursuant to such federal statutes. 
 (m) The Seller has not received any claims or notification of any
violation or non-compliance under any laws or regulations implementing California’s Proposition 65 or any other federal, state or local laws or regulations applicable to the Seller’s Business or its Products. 

(n) The Seller has not received any claims or notification of any violation or non-compliance under any laws or regulations enforced by
the Federal Trade Commission (“FTC”) or other federal, state, local or foreign governmental agency; or of any rule, guideline, or standard monitored or enforced by the National Advertising Division of the Better Business Bureau or the
National Advertising Review Council. 
 (o) Neither this Agreement (including exhibits and schedules hereto) nor any certificate
delivered or to be delivered to Buyer by or on behalf of the Seller pursuant to the terms of this Agreement, contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary in order to make
the statements contained herein or therein not misleading in light of the circumstances under which they were made. 
 3.32
Investment Representations. 
 (a) Seller represents, warrants and covenants to Buyer and Parent that Seller is acquiring
the Shares for its own account and not with a view to their distribution within the meaning of Section 2(11) of the Securities Act. Seller is (i) an “accredited investor(s)” as such term is defined in Rule 501(a) under the
Securities Act, and (ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of acquiring the Shares. 

  
 -35-

 (b) Seller acknowledges and is aware that: (i) there are substantial restrictions on
the transferability of the Shares, (ii) the Shares will not be, and Seller does not have the right to require that the Shares be, registered under the Securities Act; (iii) the certificates representing the Shares shall bear a legend
similar to the legend set out below and (iv) such legend shall not be removed from any such certificates unless either (A) such Shares are sold under an effective registration statement under the Securities Act, or (B) Seller delivers
to Buyer a written opinion of counsel, in form and substance satisfactory to Buyer, that no such registration is required and that the transfer will not otherwise violate the Securities Act, the Exchange Act or applicable state securities laws.

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), IN RELIANCE UPON ONE OR MORE EXEMPTIONS FROM REGISTRATION OR QUALIFICATION AFFORDED BY THE SECURITIES
ACT AND/OR RULES PROMULGATED BY THE COMMISSION PURSUANT THERETO. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE ALSO NOT BEEN REGISTERED OR QUALIFIED (AS THE CASE MAY BE) UNDER THE SECURITIES LAWS OF ANY STATE OR TERRITORY OF THE UNITED STATES
(THE “BLUE SKY LAWS”), IN RELIANCE UPON ONE OR MORE EXEMPTIONS FROM REGISTRATION OR QUALIFICATION (AS THE CASE MAY BE) AFFORDED UNDER SUCH SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR THE HOLDER’S OWN ACCOUNT FOR
INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW FOR RESALE OR DISTRIBUTION. 
 (c) During the course of the transaction
contemplated by this Agreement, and before acquiring the Shares, Seller has had the opportunity (i) to be provided with financial and other written information about Parent included in all documents Parent has publicly filed with the U.S.
Securities and Exchange Commission, and (ii) to ask questions and receive answers concerning the business of Parent and its finances. Seller has received satisfactory information and answers. 

(d) Seller represents that by reason of its business or financial experience or the business or financial experience of Seller’s
professional advisors who are unaffiliated with and who are not compensated by Parent, Buyer or any Affiliate or selling agent of Parent or Buyer, directly or indirectly, Seller has the capacity to protect its own interests in connection with the
transactions contemplated by this Agreement. 
 (e) Seller understands that the foregoing representations and warranties are to
be relied upon by Parent as a basis for exemption of the sale of the Shares under the Securities Act and under the securities laws of all applicable states and for other purposes. 

  
 -36-

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF THE BUYER AND THE PARENT 
 The Buyer and
the Parent hereby represent and warrant to the Seller as follows. 
 4.1 Organization and Good Standing Each of the Buyer
and the Parent is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware. 

4.2 Authorization; Binding Obligation The Buyer and the Parent each has all necessary corporate power and authority to execute and
deliver this Agreement and each Related Agreement to which it is a party and to perform all of its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by the Buyer and
the Parent of this Agreement and each Related Agreement to which it is a party, the performance of its obligations hereunder and thereunder, and the consummation by the Buyer and the Parent of the transactions contemplated hereby and thereby have
been duly and validly authorized by all action on the part of the Buyer and the Parent, as applicable, and no other corporate proceedings on the part of the Buyer or the Parent are necessary to authorize this Agreement or any Related Agreement to
which it is, or will become, a party or to consummate the transactions so contemplated herein and therein. This Agreement has been duly and validly executed and delivered by the Buyer and the Parent, and each Related Agreement to which the Buyer or
the Parent is a party, when executed and delivered by the Buyer or the Parent as applicable will be duly and validly executed and delivered by the Buyer or the Parent and this Agreement constitutes, and each Related Agreement to which the Buyer or
the Parent is a party when executed and delivered by the Buyer of the Parent will constitute, a legal, valid, and binding obligation of the Buyer or the Parent enforceable in accordance with their respective terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other Laws of general application affecting enforcement of creditors’ rights generally and, (ii) as limited by Laws relating to the availability of specific performance,
injunctive relief or other equitable remedies. 
 4.3 Consents and Approvals The execution and delivery by the Buyer and
the Parent of this Agreement, the Related Agreements to which the Buyer or the Parent is a party or any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Buyer or the Parent do not,
and the performance of this Agreement, the Related Agreements to which the Buyer or the Parent is a party and any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Buyer or the
Parent shall not, require the Buyer of the Parent to obtain any Approval of any Person or Approval of, observe any waiting period imposed by, or make any filing with or notification to, any Governmental Authority other than (i) such Approvals
required solely as a result of the status (legal, regulatory or otherwise) of the Seller or any Affiliate of the Seller, and in each case, except for such Approvals which, if not obtained, would not reasonably be likely to have a
material adverse effect on the Buyer’s ability to consummate the transactions contemplated hereby, and (ii) filings made with respect to federal and state securities agencies with respect to the offering of securities under this Agreement.

  
 -37-

 4.4 No Violation The execution and delivery by the Buyer and the Parent of this
Agreement, the Related Agreements to which the Buyer or the Parent is a party or any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Buyer or the Parent do not, and the performance
of this Agreement, the Related Agreements to which the Buyer or the Parent is a party or any other instrument or document required by this Agreement or any Related Agreement to be executed and delivered by the Buyer or the Parent, will not,
(a) conflict with or violate the Organizational Documents of the Buyer or the Parent, as applicable, (b) conflict with or violate any Law or Order applicable to the Buyer or the Parent or by which it or any of the Acquired Assets are bound
or affected, or (c) result in any breach or violation of or constitute a default (or an event that with notice or lapse of time or both would become a default) under, any material Contract to which the Buyer or the Parent is a party, in any
case, except where such conflict or breach would not reasonably be likely to have a material adverse effect on the Buyer’s or the Parent’s ability to consummate the transactions contemplated hereby. 

4.5 Legal Proceedings There is no Action pending or, to the Knowledge of the Buyer or the Parent, threatened by or against or
affecting the Buyer or the Parent that would (a) give any Person the right to enjoin or rescind the transactions contemplated by this Agreement, or (b) otherwise prevent the Buyer or the Parent from (i) executing and delivering this
Agreement or the Related Agreements to which it is a party or (ii) performing their respective obligations pursuant to, or observing any of the terms and provisions of, this Agreement or the Related Agreements to which it is a party.

 4.6 Status of Shares. The issuance of the Shares has been duly authorized by all corporate action on the part of the
Parent. The Shares, when issued in accordance with the terms of this Agreement will be validly issued, fully-paid and non-assessable. 
 4.7 Public Company Financial Reporting. As a public company, Parent has filed all financial reports required to be filed by Buyer under the Securities Act and the Exchange Act, including pursuant
to Section 13(a) or 15(d) thereof, since January 1, 2011 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”) on a
timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports (i) were complete and accurate in all material
respects and (ii) complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable. 

  
 -38-

 ARTICLE V 
 COVENANTS 
 5.1 Conduct of Business Pending Closing. 

(a) The Seller covenants and agrees that, between the date hereof and the Closing Date, or the earlier termination of this Agreement,
except as Buyer shall otherwise consent in writing, the Seller shall: 
 (i) conduct the Business only in, and shall not take
any action except in, the ordinary course of business and in a manner consistent with past practice; 
 (ii) preserve intact
the Acquired Assets in the ordinary course of business and in a manner consistent with past practice; 
 (iii) use commercially
reasonable efforts to keep available the services of the current Business Employees; 
 (iv) use commercially reasonable
efforts to maintain in effect the Assigned Contracts; 
 (v) maintain in effect the Business Licenses (if any) in accordance
with the terms thereof and renew any Business License that would otherwise expire pursuant to the terms thereof between the date of this Agreement and the Closing; and 
 (vi) use commercially reasonable efforts to preserve the present relationships of the Seller with suppliers, customers, vendors, licensees and other Persons with which the Seller has business relations in
connection with the Business. 
 (b) The Seller covenants and agrees that, between the date hereof and the Closing Date, or the
earlier termination of this Agreement, except as Buyer shall otherwise consent in writing, the Seller shall not: 
 (i) sell,
transfer, lease, license, sublicense, dispose of, encumber or otherwise dispose of any Acquired Asset, other than the sale of Inventory in the ordinary course of business; 
 (ii) hire any employee, consultant or independent contractor in connection with the Business or terminate any Business Employee; change the compensation (including bonus or commission payments) payable or
to become payable to any Business Employee, or grant any severance or termination pay to, or enter into or amend any Contract with, any Business Employee, or establish, adopt, enter into or amend any collective bargaining, bonus, profit sharing,
thrift, compensation, stock or other equity option, restricted stock or other restricted security, pension, retirement, deferred compensation, employment, termination, severance or other plan, agreement, trust, fund, policy or arrangement for the
benefit of any current or former Business Employee; 
 (iii) change any accounting policies, procedures or practices (including
procedures or practices with respect to reserves, revenue recognition, payments of accounts payable and collection of accounts receivable), or any financial reporting, unless required by GAAP; 

(iv) create, incur or assume any Lien on any of the Acquired Assets; 

  
 -39-

 (v) sell, transfer, lease, license, sublicense, mortgage, pledge, dispose of, encumber,
grant or otherwise dispose of any Seller Intellectual Property, or amend or modify any existing agreements with respect to any Seller Intellectual Property; 
 (vi) incur any Indebtedness or issue any debt securities or assume, guarantee or endorse or otherwise as an accommodation become responsible for, the obligations of any Person, or make any loans, advances
or enter into any financial commitments; make or authorize any capital expenditures which are, in the aggregate, in excess of $10,000; or acquire any asset or property, other than (i) acquisitions of any assets in the ordinary course of
business consistent with past practice that are not, in the aggregate, in excess of $10,000 or (ii) purchases of Inventory for resale (whether for cash or pursuant to an exchange) in the ordinary course of business and consistent with past
practice; 
 (vii) prepay any Indebtedness or otherwise make any payments with respect to any Indebtedness prior to the time
and to the extent such payment is required pursuant to the terms of such Indebtedness as in existence on the Effective Date; 

(viii) enter into any Contract, other than Contracts involving payments of less than $5,000 which are entered into in the ordinary
course of business; modify, amend or transfer or terminate any Assigned Contract or waive, release or assign any material rights or claims thereto or thereunder or enter into or extend any real property lease; 

(ix) make, revoke or change any Tax election, change any method of Tax accounting, settle or compromise any domestic or foreign income
Tax Liability, amend or file any amended Tax Return, agree to an extension of a statute of limitations or enter into any closing or other agreement or ruling relating to any Tax; settle any audit; or take any other action with regard to any dispute
or discussion with a Governmental Authority relating to a material Tax Liability or potential Liability; 
 (x) pay, discharge,
satisfy, settle or commence any Action or waive, assign or release any material rights or claims relating to any of the Acquired Assets or the Business; 
 (xi) fail to maintain in full force and effect all insurance and self-insurance, as the case may be, currently in effect with respect to the Acquired Assets or the Business; 

(xii) amend or otherwise change any Organizational Document of the Seller or alter through merger, liquidation, reorganization,
restructuring or in any other fashion its corporate structure or ownership; 
 (xiii) adopt a plan of complete or partial
liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization; 
 (xiv) issue, sell
or otherwise dispose of any of the capital stock or other equity interests of the Seller; 

  
 -40-

 (xv) form any Subsidiary or make any acquisition or effect any disposition of any Person or
any division, business or business unit of any Person or any equity security of or equity interest in any Person; 
 (xvi)
revalue any of the Acquired Assets, including writing off notes or accounts receivable or revaluing Inventory, except as required by GAAP; 
 (xvii) take any action or fail to take any action that would result in any of the representations and warranties set forth in ARTICLE III becoming false or inaccurate, that would, individually or in the
aggregate, have a Business Material Adverse Effect, or that would materially impair the ability of the Seller to consummate the transactions contemplated hereby in accordance with the terms hereof or materially delay such consummation; or

 (xviii) authorize or commit to do any of the foregoing, or agree or enter into any Contract to do any of the foregoing.

 5.2 Cooperation; Approvals, Filings and Consents. 

(a) Upon the terms and subject to the conditions set forth in this Agreement, each party hereto shall use commercially reasonable efforts
to take, or cause to be taken, all actions, and do, or cause to be done, and to assist and cooperate with the other party or parties in doing, all things necessary, proper or advisable to consummate the transactions contemplated hereby and to
satisfy or cause to be satisfied all of the conditions precedent that are set forth in ARTICLE VI, as applicable to each of them. 
 (b) The Seller and Buyer shall as promptly as practicable, use commercially reasonable efforts to obtain all necessary Approvals from Governmental Authorities and make all other necessary registrations
and filings under applicable Law required to be obtained or made by each of them in connection with the authorization, execution and delivery of this Agreement and the Related Agreements and the consummation of the transactions contemplated hereby
and thereby, if any. 
 (c) The Seller shall use its best efforts to obtain as promptly as practicable all other consents from
third parties that, in the reasonable discretion of Buyer, are necessary or desirable for the consummation of the transactions contemplated by this Agreement (“Third Party Consents”), including those Third Party Consents set forth
on Schedule 5.2(c) attached hereto. 
 5.3 Access to Information; Updated Financial Information. 

(a) Prior to the Closing Date and upon reasonable notice, the Seller shall afford to the Representatives of Buyer reasonable access during
normal working hours to all of Seller’s properties, books, Contracts and records relating to the Acquired Assets or the Business (other than personnel information protected by applicable privacy Laws), and the Seller shall furnish promptly to
Buyer all information concerning Seller’s properties, books, Contracts, records and personnel which relate to the Acquired Assets or the Business, as Buyer may reasonably request. The Seller shall make available to the Representatives of Buyer
upon the reasonable request of Buyer and during normal working hours all officers, employees, 

  
 -41-

 
accountants, counsel and other Representatives of the Seller or its Affiliates, in each case, as such party may reasonably request. The Seller shall use its reasonable commercial efforts to make
available to the Representatives of Buyer, upon the reasonable request of Buyer, such customers or suppliers of the Business or other Persons with whom the Seller or its Affiliates maintains a similar business or commercial relationship with respect
to the Acquired Assets or the Business. Neither the Seller, nor any of its Representatives, shall communicate with any customers, suppliers or employees of Buyer or its Affiliates or any other Person with whom Buyer or any of its Affiliates
maintains a similar business or commercial relationship with respect to the transactions contemplated by this Agreement or with respect to the business or operations of Buyer or its Affiliates without the prior written consent of Buyer. 

(b) Without limiting the generality of Section 5.3(a), prior to the Closing Date, the Seller shall deliver to Buyer within three
(3) days after the last day of each calendar month, an unaudited balance sheet for the Seller as of the end of such month and the related statements of income and cash flow for the Seller for such monthly period, prepared by the Seller and
certified by the Seller’s Chief Financial Officer (the “Pre-Closing Financial Statements”). The Pre-Closing Financial Statements shall be prepared in accordance with the books and records of the Seller consistent with past
practices and fairly and accurately present the financial condition of the Seller as of the dates indicated and the results of operations of the Seller for the respective periods indicated, and shall be prepared in accordance with GAAP, except for
the absence of complete footnote disclosure as required by GAAP, and subject to changes resulting from normal year-end audit adjustments. 
 5.4 Notice of Certain Events. 
 (a) During the period from the date hereof
until the Closing or the earlier termination of this Agreement, the Seller shall promptly notify Buyer in writing of: (i) any event, condition, fact or circumstance that occurred or existed on or prior to the date of this Agreement and that
caused or constitutes an inaccuracy in or breach of any representation or warranty made by the Seller in this Agreement which the Seller becomes aware after the date of this Agreement; (ii) any event, condition, fact or circumstance that
occurs, arises or exists after the date of this Agreement and that causes or constitutes an inaccuracy in or breach of any representation or warranty made by the Seller in this Agreement which the Seller becomes aware after the date of this
Agreement if (A) such representation or warranty had been made as of the time of the occurrence, existence or discovery of such event, condition, fact or circumstance or (B) such event, condition, fact or circumstance had occurred, arisen
or existed on or prior to the date of this Agreement; and (iii) any material breach of any covenant or obligation of the Seller. If any event, condition, fact or circumstance that is required to be disclosed pursuant to this Section 5.4
requires any change in the Written Schedule of Exceptions, the Seller shall promptly deliver to Buyer an update to the Written Schedule of Exceptions specifying such change; provided that, no such update shall be deemed to supplement
or amend the Written Schedule of Exceptions for the purpose of determining the accuracy of any of the representations and warranties made by the Seller in this Agreement, including for purposes of ARTICLE VI or ARTICLE VII hereof. 

(b) Without limiting the provisions of Section 5.4(a), prior to the Closing Date or the earlier termination of this Agreement, the
Seller shall give prompt written notice to Buyer of (i) any notice or other communication from any Person alleging that the consent of such 

  
 -42-

 
Person is or may be required in connection with the consummation of the transactions contemplated by this Agreement, (ii) any notice or other communication from any Governmental Authority in
connection with any Approval regarding the transactions contemplated by this Agreement, (iii) any Action commenced or threatened relating to or involving or otherwise affecting any Acquired Assets or the Business or the transactions
contemplated by this Agreement, (iv) the occurrence of a breach or default or event that, with notice or lapse of time or both, would constitute a breach or default under any Assigned Contract, (v) any notice or other communication from
any Person pursuant to any Assigned Contract and (vi) any change, event or circumstance which would reasonably be expected to materially delay or impede the ability of the Seller to consummate the transactions contemplated by this Agreement or
to fulfill its obligations set forth herein or that has or would reasonably be expected to have, individually or in the aggregate, a Business Material Adverse Effect. 
 (c) Prior to the Closing Date or the earlier termination of this Agreement, Buyer shall give prompt written notice to the Seller of (i) any notice or other communication from any Person alleging that
the consent of such Person is or may be required in connection with the consummation of the transactions contemplated by this Agreement, (ii) any notice or other communication from any Governmental Authority in connection with the transaction
contemplated by this Agreement, or (iii) any change, event or circumstance which would reasonably be expected to materially delay or impede the ability of Buyer to consummate the transactions contemplated by this Agreement or to fulfill its
obligations set forth herein. 
 5.5 Public Announcements. Neither the Seller nor any of its Representatives, shall issue
or permit to be issued any public announcement or statement or press release announcing the execution of this Agreement or the transactions contemplated hereby, or the Closing hereunder, otherwise make any public statements regarding the
transactions contemplated hereby or otherwise publicly disclose any of the contents of this Agreement (“Public Announcement”), without the prior written consent of the Buyer, except as the Seller may determine in good faith that a Public
Announcement is required by applicable Law, provided that (i) under no circumstances shall the Seller or any of its Representatives issue or permit to be issued any Public Announcement prior to 12:00 a.m. San Diego time on October 2, 2012,
and (ii) in such instance the Seller shall provide the Buyer an opportunity to review and provide comments regarding any such proposed Public Announcement. The Parent may in its sole discretion issue any Public Announcement pertaining to this
Agreement or any transaction contemplated hereby without the consent of the Seller; provided, however, that, subject to any public disclosure and other legal obligations of the Parent and regulatory obligations to which the Parent may be subject and
without limiting the rights of the Parent pursuant to this Section 5.5, the Parent shall use commercially reasonable efforts to provide the Seller an opportunity to review and discuss with the Parent any press release proposed to be issued by
the Parent announcing the consummation of the transactions contemplated hereby prior to issuing any such press release. 
 5.6
No Solicitation of Other Proposals. 
 (a) From the date hereof until the earlier of the Closing Date or the termination
of this Agreement in accordance with its terms, neither the Seller, nor any of its Affiliates, Representatives or shareholders (collectively, the “Seller Representatives”), shall

  
 -43-

 
directly or indirectly, (i) enter into any Contract with respect to, solicit, facilitate, initiate, entertain, or take any action to solicit, facilitate, initiate, or entertain, any
inquiries or communications or the making of any proposal or offer that constitutes or may constitute an Acquisition Proposal or (ii) participate or engage in any discussions or negotiations with, or provide any information to or take any other
action with the intent to facilitate the efforts of, any Person concerning any possible Acquisition Proposal. For purposes of this Agreement, the term “Acquisition Proposal” shall mean any inquiry, proposal or offer from any Person
(other than Buyer and its Affiliates and their respective Representatives) relating to the acquisition of the Business, the Seller, or any acquisition or license of any material portion of the assets of the Business, the Seller, or any purchase of
any equity securities or interests (or instruments convertible into equity securities or interests) of the Seller, or any other transaction, the consummation of which would reasonably be expected to impede, interfere with, prevent or materially
delay the consummation of the transactions contemplated hereby. The Seller shall immediately cease and cause to be terminated and shall cause all Seller Representatives to immediately terminate and cause to be terminated all existing discussions or
negotiations with any Persons conducted heretofore with respect to, or that would reasonably be expected to lead to, an Acquisition Proposal. Without limiting the foregoing, it is agreed that any violation of the restrictions set forth above by any
Affiliate of the Seller or any Seller Representative, whether or not such Person is purporting to act on behalf of the Seller, shall be deemed to be a breach of this Section 5.6 by the Seller. 

(b) Neither the Board of Directors of the Seller, nor any committee thereof shall (i) approve or recommend, or propose to approve or
recommend, any Acquisition Proposal other than the transactions contemplated by this Agreement, (ii) approve, enter or permit or cause the Seller to enter, into any Contract, letter of intent, agreement in principle, acquisition agreement or
other similar agreement related to any Acquisition Proposal, or (iii) resolve or announce its intention to do any of the foregoing. 
 (c) In addition to the other obligations of the Seller set forth in this Section 5.6, the Seller shall promptly (but in no case later than 24-hours after receipt) advise Buyer orally and in writing
of any Acquisition Proposal, any request for information with respect to any Acquisition Proposal, or any inquiry with respect to an Acquisition Proposal, the material terms and conditions of such request, Acquisition Proposal or inquiry, and the
identity of the Person making the same. 
 5.7 Employment Matters. 

(a) The Buyer may, but is under no obligation to, offer employment to those Business Employees listed on Schedule 5.7(a) attached
hereto, on such terms and conditions as are determined by the Buyer in its sole discretion. Each such Business Employee who accepts such offer of employment, as well as each of the Designated Employees, shall be referred to herein as a
“Transferred Employee” and collectively as the “Transferred Employees.” Effective as of the Closing Date, each Transferred Employee’s employment with the Seller, and any of its Affiliates (whether directly or
through a third-party employment agency) shall terminate. The Seller consents to the hiring of the Transferred Employees by the Buyer or any of its Affiliates and waives in perpetuity any of its claims or rights under any non-competition,
confidentiality, 

  
 -44-

 
non-solicitation, employment, assignment of inventions or similar Contract to which any Transferred Employee is a party (other than such rights that are assigned to the Buyer pursuant to this
Agreement). All Transferred Employees shall be employees at-will of the Buyer, subject to the Buyer’s employment policies, and nothing herein shall obligate the Buyer to employ any Transferred Employee for any specific time period. Nothing
herein shall be construed to grant any employee any rights as a third party beneficiary. 
 (b) As promptly as practicable, but
in no event later than such date as is required by Law, the Seller shall (i) pay or cause to be paid to each Transferred Employee all wages and other compensation earned through the Closing Date, (ii) reimburse each Transferred Employee
for all reimbursable expenses incurred by him or her through the Closing Date, (iii) make or cause to be made all required contributions to any Employee Benefit Plans with respect to each Transferred Employee, (iv) pay Transferred Employee
for all accrued vacation and sick pay, and (v) make or cause to be made all other payments as may be owed to any Transferred Employee; except for those employee-related Working Capital Liabilities which are to be assumed by the Buyer (the
“Assumed Pre-existing Employee Obligations”), which are listed on Schedule 5.7(b). 
 (c) Neither the Buyer nor
Parent shall have any Liability with respect to any current or former Business Employee of the Seller or any of its Affiliates, including any Transferred Employee, arising from such Business Employee’s employment or engagement with the Seller
or any of its Affiliates or the termination of such Business Employee’s employment or engagement with the Seller . Without limiting the generality of the foregoing, from and after the Closing Date, the Seller shall retain Liability and remain
responsible for any and all Liabilities in respect of the Business Employees and their beneficiaries and dependents, relating to or arising in connection with or as a result of (i) the employment or engagement or the termination of employment
or engagement of any such Business Employee by the Seller (including in connection with the consummation of the transactions contemplated by this Agreement), (ii) the participation in or accrual of benefits or compensation under, or the failure
to participate in or to accrue compensation or benefits under, or the operation and administration of, any Employee Benefit Plan or other employee or retiree benefit or compensation plan, program, practice, policy, agreement or arrangement of the
Seller, or any ERISA Affiliate and (iii) accrued but unpaid salaries, wages, bonuses, commissions, incentive compensation, vacation or sick pay (except as set forth above) or other compensation or payroll items (including deferred compensation)
relating to such individual’s employment by or engagement with the Seller, or an Affiliate thereof. Further, the Seller shall remain responsible for the payment of any and all retention, change in control, severance or other similar
compensation or benefits which are or may become payable in connection with the consummation of the transactions contemplated by this Agreement. 
 (d) The Seller shall be responsible for timely compliance with all federal, state and local Laws with respect to the effect to any of its employees of the transactions contemplated by this Agreement or by
any Related Agreement including, without limitation, WARN. The Seller agrees that it will not take any action which causes the notice provisions of WARN or any state or local analog to WARN to be applicable to the transactions contemplated by this
Agreement or by any Related Agreement. The Seller and its ERISA Affiliates shall, to the extent required by Law, provide COBRA Coverage to all “M&A qualified beneficiaries” associated

  
 -45-

 
with the transactions contemplated by this Agreement in accordance with Treasury Regulation § 54.4980B-9 and any Business Employees who have a “qualifying event” under
Section 4980B of the Code prior to the Closing Date or in connection with the transactions contemplated by this Agreement. 

(e) It is expressly agreed that the provisions of this Section 5.7 are not intended to be for the benefit of, or otherwise
enforceable by, any third party, including any Business Employee. 
 5.8 Use of Names From and after the Closing, the
Seller shall not use, or permit to be used, any names or other Trademarks included in the Acquired Assets or any derivations thereof. Without limiting the foregoing, promptly following the Closing, the Seller shall change its corporate name to
eliminate therefrom any name acquired by the Buyer hereunder. 
 5.9 Accounts Receivable/Collections Following the
Closing, the Seller shall permit the Buyer to collect, in the name of the Seller, all accounts receivable included in the Acquired Assets and to endorse with the name of the Seller for deposit in the Buyer’s account any checks or drafts
received in payment thereof. The Seller shall promptly deliver to the Buyer any cash, checks or other property that the Seller may receive after the Closing in respect of any accounts receivable or other assets constituting part of the Acquired
Assets. 
 5.10 Transition Matters The Seller shall take all action reasonably requested by the Buyer, at no additional
cost to the Buyer, to effectively transition the Acquired Assets and the Assumed Liabilities from the Seller to the Buyer. Without limiting the generality of the foregoing, the Seller shall forward all telephone calls, correspondence, e-mails,
inquiries and other information relating to the Business that the Seller receives to the Buyer in a timely manner. The Seller shall fully cooperate with the Buyer in developing and executing a detailed transition plan for the transition of the
Business, the Acquired Assets and the Assumed Liabilities. 
 5.11 Mutual Cooperation From and after the Closing Date,
the Seller, on the one hand, and the Buyer and the Parent, on the other hand, shall use their respective reasonable efforts to provide to the other party (the “Requesting Party”) such books, records and information and make
available to the Requesting Party such personnel (such party providing such books, records or information or making available such personnel to the Requesting Party, the “Providing Party”), in each case as may be reasonably
requested in writing by the Requesting Party, for the purpose of reasonably assisting the Requesting Party in responding to Governmental Authority or professional inquiries, making required Governmental Authority filings (including Tax filings) or
defending or prosecuting any Action relating to or arising out of the conduct of the Business prior to or after the Closing Date, involving any Person; provided that subject to the provisions of ARTICLE VII hereof, the Requesting Party shall
promptly reimburse the Providing Party for any reasonable out-of-pocket expenses incurred by the Providing Party in connection with the provision of any such assistance (including reasonable legal fees and disbursements), but the Requesting Party
shall not be required to reimburse the Providing Party for such party’s time 

  
 -46-

 
spent in such cooperation or the salaries or costs of fringe benefits or other similar expenses paid by the Providing Party to its Affiliates or related Persons or their respective
Representatives while such Persons are providing any such assistance. 
 5.12 Transfer Restrictions. Seller acknowledges
and agrees that the Shares may only be disposed of in compliance with state and federal securities laws. Without in any way limiting the representations set forth in Section 3.32, Seller further agrees not to Transfer all or any portion of the
Shares, unless and until: 
 (a) there is then in effect a registration statement under the Securities Act covering such
proposed Transfer and such Transfer is made in accordance with such registration statement; or 
 (b) Seller shall have notified
Parent of the proposed Transfer and shall have furnished Parent with a statement of the circumstances surrounding the proposed Transfer, and, at the expense of Seller or the transferee, with an opinion of counsel, reasonably satisfactory to Parent,
that such Transfer will not require registration of such securities under the Securities Act and that such Transfer is in compliance with applicable state securities laws. 
 Notwithstanding the provisions of Sections 5.12(a) and 5.12(b), no such registration statement or opinion of counsel shall be required for any Transfer of any Shares in compliance with Rule 144
promulgated under the Securities Act. 
 ARTICLE VI 

CONDITIONS PRECEDENT TO CLOSING 
 6.1 Conditions to Obligation of Each Party The respective obligations of each party to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior to
the Closing of the following conditions: 
 (a) Governmental Approvals. All necessary Approvals from Governmental
Authorities, if any, shall have been obtained or made and any applicable waiting periods shall have expired. 
 (b) No
Injunctions or Restraints; Illegality. No temporary restraining order, preliminary or permanent injunction or other Order (whether temporary, preliminary or permanent) issued by any Court of competent jurisdiction or other legal restraint or
prohibition shall be in effect which prevents the consummation of the transactions contemplated hereby, nor shall any Action brought by any Governmental Authority seeking any of the foregoing be pending, and there shall not be any action taken, or
any Law or Order enacted, entered, enforced or deemed applicable to the transactions contemplated hereby, which makes the consummation of such transactions, as contemplated herein illegal. 

  
 -47-

 6.2 Additional Conditions to Obligations of the Buyer The obligations of the Buyer to
consummate the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior to the Closing of the following additional conditions, unless waived in writing by the Buyer: 

(a) Representations and Warranties. Each of the representations and warranties set forth in ARTICLE III that is qualified by
“materiality,” “Business Material Adverse Effect” or a similar qualifier shall be true and correct in all respects, and each of such representations and warranties that is not so qualified shall be true and correct in all
material respects, in each case, as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date (except for representations and warranties made as of a specified date, the accuracy of which will be
determined only as of the specified date). 
 (b) Agreements and Covenants. The Seller shall have performed or complied
with each obligation, agreement and covenant to be performed or complied with by it under this Agreement on or prior to the Closing Date. 
 (c) No Business Material Adverse Change. From and including the date hereof, there shall not have been a Business Material Adverse Change. 

(d) Officer’s Certificate. The Seller shall have delivered to the Buyer a certificate of its President or Chief Executive
Officer, dated as of the Closing Date, in form and substance reasonably satisfactory to the Buyer, certifying that the conditions set forth in Sections 6.2(a) through 6.2(c) have been satisfied. 

(e) Good Standing Certificates. The Seller shall have delivered to the Buyer certificates of corporate good standing with respect
to the Seller from the Secretary of the State of the state of incorporation or organization of the Seller and any jurisdiction where the Seller is qualified to do business in connection with the operation of the Business, and the Seller shall
deliver to the Buyer a certificate of tax good standing with respect to the Seller from the Secretary of State of the state of incorporation or organization of the Seller and any jurisdiction where the Seller is qualified to do business in
connection with the operation of the Business, which certificates shall be dated within five (5) days prior to the Closing Date. 
 (f) Evidence of Corporate Authority. The Seller shall have delivered to the Buyer a certificate of its Secretary, dated as of the Closing Date, in form and substance reasonably satisfactory to the
Buyer, certifying as to and attaching (if applicable): (i) complete and accurate copies of its Organizational Documents, (ii) the incumbency of its officers executing this Agreement and the Related Agreements to which it is a party on its
behalf and (iii) complete and accurate copies of resolutions of its Board of Directors and stockholders or members authorizing and approving the execution, delivery and performance of this Agreement and the Related Agreements and the
transactions contemplated hereby and thereby, and the acts of its officers in carrying out the terms and provisions hereof and thereof. 
 (g) Voting Agreement. The Seller shall have delivered to the Buyer one or more executed Voting Agreements in substantially the form of Exhibit G attached hereto, signed by stockholders
holding at least Ninety percent (90%) of the outstanding shares of common stock of the Seller and Sixty-Six and Two Thirds percent (66 2/3%) of the outstanding preferred stock of the Seller. 

  
 -48-

 (h) Consents and Approvals. All Third Party Consents and all other Approvals from any
Persons, including the consent of holders of Indebtedness of the Seller or Governmental Authorities that, in the reasonable discretion of the Buyer, are necessary or desirable for the consummation of the transactions contemplated hereby on the
terms, and conferring upon the Buyer all of the rights and benefits, as contemplated herein, shall have been received in form and substance satisfactory to the Buyer. 
 (i) Legal Opinion. The Seller shall have caused to be delivered to the Buyer a legal opinion rendered to the Buyer by counsel reasonably acceptable to the Buyer in substance and form reasonably
acceptable to the Buyer. 
 (j) FIRPTA Certificate. The Seller shall have delivered to the Buyer a certificate of
non-foreign status that complies with Treasury Regulation Section 1.1445-2(b). 
 (k) Related Agreements. The Seller
shall have executed and delivered to the Buyer each of the Related Agreements to which it is a party and the actions required to be taken under the Related Agreements by the Seller at or prior to the Closing shall have been taken. 

(l) Non-Competition and Non-Disclosure Agreements. As of the Closing, each Post-Closing Non-Competition Agreement delivered by the
Seller and its officers, and each Post-Closing Non-Disclosure Agreement delivered by its directors, on the Effective Date shall be in full force and effect and each such Person shall have performed or complied with each obligation, agreement and
covenant to be performed or complied with by such Person thereunder on or prior to the Closing Date. 
 (m) Employment
Agreements. As of the Closing, each Post-Closing Employment Agreement delivered by the Designated Employees on the Effective Date shall be in full force and effect and each Designated Employee shall have performed or complied with each
obligation, agreement and covenant to be performed or complied with by such Designated Employee thereunder on or prior to the Closing Date. 
 (n) Indebtedness. As of the Closing, each of the loans or other Indebtedness of the Seller (with relation to the Acquired Assets) shall have been paid in full and discharged. 

(o) Liens. All Liens on any of the Acquired Assets shall have been fully released and discharged pursuant to such documents in
form and substance reasonably satisfactory to the Buyer, and the Seller shall have made all necessary filings and taken all other action necessary to effect such releases and discharges including filing all necessary UCC termination statements in
all applicable jurisdictions. 
 (p) Product Liability Insurance. The Seller shall have obtained an endorsement to its
product liability insurance policy in form and substance satisfactory to the Buyer providing for coverage under such policy for a period of two (2) years following the Closing Date with respect to any claims relating to any period prior to the
Closing that are asserted following the Closing. 

  
 -49-

 (q) Other Documents. The Seller shall have delivered to the Buyer such other
instruments, certificates, documents or materials as may be reasonably requested by the Buyer in connection with the consummation of the transactions contemplated hereby. 
 6.3 Additional Conditions to Obligations of the Seller The obligations of the Seller to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior
to the Closing of the following additional conditions, unless waived in writing by the Seller: 
 (a) Representations and
Warranties. Each of the representations and warranties set forth in ARTICLE IV that is qualified by “materiality” or a similar qualifier shall be true and correct in all respects, and each of such representations and warranties that is
not so qualified shall be true and correct in all material respects, in each case, on the date of this Agreement and on and as of the Closing Date as though made on and as of the Closing Date (except for representations and warranties made as of a
specified date, the accuracy of which will be determined only as of the specified date). 
 (b) Agreements and Covenants.
Each of the Buyer and the Parent shall have performed or complied with each obligation, agreement and covenant to be performed or complied with by it under this Agreement on or prior to the Closing Date. 

(c) Related Agreements. Each of the Buyer and the Parent shall have executed and delivered to the Seller each of the Related
Agreements to which it is a party and the actions required to be taken thereunder by the Buyer or the Parent at or prior to the Closing thereunder shall have been taken. 
 (d) Officer’s Certificate. Each of the Buyer and the Parent shall have delivered to the Seller a certificate of an officer, dated as of the Closing Date, certifying that the conditions set
forth in Sections 6.3(a) and 6.3(b) have been satisfied. 
 (e) Evidence of Corporate Authority. Each of the Buyer and
the Parent shall have delivered to the Seller a certificate of its Secretary, dated as of the Closing Date, certifying as to and attaching (if applicable): (i) complete and accurate copies of its Organizational Documents, (ii) the
incumbency of its officers executing this Agreement and the Related Agreements to which it is a party on its behalf and (iii) complete and accurate copies of resolutions of its Board of Directors authorizing and approving the execution,
delivery and performance of this Agreement and the Related Agreements and the transactions contemplated hereby and thereby, and the acts of its officers in carrying out the terms and provisions hereof and thereof. 

(f) Shares. The Parent shall have delivered the Shares to the Escrow Agent in accordance with Section 2.2(b) herein.

  
 -50-

 ARTICLE VII 
 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS; INDEMNIFICATION 

7.1 Survival of Representations, Warranties and Covenants Subject to the provisions of this ARTICLE VII, each of the
representations and warranties contained in this Agreement or in any other agreement, exhibit, schedule, certificate, instrument or other writing delivered by or on behalf of the Buyer, the Parent, or the Seller pursuant to this Agreement shall
survive the Closing for a period of eighteen (18) months after the Closing Date; provided, however, that the Excepted Representations shall survive the Closing until sixty (60) days following the expiration of the applicable statute of
limitations (including any extension thereof). For convenience of reference, the date upon which any representation or warranty shall terminate is referred to herein as the “Survival Date.” Unless otherwise expressly set forth in
this Agreement, the covenants and agreements set forth in this Agreement shall survive the Closing and remain in effect indefinitely. 
 7.2 Indemnification. 
 (a) From and after the Closing, the Seller shall
indemnify, defend and hold harmless the Buyer, each of its Subsidiaries and Affiliates, their respective successors and assigns, and the respective Representatives of each of the foregoing (the “Buyer Indemnified Persons”) from and
against any and all Losses of every kind, nature or description asserted against, or sustained, incurred or accrued directly or indirectly by, such Buyer Indemnified Person which arise out of or result from or as a consequence of any of the
following (“Legal Claims”): 
 (i) the breach or inaccuracy of any representation or warranty of the Seller contained
in this Agreement or in any Related Agreement or certificate delivered by the Seller pursuant to this Agreement, provided that for purposes hereof, such representations and warranties shall be interpreted without giving effect to any limitations or
qualifications as to “materiality” (including the word “material”), “Business Material Adverse Effect” or any similar limitations or qualifications; 

(ii) the breach of or non-compliance with any agreement or covenant of the Seller contained in this Agreement or in any Related
Agreement; 
 (iii) any of the Excluded Liabilities, including the failure of the Seller or other Person to honor, pay,
discharge or perform any Excluded Liability; 
 (iv) any bulk sales or similar statute applicable to the transaction
contemplated by this Agreement or the failure of any Person to comply with the provisions thereof; 

  
 -51-

 (v) any Taxes of any kind relating to or arising in connection with the transfer of the
Acquired Assets to Buyer; or 
 (vi) any of the matters set forth on Schedule 7.2(a) attached hereto. 

(b) From and after the Closing, Buyer and Parent shall, jointly and severally, indemnify, defend and hold harmless the Seller, each of
its Subsidiaries and Affiliates, their respective successors and assigns, and the respective Representatives of each of the foregoing (the “Seller Indemnified Persons”) from and against any and all Losses of every kind, nature or
description asserted against, or sustained, incurred or accrued directly or indirectly by, such Seller Indemnified Person which arise out of or result from or as a consequence of any of the following: 

(i) the breach or inaccuracy of any representation or warranty of the Buyer contained in Article IV; 

(ii) the breach of or non-compliance with any agreement or covenant of the Buyer contained in this Agreement; 

(iii) the operation of any business of the Buyer, including, without limitation, the operation of the Business or in anyway relating to
the use or non-use of the Acquired Assets on or after the Closing Date for periods on or after the Closing Date; and 
 (iv)
the Assumed Liabilities. 
 7.3 Limitations on Indemnification Subject to the provisions of Section 7.5: 

(a) no indemnification shall be payable to a Buyer Indemnified Person or a Seller Indemnified Person as a result of any Losses arising
under Section 7.2(a) or Section 7.2(b), as applicable, until the aggregate amount of all Losses incurred by all Buyer Indemnified Persons or Seller Indemnified Persons, as applicable, including, without limitation, losses associated with
any Legal Claims, exceeds $25,000, whereupon the Buyer Indemnified Persons or Seller Indemnified Persons, as applicable, shall be entitled to receive the full amount of all Losses (including the first $25,000 of such Losses) provided,
however, that the foregoing limitations on indemnification shall not apply to any Losses resulting from or arising out of any breach or inaccuracy of the Excepted Representations or of the representations and warranties set forth in Sections
3.7(c) and 3.20(c); 
 (b) the maximum aggregate liability of the Seller for all Losses arising under Section 7.2(a) shall
be limited to the Claim Shares (which shall be subject to return or, at Cardium’s election, cancellation in satisfaction of such Losses); provided, however, that the foregoing maximum aggregate liability shall not apply to any Losses resulting
from or arising out of any breach or inaccuracy of the Excepted Representations; 
 (c) the maximum aggregate liability of the
Buyer and Parent for all Losses arising under Section 7.2(b) shall be limited to the aggregate value of the Claim Shares upon deposit with the Escrow Agent. 

  
 -52-

 (d) An Indemnified Person (as defined below) shall not be entitled to a duplicate recovery
under this ARTICLE VII to the extent that the state of facts giving rise to indemnification hereunder constitutes a breach of more than one representation, warranty or covenant hereunder; 

(e) in determining the amount of any Loss for which an Indemnified Person is entitled to indemnification pursuant to this ARTICLE VII,
there shall be subtracted an amount equal to all insurance proceeds actually received by such Indemnified Person in connection with such Loss, provided that, no Indemnified Person shall have any obligation to pursue any insurance claim or recovery;
and 
 (f) in no event shall any party to this Agreement be liable for indirect, punitive, exemplary, special or consequential
damages including lost profits pursuant to this ARTICLE VII. 
 7.4 Indemnification Process. 

(a) Any Buyer Indemnified Person or Seller Indemnified Person seeking indemnification under this ARTICLE VII (an “Indemnified
Person”) shall give each party from whom indemnification is being sought (each, an “Indemnifying Person”) notice of any matter (a “Notice of Claim”) which such Indemnified Person has determined has given
rise to or would reasonably be expected to give rise to a right of indemnification under this Agreement, stating the amount of the Loss, if known (a “Loss Estimate”), and containing a reference to the provisions of this Agreement in
respect of which such right of indemnification is claimed or arises as promptly as practicable after becoming aware of such matter; provided, however, that the failure so to provide such Notice of Claim will not relieve the Indemnifying Person from
Liability under this Agreement except, and only to the extent that, such failure to notify the Indemnifying Person results in the actual and material impairment or loss of rights and defenses that would have otherwise been available to the
Indemnifying Person. Notwithstanding the foregoing, no claim shall be brought under this ARTICLE VII with respect to an event of indemnification described in Section 7.2(a) unless an Indemnified Person, at any time prior to the applicable
Survival Date, gives the Indemnifying Person(s) a Notice of Claim with respect to such claim. If a Notice of Claim has been given on or prior to the applicable Survival Date, the relevant representations and warranties shall survive as to such claim
until the claim has been finally resolved. 
 (b) Claims for indemnification hereunder resulting from the assertion of liability
by third parties (each, a “Third Party Claim”) shall be subject to the following terms and conditions: 
 (i)
The Indemnified Person may defend any Third Party Claim with counsel of its own choosing, at the Indemnifying Person’s cost, and shall act reasonably and in accordance with its good faith business judgment in handling such Third Party Claim. If
the Indemnified Person elects not to defend such Third Party Claim, the Indemnified Person shall promptly provide notice to the Indemnifying Person. The Indemnifying Person shall have ten (10) days to advise the Indemnified Person whether the
Indemnifying Person accepts the defense 

  
 -53-

 
of such claim, and the Indemnifying Person shall have no obligation to the Indemnified Person for legal fees incurred by the Indemnified Person after the date of any assumption of the defense by
the Indemnifying Person. If the Indemnifying Person determines to accept the defense of such Third Party Claim, it shall defend such Third Party Claim with counsel of its own choice that is reasonably satisfactory to the Indemnified Person and at
its own expense, provided that, the Indemnified Person shall have the right to be represented by its own counsel at its own expense. If the Indemnifying Person fails to undertake the defense of or settle or pay any such Third Party Claim within ten
(10) days after the Indemnified Person has given written notice to the Indemnifying Person of the claim, or if the Indemnifying Person, after having given such notification to the Indemnified Person, fails within ten (10) days, or at any
time thereafter, to defend to the reasonable satisfaction of the Indemnified Person, settle or pay such claim, then the Indemnified Person may take any and all necessary action to dispose of such claim at the Indemnifying Person’s cost. The
Indemnifying Person and the Indemnified Person shall make available to each other and their counsel and accountants all books and records and information relating to any Third Party Claims, keep each other apprised as to the details and progress of
all proceedings relating thereto and render to each other such assistance as may be reasonably required to ensure the proper and adequate defense of any and all Third Party Claims. 

(ii) The party controlling the defense of a Third Party Claim may settle such Third Party Claim on any terms which it may deem
reasonable, provided that, an Indemnifying Person shall not without the Indemnified Person’s prior written consent settle or compromise such proceeding, claim or demand, or consent to the entry of any judgment which does not include as an
unconditional term thereof the delivery by the claimant or plaintiff to the Indemnified Person of a written release from all liability in respect of such proceeding, claim or demand. 

7.5 Fraud and Related Claims; Characterization of Payments. Notwithstanding any provision of this Agreement to the contrary,
nothing contained in this Agreement shall in any way limit, impair, modify or otherwise affect the rights of an Indemnified Person to bring any claim, demand, suit or cause of action otherwise available to such Indemnified Person based upon, or to
seek or recover any Losses arising from or related to, nor shall any of the limitations set forth in Section 7.1 or Section 7.3 apply with respect to, an allegation or allegations of fraud, willful breach or intentional misrepresentation,
in connection with this Agreement or any of the Related Agreements or the transactions contemplated hereby or thereby. Subject to the foregoing, the parties acknowledge that, absent fraud, willful breach or intentional misrepresentation, the
remedies provided in this ARTICLE VII shall be the exclusive remedies of the Buyer Indemnified Persons and Seller Indemnified Persons after the Closing in connection with any breach of this Agreement by the Seller or Buyer, as applicable, except
remedies of specific performance, injunction and other equitable relief. The parties agree that any payment pursuant to an indemnification obligation under this ARTICLE VII shall be treated for Tax purposes as an adjustment to the Purchase Price.
If, notwithstanding the treatment required by the preceding sentence, any indemnification payment under this ARTICLE VII is determined to be taxable to a Buyer Indemnified Person, the Seller shall also indemnify the Buyer Indemnified Person for any
Taxes incurred by reason of the receipt of such payment and any Losses incurred by the Buyer Indemnified Person in connection with such Taxes (or any asserted deficiency, claim, demand, action, suit, proceeding, judgment or assessment, including the
defense or settlement thereof, relating to such Taxes). 

  
 -54-

 7.6 Insurance Claims If Losses with respect to any claim for indemnification under
Section 7.2 may be covered by an insurance policy of the Seller, at the request of a Buyer Indemnified Person and without further consideration, the Seller shall use commercially reasonable efforts to seek and recover all payments under any
such insurance policy to which the Seller may be entitled with respect to such Losses and pay over such amounts to the applicable Buyer Indemnified Person, subject to the provisions of Section 7.3(b). 

ARTICLE VIII 
 TERMINATION, AMENDMENT, WAIVER AND EXPENSES 
 8.1 Termination. This
Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time prior to the Closing: 
 (a)
By written consent of Buyer and the Seller; 
 (b) By either Buyer or the Seller if the Closing shall not have occurred on or
before October 2, 2012 (the “Outside Date”); provided, however, that the right to terminate this Agreement under this Section 8.1(b) shall not be available to any party whose failure to fulfill any obligation
or satisfy any closing condition under this Agreement has been the cause of, or resulted in, the failure of the Closing to occur on or before such date; 
 (c) By either Buyer or the Seller if a Court or Governmental Authority shall have issued an Order or taken any other action, in each case, which has become final and non-appealable and which restrains,
enjoins or otherwise prohibits the Closing; 
 (d) By Buyer, if Buyer is not in material breach of any its obligations under
this Agreement, and if the Seller shall have breached any of its representations or warranties or failed to perform any of its covenants or other agreements contained in this Agreement, which breach or failure to perform would render unsatisfied any
condition contained in Section 6.1 or 6.2 and (i) is incapable of being cured or (ii) if capable of being cured is not cured prior to the earlier of (A) the Business Day prior to the Outside Date or (B) the date that is
twenty (20) days from the date that the Seller is notified of such breach; or 
 (e) By the Seller, if the Seller is not in
material breach of any of its obligations under this Agreement, and if Buyer shall have breached any of its representations or warranties or failed to perform any of its covenants or other agreements contained in this Agreement, which breach or
failure to perform would render unsatisfied any condition contained in Section 6.1 or 6.3 and (i) is incapable of being cured or (ii) if capable of being cured is not cured prior to the earlier of (A) the Business Day prior to
the Outside Date or (B) the date that is twenty (20) days from the date that Buyer is notified of such breach. 
 8.2
Effect of Termination. In the event of the termination of this Agreement pursuant to Section 8.1, this Agreement (other than this ARTICLE VIII and ARTICLE IX, which shall survive such termination) will forthwith become void, and there
will be no Liability on the part of any party hereto or any of their respective officers or directors to the other and all rights and obligations of any party hereto will cease, except that nothing herein will relieve any 

  
 -55-

 
party from any Losses arising out of, resulting from or relating to any breach, prior to termination of this Agreement in accordance with its terms, of any representation, warranty, covenant or
agreement contained in this Agreement or any Related Agreement. 
 8.3 Expenses Except as provided herein, all fees,
costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby including legal, accounting and investment banking fees (collectively, “Transaction Expenses”), shall be paid by the party incurring
such Transaction Expenses, whether or not the Closing occurs. 
 8.4 Amendment and Waiver This Agreement may be amended
only by an instrument in writing specifically amending this Agreement signed by duly authorized Representatives of the Parent, the Buyer, and the Seller. Any party hereto may extend the time for the performance of any of the obligations or other
acts required hereunder, waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto and waive compliance with any of the agreements or conditions contained herein. Any such extension or
waiver shall be valid if set forth in an instrument in writing specifically waiving this Agreement signed by the party or parties to be bound thereby. 
 ARTICLE IX 
 MISCELLANEOUS 

9.1 Entire Agreement This Agreement, together with its schedules and exhibits, the Related Agreements and all other ancillary
agreements, documents and instruments to be delivered in connection herewith contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements, either oral or written; provided,
however, that the Confidentiality Agreement shall survive the execution of this Agreement until the consummation of the transactions contemplated hereby, at which time it shall terminate with respect to any Confidential Information (as
defined in the Confidentiality Agreement) included in the Acquired Assets, it being understood that any Confidential Information that is not included in the Acquired Assets shall remain subject to the Confidentiality Agreement. Without limiting the
generality of foregoing and notwithstanding anything in this Agreement to the contrary, no party is making any representation or warranty whatsoever, oral or written, express or implied, in connection with the transactions contemplated by this
Agreement and the Related Agreements other than those set forth in this Agreement or in the Related Agreements and no party is relying on any statement, representation or warranty, oral or written, express or implied, made by any other party except
for the representations and warranties set forth in this Agreement or in the Related Agreements. The parties hereto agree that, notwithstanding any access to information by any party or any right of any party to this Agreement to investigate the
affairs of any other party to this Agreement, the party having such access and right to investigate shall have the right to rely fully upon the representations and warranties of the other party expressly contained in this Agreement and on the
accuracy of any schedule, exhibit or other document attached hereto or referred to herein or delivered by such other party or pursuant to this Agreement. 

  
 -56-

 9.2 Assignment The Seller shall not assign or otherwise transfer this Agreement or
any of its rights hereunder, or delegate any of its obligations hereunder, without the prior written consent of the Buyer. The Buyer may assign or otherwise transfer this Agreement or any of its rights hereunder, or delegate any of its obligations
hereunder; provided that, no such assignment or transfer shall relieve the Buyer of its obligations hereunder. Subject to the foregoing, this Agreement and the rights and obligations set forth herein shall inure to the benefit of, and be binding
upon the parties hereto, and each of their respective successors, heirs and permitted assigns. 
 9.3 Counterparts This
Agreement may be executed in two or more counterparts, any one of which need not contain the signatures of all parties, but all of which counterparts when taken together will constitute one and the same agreement. Counterparts may be executed and
delivered by facsimile transmission, electronic mail in portable document format, or other means intended to preserve the original graphic content of a signature. Each counterpart so executed shall have the legal effect of an original signature.

 9.4 Governing Law; Venue; Waiver of Jury Trial This Agreement shall be governed by the Laws of the State of California
without giving effect to any choice of law or conflict of law provision or rule (whether of the State of California or any other jurisdictions) that would cause application of the Laws of any jurisdiction other than the State of California. All
Actions arising out of or relating to this Agreement shall be heard and determined in any state or federal court sitting in the State of California. Each of the parties to this Agreement irrevocably submits to the exclusive jurisdiction of the state
courts of California and to the jurisdiction of the United States District Court for the Southern District of California, for the purpose of any Action arising out of or relating to this Agreement and each of the parties to this Agreement
irrevocably agrees that all claims in respect to such Action may be heard and determined exclusively in any California state or federal court sitting in the Southern District of California. Each of the parties to this Agreement consents to service
of process by delivery pursuant to Section 9.8 hereof and agrees that a final judgment in any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. 

9.5 Specific Performance The rights and remedies of the parties hereto shall be cumulative. The transactions contemplated by this
Agreement are unique transactions and any failure on the part of any party to complete the transactions contemplated by this Agreement on the terms of this Agreement will not be fully compensable in damages and the breach or threatened breach of the
provisions of this Agreement would cause the other parties hereto irreparable harm. Accordingly, in addition to and not in limitation of any other remedies available to the parties hereto for a breach or threatened breach of this Agreement, the
parties shall be entitled to seek specific performance of this Agreement and seek an injunction restraining any such party from such breach or threatened breach, without the need to post a bond or other collateral. 

9.6 Interpretation The schedules and exhibits attached hereto are an integral part of this Agreement. All schedules and exhibits
attached to this Agreement are incorporated herein by this reference and 

  
 -57-

 
all references herein to this “Agreement” shall mean this Agreement together with all such schedules and exhibits. When a reference is made in this Agreement to Sections, subsections,
schedules or exhibits, such reference shall be to a Section, subsection, schedule or exhibit to this Agreement unless otherwise indicated. The words “include,” “includes” and “including” when used herein shall be deemed
in each case to be followed by the words “without limitation.” The word “herein” and similar references mean, except where a specific Section or ARTICLE reference is expressly indicated, the entire Agreement rather than any
specific Section or ARTICLE. The table of contents and the headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. The term “$” shall mean
dollars of the United States of America. As used herein, all pronouns shall include the masculine, feminine, neuter, singular and plural thereof whenever the context and facts require such construction. 

9.7 Severability If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule
of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible. 
 9.8 Notices All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if delivered personally or sent by nationally-recognized overnight
courier or by registered or certified mail, postage prepaid, return receipt requested or by facsimile, with confirmation as provided above addressed as follows: 
 If to the Buyer or the Parent: 
 Cardium Therapeutics, Inc. 

12255 El Camino Real, Suite 250 
 San Diego, CA 92130 
 with a copy to (which shall not constitute notice):

 Sheppard Mullin Richter & Hampton LLP 
 12275 El Camino Real, Suite 200 
 San Diego, CA 92130 

Attn: James A. Mercer III 
 If to the Seller: 
 To Go Brands, Inc. 

8505 Commerce Ave. 
 San Diego, CA 92121 

  
 -58-

 with a copy to (which shall not constitute notice): 

Kolesar & Leatham 
 400 S. Rampart, Suite 400 
 Las Vegas, NV 89145 

Attn: Joseph J. Mugan, Esq. 

or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. All such
notices or communications shall be deemed to be received (a) in the case of personal delivery, on the date of such delivery, (b) in the case of nationally-recognized overnight courier, on the next Business Day after the date when sent if
properly addressed and all charges prepaid (c) in the case of facsimile transmission, upon confirmed receipt, and (d) in the case of mailing, on the fifth Business Day following the date on which the piece of mail containing such
communication was posted if properly addressed and postage prepaid. 
 9.9 Representation by Counsel Each party hereto
acknowledges that it has been or has had an opportunity to be advised by legal counsel retained by such party in its sole discretion. Each party acknowledges that such party has had a full opportunity to review this Agreement and all related
exhibits, schedules and ancillary agreements and to negotiate any and all such documents in its sole discretion, without any undue influence by any other party hereto or any third party. 

9.10 Construction The parties have participated jointly in the negotiations and drafting of this Agreement and in the event of any
ambiguity or question of intent or interpretation, no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. 

9.11 Waivers No waiver by any party, whether express or implied, of its rights under any provision of this Agreement shall
constitute a waiver of the party’s rights under such provisions at any other time or a waiver of the party’s rights under any other provision of this Agreement. No failure by any party to take any action against any breach of this
Agreement or default by another party shall constitute a waiver of the former party’s right to enforce any provision of this Agreement or to take action against such breach or default or any subsequent breach or default by the other party. To
be effective any waiver must be in writing and signed by the waiving party. 
 9.12 Third Party Beneficiaries Nothing
express or implied in this Agreement is intended to confer, nor shall anything herein confer, upon any Person other than the parties to hereto and their respective successors and permitted assigns, any rights, remedies, obligations or liabilities
whatsoever, except to the extent that such third person is an indemnified person in respect of the indemnification provided in accordance with ARTICLE VII of this Agreement. The representations and warranties contained in this Agreement are for the
sole benefit of the parties hereto and no other Person may rely on such representations and warranties for any purpose whatsoever. 

  
 -59-

 9.13 Bulk Sales Law Each party hereby waives compliance by each other with the
so-called “bulk sales law” and other similar Law in any jurisdiction in respect of the transactions contemplated by this Agreement. 
 9.14 Waiver of Jury Trial EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUR OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY. 
 [Signature Pages Follow] 

  
 -60-

 NOW THEREFORE, the parties hereto have executed, or caused this Asset Purchase Agreement to
be executed by their duly authorized representatives, as of the date first written above. 
  

					
	BUYER:
	
	 MEDPODIUM HEALTH PRODUCTS, INC.

		
	 By:
	 	 /s/ Tyler M. Dylan-Hyde

		 	Name:	 	Tyler M. Dylan-Hyde
		 	 Title:
	 	Chief Business Officer
	
	PARENT:
	
	 CARDIUM THERAPEUTICS, INC.

		
	 By:
	 	 /s/ Tyler M. Dylan-Hyde

		 	Name:	 	Tyler M. Dylan-Hyde
		 	Title:	 	 Chief Business Officer

	
	SELLER:
	
	 TO GO BRANDS, INC.

		
	 By:
	 	 /s/ Derek Howe

		 	Name:	 	Derek Howe
		 	Title:	 	Chief Executive Officer

  
 -61-

 Schedule I 
 INDEX OF DEFINED TERMS 
  

			
	 Defined Term
	  	Section
	 Acquired Assets
	  	Section 1.1
	 Acquisition Proposal
	  	Section 5.6(a)
	 Action
	  	Schedule I
	 Affiliate
	  	Schedule I
	 Affiliate Transaction
	  	Section 3.18
	 Agreement
	  	Preamble
	 Allocation Schedule
	  	Section 2.4
	 Anti-Kickback Statute
	  	Section 3.31(j)
	 Approval
	  	Schedule I
	 Assigned Contracts
	  	Section 1.1(a)
	 Assignment of Trademark and Domains
	  	Section 1.6(d)
	 Assumed Liabilities
	  	Section 1.3
	 Assumed Pre-Existing Employee Obligations
	  	Section 5.7(b)
	 Assumption Agreement
	  	Section 1.6(b)
	 Bill of Sale and Assignment Agreement
	  	Section 1.6(a)
	 Board of Directors
	  	Schedule I
	 Business
	  	Preamble
	 Business Day
	  	Schedule I
	 Business Employee
	  	Schedule I
	 Business Licenses
	  	Section 3.6
	 Business Material Adverse Change
	  	Section 3.12
	 Business Material Adverse Effect
	  	Schedule I
	 Buyer
	  	Preamble
	 Buyer Indemnified Persons
	  	Section 7.2(a)
	 CERCLA
	  	Schedule I
	 Claim Shares
	  	Section 2.2
	 Closing
	  	Section 1.5
	 Closing Date
	  	Section 1.5
	 COBRA Coverage
	  	Schedule I
	 Code
	  	Schedule I
	 Confidentiality Agreement
	  	Schedule I
	 Contract
	  	Schedule I
	 Copyright
	  	Schedule I (See Intellectual Property)
	 Copyright Assignment
	  	Section 1.6(c)
	 Court
	  	Schedule I
	 Current Working Capital
	  	Section 2.3(a)
	 Customers
	  	Section 3.28
	 Databases
	  	Section 3.20(k)
	 Designated Employees
	  	Preamble
	 Written Schedule of Exceptions
	  	Article III
	 Effective Date
	  	Preamble

  
 -62-

			
	 Employee Benefit Plans
	  	Schedule I
	 Environmental Law
	  	Schedule I
	 ERISA
	  	Schedule I
	 ERISA Affiliate
	  	Schedule I
	 Escrow Agent
	  	Schedule I
	 Escrow Agreement
	  	Section 1.6(f)
	 Excepted Representations
	  	Schedule I
	 Excluded Assets
	  	Section 1.2
	 Excluded Contracts
	  	Section 1.2(a)
	 Excluded Liabilities
	  	Section 1.4
	 FDA
	  	Section 3.6
	 Fifteen Day VWAP
	  	Schedule I
	 Financial Statements
	  	Section 3.11
	 GAAP
	  	Schedule I
	 Governmental Authority
	  	Schedule I
	 Government Bid
	  	Schedule I
	 Government Contract
	  	Schedule I
	 HIPAA
	  	Section 3.14(b)
	 Indebtedness
	  	Schedule I
	 Indemnified Person
	  	Section 7.4(a)
	 Indemnifying Person
	  	Section 7.4(a)
	 Intellectual Property
	  	Schedule I
	 Interim Balance Sheet
	  	Section 3.11(a)
	 Interim Financial Statements
	  	Section 3.11(a)
	 Inventory
	  	Section 3.25
	 IRS
	  	Schedule I
	 Knowledge
	  	Schedule I
	 Laws
	  	Schedule I
	 Leased Personal Property
	  	Section 3.9
	 Leased Real Property
	  	Section 3.8(a)
	 Legal Claims
	  	Section 7.2(a)
	 Liabilities
	  	Schedule I
	 License Agreements
	  	Section 3.20(b)
	 Licensed Intellectual Property
	  	Section 3.20(b)
	 Lien
	  	Schedule I
	 Losses
	  	Schedule I
	 Loss Estimate
	  	Section 7.4(a)
	 Materials of Environmental Concern
	  	Schedule I
	 Members
	  	Preamble
	 Non-Competition and Non-Disclosure Agreements
	  	Section 6.2(m)
	 Nonqualified Deferred Compensation Claim
	  	Section 3.15(m)
	 Notice of Claim
	  	Section 7.4(a)
	 Office Lease
	  	Schedule I
	 Order
	  	Schedule I
	 Organizational Documents
	  	Schedule I
	 Outside Date
	  	Section 8.1(b)

  
 -63-

			
	 Parent
	  	Preamble
	 Parent Common Stock
	  	Schedule I
	 Patent Assignment
	  	Section 1.6(e)
	 Payment Program
	  	Schedule I
	 Person
	  	Schedule I
	 Personally Identifiable Information
	  	Schedule I
	 Personal Property Leases
	  	Section 3.9
	 Premises
	  	Section 3.8(b)
	 Post-Closing Employment Agreement
	  	Preamble
	 Pre-Closing Financial Statements
	  	Section 5.3(b)
	 Post-Closing Non-Competition Agreements
	  	Preamble
	 Post-Closing Non-Disclosure Agreements
	  	Preamble
	 Pre-Closing Financial Statements
	  	Section 5.3(b)
	 Prior Actions
	  	Section 3.13(b)
	 Providing Party
	  	Section 5.11
	 Public Announcement
	  	Section 5.5
	 Purchase Price
	  	Section 2.1
	 Regulation
	  	Schedule I
	 Related Agreements
	  	Schedule I
	 Representative
	  	Schedule I
	 Requesting Party
	  	Section 5.11
	 Retained Cash
	  	Section 1.1(d)
	 Securities Act
	  	Section 3.2
	 Scheduled Contracts
	  	Section 3.17(a)
	 Seller
	  	Preamble
	 Seller Bank Account
	  	Schedule I
	 Seller Expenses
	  	Section 1.1(d)
	 Seller Indemnified Persons
	  	Section 7.2(b)
	 Seller Intellectual Property
	  	Schedule I
	 Seller Products
	  	Schedule I
	 Seller Representatives
	  	Section 5.6(a)
	 Shares
	  	Section 2.1(a)
	 Software
	  	Schedule I
	 Stakeholders
	  	Preamble
	 Stark Law
	  	Section 3.13(h)
	 Subsidiary
	  	Schedule I
	 Survival Date
	  	Section 7.1
	 Taxes
	  	Schedule I
	 Tax Liability
	  	Schedule I
	 Tax Returns
	  	Schedule I
	 Trade Secrets
	  	Schedule I (See Intellectual Property)
	 Third Party Claim
	  	Section 7.4(b)
	 Third Party Consents
	  	Section 5.2(c)
	 Trading Day
	  	Schedule I
	 Transaction
	  	Preamble
	 Transaction Expenses
	  	Section 8.3

  
 -64-

			
	 Transfer Documents
	  	Section 1.6
	 Transfer Tax Returns
	  	Section 1.9
	 Transfer Taxes
	  	Section 1.9
	 Transferred Employee
	  	Section 5.7(a)
	 Transition Services Agreement
	  	Schedule I
	 Updated Working Capital Statement
	  	Section 2.3(b)
	 Voting Agreement
	  	Section 1.6(g)
	 Working Capital
	  	Schedule I
	 Working Capital Assets
	  	Schedule I
	 Working Capital Liabilities
	  	Schedule I
	 Written Schedule of Exceptions
	  	Article III

  
 -65-

 TABLE OF DEFINITIONS 

“Action” means any suit, action, arbitration, cause of action, claim, complaint, prosecution, audit, inquiry,
investigation, governmental or other proceeding, whether civil, criminal, administrative, investigative or informal, at law or at equity, before or by any Court, Governmental Authority, arbitrator or other tribunal. 

“Affiliate” means, with respect to any Person, any other Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, the first mentioned Person; including any partnership or joint venture in which the Seller (either alone, or through or together with any other Subsidiary) has, directly or
indirectly, an interest of 10% or more; and “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of a Person, whether through the ownership of stock or other securities, as trustee or executor, by contract or credit arrangement or otherwise. 

“Approval” means any license, permit, consent, approval, authorization, registration, filing, waiver, exemption,
clearance, qualification or certification, including all pending applications therefor or renewals thereof, issued by, made available by or filed with any Government Authority. 

“Board of Directors” means the governing board of a corporation duly elected by the stockholders of the corporation to carry
out the specific responsibilities and oversight duties set forth in the Organizing Documents of the corporation and the laws of the state under which the corporation is incorporated and validly existing. 

“Business Day” means any day other than a Saturday, Sunday or day on which banks are permitted to close in the State of
California. 
 “Business Employee” means any individual who is or was employed or engaged by the Seller on or
at any time prior to the Closing Date or any individual who is or was employed by an Affiliate of the Seller on or at any time prior to the Closing Date to the extent that such individual provided services with respect to the Business. 

“Business Material Adverse Effect” means a material adverse effect on the condition (financial or otherwise),
properties, operations or results of operations of the Business or the Seller’s ability to perform its obligations as contemplated in this Agreement or any Related Agreement; provided, however, that no effect, to the extent
arising out of or resulting from any of the following, shall constitute or be taken into account in determining whether or not there has been a Business Material Adverse Effect: 

(a) general political, economic, financial or capital market conditions or other conditions generally affecting the industry in which the
Business competes, but only to the extent the Business is not disproportionately affected; 
 (b) changes in applicable Laws or
in GAAP; 

  
 -66-

 (c) the public disclosure of this Agreement or the transactions contemplated thereby in
accordance with the terms and conditions of this Agreement; or 
 (d) natural disasters or acts of war, sabotage or terrorism,
or an escalation or worsening thereof. 
 “CERCLA” means the Comprehensive Environmental Response, Compensation
and Liability Act of 1980, as amended. 
 “COBRA Coverage” means the group health plan continuation coverage
requirements of Section 4980B of the Code, Sections 601 through 608 of ERISA and the applicable provisions of the American Recovery and Reinvestment Act of 2009. 
 “Code” means the Internal Revenue Code of 1986, as amended, and all Regulations promulgated thereunder. 
 “Confidentiality Agreement” means that certain Mutual Non-Disclosure Agreement, dated as of March 15, 2012, between the Seller and the Parent. 

“Contract” means any loan agreement, indenture, letter of credit (including related letter of credit applications and
reimbursement obligations), mortgage, security agreement, pledge agreement, deed of trust, bond, note, guarantee, surety obligation, warranty, license, franchise, permit, power of attorney, invoice, quotation, purchase order, sales order, lease,
endorsement agreement, and any other agreement, contract, instrument, obligation, offer, commitment, plan, arrangement, understanding or undertaking, written or oral, express or implied, to which a Person is a party or by which any of its
properties, assets or Intellectual Property may be bound or affected, in each case as amended, supplemented, waived or otherwise modified. 
 “Court” means any court or arbitration tribunal of any country or territory, or any state, province or other subdivision thereof. 

“Employee Benefit Plans” means each plan, program, policy, practice, contract, agreement or other arrangement providing
for compensation, pension, retirement, cash balance, money purchase, savings, profit sharing, annuity, deferred compensation, bonus, incentive (including cash, stock option, stock bonus, stock appreciation, phantom stock, restricted stock and stock
purchase), medical, dental, vision, hospitalization, long-term care, prescription drug and other health, employee assistance, cafeteria, flexible benefits, life insurance, short and long term disability, vacation pay, severance or other termination
pay, other welfare and fringe benefit or remuneration of any kind, whether written or unwritten or otherwise funded or unfunded, including all employee benefit plans within the meaning of Section 3(3) of ERISA which is or has been sponsored,
maintained, contributed to or required to be contributed to, by the Seller or any ERISA Affiliate for the benefit of any employee, officer or director of the Seller or under which the Seller or any ERISA Affiliate has or may have any current or
future liability or obligation. 
 “Environmental Law” means any Law or Order relating to the environment or
occupational health and safety, including any Law or Order pertaining to (i) treatment, storage, disposal, generation and transportation of Materials of Environmental Concern; (ii) air, water and

  
 -67-

 
noise pollution; (iii) the protection of groundwater, surface water or soil; (iv) the release or threatened release into the environment of Materials of Environmental Concern, including
emissions, discharges, injections, spills, escapes or dumping; (v) storage tanks, vessels, containers, abandoned or discarded barrels, and other closed receptacles used for Materials of Environmental Concern; or (vi) occupational health
and safety. As used above, the terms “release” and “environment” shall have the meaning set forth in CERCLA. 
 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and all Regulations promulgated thereunder. 

“ERISA Affiliate” means any person, trade, business or other entity treated as a single employer with the Seller under
Section 414 of the Code or Section 4001(a)(14) of ERISA. 
 “Escrow Agent” means Computer Trust
Company, N.A., or such other person or entity as may be mutually agreed upon by the Seller and the Buyer. 
 “Excepted
Representations” means the representations and warranties set forth in Sections 3.3–3.5, 3.7(a), 3.10, 3.15, 3.16,
 3.20(e), 3.27, 3.30, 4.2, 4.3 and 4.4. 
 “Fifteen Day VWAP” means, with respect to any date of determination, the arithmetic mean of the VWAP for the fifteen (15) consecutive Trading Days ending on such date. 

“GAAP” means generally accepted accounting principles in the United States consistently applied and interpreted.

 “Governmental Authority” means: (a) any nation, state, county, city, town, municipality, village,
district, territory or other jurisdiction of any nature; (b) any federal, state, municipal or local governmental or quasi-governmental entity or authority of any nature; (c) any Court or tribunal exercising or entitled to exercise judicial
authority or power of any nature; (d) any multinational organization or body exercising any administrative, executive, judicial, legislative, police, regulatory or taxing authority of any nature; and (e) any department or subdivision of
any of the foregoing, including any commission, branch, board, bureau, agency, official or other instrumentality exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power
of any nature. 
 “Government Bid” means any offer, proposal or quote made by the Seller (in connection with
the Business) prior to the Closing Date which is outstanding and which, if accepted, would result in a Government Contract. 

“Government Contract” means any contract, subcontract, teaming agreement or arrangement, joint venture, basic ordering
agreement, blanket purchasing agreement, Federal Supply Schedule contract, pricing agreement, CRADA, letter agreement, grant or other similar Contract of any kind, between the Seller, on the one hand, and (a) any Governmental Authority,
(b) any prime contractor of a Governmental Authority in its capacity as a prime contractor, or (c) any subcontractor with respect to any Contract of a type described in clauses (a) or (b) of this definition, on the other hand. A
task, purchase or delivery order under a Government Contract shall not constitute a separate Government Contract, for purposes of this definition, but shall be part of the Government Contract to which it relates. 

  
 -68-

 “Indebtedness” means Liabilities (including Liabilities for principal,
accrued interest, penalties, fees and premiums) (i) for borrowed money, or with respect to deposits or advances of any kind (other than deposits, advances or excess payments accepted in connection with the sale of products or services in the
ordinary course of business), (ii) evidenced by bonds, debentures, notes or similar instruments, (iii) upon which interest charges are customarily paid (other than obligations accepted in connection with the purchase of products or
services in the ordinary course of business), (iv) under conditional sale or other title retention agreements, (v) issued or assumed as the deferred purchase price of property or services (other than accounts payable to suppliers incurred
in the ordinary course of business and paid when due), (vi) of others secured by (or for which the holder of such Liabilities has an existing right, contingent or otherwise, to be secured by) any Lien or security interest on property owned
or acquired by the Person in question whether or not the obligations secured thereby have been assumed, and (vii) under leases required to be accounted for as capital leases under GAAP. 

“Intellectual Property” means worldwide trademarks, service marks, trade names, trade dress, designs, logos, slogans and
general intangibles of like nature, together with all goodwill related to the foregoing (whether registered or not, but including any registrations and applications for any of the foregoing) (collectively, “Trademarks”); patents
(including the ideas, inventions and discoveries described therein, any pending applications, any registrations, patents or patent applications based on applications that are continuations, continuations-in-part, divisional, reexamination, reissues,
renewals of any of the foregoing and applications and patents granted on applications that claim the benefit of priority to any of the foregoing) (collectively, “Patents”); works of authorship or copyrights (including any
registrations, applications and renewals for any of the foregoing) and other rights of authorship (collectively, “Copyrights”); trade secrets and other confidential or proprietary information, know-how, confidential or proprietary
technology, processes, work flows, formulae, algorithms, models, user interfaces, customer, supplier and user lists, databases, pricing and marketing information, inventions, marketing materials, inventions and discoveries (whether patentable or
not) (collectively, “Trade Secrets”); computer programs and other Software, macros, scripts, source code, object code, binary code, methodologies, processes, work flows, architecture, structure, display screens, layouts, development
tools, instructions and templates; published and unpublished works of authorship, including audiovisual works, databases and literary works; rights in, or associated with a person’s name, voice, signature, photograph or likeness, including
rights of personality, privacy and publicity; rights of attribution and integrity and other moral rights; Uniform Resource Locators (URLs) and Internet domain names and applications therefor (and all interest therein), IP addresses, adwords, key
word associations and related rights; all other proprietary, intellectual property and other rights relating to any or all of the foregoing; all copies and tangible embodiments of any or all of the foregoing (in whatever form or medium, including
electronic media); and all rights to sue for and any and all remedies for past, present and future infringements of any or all of the foregoing and rights of priority and protection of interests therein under the Laws of any jurisdiction.

 “IRS” means the United States Internal Revenue Service and, to the extent relevant, the United States
Department of Treasury. 

  
 -69-

 “Knowledge” (and similar terms and phrases) means the actual knowledge of
(i) any officer or director of Seller or (ii) any knowledge which would reasonably have been obtained by any such Person in the prudent exercise of his or her duties to the Seller. 

“Laws” means all laws, statutes, codes, written policies, licensing requirements, ordinances and Regulations of any
Governmental Authority including all Orders having the effect of law in each such jurisdiction. 

“Liabilities” means any debts, liabilities, obligations, claims, charges, damages, demands and assessments of any kind,
character or description, including those with respect to any Governmental Authority, whether accrued or not, known or unknown, disclosed or undisclosed, fixed or contingent, asserted or unasserted, liquidated or unliquidated, joint or several, due
or to become due, whenever or however arising (including, those arising out of any contract or tort based on negligence or strict liability) and whether or not the same would be required by GAAP to be reflected in financial statements or disclosed
in the notes thereto. 
 “Lien” means any mortgage, easement, right of way, charge, claim, community property
interest, condition, equitable interest, lien, option, pledge, security interest, right of first refusal, or restriction or adverse claim of any kind, including any restriction on use, voting, transfer, receipt of income, or exercise of any other
attribute of ownership, or any other encumbrance or exception to title of any kind. 
 “Losses” means losses,
damages, liabilities, demands, taxes, sanctions, deficiencies, assessments, judgments, costs, interest, penalties and expenses (including reasonable attorneys’ fees, which shall include a reasonable estimate of the allocable costs of in-house
legal counsel and staff). 
 “Materials of Environmental Concern” means any substances, chemicals, compounds,
solids, liquids, gases, materials, pollutants or contaminants, hazardous substances (including as such term is defined under CERCLA), solid wastes and hazardous wastes (including as such terms are defined under the Resource Conservation and Recovery
Act), toxic materials, oil or petroleum and petroleum products, asbestos or substances containing asbestos, polychlorinated biphenyls or any other material subject to regulation under any Environmental Law. 

“Office Lease” means that certain “Standard Industrial/Commercial Single-Tenant Lease – Gross” regarding
the premises at 8505 Commerce Avenue, San Diego CA, dated as of May 11, 2012, entered into between Seller and Pinchas Nissanoff, together with any and all amendments thereto. 

“Order” means any judgment, order, writ, injunction, ruling, decision or decree of, or any settlement under the
jurisdiction of any Court or Governmental Authority. 
 “Organizational Documents” means, with respect to any
corporation, those instruments that at the time constitute its corporate charter as filed or recorded under the Laws of the jurisdiction of its incorporation, including the articles or certificate of incorporation, organization or association, and
its by-laws or memorandum of association, in each case including all amendments thereto, as the same may have been restated and, with respect to any other entity, the equivalent organizational or governing documents of such entity. 

  
 -70-

 “Parent Common Stock” means the common stock, $0.0001 par value per share,
of the Parent. 
 “Payment Program” means Medicare, TRICARE, Medicaid, Worker’s Compensation, Blue
Cross/Blue Shield programs, and all other health maintenance organizations, preferred provider organizations, health benefit plans, health insurance plans, and other third party reimbursement and payment programs. 

“Person” means an individual, corporation, partnership, association, trust, unincorporated organization, limited
liability company or other legal entity. 
 “Personally Identifiable Information” means information that can be
used to identify or contact Persons, which may include their first and last name, physical address, e-mail address and telephone number. 
 “Permitted Liens” means (i) those Liens resulting from Taxes that have not yet become due and payable (ii) Liens listed in Schedule I(a) attached hereto that will be
terminated prior to or at the Closing, (iii) obligations of the Seller for performance arising after the Closing under the Assigned Contracts to the extent that the Seller’s rights thereunder are actually (with consent where required)
assigned to the Buyer, and (iv) covenants, conditions, restrictions, easements, encumbrances, and other similar matters of record affection title to, but not affecting the value of, or the current occupancy or use of, the Leased Real Property
in any material respect. 
 “Regulation” means any rule or regulation of any Governmental Authority.

 “Related Agreements” means the Bill of Sales and Assignment Agreement, the Assumption Agreement, the
Copyright Assignment, the Trademark Assignment, the Patent Assignment, the Escrow Agreement each Voting Agreement and each Post-Closing Non-Competition Agreement and Post-Closing Non-Disclosure Agreement to which the Seller, its officers or its
directors is a party. 
 “Representative” means, with respect to any specified Person, the officers, directors,
employees, accountants, counsel and other representatives or agents of such Person or such Person’s Affiliates. 

“Seller Bank Account” means a United States bank account designated in a writing delivered by the Seller to the Buyer at
least two (2) Business Days prior to the Closing. 
 “Seller Intellectual Property” means all Intellectual
Property owned, licensed, used or held by the Seller, including all such Intellectual Property used to develop, manufacture, market and distribute the Seller Products. 
 “Seller Products” means (A) the products that the Seller or the Business (i) is currently developing, (ii) currently manufactures, markets, sells or licenses or
(iii) previously manufactured, marketed, sold or licensed and (B) the services that the Seller or Business currently offers or provides. 

  
 -71-

 “Software” means computer programs, known by any name, including all
versions thereof, and all related documentation, training manuals and materials, user manuals, technical and support documentation, source code and object code, code libraries, debugging files, linking files, program files, data files, computer and
related data, field and date definitions and relationships, data definition specifications, data models, program and system logic, interfaces, program modules, routines, sub-routines, algorithms, macros, scripts, compiler directives, program
architecture, design concepts, system designs, program structure, sequence and organizations, screen displays and report layouts and all other material related to any such computer programs. 

“Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture, limited liability company,
trust or other legal entity of which such Person (either alone or through or together with any other Subsidiary) owns, directly or indirectly, at least fifty percent (50%) of the stock or other equity interests in such entity. 

“Tax Liabilities” means any liabilities which arise from Taxes. 

“Tax Returns” means any and all returns, declarations, reports, claims for refunds and information returns or statements
relating to Taxes, including all schedules or attachments thereto and including any amendment thereof, required to be filed with any Governmental Authority, including consolidated, combined and unitary tax returns. 

“Taxes” means all taxes and governmental impositions of any kind in the nature of (or similar to) taxes, payable to any
Governmental Authority, including those on or measured by or referred to as income, franchise, profits, gross receipts, capital, ad valorem, custom duties, alternative or add-on minimum taxes, estimated, environmental, disability,
registration, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation, health insurance, utility, severance,
production, excise, stamp, occupation, premiums, windfall profits, transfer and gains taxes, and interest, penalties and additions to tax imposed with respect thereto. 
 “Trading Day” means a day that the New York Stock Exchange is open and available for making trades. 
 “Transfer” means any sale, assignment, transfer, conveyance, pledge, hypothecation or other disposition, voluntarily or involuntarily, by operation of law, with or without consideration,
or otherwise (including by way of intestacy, will, gift, bankruptcy, receivership, levy, execution, charging order or other similar sale or seizure by legal process). 
 “VWAP” means, with respect to any Trading Day, the volume weighted average price (the aggregate sales price of all trades of Parent Common Stock during such Trading Day divided by the
total number of shares of Parent Common Stock traded during such Trading Day), as reported by NYSE Amex. 

“WARN” means the Worker Adjustment and Retraining Notification Act, as amended, and the Regulations promulgated
thereunder. 

  
 -72-

 “Working Capital” means an amount equal to the Working Capital Assets minus
the Working Capital Liabilities, all as of the close of business on the Business Day immediately preceding the Closing Date. 

“Working Capital Assets” means the current assets of the Seller determined in accordance with GAAP applied on a
consistent basis and in a manner consistent with the calculation of Current Assets set forth on Schedule II hereto and subject to the principles, if any, set forth on Schedule II hereto. 

“Working Capital Liabilities” means the current liabilities of the Seller determined in accordance with GAAP applied on
a consistent basis and in a manner consistent with the calculation of Current Liabilities set forth on Schedule II hereto, together with the liabilities, and subject to the principles, if any, set forth on Schedule II hereto.

  
 -73-

 EXHIBT A 
 FORM OF BILL OF SALE AND ASSIGNMENT AGREEMENT 
 BILL OF SALE AND ASSIGNMENT
AGREEMENT, made, executed and delivered on September 28, 2012, by To Go Brands, Inc., a Nevada corporation (“Seller”), to MedPodium Health Products, Inc. a Delaware corporation (“Buyer”), a wholly-owned
subsidiary of Cardium Therapeutics, Inc., a Delaware corporation (“Parent”). 
 W I T N E S S E T H: 

WHEREAS, Seller, Buyer and Parent are parties to an Asset Purchase Agreement dated as of September 28, 2012 (the “Purchase
Agreement”; capitalized terms used and not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement), providing for, among other things, the conveyance, sale, transfer, assignment and delivery to Buyer of the
Acquired Assets; and 
 WHEREAS, Seller, Buyer and Parent now desire to carry out the intent and purpose of the Purchase
Agreement by the execution and delivery to Buyer of this instrument evidencing the sale, conveyance, assignment, transfer and delivery to Buyer of the Acquired Assets. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller hereby conveys, sells, transfers, assigns and delivers unto Buyer and its
successors and assigns, forever, their respective entire right, title and interest in, to and under the Acquired Assets, including, without limitation, the Assigned Contracts. 
 TO HAVE AND TO HOLD the Acquired Assets, unto Buyer, its successors and assigns, FOREVER. 
 In the event that any provision of this Bill of Sale and Assignment Agreement is in conflict with a provision in the Purchase Agreement, the provision in the Purchase Agreement shall be deemed to be
controlling. 
 This Bill of Sale and Assignment Agreement shall be construed and enforced in accordance with the laws of the
State of California, without giving effect to its conflict of laws principles. 
 This instrument shall be binding upon and
shall inure to the benefit of the respective successors and assigns of Parent, Buyer, and Seller. 
 EXHIBIT A – FORM OF BILL
OF SALE AND ASSIGNMENT AGREEMENT 

 IN WITNESS WHEREOF, the party hereto has caused this Bill of Sale and Assignment Agreement
to be executed as of the date first above written. 
  

			
	To Go Brands, Inc.
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	  

STATE OF
                                    

 
 COUNTY OF
                                

 

On                      before 
me,                                        
                                         
,

            Date            
     Name, Title of Officer, e.g., “Jane Doe, Notary Public”
  

personally appeared                     
                                         
                               
                                   
                                         
                 Name(s) of Signer(s)
  

[  ] personally known to me - OR - [  ] proved to me on the basis of satisfactory evidence to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of
which the person(s) acted, executed the instrument.
  

                         
                                       Witness my hand
and official seal.
  

                         
                                         
                                         
                     

                         
                                         
                              Signature of Notary
	 	
CAPACITY CLAIMED BY SIGNER
  

[  ] INDIVIDUAL(S)
 [X] CORPORATE
                                         
   
       OFFICER(S)
                                         
      

                         
                                       
Title(s)
 [  ] PARTNER(S)
 [  ] ATTORNEY-IN-FACT
 [  ] TRUSTEE(S)

[  ] SUBSCRIBING WITNESS

[  ] GUARDIAN/CONSERVATOR

[  ] OTHER:
                                         
         

                         
                                         
       

                         
                                         
       
  
 SIGNER IS
REPRESENTING:
 Name of Person(s) or Entity(ies)
  

                         
                                         
      

	 
	ATTENTION NOTARY: Although the information requested below is
OPTIONAL, it could prevent fraudulent attachment of this certificate to unauthorized document.

			
	 THIS
CERTIFICATE MUST BE
 ATTACHED TO THE DOCUMENT DESCRIBED AT RIGHT:
	  	 Title or Type of Document:
                                        
                                        

 Number of Pages:             Date of Document:
                                         
           
 Signer(s) Other Than Named Above:
                                         
                         

 EXHIBIT A – FORM OF BILL OF SALE AND ASSIGNMENT AGREEMENT 

 EXHIBIT B 
 FORM OF ASSUMPTION AGREEMENT 
 ASSUMPTION AGREEMENT (“Assumption
Agreement”), dated September 28, 2012, by and among To Go Brands, a Nevada corporation (“Seller”), MedPodium Health Products, Inc., a Delaware corporation (“Buyer”) and Cardium Therapeutics, Inc., a
Delaware corporation (“Parent”). 
 W I T N E S S E T H: 

WHEREAS, Seller, Buyer, and Parent are parties to an Asset Purchase Agreement dated as of September 28, 2012 (the “Purchase
Agreement”; capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement), providing for, among other things, the conveyance, sale, transfer, assignment and delivery to Buyer of
the Acquired Assets, including, without limitation, the Assigned Contracts; 
 WHEREAS, pursuant to the Purchase Agreement,
Buyer has agreed to assume the Assumed Liabilities. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, Buyer hereby assumes and undertakes to pay, perform and discharge all of the Assumed Liabilities, effective from and after the Closing Date, subject to the terms and conditions set forth in the Purchase
Agreement. 
 In the event that any provision of this Assumption Agreement is in conflict with a provision of the Purchase
Agreement, the provision in the Purchase Agreement shall be deemed controlling. 
 This Assumption Agreement shall be construed
and enforced in accordance with the laws of the State of California, without giving effect to its conflict of laws principles. 

This Assumption Agreement shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors in
interest and permitted assigns. 
 [SIGNATURE PAGE FOLLOWS] 

EXHIBIT B – FORM OF ASSUMPTION AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Assumption Agreement to be executed
as of the date first above written. 
  

			
	SELLER:
	To Go Brands, Inc.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	BUYER:
	NEWCO, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	PARENT:
	CARDIUM THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

 EXHIBIT B – FORM OF ASSUMPTION AGREEMENT 

			
	  

STATE OF
                                    

 
 COUNTY OF
                                

 

On                      before 
me,                                        
                                         
,

            Date            
     Name, Title of Officer, e.g., “Jane Doe, Notary Public”
  

personally appeared                     
                                         
                               
                                   
                                         
                 Name(s) of Signer(s)
  

[  ] personally known to me - OR - [  ] proved to me on the basis of satisfactory evidence to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of
which the person(s) acted, executed the instrument.
  

                         
                                       Witness my hand
and official seal.
  

                         
                                         
                                         
                     

                         
                                         
                              Signature of Notary
	 	
CAPACITY CLAIMED BY SIGNER
  

[  ] INDIVIDUAL(S)
 [X] CORPORATE
                                         
   
       OFFICER(S)
                                         
      

                         
                                       
Title(s)
 [  ] PARTNER(S)
 [  ] ATTORNEY-IN-FACT
 [  ] TRUSTEE(S)

[  ] SUBSCRIBING WITNESS

[  ] GUARDIAN/CONSERVATOR

[  ] OTHER:
                                         
         

                         
                                         
       

                         
                                         
       
  
 SIGNER IS
REPRESENTING:
 Name of Person(s) or Entity(ies)
  

                         
                                         
      

	 
	ATTENTION NOTARY: Although the information requested below is
OPTIONAL, it could prevent fraudulent attachment of this certificate to unauthorized document.

			
	 THIS
CERTIFICATE MUST BE
 ATTACHED TO THE DOCUMENT DESCRIBED AT RIGHT:
	  	 Title or Type of Document:
                                        
                                        

 Number of Pages:             Date of Document:
                                         
           
 Signer(s) Other Than Named Above:
                                         
                         

  
 3 

 EXHIBIT C 
 FORM OF COPYRIGHT ASSIGNMENT 
 To Go Brands, Inc., a Nevada
corporation (“Assignor”) is the owner of numerous copyrighted works including the copyrights identified in Schedule A attached hereto and fully incorporated herein (collectively “Copyrights”). Assignors
desire to sell, transfer and assign to MedPodium Health Products, Inc., a Delaware corporation (“Assignee”), all of their right, title and interest in and to all of their Copyrights in connection with an Asset Purchase Agreement
dated as of September 28, 2012. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, Assignor hereby sell, assign, transfer and deliver to Assignee, its successors and assigns, their entire right, title and interest in and to the Copyrights, and the right to register the Copyrights, in the United
States and throughout the world, and any and all renewals and extensions of any such Copyrights, including but not limited to all causes of action and the right to bring any cause of action relating to any and all previously occurring acts including
the rights being assigned and the right to receive and retain the proceeds relating to those causes of action or the settlement of such causes of action. Assignor agrees to execute any further papers and to do such other acts (without the
expenditure of funds) as may be necessary and proper to vest full title in and to the Copyrights in the Assignee. 
 IN WITNESS WHEREOF,
the undersigned have caused this Copyright Assignment to be executed by their duly authorized officer as of this      day of         , 2012. 

 

			
	To Go Brands, Inc.
		
	By:	 	  

	
	Print Name:
		
	Title:	 	

 EXHIBIT C – FORM OF COPYRIGHT ASSIGNMENT 

 SCHEDULE A 
 COPYRIGHTS 
 All copyrighted works 

  

			
	2	 	EXHIBIT C – FORM OF COPYRIGHT ASSIGNMENT

			
	  

STATE OF
                                    

 
 COUNTY OF
                                

 

On                      before 
me,                                        
                                         
,

            Date            
     Name, Title of Officer, e.g., “Jane Doe, Notary Public”
  

personally appeared                     
                                         
                               
                                   
                                         
                 Name(s) of Signer(s)
  

[  ] personally known to me - OR - [  ] proved to me on the basis of satisfactory evidence to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of
which the person(s) acted, executed the instrument.
  

                         
                                       Witness my hand
and official seal.
  

                         
                                         
                                         
                     

                         
                                         
                              Signature of Notary
	 	
CAPACITY CLAIMED BY SIGNER
  

[  ] INDIVIDUAL(S)
 [X] CORPORATE
                                         
   
       OFFICER(S)
                                         
      

                         
                                       
Title(s)
 [  ] PARTNER(S)
 [  ] ATTORNEY-IN-FACT
 [  ] TRUSTEE(S)

[  ] SUBSCRIBING WITNESS

[  ] GUARDIAN/CONSERVATOR

[  ] OTHER:
                                         
         

                         
                                         
       

                         
                                         
       
  
 SIGNER IS
REPRESENTING:
 Name of Person(s) or Entity(ies)
  

                         
                                         
      

	 
	ATTENTION NOTARY: Although the information requested below is
OPTIONAL, it could prevent fraudulent attachment of this certificate to unauthorized document.

			
	 THIS
CERTIFICATE MUST BE
 ATTACHED TO THE DOCUMENT DESCRIBED AT RIGHT:
	  	 Title or Type of Document:
                                        
                                        

 Number of Pages:             Date of Document:
                                         
           
 Signer(s) Other Than Named Above:
                                         
                         

  

			
	3	 	EXHIBIT C – FORM OF COPYRIGHT ASSIGNMENT

 EXHIBIT D 
 FORM OF ASSIGNMENT OF TRADEMARKS AND DOMAINS 
 To Go Brands, a Nevada
corporation (“Assignor”), is the owner of numerous trademarks and internet domains including, without limitation, those identified in Schedule 1 attached hereto and fully incorporated herein (“Trademarks”).
Assignor desires to sell, transfer and assign to MedPodium Health Products, Inc., a Delaware corporation (“Assignee”), all of their right, title and interest in and to (i) all of its Trademarks and the federal trademark
registrations with the United States Patent and Trademark Office owned by Assignor including those listed on Schedule 1 (“Trademark Registrations”); and (ii) all of their internet domain name registrations including,
without limitation, those listed on Schedule 1 (“Domain Registrations”) in connection with an Asset Purchase Agreement dated as of September 28, 2012. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby
irrevocably sells, assigns, transfers and delivers to Assignee all of Assignor’s worldwide right, title and interest in and to the Trademarks, the Trademark Registrations and the Domain Registrations (and all renewals and extensions thereof),
together with the goodwill of the business associated with or symbolized by the Trademarks, Trademark Registrations, and the Domain Registrations and all rights to profits, damages and other relief for any past, present and future infringement of
the Trademarks, Trademark Registrations, or the Domain Registrations and the right to sue and collect the same for Assignee’s own use and benefit and the benefit of Assignee’s successors, assigns, or legal representatives. 

SIGNATURE PAGE FOLLOWS 
 EXHIBIT D – FORM OF ASSIGNMENT OF TRADEMARKS AND DOMAINS 

 IN WITNESS WHEREOF, the undersigned has caused this Assignment of Trademarks and
Domains to be executed by a duly authorized officer as of this      day of         , 2012. 
  

			
	WITNESS:
		
	By:	 	  

	
	Print Name:
		
	Title:	 	
	
	To Go Brands, Inc.
		
	By:	 	  

	
	Print Name:
		
	Title:	 	

 SCHEDULE 1 OF ASSIGNMENT OF TRADEMARKS AND DOMAINS 

TRADEMARKS: 
  

													
	Mark	  	Docket No.	 	  	Serial No.	 	  	Reg. No.	 
				
	 GO FOCUS
	  	 	BPI-49TM	  	  	 	77707730	  	  			
	 BRAIN BITES
	  	 	BPI-54TM	  	  	 	77775198	  	  			
	 ACTIV BALANCE
	  	 	BPI-55TM	  	  	 	77775199	  	  			
	 POWER PLAY
	  	 	BPI-64TM	  	  	 	85078516	  	  			
	 SMOOTHIE COMPLETE
	  	 	BPI-66TM	  	  	 	85372985	  	  			
	 WATER’S NEW BEST FRIEND
	  	 	BPI-05TM	  	  	 	77114166	  	  	 	3,463,338	  
	 HEALTHY TO GO
	  	 	BPI-06TM	  	  	 	77114170	  	  	 	3,463,339	  
	 GO GREENS
	  	 	BPI-07TM	  	  	 	77114171	  	  	 	3,454,734	  
	 A SALAD BAR IN EVERY PACKET
	  	 	BPI-08TM	  	  	 	77114173	  	  	 	3,456,330	  
	 GREENS TO GO
	  	 	BPI-11TM	  	  	 	78/855,097	  	  	 	3,288,048	  
	 RIP. MIX. 
	  	 	BPI-27TM	  	  	 	77/138,636	  	  	 	3,394,248	  
	 RIP. POUR. GO.
	  	 	BPI-35TM	  	  	 	77/350,035	  	  	 	3,652,028	  
	 OMEGA TO GO
	  	 	BPI-37TM	  	  	 	77/350,233	  	  	 	3,596,049	  
	 [Image]
	  	 	BPI-46TM	  	  	 	77592691	  	  	 	3,717,095	  
	 GREEN ENERGY TEA FUSION
	  	 	BPI-28TM	  	  	 	77247155	  	  	 	3,724,171	  
	 [Image]
	  	 	BPI-48TM	  	  	 	77667684	  	  	 	3,760,037	  
	 TRIM ENERGY
	  	 	BPI-50TM	  	  	 	77707770	  	  	 	3,773,285	  
	 EXTREME BERRIES TO GO
	  	 	BPI-51TM	  	  	 	77724953	  	  	 	3,773,325	  
	 TO GO BRANDS
	  	 	BPI-25TM	  	  	 	77177100	  	  	 	3,828,662	  
	 VITAROCKS
	  	 	BPI-45TM	  	  	 	77540726	  	  	 	3,832,475	  
	 GO SPORT
	  	 	BPI-41TM	  	  	 	77493266	  	  	 	3,904,727	  
	 HEALTHY BELLY
	  	 	BPI-52TM	  	  	 	77739281	  	  	 	3,911,761	  
	 VITA ROCKS
	  	 	BPI-65TM	  	  	 	85119708	  	  	 	4,001,425	  
	 HIGH OCTANE
	  	 	BPI-53TM	  	  	 	77770147	  	  	 	3,915,560	  

 DOMAIN NAMES: 
 ACAINATURALENERGYBOOST.CO 
 ACTIVBALANCE.COM 

BCOMPLX.COM 
 COQ10CAPS.COM 

COQ10SOFTGEL.COM 
 CRANACTIVE.COM 

CRANADAY.COM 
 CRANNATURALS.COM 

DAILYFOCUSTOGO.COM 
 DHAMEGA3.COM 

FISHINOIL.COM 
 FISHOILOIL.COM 

FISHOILSOFTGEL.COM 
 GETGOGREENS.COM 

GOGREENSBERRY.COM 
 GOGREENSCAPS.COM 

GOGREENSCAPSULES.COM 
 GOGREENSDRINK.COM

 GREENCOFFEBEAN.COM 
 GREENSTOGO.COM

 GREENTEAENERGYFUSION.COM 

GREENTEAFUSION.COM 
 HEALTHY-BELLY.COM

 HEALTHYBELLY.NET 

HEALTHYBELLYBRANDS.COM 

HEALTHYBELLYDIGESTION.COM 

HEALTHYBELLYPROBIOTIC.COM 

HEALTHYBELLYPROBIOTICS.COM 

  

 HEALTHYBELLYSOOTHER.COM 
 HEALTHYBELLYTOGO.COM 
 HEALTHYTOGO.ORG 
 HEALTHYTOGOBRANDS.COM 
 HEALTHYTOGOVITAMINS.COM 

HIGHOCTANEENERGY.COM 
 IDAREME.ME 

IDAREME.NET 
 KRILLOILCAPS.COM 

KRILLOILSOFTGEL.COM 
 MAQUIDRINK.COM 

MAQUIENERGY.COM 
 MAQUIENERGYBOOST.COM

 MULTIVITAMINCAPS.COM 

MULTIVITAMINTABS.COM 
 NUTRACOATC.COM 

NUTRICOAT.COM 
 OMEGA2GO.COM 

OMEGATOGO.COM 
 ONFISHOIL.COM 

PHYTORED.COM 
 RESVERAPLUS.COM 

SMOOTHIECOMPLETE.COM 
 SUPERFOOD2GO.COM

 SUPERFOODS2GO.COM 
 VEGETABLECAPS.COM

 SUPERFOODTOGO.COM 

SUPERFRUITSPLUS.COM 
 SUPERFRUITSTOGO.COM

 TESTOSTERX.COM 
 TESTOSTERX.NET

  
 5 

 VEGETABLECAPS.COM 
 VEGGIEANDFRUITCAPS.COM 
 VEGGIEFRUITCAPS.COM 

VITABCOMPLEX.COM 
 VITACROCKS.COM 

VITAMINC-COMPLEX.COM 
 VITAMINCROCKS.COM

 VITAMINDLIQUID.COM 

VITAMINDTHREE.COM 
 VITAMINFISHOIL.COM

 VITAMINSTHATPOP.COM 
 VITAPOPPERS.COM

 VITAROCKS.COM 
 VITAROCKSC.COM

 WOMENMULTI.COM 

WOMENMULTIVITAMIN.COM 

WOMENSDAILYMULTIVITAMIN.COM 

YOURHEALTHYBELLY.COM 

  
 6 

			
	  

STATE OF
                                    

 
 COUNTY OF
                                

 

On                      before 
me,                                        
                                         
,

            Date            
     Name, Title of Officer, e.g., “Jane Doe, Notary Public”
  

personally appeared                     
                                         
                               
                                   
                                         
                 Name(s) of Signer(s)
  

[  ] personally known to me - OR - [  ] proved to me on the basis of satisfactory evidence to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of
which the person(s) acted, executed the instrument.
  

                         
                                       Witness my hand
and official seal.
  

                         
                                         
                                         
                     

                         
                                         
                              Signature of Notary
	 	
CAPACITY CLAIMED BY SIGNER
  

[  ] INDIVIDUAL(S)
 [X] CORPORATE
                                         
   
       OFFICER(S)
                                         
      

                         
                                       
Title(s)
 [  ] PARTNER(S)
 [  ] ATTORNEY-IN-FACT
 [  ] TRUSTEE(S)

[  ] SUBSCRIBING WITNESS

[  ] GUARDIAN/CONSERVATOR

[  ] OTHER:
                                         
          

                         
                                         
       

                         
                                         
       
  
 SIGNER IS
REPRESENTING:
 Name of Person(s) or Entity(ies)
  

                         
                                         
      

	 
	ATTENTION NOTARY: Although the information requested below is
OPTIONAL, it could prevent fraudulent attachment of this certificate to unauthorized document.

			
	 THIS
CERTIFICATE MUST BE
 ATTACHED TO THE DOCUMENT DESCRIBED AT RIGHT:
	  	 Title or Type of Document:
                                        
                                        

 Number of Pages:             Date of Document:
                                         
           
 Signer(s) Other Than Named Above:
                                         
                         

  
 7 

 EXHIBIT E 
 FORM OF PATENT ASSIGNMENT 
 To Go Brands, Inc. a Nevada corporation with
offices at 8505 Commerce Ave., San Diego, CA 92121 ( “Assignor”), hereby acknowledges that pursuant to that certain Asset Purchase Agreement, dated September 28, 2012, by and among Assignor, Cardium Therapeutics, Inc., a
Delaware corporation, with offices at 12255 El Camino Real, Suite 250, San Diego, CA 92130 (“Parent”), and MedPodium Health Products, Inc., a Delaware corporation, with offices at 12255 El Camino Real, Suite 250, San Diego, CA 92130 and
its successors, assigns and legal representatives (herein referred to as “Assignee”), Assignor sells, assigns, transfers, and sets over unto Assignee: (1) Assignor’s entire right, title and interest in, to, and under the
patents and patent applications, and any and all inventions, discoveries and applications that are disclosed in these patents and patent applications, for the United States and in all countries, as identified in Schedule A attached to this
Patent Assignment and any other of Assignor’s patents, inventions, discoveries, or applications (all of which are individually and collectively referred to herein as the “Patents”), and including any and all divisional,
continuation, continuation-in-part, renewal, reissue, reexamination, revival, extension, and any substitute application based upon the Patents, and any patent and reexamination certificate issuing from any divisional, continuation,
continuation-in-part, renewal, reissue, reexamination, revival, extension, and any substitute application based upon the Patents; (2) its full and complete right to file patent applications in the name of the Assignee, its designee, or its
designee’s election, in all countries of the world, on the aforesaid Patents and any inventions, discoveries and applications disclosed in the Patents; (3) its entire right, title and interest in and to any Letters Patents that may issue
thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; (4) its entire right, title and interest in
all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the Patents and the inventions, discoveries and applications that are disclosed in the Patents; and
(5) any and all of Assignor’s claims, demands, causes of action, damages, and remedies of every kind recoverable at law or in equity or otherwise from any and every party for any and every infringement of the Patents and any Letters Patent
that may issue thereon together with the rights to bring and maintain any action for past, present, and future acts of infringements and for the recovery of damages and fees in the United States or in any country. 

Assignor hereby authorize and request the competent authorities to grant and to issue any and all Letters Patents that may issue from the
Patents in the United States and throughout the world to the Assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment, sale and transfer not been
made. 
 EXHIBIT E – FORM OF PATENT ASSIGNMENT 

 Page 2 of 4 
 Assignor agrees, at any time, upon the request of the Assignee, to execute and to deliver to the Assignee any additional applications for patents for any of the inventions and discoveries disclosed in the
Patents, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on the Patents, and any divisionals, continuations, continuations-in-part, renewals, reissues,
reexaminations, revivals, extensions, and any substitute applications based upon the Patents as reasonably requested by Assignee. 
 Assignor further agrees at any time to execute and to deliver upon request of the Assignee such additional documents, if any, as are reasonably necessary to secure patent protection in the Patents and
said inventions, discoveries and applications disclosed in the Patents throughout all countries of the world, and otherwise to do the reasonably necessary to give full effect to and to perfect the rights of the Assignee under this Patent Assignment,
including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be reasonably necessary. 
 Assignor hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into that would conflict with this Patent Assignment. 

Assignor further covenants that Assignee will, upon its reasonable request, be provided promptly with all pertinent facts and documents
relating to the Patents and any Letters Patents issuing therefrom and legal equivalents thereto as may be reasonably known and accessible to Assignor and will testify as to the same in any interference, litigation or proceeding related thereto and
will promptly execute and deliver to Assignee or its legal representatives any and all papers, instruments or affidavits reasonably required to apply for, obtain, maintain, issue and enforce the Patents and any Letters Patents issuing therefrom and
said equivalents thereof that may be reasonably necessary to carry out the purposes thereof. 
  

									
		 		 		 	ASSIGNORS: To Go Brands, Inc.
					
	Date:	 		 		 		 	  

		 		 		 		 	Signature
		 		 		 		 	Name:
		 		 		 		 	Title:
				
		 		 		 	ASSIGNEE: MedPodium Health Products, Inc.
					
	Date:	 		 		 		 	  

		 		 		 		 	Signature
		 		 		 		 	Name:
		 		 		 		 	Title:

  
 – 2
– 
 EXHIBIT E – FORM OF PATENT ASSIGNMENT 

 Page 3 of 4 
 SCHEDULE A 
 ASSIGNED PATENTS AND APPLICATIONS 

U.S. Patent Application No. 13/197,709 – Surface Treatment for Gasified Consumable Materials 

U.S. Patent Application No. 13/251,860 – Liposomes for the Oral Delivery of Therapeutic Agents 

  
 – 3
– 
 EXHIBIT E – FORM OF PATENT ASSIGNMENT 

 Page 4 of 4 
  

			
	  

STATE OF
                                    

 
 COUNTY OF
                                

 

On                      before 
me,                                        
                                         
,

            Date            
     Name, Title of Officer, e.g., “Jane Doe, Notary Public”
  

personally appeared                     
                                         
                               
                                   
                                         
                 Name(s) of Signer(s)
  

[  ] personally known to me - OR - [  ] proved to me on the basis of satisfactory evidence to be the person(s) whose name(s)
is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of
which the person(s) acted, executed the instrument.
  

                         
                                       Witness my hand
and official seal.
  

                         
                                         
                                         
                     

                         
                                         
                              Signature of Notary
	 	
CAPACITY CLAIMED BY SIGNER
  

[  ] INDIVIDUAL(S)
 [X] CORPORATE
                                         
   
       OFFICER(S)
                                         
      

                         
                                       
Title(s)
 [  ] PARTNER(S)
 [  ] ATTORNEY-IN-FACT
 [  ] TRUSTEE(S)

[  ] SUBSCRIBING WITNESS

[  ] GUARDIAN/CONSERVATOR

[  ] OTHER:
                                         
          

                         
                                         
       

                         
                                         
       
  
 SIGNER IS
REPRESENTING:
 Name of Person(s) or Entity(ies)
  

                         
                                         
      

	 
	ATTENTION NOTARY: Although the information requested below is
OPTIONAL, it could prevent fraudulent attachment of this certificate to unauthorized document.

			
	 THIS
CERTIFICATE MUST BE
 ATTACHED TO THE DOCUMENT DESCRIBED AT RIGHT:
	  	 Title or Type of Document:
                                        
                                        

 Number of Pages:             Date of Document:
                                         
           
 Signer(s) Other Than Named Above:
                                         
                         

  
 – 4
– 
  

			
		 	EXHIBIT E – FORM OF PATENT ASSIGNMENT

 EXHIBIT F 
 FORM OF ESCROW AGREEMENT 
 This Escrow Agreement
(“Agreement”) dated September 28, 2012, is made and entered into by and among Cardium Therapeutics, Inc., a Delaware corporation (“Cardium”), To Go Brands, Inc., a Nevada corporation
(“Seller”), (referred to collectively herein as the “Interested Parties”) and Computershare Trust Company, N.A. (“Escrow Agent”). 

A. This Agreement is being entered into in connection with that certain Asset Purchase Agreement (the “APA”) dated as of
September 28, 2012, by and among Cardium, MedPodium Health Products, Inc., and Seller. Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the APA. 

B. In consideration of the Acquired Assets and other consideration set forth in the APA, Cardium has agreed to pay Purchaser up to Ten
Million (10,000,000) shares of Cardium’s authorized but unissued common stock (the “Shares”) valued at up to Two Million Five Hundred Thousand Dollars ($2,500,000) at a purchase price per share equal to the
greater of Twenty-Five cents ($0.25) or the Fifteen Day VWAP as of the Trading Day immediately preceding the Closing Date less an adjustment to account for Retained Cash as provided under Section 1.1(d) of the APA, subject to the terms and
conditions contained in the APA and this Agreement. 
 C. Pursuant to the APA and to secure payment of Buyer’s right to
indemnification under Article VII of the APA, Cardium shall deposit or cause to be deposited with the Escrow Agent twelve and one half percent (12.5%) of the number of Shares (the “Claim Shares”) to be held as a reserve for a
period of eighteen (18) months following the Closing Date (the “Escrow Release Date”), which shall be subject to transfer, cancellation or release in accordance with the terms of this Agreement. 

D. Pursuant to the APA, Cardium shall deposit or cause to be deposited with the Escrow Agent the remaining eighty seven and one half
percent (87.5%) of the Shares (the “Remaining Shares”), which shall be held in escrow and released to Seller in a series of 12 equal monthly installments beginning six months following the Closing Date in accordance with the
terms of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, and
intending to be legally bound, the parties agree as follows: 
 ARTICLE I 

ENGAGEMENT OF THE ESCROW AGENT 
 The Escrow Agent is hereby engaged to act as escrow agent hereunder, and the Escrow Agent agrees to act as such. 

  
 EXHIBIT F
– FORM OF ESCROW AGREEMENT 

 ARTICLE II 
 THE ESCROW FUND 
 2.1 Establishment of Escrow, Maintenance and Voting of the Claim
Shares. 
 (a) Cardium will deposit or cause to be deposited with the Escrow Agent: 

(i) the Claim Shares by instructing the transfer agent to issue such Claim Shares in book-entry form into the name of the
Escrow Agent for the benefit of Seller and Buyer Indemnified Persons; and 
 (ii) the Remaining Shares by
instructing the transfer agent to issue the Remaining Shares in book-entry form into the name of the Escrow Agent, which the Escrow Agent shall hold in escrow and release to Seller in a series of 12 equal monthly installments beginning six months
following the Closing Date. 
 (b) Any distributions of the Shares shall be made in accordance with Section 2.2 hereof.

 (c) Prior to distribution, the Shares will be voted according to the recommendations of the Chief Executive Officer of
Cardium and the Escrow Agent shall have the authority to and shall vote the Shares accordingly. 
  

	 	(d)	Any cash dividends paid in connection with any of the Shares shall be held in escrow by the Escrow Agent for the benefit of Seller and be released to Seller in
connection with the release of the corresponding Shares pursuant to Section 2.2. 

  

	 	(e)	In the event of any stock split, reverse stock split, stock dividend, recapitalization, reorganization, merger, consolidation, combination, exchange of shares,
liquidation, spin-off or other similar change in capitalization or event, or any distribution to holders of the common stock of Cardium other than a regular cash dividend, the Claim Shares and Remaining Shares shall be appropriately adjusted on a
pro rata basis, provided, however, that the Escrow Agent shall have received notice of such stock split or other action and shall have received the appropriate number of additional shares of the Shares or other property pursuant the terms of this
Section. 

 2.2 Distribution of the Shares; Resolution of Claims. 

(a) The Escrow Agent shall continue to hold the Claim Shares and Remaining Shares in its possession until authorized to make distributions
therefrom in accordance with this Section 2.2. Except as otherwise provided in this Section 2.2, the Escrow Agent shall disburse the Claim Shares, or any portion thereof, only in accordance with (i) joint written instructions from the
Seller and the Buyer or (ii) a final order, decree or judgment of a court of competent jurisdiction or arbitral panel, with respect to any arbitrated disputes, in the United States of America (the time for appeal having expired with no appeal
having been taken) in a proceeding to which the Interested Parties are parties. 

  

			
	2	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 (b) On the date that is six months following the Closing Date, the Escrow Agent shall cause
to be delivered to Seller in Seller’s name 1/12 of the Remaining Shares, which shall contain a restricted securities legend. Thereafter, on the same day of the month of each of the next 11 months, the Escrow Agent shall deliver to Seller an
additional 1/12 of the Remaining Shares (with a restricted securities legend), such that on the one year anniversary of the date that is six months following the Closing Date the entirety of the Remaining Shares shall have been delivered to Seller.

 (c) If Cardium, MedPodium Health Products, Inc.,or other affiliate, subsidiary, or successor in interest of Cardium (the
“Claiming Person”) asserts a right of indemnity against the Seller in accordance with Article VII of the APA, or for Losses arising from Legal Claims, or for any breaches of warranties by Seller for which such Claiming Person seeks
recovery from the Claim Shares (individually a “Claim” and collectively “Claims”), such Claiming Person may deliver to the Escrow Agent (with a copy being sent to the Seller) a written notice to such effect (a
“Notice of Claim”) describing the Claim and identifying the date on which the Notice of Claim was delivered to Seller in accordance with Section 8.1 hereof. 

(d) For the purposes of this section 2.2, the value of the Claim Shares shall be calculated based on the greater of Twenty-Five cents
($0.25) per share or the Fifteen Day VWAP as of the Trading Day immediately preceding the Closing Date (the “Claim Share Value”) which Claim Share Value shall be supplemented by the value of any distributions which may be made in
connection with the Claim Shares pursuant to Section 2.1(d). The Claim Share Value shall be used to calculate the number of shares (the “Claimed Shares”) which are to be cancelled or returned to Cardium or its designee at its
election, in satisfaction of a Claim. 
 (e) Unless the Notice of Claim is objected to in a writing explaining in detail the
basis for any objection (an “Escrow Objection Notice”), delivered by Seller to Cardium and to the Escrow Agent within ten (10) days following delivery of the Notice of Claim in accordance with Section 8.1 hereof, then the
Escrow Agent shall cancel or return the Claimed Shares, as specified in the Notice of Claim. 
 (f) In the event that the
Interested Parties cannot reach agreement within thirty (30) days following the Escrow Objection Notice, and in order to encourage the Interested Parties to resolve any such dispute without resorting to legal action, the parties agree to submit
any dispute between them regarding the Claimed Shares (an “Escrow Dispute”) to mediation before a mutually-agreeable Judicate West mediator handling commercial disputes in San Diego, California rather than filing any legal action.
In the event that the parties cannot agree on such a Judicate West mediator, then the mediator proposed by each of the parties shall meet and they shall select a mediator to handle the matter (the “Mediator”). The Mediator shall
attempt to bring the parties to a mutually-agreeable resolution of the dispute. In the event the parties cannot reach agreement, the Mediator shall request confidential position statements from each party, including any additional documentation
deemed pertinent by the Mediator, and shall thereafter deliver a proposed Mediator’s settlement to the parties. Each party shall advance the costs equivalent to one full day of mediation (representing two full days in total) to the Mediator or
Judicate West, as applicable, prior to the mediation. In the event the parties reach agreement, any excess amount paid shall be returned equally to the parties. In the event the parties do not reach agreement, any excess of amount paid shall be
returned to the party whose final proposal as reflected in its position statement is closest to that of the Mediator’s proposed settlement, any 

  

			
	3	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 
amount remaining due shall be paid by the party whose final proposal as reflected in its position statement is furthest from that proposed in the Mediator’s settlement, and the matter shall
be submitted to binding arbitration using the same selection procedure and dispute resolution process as described above, provided that each party shall advance the costs equivalent to two full days of time (representing four full days in total)
with the selected arbitrator (“the “Arbitrator”). The Arbitrator shall attempt to bring the parties to a mutually-agreeable resolution of the dispute. In the event the parties cannot reach agreement, the Arbitrator shall
request confidential position statements from each party, including any additional documentation deemed pertinent by the Arbitrator, and shall thereafter deliver a proposed Arbitrator’s settlement to the parties. In the event the parties reach
agreement on the Arbitrator’s proposed settlement, any excess amount paid shall be returned equally to the parties. In the event the parties do not reach agreement, any excess of amount paid shall be returned to the party whose final proposal
as reflected in its position statement is closest to that of the Arbitrator’s proposed settlement, any amount remaining due shall be paid by the party whose final proposal as reflected in its position statement is furthest from that proposed in
the Arbitrator’s proposed settlement. The Arbitrator’s decision shall be deemed be final and binding against the Interested Parties, and shall be carried out by the Escrow Agent. 

(g) Promptly following the Escrow Release Date, the Escrow Agent shall distribute to the Seller the entire then remaining balance, if
any, of the Claim Shares and any distributions made in connection with such shares pursuant to Section 2.1(d); provided, however, that if any Notices of Claim have been delivered in accordance with Section 2.2(c) prior to the
Escrow Release Date but the Claims specified therein have not been resolved or settled prior to the Escrow Release Date (the “Remaining Claims”), the Escrow Agent will retain in the Claim Shares an amount equal to all Claimed
Amounts specified in such Remaining Claims (the “Remaining Claimed Amounts”) and distribute the balance to Seller. Any portion of the Claim Shares which shall continue to be held by the Escrow Agent pursuant to the preceding
sentence shall be so held until such time as all Remaining Claims hereunder have been settled or resolved. 
 (h) Under no
circumstances shall the Escrow Agent be required to release or distribute any portion of the Claim Shares or take any action under this Agreement sooner than five (5) Business Days after the Escrow Agent has received the requisite notices or
other required documents in good form, or passage of the applicable claims period or release date, as the case may be. 
 (i)
Under no circumstances shall the Escrow Agent be required to calculate the Claim Share Value. 
 (j) No fractional shares of
Cardium shall be retained in or released from the Escrow Account pursuant to this Agreement. In connection with any release of Claim Shares or Remaining Shares from escrow, Cardium and the Escrow Agent shall “round down” in order to avoid
retaining any fractional shares in the [Escrow Account] and in order to avoid releasing any fractional shares from escrow. When shares are “rounded down,” no cash-in-lieu payments need to be made. 

  

			
	4	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 ARTICLE III 
 TERMINATION 
 This Agreement shall automatically terminate if and when the
entirety of the Claim Shares shall have been completely distributed by the Escrow Agent in accordance with the terms of this Agreement. 
 ARTICLE IV 
 THE ESCROW AGENT 

4.1 Escrow Agent Responsibilities. 
 (a) The Escrow Agent and its agent and affiliates shall not be liable for any action taken or omitted by it, or any action suffered by it to be taken or omitted, in good faith and in the exercise of its
own best judgment, absent gross negligence or willful misconduct, and may rely conclusively and shall be protected in acting upon any order, notice, demand, certificate, opinion or advice of counsel, statement, instrument, report or other paper or
document (not only as to its due execution and the validity and effectiveness of its provisions, but also to the truth and acceptability of any information therein contained) which is believed in good faith by the Escrow Agent to be genuine and to
be signed or presented by Seller and Cardium. The Escrow Agent shall not be bound by any notice or demand, or any waiver, modification, termination or rescission of this Agreement, unless evidenced by a writing delivered to the Escrow Agent signed
by Seller and Cardium. In performing any duties under this Agreement, the Escrow Agent and its affiliates and agents shall not be liable to any party for any incidental, indirect, special or consequential damages of any nature whatsoever, including,
but not limited to, loss of anticipated profits, occasioned by a breach of any provision of this Agreement even if apprised of the possibility of such damages, losses, or expenses, except for gross negligence or willful misconduct on the part of the
Escrow Agent. 
 (b) The Escrow Agent shall not be responsible for the sufficiency or accuracy, the form of, or the execution,
validity, value or genuineness of, any document or property received, held or delivered by it hereunder, or of any signature or endorsement thereon, or for any description therein, nor shall the Escrow Agent be responsible or liable in any respect
or on account of the identity, authority or rights of the persons executing or delivering or purporting to execute or deliver any document or property paid or delivered by the Escrow Agent pursuant to the provisions hereof, if in all cases the
Escrow Agent acts in good faith, using reasonable judgment. 
 (c) The Escrow Agent may at any time resign and thereupon be
discharged of its duties as Escrow Agent hereunder by giving thirty (30) calendar days written notice thereof to the other parties hereto and transferring the Claim Shares and any Remaining Shares and any other documents or items held by it
hereunder to a successor agent designated by all parties. Such resignation shall not take effect until receipt by the Escrow Agent of an instrument of acceptance executed by a successor escrow agent and subscribed and consented to by each of the
parties hereto and delivery of the documents and items held hereunder by the Escrow Agent to such successor. Any successor escrow agent appointed hereunder shall be jointly designated by Seller and Cardium. The Escrow Agent shall also be discharged
of its duties and obligations hereunder upon deposit of all documents and items held hereunder to, and acceptance thereof, by any court in San Diego County, California having jurisdiction over the parties hereto and willing to accept same. In
addition, Seller and Cardium acting together may jointly discharge the Escrow Agent at any time during the term hereof upon thirty (30) calendar days prior written notice. 

  

			
	5	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 (d) Upon delivery of all or any portion of the documents or items held hereunder by the
Escrow Agent in accordance with the terms hereof, the Escrow Agent shall be relieved of any and all further obligations hereunder in respect to the portion so delivered. 
 (e) This Agreement shall inure to the benefit of and be binding upon the Escrow Agent and its successors and assigns. The Escrow Agent may perform its duties through its agents and affiliates. The Escrow
Agent shall have no duties or obligations hereunder except as expressly set forth herein, shall be responsible only for the performance of such duties and obligations, shall not be required to take any action otherwise than in accordance with the
terms hereof and shall not in any manner be liable or responsible for any loss or damage arising by reason of any act or omission by it or in connection with any of the transactions contemplated hereby, including, but not limited to any loss that
may occur by reason of forgery, false representations or the exercise of its discretion in any particular manner or for any other reason, except for its own gross negligence, willful misconduct, unlawful act, or failure to act in good faith.

 (f) The Escrow Agent shall receive the sum of $3,500 for its services rendered hereunder, so long as the time spent in
the performance of its duties hereunder does not exceed fifteen (15) hours. The Escrow Agent shall keep records of the time spent in the performance of its services hereunder and shall submit a monthly statement of same to both Seller and
Cardium. If the services of the Escrow Agent shall exceed fifteen (15) hours in the aggregate, then the Escrow Agent shall be paid for such excess hours at the rate of $125 per hour. All fees for the services of the Escrow Agent hereunder are
to be paid one-half by Cardium and one-half by Seller. 
 (g) Disputes. It is understood and agreed that should any dispute
arise between the parties to this Agreement or the APA, with respect to the delivery, ownership, right of possession and/or disposition of the Shares, should any claim be made upon such Shares by a third party or should the Escrow Agent be unable to
determine, to the Escrow Agent’s reasonable satisfaction, the proper disposition of any portion of the Shares or the Escrow Agent’s proper actions with respect to its obligations hereunder, then Escrow Agent may, in its sole discretion,
take either or both of the following actions: 
  

	 	(i)	suspend the performance of any of its obligations under this Agreement until such dispute or uncertainty shall be resolved to the sole satisfaction of the Escrow Agent;
or 

  

	 	(ii)	petition (by means of interpleader action or any other appropriate method) any court of competent jurisdiction, for instructions with respect to such dispute or
uncertainty, and pay into or deposit with such court all disputed Shares held by it in the Escrow for holding and disposition in accordance with the instructions of the court. 

 The Escrow Agent shall have no liability to the parties to this Agreement or to the APA or any other person with respect to any such suspension or performance or disbursement into court, 

  

			
	6	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 
specifically including any liability that may arise, or be alleged to have arisen, out of or as a result of any delay in the disbursement of the Shares held in escrow pursuant to this Agreement
or any delay in or with respect to any other action required of or requested of the Escrow Agent. 
 ARTICLE V 

INDEMNIFICATION 
 Without determining or limiting any rights as between the Interested Parties, but subject to the provisions of Articles VI and VII, each of the Interested Parties covenants and agrees, jointly and
severally, to indemnify the Escrow Agent (and its directors, officers and employees) and hold it (and such directors, officers and employees) harmless from and against any loss, liability, damage, cost and expense of any nature incurred by the
Escrow Agent arising out of or in connection with this Agreement or with the administration of its duties hereunder, including but not limited to, reasonable attorneys’ fees and other costs and expenses of defending or preparing to defend
against any claim of liability unless and except to the extent such loss, liability, damage, cost and expense shall be caused by the Escrow Agent’s gross negligence, bad faith or willful misconduct. The Escrow Agent shall not be liable for any
incidental, indirect, special or consequential damages of any nature whatsoever, including, but not limited to, loss of anticipated profits, occasioned by a breach of any provision of this Agreement even if apprised of the possibility of such
damages. The foregoing indemnification obligation shall survive the termination of this Agreement and the resignation or removal of the Escrow Agent. 
 ARTICLE VI 
 TAX MATTERS 

6.1 Obligations of the Interested Parties. Without determining or limiting any rights as between the Interested
Parties, each of the Interested Parties agrees severally, and not jointly, (i) to assume any and all obligations now or hereafter arising under any applicable tax law with respect to any payment or distribution of the Claim Shares or Remaining
Shares to, or performance of other activities under this Agreement by, such Interested Party, (ii) to instruct the Escrow Agent in writing with respect to the Escrow Agent’s responsibility for withholding and other taxes, assessments or
other governmental charges, and to instruct the Escrow Agent with respect to any certifications and governmental reporting that may be required under any laws or regulations that may be applicable in connection with its action as Escrow Agent under
this Agreement, and (iii) to indemnify and hold the Escrow Agent harmless from any liability or obligation on account of taxes, assessments, additions for late payment, interest, penalties, expenses and other governmental charges that may be
assessed or asserted against the Escrow Agent in connection with or relating to any payment made or other activities performed under the terms of this Agreement including, without limitation, any liability for the withholding or deduction of (or the
failure to withhold or deduct) the same, and any liability for failure to obtain proper certifications or to report properly to governmental authorities in connection with this Agreement, including costs and expenses (including reasonable legal fees
and expenses), interest and penalties, to the extent that it relates to such individual Interested Party. The foregoing indemnification obligation shall survive the termination of this Agreement and the resignation or the removal of the Escrow
Agent. 

  

			
	7	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 6.2 Treatment of Earnings. The Interested Parties agree that Seller will be
treated for federal, state and local income and other tax purposes as owning the Claim Shares and the Remaining Shares, and agree that all earnings, if any, with respect thereto will be reported by the Escrow Agent as earnings of Seller whether or
not distributed. On or promptly after the date hereof, the Seller shall provide the Escrow Agent with a completed IRS Form W-9 certifying thereon the Seller’s taxpayer identification number. The Seller acknowledges that withholding of a portion
of the earnings on the Claim Shares and the Remaining Shares may be required for federal, state or local income tax purposes in the event the Seller fails to certify its taxpayer identification number to the Escrow Agent. 

ARTICLE VII 
 DISPUTES 
 If any dispute should arise with respect to the distribution or
ownership or right of possession of all or any portion the Remaining Shares or the Claim Shares (including, without limitation, any Contested Claim), or the duties of the Escrow Agent hereunder, or should any claim be made upon the Escrow Agent, the
Remaining Shares or the Claim Shares by any third party, the Escrow Agent is authorized and shall be entitled (at its sole option and election) to retain in its possession, without liability to anyone, all or any part of the Remaining Shares and the
Claim Shares in dispute until such dispute shall have been settled either by mutual agreement of the Interested Parties (evidenced by appropriate instructions in writing to the Escrow Agent signed by the Interested Parties) or by the final order,
decree or judgment of a court of competent jurisdiction or arbitral panel, with respect to any arbitrated disputes, in the United States of America (the time for appeal having expired with no appeal having been taken) in a proceeding to which the
Interested Parties are parties, but the Escrow Agent shall be under no duty whatsoever to institute or defend any such proceedings. 
 ARTICLE VIII 
 MISCELLANEOUS 

8.1 Notices. All notices or other communications which are required or permitted hereunder shall be in writing and
sufficient if delivered personally or sent by nationally-recognized overnight courier, or by facsimile transmission with a copy thereof to be delivered by nationally-recognized overnight courier within 24 hours of such facsimile transmission
addressed as follows: 
  

	 	(i)	if to Cardium, to: 

 Cardium
Therapeutics 
 12255 El Camino Real, Suite 250 
 San Diego, CA 92130 
 Attention: Tyler M. Dylan-Hyde 

Facsimile: 858-436-1001 

  

			
	8	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 with a copy to (which shall not constitute notice): 

Sheppard Mullin Richter & Hampton 
 12275 El Camino Real, Suite 250 
 San Diego, CA 92130 

Attention: Edwin Astudillo 
 Facsimile: 858-847-4848 
  

	 	(ii)	if to the Seller or to: 

 To Go
Brands, Inc. 
 8505 Commerce Ave. 
 San Diego, CA 92121 
 Attention: Derek Howe 

Facsimile: 858-200-0687 
 with a copy to (which shall not constitute notice): 
 Kolesar & Leatham

 400 S. Rampart, Suite 400 
 Las Vegas, NV 89145 
 Attention: Joseph J. Mugan 

Facsimile: 702-362-9472 
  

	 	(iii)	if to the Escrow Agent, to: 

Computershare Trust Company, N.A. 
 Attn: Corporate Trust Officer 
 350 Indiana St., Suite 750, 

Golden, CO 80401 
 Attention: John M. Wahl 
 Facsimile: 303-262-0608 

All such notices or communications shall be deemed to be delivered and received (a) in the case of personal delivery, on the date of such delivery,
(b) in the case of nationally-recognized overnight courier, on the next Business Day after the date when sent, or (c) in the case of facsimile or email transmission upon confirmed receipt; provided, however, that no notice to the Escrow
Agent shall be deemed delivered until actually received by the Escrow Agent. 
 8.2 Counterparts. This Agreement
may be executed in any number of counterparts by original or facsimile signature, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. 

8.3 Governing Law. This Agreement will be governed by and construed and enforced in accordance with the laws of the State
of California without giving effect to any choice of law or conflicting provision or rule that would cause the laws of any jurisdiction other than The State of California to be applied. 

  

			
	9	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 8.4 Wiring Instructions. All funds, if any, to be paid to or by the Escrow
Agent shall be sent by wire transfer in accordance with the instructions provided on Schedule A hereto, or by such other method of payment and in accordance with such instructions as may be given in advance and in writing to the Escrow Agent
or the Interested Parties by notice in compliance with Section 8.1 of this Agreement. 
 8.5 Parties in
Interest. This Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and assigns. 
 8.6 Amendments. This Agreement may be amended only by a written instrument duly executed by the parties hereto. No course of conduct shall constitute a waiver of any of the terms and
conditions of this Agreement, unless such waiver is specified in a writing signed by the party against whom enforcement of any waiver is sought, and then only to the extent so specified. A waiver of any of the terms and conditions of this Agreement
on one occasion shall not constitute a waiver of the other terms of this Agreement, or of such terms and conditions on any other occasion. 
 8.7 Headings. The section and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 8.8 Entire Agreement. This Agreement and, with respect to the Interested Parties only, the APA and the
documents delivered in connection therewith, contain the entire agreement among the parties hereto with respect to the transactions contemplated hereby and supersede all prior agreements or understandings, written or oral, among the parties
identified above with respect thereto; provided, however, that anything contained herein to the contrary notwithstanding, the parties hereto agree that the Escrow Agent shall perform its obligations under this Agreement solely by
reference to this Agreement. 
 8.9 Force Majeure. The Escrow Agent shall not be responsible for delays or
failures in performing its duties resulting from acts beyond its control such as, but not limited to, acts of God, strikes, lockouts, riots, acts of war, epidemics, acts of terrorism, governmental regulations superimposed after the fact, fire,
communication line failures, computer viruses, power failures, earthquakes or other disasters. 
 8.10 Consent to
Jurisdiction and Service of Process. Each of the Interested Parties hereby absolutely and irrevocably consents and submits to the jurisdiction and venue of the federal and state courts sitting in San Diego County, California in connection
with any actions or proceedings brought against any of the Interested Parties or the Escrow Agent (or each of them) arising out of or relating to this Agreement. In any such action or proceeding, the Escrow Agent and the Interested Parties each
hereby absolutely and irrevocably (i) waives any objection to jurisdiction or venue, (ii) waives personal service of any summons, complaint, declaration or other process, and (iii) agrees that the service thereof may be made by
overnight courier in accordance with Section 8.1 hereof. 

  

			
	10	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 8.11 Severability. If any provision of this Agreement, including any phrase,
sentence, clause, section or subsection is inoperative or unenforceable for any reason, such circumstances shall not have the effect of rendering the provision in question inoperative or unenforceable in any other case or circumstance, or of
rendering any other provision or provisions herein contained invalid, inoperative, or unenforceable to any extent whatsoever. 

8.12 Waiver of Jury Trial. THE ESCROW AGENT AND THE INTERESTED PARTIES, TO THE EXTENT ALLOWABLE BY ANY APPLICABLE LAWS,
HEREBY WAIVE A TRIAL BY JURY OF ANY AND ALL ISSUES ARISING IN ANY ACTION OR PROCEEDING BETWEEN THEM OR THEIR SUCCESSORS OR ASSIGNS, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF ITS PROVISIONS OR ANY NEGOTIATIONS IN CONNECTION HEREWITH.

 [SIGNATURE PAGE FOLLOWS] 

  

			
	11	 	EXHIBIT F – FORM OF ESCROW AGREEMENT

 IN WITNESS WHEREOF, the parties hereto have caused this Escrow Agreement to be
executed and delivered on the date first above written. 
  

			
	CARDIUM:
	
	CARDIUM THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	THE SELLER:
	
	TO GO BRANDS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	THE ESCROW AGENT:
	
	COMPUTERSHARE TRUST COMPANY, N.A.
		
	By:	 	  

	Name:	 	
	Title:	 	

 SCHEDULE A 
 Wiring instructions for payment to Escrow Agent: 
 Bank of America 

100 West 33rd St. 
 New
York, NY 
 ABA: 026-009-593 
 Account
No.: 4426874722 
 Acct. Name: Computershare Trust Company, NA as Escrow Agent for Clients 

Ref: Cardium / To Go Escrow 

 EXHIBIT G 
 FORM OF VOTING AGREEMENT 
 THIS VOTING
AGREEMENT (“Agreement”) is entered into as of September 28, 2012, by and Cardium Therapeutics, Inc., a Delaware corporation (“Cardium”), and each of the persons and entities listed on
Exhibit B hereto (each, a “Stockholder”). 
 RECITALS 

A. Each Stockholder is a holder of record and/or the “beneficial owner” (within the meaning of Rule 13d-3 under the
Securities Exchange Act of 1934 (the “Exchange Act”) of certain shares of capital stock of To Go Brands, Inc., a Nevada corporation (the “Company”). 

B. Cardium, MedPodium Health Products, Inc., a Delaware corporation and a wholly owned subsidiary of Cardium
(“Buyer”) and the Company are entering into an Asset Purchase Agreement of even date herewith (the “APA”) which provides (subject to the conditions set forth therein) for the purchase by Buyer of the Acquired Assets
from the Company (the “Asset Purchase”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the APA. 

C. In order to induce Cardium and Buyer to enter into the APA, each Stockholder is entering into this Agreement. 

AGREEMENT 

The parties to this Agreement, intending to be legally bound, agree as follows: 
 SECTION 1. CERTAIN DEFINITIONS 
 For purposes
of this Agreement: 
 (a) “Acquisition Proposal” shall mean (other than an offer or
proposal made or submitted by Cardium or Buyer), (a) any proposal or offer from any Person or group of Persons (other than Cardium or Buyer or their respective Affiliates or representatives) for (i) any acquisition by such Person or group
of Persons of a substantial amount of assets of the Company having a fair market value (as determined by the Board of Directors of the Company in good faith) in excess of 20% of the fair market value of all the assets of the Company immediately
prior to such acquisition or more than a 20% interest in the total voting securities of the Company or (ii) any tender offer, exchange offer or other transaction that if consummated would result in any Person or group of Persons beneficially
owning 20% or more of any class of equity securities of the Company, (b) any proposal or offer with respect to any merger, consolidation, or business combination of the Company with any unaffiliated third party, other than the transactions
contemplated by the APA or (c) any license or sublicense involving a substantial amount of the assets of the Company. 

  

			
	1	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 (b) “Company Capital Stock” shall mean the Company Common
Stock and Company Preferred Stock. 
 (c) “Company Common Stock” shall mean the Common Stock,
$0.001 par value per share, of the Company. 
 (d) “Company Preferred Stock” shall mean the
Series A Preferred Stock, $0.001 par value per share of the Company 
 (e) A Stockholder shall be
deemed to “Own,” or to have acquired “Ownership” of, a security if such Stockholder: (i) is the record owner of such security; or (ii) is the “beneficial owner” (within the meaning of Rule 13d-3
under the Exchange Act) of such security. 
 (f) “Person” shall mean any (i) individual,
(ii) corporation, limited liability company, partnership or other entity, or (iii) governmental authority. 
 (g) With respect to each Stockholder, “Subject Securities” shall mean (i) all securities of the Company (including all shares of Company Capital Stock and all options,
warrants and other rights to acquire shares of Company Capital Stock) Owned by such Stockholder as of the date of this Agreement; and (ii) all additional securities of the Company (including all additional shares of Company Capital Stock and
all additional options, warrants and other rights to acquire shares of Company Capital Stock) of which such Stockholder acquires Ownership during the period from the date of this Agreement through the Voting Covenant Expiration Date. 

(h) A Person shall be deemed to have a effected a “Transfer” of a security if such Person directly
or indirectly: (i) sells, pledges, encumbers, grants an option with respect to, transfers or disposes of such security or any interest in such security to any Person other than Cardium; (ii) enters into an agreement or commitment
contemplating the possible sale of, pledge of, encumbrance of, grant of an option with respect to, transfer of or disposition of such security or any interest therein to any Person other than Cardium; or (iii) reduces such Person’s
beneficial ownership of, interest in or risk relating to such security. 
 (i) “Voting Covenant
Expiration Date” shall mean the earlier of the date upon which the APA is validly terminated, or the Closing Date. 
 SECTION 2.
TRANSFER OF SUBJECT SECURITIES AND VOTING RIGHTS 
 2.1 Transfer of Subject Securities. Prior to the Voting Covenant Expiration Date, each Stockholder agrees, severally and not jointly, that it shall not Transfer any Subject Securities to any
Person other than to a Person that agrees in a writing, reasonably satisfactory in form and substance to Cardium, to be bound by the terms of this Agreement with respect to all Subject Securities Transferred to such Person. 

2.2 Transfer of Voting Rights. Prior to the Voting Covenant Expiration Date, each Stockholder agrees, severally and not jointly,
that it shall ensure that: (a) none of such 

  

			
	2	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 
Stockholder’s Subject Securities is deposited into a voting trust; and (b) no proxy or power of attorney is granted (other than in connection with such Stockholder’s compliance
with Section 3.2 of this Agreement), and no voting agreement or similar agreement is entered into, with respect to such Stockholder’s Subject Securities. 
 SECTION 3. VOTING OF SHARES 

3.1 Voting Covenant Prior to Termination of APA. Each Stockholder hereby agrees, severally and not jointly, that, prior to
the Voting Covenant Expiration Date, at any meeting of the stockholders of the Company, however called, and in any written action by consent of stockholders of the Company, unless otherwise directed in writing by Cardium, such Stockholder shall
cause the Subject Securities to be voted, as applicable: 
 (a) in favor of the Asset Purchase, the
execution and delivery by the Company of the APA and the adoption and approval of the APA and the terms thereof, in favor of each of the other actions contemplated by the APA and in favor of any action in furtherance of any of the foregoing; and

 (b) against any action or agreement that would result in a breach of any representation, warranty,
covenant or obligation of the Company or any subsidiary of the Company in the APA; and 
 (c) against the
following actions (other than the Asset Purchase and the transactions contemplated by the APA): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving the Company or any subsidiary
of the Company; (B) any sale, lease or transfer of a material amount of assets of the Company or any subsidiary of the Company; (C) any reorganization, recapitalization, dissolution or liquidation of the Company or any subsidiary of the
Company; (D) any change in a majority of the board of directors of the Company; (E) any amendment to the Company’s articles of incorporation or bylaws; (F) any material change in the capitalization of the Company or the
Company’s corporate structure; and (G) any other action which is intended, or could reasonably be expected, to impede, interfere with, delay, postpone, discourage or adversely affect the Asset Purchase or any of the other transactions
contemplated by the APA or this Agreement. 
 Prior to the Voting Covenant Expiration Date, each Stockholder agrees that it shall not enter into
any agreement or understanding with any Person to vote or give instructions in any manner inconsistent with clause “(a)”, “(b)”, or “(c)” of the preceding sentence. 

3.2 Proxy; Further Assurances. 
 (a) Contemporaneously with the execution of this Agreement: (i) each Stockholder shall deliver to Cardium a proxy in the form attached to this Agreement as Exhibit A, which shall
be irrevocable to the fullest extent permitted by law (at all times prior to the Voting Covenant Expiration Date) with respect to the shares referred to therein (the “Proxy”); and (ii) each Stockholder shall cause to be
delivered to Cardium an additional proxy (in the form attached hereto as Exhibit A) executed on behalf of the record owner of any outstanding shares of Company Common Stock that are owned beneficially (within the meaning of Rule 13d-3
under the Exchange Act), but not of record, by such Stockholder. 

  

			
	3	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 (b) Each Stockholder shall, at such Stockholder’s own expense,
perform such further acts and execute such further proxies and other documents and instruments as may reasonably be required to vest in Cardium the power to carry out and give effect to the provisions of this Agreement with respect to such
Stockholder’s Subject Securities. 
 SECTION 4. WAIVER OF APPRAISAL RIGHTS

 Each Stockholder hereby irrevocably and unconditionally waives, and agrees to cause to be waived and to prevent the
exercise of, any rights of appraisal, any dissenters’ rights and any similar rights relating to the Asset Purchase or any related transaction that such Stockholder or any other Person may have by virtue of any outstanding shares of Company
Capital Stock Owned by Stockholder (“Appraisal Rights”). 
 SECTION 5. NO SOLICITATION

 Each Stockholder agrees, severally and not jointly, that, prior to the Voting Covenant Expiration Date, such Stockholder
shall not, directly or indirectly: (i) solicit, initiate, encourage, induce or facilitate the making, submission or announcement of any Acquisition Proposal or take any action that could reasonably be expected to lead to an Acquisition
Proposal; (ii) furnish any information regarding the Company or any subsidiary of the Company to any Person in connection with or in response to an Acquisition Proposal or an inquiry or indication of interest that could lead to an Acquisition
Proposal; (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal; (iv) approve, endorse or recommend any Acquisition Proposal; or (v) enter into any letter of intent or similar document or
any agreement or understanding contemplating or otherwise relating to any transaction that contemplated by the term Acquisition Proposal. Each Stockholder shall immediately cease and discontinue any existing discussions with any Person that relate
to any Acquisition Proposal. 
 SECTION 6. REPRESENTATIONS AND WARRANTIES OF
STOCKHOLDER 
 Each Stockholder, severally and not jointly, hereby represents and warrants to Cardium as
follows: 
 6.1 Authorization, etc. Such Stockholder has the absolute and unrestricted right, power,
authority and capacity to execute and deliver this Agreement and the Proxy and to perform such Stockholder’s obligations hereunder and thereunder. This Agreement and the Proxy have been duly executed and delivered by such Stockholder and
constitute legal, valid and binding obligations of such Stockholder, enforceable against such Stockholder in accordance with their terms, subject to (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors,
and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. If Stockholder is a general or limited partnership, then Stockholder is a partnership duly organized, validly existing and in good standing
under the laws of the jurisdiction in which it was organized. If Stockholder is a limited liability company, then Stockholder is a limited liability company duly organized, validly existing and in good standing under the laws of the jurisdiction in
which it was organized. 

  

			
	4	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 6.2 No Conflicts or Consents. 

(a) The execution and delivery of this Agreement and the Proxy by such Stockholder does not, and the performance of
this Agreement and the Proxy by such Stockholder will not: (i) conflict with or violate any law, rule, regulation, order, decree or judgment applicable to such Stockholder or by which such Stockholder or any of such Stockholder’s
properties is or may be bound or affected; or (ii) result in or constitute (with or without notice or lapse of time) any breach of or default under, or give to any other Person (with or without notice or lapse of time) any right of termination,
amendment, acceleration or cancellation of, or result (with or without notice or lapse of time) in the creation of any encumbrance or restriction on any of such Stockholder’s Subject Securities pursuant to any contract to which such Stockholder
is a party or by which Stockholder or any of Stockholder’s affiliates or properties is or may be bound or affected. 
 (b) The execution and delivery of this Agreement and the Proxy by such Stockholder do not, and the performance of this Agreement and the Proxy by such Stockholder will not, require any consent or
approval of any Person. 
 6.3 Title to Securities. As of the date of this Agreement: (a) Stockholder holds of
record (free and clear of any encumbrances or restrictions) the number of outstanding shares of Company Common Stock and Company Preferred Stock set forth under the heading “Shares Held of Record” on the signature page hereof;
(b) Stockholder holds (free and clear of any encumbrances or restrictions) the options, warrants and other rights to acquire shares of Company Common Stock and Company Preferred Stock set forth under the heading “Options and Other
Rights” on the signature page hereof; (c) Stockholder Owns the additional securities of the Company set forth under the heading “Additional Securities Beneficially Owned” on the signature page hereof; and (d) Stockholder
does not directly or indirectly Own any shares of capital stock or other securities of the Company, or any option, warrant or other right to acquire (by purchase, conversion or otherwise) any shares of capital stock or other securities of the
Company, other than the shares and options, warrants and other rights set forth on the signature page hereof. 
 6.4 Accuracy
of Representations. The representations and warranties contained in this Agreement are accurate in all respects as of the date of this Agreement, will be accurate in all respects at all times through the Voting Covenant Expiration Date and will
be accurate in all respects as of the date of the consummation of the Asset Purchase as if made on that date. 
 SECTION 7.
ADDITIONAL COVENANTS 
 7.1 Further Assurances. From time to time and without
additional consideration, each Stockholder shall (at such Stockholder’s sole expense) execute and deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, proxies, consents and other instruments, and
shall (at such Stockholder’s sole expense) take such further actions, as Cardium may request for the purpose of carrying out and furthering the intent of this Agreement and the Proxy. 

  

			
	5	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 7.2 Legends. If requested by Cardium, immediately after the execution of this
Agreement (and from time to time upon the acquisition by any Stockholder of Ownership of any shares of Company Capital Stock prior to the Voting Covenant Expiration Date), each Stockholder shall cause each certificate evidencing any outstanding
shares of Company Capital Stock or other securities of the Company Owned by such Stockholder to be surrendered so that the transfer agent for such securities may affix thereto a legend in the following form: 

THE SECURITY OR SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, EXCHANGED OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN
COMPLIANCE WITH THE TERMS AND PROVISIONS OF A VOTING AGREEMENT DATED AS OF SEPTEMBER 28, 2012, AS IT MAY BE AMENDED, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER. 

SECTION 8. MISCELLANEOUS 
 8.1 Survival of Representations, Warranties and Agreements. The representations, warranties, covenants and agreements made by each Stockholder in this Agreement shall survive until the Voting
Covenant Expiration Date. 
 8.2 Expenses. All costs and expenses incurred in connection with the transactions
contemplated by this Agreement shall be paid by the party incurring such costs and expenses. 
 8.3 Notices. Any notice
or other communication required or permitted to be delivered to either party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express
delivery service or by facsimile) to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the
other party): 
 if to Stockholder: 
 at the address set forth on the signature page hereof; and 
 if to Cardium:

 Cardium Therapeutics 
 12255 El Camino Real, Suite 250 
 San Diego, CA 92130 

Attention: Tyler M. Dylan-Hyde 
 Facsimile: 858-436-1001 
 with a required copy to (which alone shall not
constitute notice): 
 Sheppard Mullin Richter & Hampton 

12275 El Camino Real, Suite 250 
 San Diego, CA 92130 
 Attention: James A. Mercer 

Facsimile: (858) 509-3691 

  

			
	6	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 8.4 Severability. Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any
other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit
the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term
or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. 

8.5 Entire Agreement. This Agreement and the proxies required to be delivered by each Stockholder pursuant to Section 3.2
constitute the entire agreement between each Stockholder and Cardium with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings between each Stockholder and Cardium with respect to the subject matter
hereof and thereof. 
 8.6 Assignment; Binding Effect. Except as provided herein, neither this Agreement nor any of the
interests or obligations hereunder may be assigned or delegated by any Stockholder, and any attempted or purported assignment or delegation of any of such interests or obligations shall be void. Subject to the preceding sentence, this Agreement
shall be binding upon each Stockholder and such Stockholder’s heirs, estate, executors and personal representatives and such Stockholder’s successors and assigns, and shall inure to the benefit of Cardium and its successors and assigns.
Without limiting any of the restrictions set forth in Section 2 or elsewhere in this Agreement, this Agreement shall be binding upon any Person to whom any Subject Securities are transferred. Nothing in this Agreement is intended to confer on
any Person (other than Cardium and its successors and assigns) any rights or remedies of any nature. 
 8.7 Fiduciary
Duties. Each Stockholder is signing this Agreement in such Stockholder’s capacity as an owner of such Stockholder’s Subject Securities, and nothing in this Agreement shall prohibit, prevent or preclude such Stockholder from taking or
not taking any action in such Stockholder’s capacity as an officer or director of the Company (including any withholding, amendment, withdrawal or modification of the recommendation by the board of directors to adopt the APA and approve the
Asset Purchase). 
 8.8 Specific Performance. The parties agree that irreparable damage would occur in the event that any
of the provisions of this Agreement or the Proxy were not performed in accordance with its specific terms or were otherwise breached. Each Stockholder agrees that, in the event of any breach or threatened breach by such Stockholder of any covenant
or obligation contained in this Agreement or in the Proxy, Cardium shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to seek and obtain (a) a decree 

  

			
	7	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 
or order of specific performance to enforce the observance and performance of such covenant or obligation, and (b) an injunction restraining such breach or threatened breach. Each
Stockholder further agrees that neither Cardium nor any other Person shall be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this section, and each
Stockholder irrevocably waives any right such Stockholder may have to require the obtaining, furnishing or posting of any such bond or similar instrument. 
 8.9 Non-Exclusivity. The rights and remedies of Cardium under this Agreement are not exclusive of or limited by any other rights or remedies which it may have, whether at law, in equity, by
contract or otherwise, all of which shall be cumulative (and not alternative). Without limiting the generality of the foregoing, the rights and remedies of Cardium under this Agreement, and the obligations and liabilities of each Stockholder under
this Agreement, are in addition to their respective rights, remedies, obligations and liabilities under common law requirements and under all applicable statutes, rules and regulations. 

8.10 Governing Law; Waiver of Jury Trial. 
 (a) This Agreement and the Proxy shall be construed in accordance with, and governed in all respects by, the laws of the State of Nevada (without giving effect to principles of conflicts of laws).

 (b) STOCKHOLDER IRREVOCABLY WAIVES THE RIGHT TO A JURY TRIAL IN CONNECTION WITH ANY LEGAL PROCEEDING
RELATING TO THIS AGREEMENT OR THE PROXY OR THE ENFORCEMENT OF ANY PROVISION OF THIS AGREEMENT OR THE PROXY. 
 8.11
Counterparts. This Agreement may be executed in any number of original, facsimile or PDF counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same
instrument. 
 8.12 Captions. The captions contained in this Agreement are for convenience of reference only, shall not
be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. 
 8.13 Attorneys’ Fees. If any legal action or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement is brought against any Stockholder, the
prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled) from such Stockholder. 

8.14 Waiver. No failure on the part of Cardium to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of Cardium in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. Cardium shall not be deemed to have waived any claim available to Cardium arising out of this Agreement, or any power, right, privilege or
remedy of Cardium under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set 

  

			
	8	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 
forth in a written instrument duly executed and delivered on behalf of Cardium; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is
given. 
 8.15 Amendments. This Agreement may not be amended, changed, supplemented, or otherwise modified or terminated,
except upon the execution and delivery of a written agreement executed by the parties hereto. 
 8.16 Construction.

 (a) For purposes of this Agreement, whenever the context requires: the singular number shall include
the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. 

(b) The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the
drafting party shall not be applied in the construction or interpretation of this Agreement. 
 (c) As
used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

 (d) Except as otherwise indicated, all references in this Agreement to “Sections” and
“Exhibits” are intended to refer to Sections of this Agreement and Exhibits to this Agreement. 

  

			
	9	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 IN WITNESS WHEREOF, Cardium and each
Stockholder have caused this Agreement to be executed as of the date first written above. 
  

			
	 CARDIUM THERAPEUTICS, INC.

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[STOCKHOLDER]:
		
	By:	 	  

	Name:	 	
	Address:	 	

  

					
	 Shares Held of Record
	  	 Options and Other Rights
	  	 Additional Securities Beneficially

Owned

	  	  	  	  	  
	  	  	  	  	  
	  	  	  	  	  

  

			
	10	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 EXHIBIT A 
 FORM OF IRREVOCABLE PROXY 
 The undersigned stockholder (the
“Stockholder”) of To Go Brands, Inc., a Nevada corporation (the “Company”), hereby irrevocably (to the fullest extent permitted by law) appoints and constitutes Christopher J. Reinhard, Tyler M. Dylan-Hyde and
Cardium Therapeutics, Inc., a Delaware corporation (“Cardium”), and each of them, as attorneys and proxies of the Stockholder with full power of substitution and resubstitution, to the full extent of the Stockholder’s rights
with respect to (i) the outstanding shares of capital stock of the Company owned of record or beneficially by the Stockholder as of the date of this proxy, which shares are specified on the final page of this proxy, and (ii) any and all
other shares of capital stock of the Company which the Stockholder may own of record or beneficially on or after the date hereof. The shares of the capital stock of the Company referred to in clauses “(i)” and “(ii)” of the
immediately preceding sentence are collectively referred to as the “Shares.” Upon the execution hereof, all prior proxies given by the Stockholder with respect to any of the Shares are hereby revoked, and the Stockholder agrees that
no subsequent proxies will be given with respect to any of the Shares. 
 This proxy is irrevocable, is coupled with an interest
and is granted in connection with the Voting Agreement, dated as of the date hereof, between Cardium and the Stockholder (the “Voting Agreement”), and is granted in consideration of Cardium entering into the Asset Purchase Agreement
dated as of the date hereof, among Cardium, MedPodium Health Products, Inc., and the Company (the “APA”). This proxy will terminate on the Voting Covenant Expiration Date (as defined in the Voting Agreement). 

Prior to the Voting Covenant Expiration Date (as defined in the Voting Agreement), the attorneys and proxies named above will be
empowered, and may exercise this proxy, to vote the Shares at any meeting of the stockholders of the Company, however called, and in connection with any action by written consent of stockholders of the Company, as applicable: 

(i) in favor of the asset purchase contemplated by the APA (the “Asset Purchase”), the execution and
delivery by the Company of the APA and the adoption and approval of the APA and the terms thereof, in favor of each of the other actions contemplated by the APA and in favor of any action in furtherance of any of the foregoing; and 

(ii) against any action or agreement that would result in a material breach of any representation, warranty, covenant or
obligation of the Company in the APA; and 
 (iii) against the following actions (other than the Asset Purchase
and the other transactions contemplated by the APA): (A) any extraordinary corporate transaction, such as a merger, consolidation or other business combination involving the Company or any subsidiary of the Company; (B) any sale, lease or
transfer of a material amount of assets of the Company or any subsidiary of the Company; (C) any reorganization, recapitalization, dissolution 

  

			
	1	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 
or liquidation of the Company or any subsidiary of the Company; (D) any change in a majority of the board of directors of the Company; (E) any amendment to the Company’s
certificate of incorporation or bylaws; (F) any material change in the capitalization of the Company or the Company’s corporate structure; and (G) any other action which is intended, or could reasonably be expected to impede,
interfere with, delay, postpone, discourage or adversely affect the Asset Purchase or any of the other transactions contemplated by the APA. 
 The Stockholder may vote the Shares on all other matters not referred to in this proxy, and the attorneys and proxies named above may not exercise this proxy with respect to such other matters.

 This proxy shall be binding upon the heirs, estate, executors, personal representatives, successors and assigns of the
Stockholder (including any transferee of any of the Shares). 
 Any term or provision of this proxy that is invalid or
unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any
other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Stockholder agrees that the court making such determination shall have the power to limit the
term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this proxy shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Stockholder agrees to replace such invalid or unenforceable term or
provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. 
 Dated: September     , 2012 
  

			
		 	 Number of shares of common stock and/or preferred stock of the
Company owned of record as of the date of this proxy:
  

  

			
	2	 	EXHIBIT G – FORM OF VOTING AGREEMENT

 EXHIBIT B 

  

			
	3	 	EXHIBIT G – FORM OF VOTING AGREEMENTCommon Stock Purchase Agreement

 EXHIBIT 10.1 

EXECUTION COPY 
 COMMON STOCK PURCHASE AGREEMENT 
 DATED AS OF OCTOBER 4, 2012

 BY AND BETWEEN 
 ENTEROMEDICS INC. 
 AND 

TERRAPIN OPPORTUNITY, L.P. 

 TABLE OF CONTENTS 

 

					
	 ARTICLE I PURCHASE AND SALE OF COMMON STOCK
	  	 	1	  
	 Section 1.1 Purchase and Sale of Stock
	  	 	1	  
	 Section 1.2 Effective Date; Settlement Dates
	  	 	1	  
	 Section 1.3 Reservation of Common Stock
	  	 	2	  
	 Section 1.4 Current Report; Prospectus Supplement
	  	 	2	  
		
	 ARTICLE II FIXED REQUEST TERMS; OPTIONAL AMOUNT
	  	 	3	  
	 Section 2.1 Fixed Request Notice
	  	 	3	  
	 Section 2.2 Fixed Requests
	  	 	3	  
	 Section 2.3 Share Calculation
	  	 	4	  
	 Section 2.4 Limitation of Fixed Requests
	  	 	5	  
	 Section 2.5 Reduction of Commitment
	  	 	5	  
	 Section 2.6 Below Threshold Price
	  	 	5	  
	 Section 2.7 Settlement
	  	 	6	  
	 Section 2.8 Reduction of Pricing Period
	  	 	6	  
	 Section 2.9 Optional Amount
	  	 	7	  
	 Section 2.10 Calculation of Optional Amount Shares
	  	 	7	  
	 Section 2.11 Exercise of Optional Amount
	  	 	8	  
	 Section 2.12 Exchange Cap; Single Fixed Request Limit
	  	 	8	  
	 Section 2.13 Trading Market Regulation
	  	 	10	  
	 Section 2.14 Blackout Periods
	  	 	10	  
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE INVESTOR
	  	 	12	  
	 Section 3.1 Organization and Standing of the Investor
	  	 	12	  
	 Section 3.2 Authorization and Power
	  	 	12	  
	 Section 3.3 No Conflicts
	  	 	12	  
	 Section 3.4 Information
	  	 	12	  
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	  	 	13	  
	 Section 4.1 Organization, Good Standing and Power
	  	 	13	  
	 Section 4.2 Authorization, Enforcement
	  	 	13	  
	 Section 4.3 Capitalization
	  	 	13	  
	 Section 4.4 Issuance of Shares
	  	 	14	  
	 Section 4.5 No Conflicts
	  	 	14	  
	 Section 4.6 Commission Documents, Financial Statements
	  	 	15	  
	 Section 4.7 Subsidiary
	  	 	16	  
	 Section 4.8 No Material Adverse Effect
	  	 	16	  
	 Section 4.9 No Undisclosed Liabilities
	  	 	16	  
	 Section 4.10 No Undisclosed Events or Circumstances
	  	 	16	  
	 Section 4.11 Indebtedness
	  	 	17	  
	 Section 4.12 Title To Assets
	  	 	17	  
	 Section 4.13 Actions Pending
	  	 	17	  
	 Section 4.14 Compliance With Law
	  	 	18	  

  
 i 

					
	 Section 4.15 Certain Fees
	  	 	18	  
	 Section 4.16 Operation of Business
	  	 	18	  
	 Section 4.17 Environmental Compliance
	  	 	20	  
	 Section 4.18 Material Agreements
	  	 	21	  
	 Section 4.19 Transactions With Affiliates
	  	 	21	  
	 Section 4.20 Securities Act
	  	 	21	  
	 Section 4.21 Employees
	  	 	23	  
	 Section 4.22 Use of Proceeds
	  	 	23	  
	 Section 4.23 Investment Company Act Status
	  	 	23	  
	 Section 4.24 ERISA
	  	 	23	  
	 Section 4.25 Taxes
	  	 	24	  
	 Section 4.26 Insurance
	  	 	24	  
	 Section 4.27 U.S. Real Property Holding Corporation
	  	 	24	  
	 Section 4.28 Listing and Maintenance Requirements
	  	 	24	  
	 Section 4.29 Foreign Corrupt Practices Act
	  	 	25	  
	 Section 4.30 Money Laundering Laws
	  	 	25	  
	 Section 4.31 OFAC
	  	 	25	  
	 Section 4.32 Manipulation of Price
	  	 	25	  
	 Section 4.33 Acknowledgement Regarding Investor’s Acquisition of Shares
	  	 	25	  
		
	 ARTICLE V COVENANTS
	  	 	26	  
	 Section 5.1 Securities Compliance; FINRA Filing
	  	 	26	  
	 Section 5.2 Registration and Listing
	  	 	27	  
	 Section 5.3 Compliance with Laws
	  	 	28	  
	 Section 5.4 Due Diligence
	  	 	29	  
	 Section 5.5 Limitations on Holdings and Issuances
	  	 	29	  
	 Section 5.6 Other Agreements and Other Financings
	  	 	29	  
	 Section 5.7 Stop Orders
	  	 	31	  
	 Section 5.8 Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses
	  	 	32	  
	 Section 5.9 Prospectus Delivery
	  	 	33	  
	 Section 5.10 Selling Restrictions
	  	 	34	  
	 Section 5.11 Effective Registration Statement
	  	 	34	  
	 Section 5.12 Non-Public Information
	  	 	35	  
	 Section 5.13 Broker/Dealer
	  	 	35	  
	 Section 5.14 Earnings Statement
	  	 	36	  
	 Section 5.15 Disclosure Schedule
	  	 	36	  
		
	 ARTICLE VI OPINION OF COUNSEL AND CERTIFICATE; CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES
	  	 	36	  
	 Section 6.1 Opinion of Counsel; Certificate
	  	 	36	  
	 Section 6.2 Conditions Precedent to the Obligation of the Company
	  	 	37	  
	 Section 6.3 Conditions Precedent to the Obligation of the Investor
	  	 	38	  
		
	 ARTICLE VII TERMINATION
	  	 	41	  
	 Section 7.1 Term, Termination by Mutual Consent
	  	 	41	  
	 Section 7.2 Other Termination
	  	 	42	  
	 Section 7.3 Effect of Termination
	  	 	42	  

  
 ii 

					
		
	 ARTICLE VIII INDEMNIFICATION
	  	 	43	  
	 Section 8.1 General Indemnity
	  	 	43	  
	 Section 8.2 Indemnification Procedures
	  	 	45	  
		
	 ARTICLE IX MISCELLANEOUS
	  	 	46	  
	 Section 9.1 Fees and Expenses
	  	 	46	  
	 Section 9.2 Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial
	  	 	46	  
	 Section 9.3 Entire Agreement; Amendment
	  	 	47	  
	 Section 9.4 Notices
	  	 	48	  
	 Section 9.5 Waivers
	  	 	49	  
	 Section 9.6 Headings; Construction
	  	 	49	  
	 Section 9.7 Successors and Assigns
	  	 	49	  
	 Section 9.8 Governing Law
	  	 	50	  
	 Section 9.9 Survival
	  	 	50	  
	 Section 9.10 Counterparts
	  	 	50	  
	 Section 9.11 Publicity
	  	 	50	  
	 Section 9.12 Severability
	  	 	51	  
	 Section 9.13 No Third Party Beneficiaries
	  	 	51	  
	 Section 9.14 Further Assurances
	  	 	51	  

 Annex A. Definitions 

  
 iii

 COMMON STOCK PURCHASE AGREEMENT 

This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 4th day of October 2012 (this “Agreement”),
by and between Terrapin Opportunity, L.P., a limited partnership organized under the laws of the British Virgin Islands (the “Investor”), and EnteroMedics Inc., a corporation organized and existing under the laws of the State of
Delaware (the “Company”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in Annex A hereto. 
 RECITALS 
 WHEREAS, the parties desire that, upon the terms and
subject to the conditions and limitations set forth herein, the Company may issue and sell to the Investor, and the Investor shall thereupon purchase from the Company, up to $45,000,000 worth of newly issued shares of the Company’s common
stock, par value $0.01 per share (“Common Stock”), subject, in all cases, to the Exchange Cap (except to the extent the Exchange Cap shall be inapplicable as expressly provided in Sections 2.12 and 2.13); and 

WHEREAS, the offer and sale of the Shares hereunder have been registered by the Company in the Registration Statement, which has
been declared effective by order of the Commission under the Securities Act. 
 NOW, THEREFORE, the parties hereto,
intending to be legally bound, hereby agree as follows: 
 ARTICLE I 

PURCHASE AND SALE OF COMMON STOCK 
 Section 1.1 Purchase and Sale of Stock. Upon the terms and subject to the conditions and limitations of this Agreement, during the Investment Period, the Company, in its discretion, may
issue and sell to the Investor up to $45,000,000 (the “Total Commitment”) worth of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock (subject in all cases to the Exchange Cap (except to the extent
the Exchange Cap shall be inapplicable as expressly provided in Sections 2.12 and 2.13), the “Aggregate Limit”), by (i) the delivery to the Investor of not more than 24 separate Fixed Request Notices (unless the Investor and
the Company mutually agree that a different number of Fixed Request Notices may be delivered) as provided in Article II hereof and (ii) the exercise by the Investor of Optional Amounts, which the Company may in its discretion grant to the
Investor and which may be exercised by the Investor, in whole or in part, as provided in Article II hereof. The aggregate of all Fixed Request Amounts and Optional Amount Dollar Amounts shall not exceed the Aggregate Limit. 

Section 1.2 Effective Date; Settlement Dates. This Agreement shall become effective and binding upon the payment of the
fees required to be paid on or prior to the Effective Date pursuant to Section 9.1, the delivery of counterpart signature pages of this Agreement executed by each of the parties hereto, and the delivery of all other documents, instruments and
writings required to be delivered on the Effective Date, in each case as provided 

  
 1 

 
in Section 6.1 hereof, to the offices of Greenberg Traurig, LLP, 200 Park Avenue, New York, New York 10166, at 5:00 p.m., New York time, on the Effective Date. In consideration of and in
express reliance upon the representations, warranties and covenants, and otherwise upon the terms and subject to the conditions, of this Agreement, from and after the Effective Date and during the Investment Period (i) the Company shall issue
and sell to the Investor, and the Investor agrees to purchase from the Company, the Shares in respect of each Fixed Request and (ii) the Investor may in its discretion elect to purchase Shares in respect of each Optional Amount. The issuance
and sale of Shares to the Investor pursuant to any Fixed Request or Optional Amount shall occur on the applicable Settlement Date in accordance with Sections 2.7 and 2.9 (or on such Trading Day in accordance with Section 2.8, as applicable),
provided in each case that all of the conditions precedent thereto set forth in Article VI theretofore shall have been fulfilled or (to the extent permitted by applicable law) waived. 

Section 1.3 Reservation of Common Stock. The Company has or will have duly authorized and reserved for issuance, and
covenants to continue to so reserve once reserved for issuance, free of all preemptive and other similar rights, at all times during the Investment Period, the requisite aggregate number of authorized but unissued shares of its Common Stock to
timely effect the issuance, sale and delivery in full to the Investor of all Shares to be issued in respect of all Fixed Requests and Optional Amounts under this Agreement, in any case prior to the issuance to the Investor of such Shares.

 Section 1.4 Current Report; Prospectus Supplement. As soon as practicable, but in any event not later than 5:30
p.m. (New York time) on the first Trading Day immediately following the Effective Date, the Company shall file with the Commission (i) a report on Form 8-K relating to the transactions contemplated by, and describing the material terms and
conditions of, this Agreement (the “Current Report”), and (ii) a Prospectus Supplement pursuant to Rule 424(b) under the Securities Act specifically relating to the transactions contemplated by, and describing the material
terms and conditions of, this Agreement, containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rule 430B under the Securities Act, and disclosing all information relating to the
transactions contemplated hereby required to be disclosed in the Registration Statement and the Prospectus as of the Effective Date, including, without limitation, information required to be disclosed in the section captioned “Plan of
Distribution” in the Prospectus (the “Initial Prospectus Supplement”). The Current Report shall include a copy of this Agreement as an exhibit and shall be incorporated by reference in the Registration Statement and the
Prospectus. The Company shall provide the Investor a reasonable opportunity to comment on a draft of the Current Report and the Initial Prospectus Supplement prior to filing the Current Report and Initial Prospectus Supplement with the Commission,
shall give due consideration to all such comments and shall not file the Current Report or Initial Prospectus Supplement to the extent the Investor reasonably objects to the form or content thereof (provided, however, that the
failure of the Investor to make such objection shall not relieve the Company of any obligation or liability under this Agreement or affect the Investor’s right to rely on the representations and warranties made by the Company in this
Agreement). If the transactions contemplated by any Fixed Request are material to the Company (individually or collectively with other prior Fixed Requests, the consummation of which have not previously been reported in any Prospectus Supplement
filed with the Commission under Rule 424(b) under the Securities Act or in any report, statement or other 

  
 2 

 
document filed by the Company with the Commission under the Exchange Act), or if otherwise required under the Securities Act (or the interpretations of the Commission thereof), in each case as
reasonably determined by the Company or the Investor, then, on the first Trading Day immediately following the last Trading Day of the Pricing Period with respect to such Fixed Request, the Company shall file with the Commission a Prospectus
Supplement pursuant to Rule 424(b) under the Securities Act with respect to the applicable Fixed Request(s), disclosing the total number of Shares that are to be (and, if applicable, have been) issued and sold to the Investor pursuant to such Fixed
Request(s), the total purchase price for the Shares subject to such Fixed Request(s), the applicable Discount Price(s) for such Shares and the net proceeds that are to be (and, if applicable, have been) received by the Company from the sale of such
Shares. To the extent not previously disclosed in a Prospectus Supplement, the Company shall disclose in its Quarterly Reports on Form 10-Q and in its Annual Reports on Form 10-K the information described in the immediately preceding sentence
relating to all Fixed Request(s) consummated during the relevant fiscal quarter. 
 ARTICLE II 

FIXED REQUEST TERMS; OPTIONAL AMOUNT 
 Subject to the satisfaction or (to the extent permitted by applicable law) waiver of the conditions set forth in this Agreement, the parties agree (unless otherwise mutually agreed upon by the parties in
writing) as follows: 
 Section 2.1 Fixed Request Notice. The Company may, from time to time in its sole
discretion, no later than 9:30 a.m. (New York time) on the first Trading Day of the Pricing Period, provide to the Investor a Fixed Request notice, substantially in the form attached hereto as Exhibit A (the “Fixed Request
Notice”), which Fixed Request Notice shall become effective at 9:30 a.m. (New York time) on the first Trading Day of the Pricing Period specified in the Fixed Request Notice; provided, however, that if the Company delivers the
Fixed Request Notice to the Investor later than 9:30 a.m. (New York time) on a Trading Day, then the first Trading Day of such Pricing Period shall not be the Trading Day on which the Investor received such Fixed Request Notice, but rather shall be
the next Trading Day (unless a subsequent Trading Day is therein specified). The Company shall provide the Investor with at least one Trading Day’s prior notice of its intent to deliver a Fixed Request Notice to the Investor. The Fixed Request
Notice shall specify the Fixed Amount Requested, establish the Threshold Price for such Fixed Request, designate the first and last Trading Day of the Pricing Period and specify the Optional Amount, if any, that the Company elects to grant to the
Investor during the Pricing Period and the applicable Threshold Price for such Optional Amount (the “Optional Amount Threshold Price”). The Threshold Price and the Optional Amount Threshold Price established by the Company in a
Fixed Request Notice may be the same or different, in the Company’s sole discretion. Upon the terms and subject to the conditions of this Agreement, the Investor is obligated to accept each Fixed Request Notice prepared and delivered in
accordance with the provisions of this Agreement. 
 Section 2.2 Fixed Requests. From time to time during the
Investment Period, the Company may, in its sole discretion, deliver to the Investor a Fixed Request Notice for a specified Fixed Amount Requested, and the applicable discount price (the “Discount Price”)

  
 3 

 
shall be determined, in accordance with the price and share amount parameters as set forth below or such other parameters mutually agreed upon by the Investor and the Company, and upon the terms
and subject to the conditions of this Agreement, the Investor shall purchase from the Company the Shares subject to such Fixed Request Notice at the Discount Price; provided, however, that (i) if an ex-dividend date is established
by the Trading Market in respect of the Common Stock on or between the first Trading Day of the applicable Pricing Period and the applicable Settlement Date, the Discount Price shall be reduced by the per share dividend amount and (ii) unless
the parties otherwise mutually agree, the Company may not deliver any single Fixed Request Notice for a Fixed Amount Requested in excess of the lesser of (a) the amount in the applicable Fixed Amount Requested column below and (b) 2.5% of
the Market Capitalization: 
  

									
	 Threshold Price
	  	Fixed Amount Requested	 	  	Discount Price	 
	 Equal to or greater than $12.00
	  	Not to exceed $	10,000,000	  	  	 	96.00% of the VWAP	  
			
	 Equal to or greater than $9.00 and less than $10.00
	  	Not to exceed $	7,000,000	  	  	 	95.75% of the VWAP	  
			
	 Equal to or greater than $5.75 and less than $9.00
	  	Not to exceed $	4,500,000	  	  	 	95.50% of the VWAP	  
			
	 Equal to or greater than $5.25 and less than $5.75
	  	Not to exceed $	4,000,000	  	  	 	95.25% of the VWAP	  
			
	 Equal to or greater than $4.75 and less than $5.25
	  	Not to exceed $	3,500,000	  	  	 	95.00% of the VWAP	  
			
	 Equal to or greater than $4.25 and less than $4.75
	  	Not to exceed $	3,000,000	  	  	 	94.50% of the VWAP	  
			
	 Equal to or greater than $3.75 and less than $4.25
	  	Not to exceed $	2,500,000	  	  	 	94.25% of the VWAP	  
			
	 Equal to or greater than $3.25 and less than $3.75
	  	Not to exceed $	2,000,000	  	  	 	94.00% of the VWAP	  
			
	 Equal to or greater than $2.75 and less than $3.25
	  	Not to exceed $	1,750,000	  	  	 	93.80% of the VWAP	  
			
	 Equal to or greater than $2.25 and less than $2.75
	  	Not to exceed $	1,500,000	  	  	 	93.60% of the VWAP	  
			
	 Equal to or greater than $1.75 and less than $2.25
	  	Not to exceed $	1,250,000	  	  	 	93.40% of the VWAP	  
			
	 Equal to or greater than $1.25 and less than $1.75
	  	Not to exceed $	1,000,000	  	  	 	93.20% of the VWAP	  

 Anything to the contrary in this Agreement notwithstanding, unless otherwise mutually agreed upon by the
Investor and the Company, at no time shall the Investor be required to purchase more than $45,000,000 worth of Common Stock in respect of any Pricing Period (not including Common Stock subject to any Optional Amount). The date on which the Company
delivers any Fixed Request Notice in accordance with this Section 2.2 hereinafter shall be referred to as a “Fixed Request Exercise Date”. 
 Section 2.3 Share Calculation. With respect to each Trading Day during the applicable Pricing Period for which the VWAP equals or exceeds the Threshold Price, the number of Shares to be
issued by the Company to the Investor pursuant to a Fixed Request shall equal the quotient (calculated for each Trading Day during the applicable Pricing Period for 

  
 4 

 
which the VWAP equals or exceeds the Threshold Price) determined pursuant to the following equation (rounded to the nearest whole Share): 
 N = (A x B)/C, where: 
 N = the number of Shares to be issued by the Company to the Investor in
respect of a Trading Day during the applicable Pricing Period for which the VWAP equals or exceeds the Threshold Price, 
 A = 0.10 (the
“Multiplier”), provided, however, that if the Company and the Investor mutually agree prior to the commencement of a Pricing Period that the number of consecutive Trading Days constituting a Pricing Period shall be
less than 10, then the Multiplier correspondingly shall be increased to equal the decimal equivalent (in 10-millionths) of a fraction, the numerator of which is one and the denominator of which equals the number of Trading Days in the reduced
Pricing Period (it being hereby acknowledged and agreed that this proviso shall not apply to any unilateral determination by the Company to reduce a Pricing Period, but rather, in the event of such unilateral determination, Section 2.8 hereof
shall apply), 
 B = the total Fixed Amount Requested, and 
 C = the applicable Discount Price for such Trading Day. 
 Section 2.4
Limitation of Fixed Requests. The Company shall not make more than one Fixed Request in each Pricing Period. Not less than five Trading Days shall elapse between the end of one Pricing Period and the commencement of any other Pricing
Period during the Investment Period. There shall be permitted a maximum of 24 Fixed Requests during the Investment Period. Each Fixed Request automatically shall expire immediately following the last Trading Day of each Pricing Period. 

Section 2.5 Reduction of Commitment. On the Settlement Date with respect to a Pricing Period, the Investor’s Total
Commitment under this Agreement automatically (and without the need for any amendment to this Agreement) shall be reduced, on a dollar-for-dollar basis, by the total amount of the Fixed Request Amount and the Optional Amount Dollar Amount, if any,
for such Pricing Period paid to the Company at such Settlement Date. 
 Section 2.6 Below Threshold Price. If the
VWAP on any Trading Day in a Pricing Period is lower than the Threshold Price, then for each such Trading Day the Fixed Amount Requested shall be reduced, on a dollar-for-dollar basis, by an amount equal to the product of (x) the Multiplier and
(y) the total Fixed Amount Requested, and no Shares shall be purchased or sold with respect to such Trading Day, except as provided below. If trading in the Common Stock on NASDAQ (or any other Trading Market on which the Common Stock is then
listed or quoted) is suspended for any reason for more than three hours on any Trading Day, the Investor may at its option deem the price of the Common Stock to be lower than the Threshold Price for such Trading Day and, for each such Trading Day,
the total amount of the Fixed Amount Requested shall be reduced as provided in the immediately preceding sentence, and no Shares shall be purchased or sold with respect to such Trading Day, except as provided below. For each Trading Day during a
Pricing Period on which the VWAP is lower (or is deemed to be lower as 

  
 5 

 
provided in the immediately preceding sentence) than the Threshold Price, the Investor may in its sole discretion elect to purchase such U.S. dollar amount of Shares equal to the amount by which
the Fixed Amount Requested has been reduced in accordance with this Section 2.6, at the Threshold Price multiplied by the applicable percentage set forth in the column entitled “Discount Price” for the row corresponding to the
applicable Threshold Price in Section 2.2. The Investor shall inform the Company via facsimile transmission not later than 8:00 p.m. (New York time) on the last Trading Day of such Pricing Period as to the number of Shares, if any, the Investor
elects to purchase as provided in this Section 2.6. 
 Section 2.7 Settlement. The payment for, against
simultaneous delivery of, Shares in respect of each Fixed Request shall be settled on the second Trading Day next following the last Trading Day of each Pricing Period, or on such earlier date as the parties may mutually agree (the
“Settlement Date”). On each Settlement Date, the Company shall, or shall cause its transfer agent to, electronically transfer the Shares purchased by the Investor by crediting the Investor’s or its designees’ account at
DTC through its Deposit/Withdrawal at Custodian (DWAC) system, which Shares shall be freely tradable and transferable and without restriction on resale, against simultaneous payment therefor to the Company’s designated account by wire transfer
of immediately available funds; provided that if the Shares are received by the Investor later than 1:00 p.m. (New York time), payment therefor shall be made with next day funds. As set forth in Section 9.1(ii), a failure by the Company
to deliver such Shares shall result in the payment of partial damages by the Company to the Investor. 
 Section 2.8
Reduction of Pricing Period. If during a Pricing Period the Company elects to reduce the number of Trading Days in such Pricing Period (and thereby amend its previously delivered Fixed Request Notice), the Company shall so notify the
Investor before 9:00 a.m. (New York time) on any Trading Day during a Pricing Period (a “Reduction Notice”) and the last Trading Day of such Pricing Period shall be the Trading Day immediately preceding the Trading Day on which the
Investor received such Reduction Notice; provided, however, that if the Company delivers the Reduction Notice later than 9:00 a.m. (New York time) on a Trading Day during a Pricing Period, then the last Trading Day of such Pricing
Period instead shall be the Trading Day on which the Investor received such Reduction Notice. 
 Upon receipt of a Reduction
Notice, the Investor (i) shall purchase the Shares in respect of each Trading Day in such reduced Pricing Period for which the VWAP equals or exceeds the Threshold Price in accordance with Section 2.3 hereof; (ii) may elect to
purchase the Shares in respect of any Trading Day in such reduced Pricing Period for which the VWAP is (or is deemed to be) lower than the Threshold Price in accordance with Section 2.6 hereof; and (iii) may elect to exercise all or any
portion of an Optional Amount on any Trading Day during such reduced Pricing Period in accordance with Sections 2.10 and 2.11 hereof. 
 In addition, upon receipt of a Reduction Notice, the Investor may elect to purchase, by providing written notice to the Company not later than 10:00 a.m. (New York time) on the first Trading Day following
the last Trading Day of the reduced Pricing Period, such U.S. dollar amount of additional Shares equal to the product determined pursuant to the following equation: 
 D = (A/B) x (B – C), where: 
  

  
 6 

 
D = the U.S. dollar amount of additional Shares to be purchased, 
 A = the Fixed Amount
Requested, 
 B = 10 or, for purposes of this Section 2.8, such lesser number of Trading Days as the parties may mutually agree to, and

 C = the number of Trading Days in the reduced Pricing Period, 
 at a per Share price equal to the average per share price to be paid for Shares to be purchased during such reduced Pricing Period pursuant to clauses (i) and (ii) (as applicable) of the
immediately preceding paragraph. 
 The Investor may also elect to exercise any portion of the applicable Optional Amount which
was unexercised during the reduced Pricing Period by issuing an Optional Amount Notice to the Company not later than 10:00 a.m. (New York time) on the first Trading Day next following the last Trading Day of the reduced Pricing Period. The number of
Shares to be issued upon exercise of such Optional Amount shall be calculated pursuant to the equation set forth in Section 2.10 hereof, except that “C” shall equal the greater of (i) the VWAP for the Common Stock on the last
Trading Day of the reduced Pricing Period or (ii) the Optional Amount Threshold Price. 
 The payment for, against
simultaneous delivery of, Shares to be purchased and sold in accordance with this Section 2.8 shall be settled on the second Trading Day next following the Trading Day on which the Investor receives a Reduction Notice. 

Section 2.9 Optional Amount. With respect to any Pricing Period, the Company may in its sole discretion grant to the
Investor the right to exercise, from time to time during the Pricing Period (but not more than once on any Trading Day), all or any portion of an Optional Amount. The maximum Optional Amount Dollar Amount and the Optional Amount Threshold Price
shall be set forth in the Fixed Request Notice. If an ex-dividend date is established by the Trading Market in respect of the Common Stock on or between the first Trading Day of the applicable Pricing Period and the applicable Settlement Date, the
applicable exercise price in respect of the Optional Amount shall be reduced by the per share dividend amount. Each daily Optional Amount exercise shall be aggregated during the Pricing Period and settled on the next Settlement Date. The Optional
Amount Threshold Price designated by the Company in its Fixed Request Notice shall apply to each Optional Amount exercised during the applicable Pricing Period. 
 Section 2.10 Calculation of Optional Amount Shares. The number of shares of Common Stock to be issued in connection with the exercise of an Optional Amount shall be the quotient determined
pursuant to the following equation (rounded to the nearest whole Share): 
 O = A/(B x C), where: 

O = the number of shares of Common Stock to be issued in connection with such Optional Amount exercise, 

  
 7 

 A = the Optional Amount Dollar Amount with respect to which the Investor has delivered an Optional Amount
Notice, 
 B = the applicable percentage set forth in the column entitled “Discount Price” for the row corresponding to the applicable
Threshold Price in Section 2.2 (with the Optional Amount Threshold Price serving as the Threshold Price for such purposes), and 
 C = the
greater of (i) the VWAP for the Common Stock on the day the Investor delivers the Optional Amount Notice or (ii) the Optional Amount Threshold Price. 
 Section 2.11 Exercise of Optional Amount. If granted by the Company to the Investor with respect to a Pricing Period, all or any portion of the Optional Amount may be exercised by the
Investor on any Trading Day during the Pricing Period, subject to the limitations set forth in Section 2.9. As a condition to each exercise of an Optional Amount pursuant to this Section 2.11, the Investor shall issue an Optional Amount
Notice to the Company no later than 8:00 p.m. (New York time) on the day of such Optional Amount exercise. If the Investor does not exercise an Optional Amount in full by 8:00 p.m. (New York time) on the last Trading Day of the applicable Pricing
Period, such unexercised portion of the Investor’s Optional Amount with respect to that Pricing Period automatically shall lapse and terminate. 
 Section 2.12 Exchange Cap; Single Fixed Request Limit. Notwithstanding anything to the contrary contained in this Agreement, subject to Section 2.13 below, (i) the Company shall
not issue or sell any shares of Common Stock pursuant to this Agreement (including, without limitation, as partial damages pursuant to Section 9.1(ii)), and the Investor shall not purchase or acquire any shares of Common Stock pursuant to this
Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement would exceed the Exchange Cap, and (ii) the Company shall not issue or sell any shares of
Common Stock pursuant to any single Fixed Request or Optional Amount (including, without limitation, as partial damages pursuant to Section 9.1(ii)), and the Investor shall not purchase or acquire any shares of Common Stock pursuant to any
single Fixed Request or Optional Amount, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to such Fixed Request and Optional Amount would exceed the Single Fixed Request
Limit (taking into account all shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated by such Fixed Request and Optional Amount under applicable rules
of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted), in each case, unless and until the stockholders of the Company have approved the transactions contemplated by this Agreement in accordance with the applicable
rules and regulations of NASDAQ, any other Trading Market on which the Common Stock may be listed or quoted, and the Charter and Bylaws of the Company. For the avoidance of doubt, the Company may, but shall be under no obligation to, solicit
stockholder approval of the transactions contemplated by this Agreement; provided, that if stockholder approval of the transactions contemplated hereby is not obtained, each of the Exchange Cap and the Single Fixed Request Limit shall be
applicable for all purposes of this Agreement and the transactions contemplated hereby at all times during the term of this Agreement (except as set forth in Section 2.13 below). If the Company issues a Fixed Request Notice or Optional Amount

  
 8 

 
that otherwise would permit the Investor to purchase shares of Common Stock which would cause the aggregate purchases by the Investor under this Agreement to exceed the Aggregate Limit, such
Fixed Request Notice or Optional Amount shall be void ab initio to the extent of the amount by which the dollar value of shares or number of shares, as the case may be, of Common Stock otherwise issuable pursuant to such Fixed Request Notice
or Optional Amount together with the dollar value of shares or number of shares, as the case may be, of all other Common Stock purchased by the Investor pursuant to this Agreement, or issued as partial damages pursuant to Section 9.1(ii), would
exceed the Aggregate Limit. If the Company issues a Fixed Request Notice or Optional Amount that otherwise would permit the Investor to purchase shares of Common Stock which, when aggregated with all other shares of Common Stock issued or sold
pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated by such Fixed Request Notice and Optional Amount under applicable rules of NASDAQ or any other Trading Market on which the Common Stock
may be listed or quoted, would exceed the Single Fixed Request Limit, such Fixed Request Notice or Optional Amount, as the case may be, shall be void ab initio to the extent of the amount by which the number of shares of Common Stock
otherwise issuable pursuant to such Fixed Request Notice or Optional Amount, as the case may be, together with all shares of Common Stock issued pursuant to all such other aggregated transactions, would exceed the Single Fixed Request Limit. The
Company hereby represents, warrants and covenants that it (i) has not effected any transaction or series of transactions, (ii) is not a party to any pending transaction or series of transactions or (iii) shall not enter into any
contract, agreement, agreement-in-principle, arrangement or understanding with respect to, or shall effect, any Other Financing which, in any of such cases, may be aggregated with the transactions contemplated by this Agreement for purposes of
determining whether approval of the Company’s stockholders is required under applicable rules of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted; provided, however, that the Company shall be
permitted to take any action referred to in clause (iii) of this sentence if (a) the Company has timely provided the Investor with an Integration Notice as provided in Section 5.6(ii) hereof and (b) unless the Investor has
previously terminated this Agreement pursuant to Section 7.2, the Company obtains any requisite stockholder approval which may be required for the Company to consummate such Other Financing described in such Integration Notice. 

At the Company’s sole discretion, and effective automatically upon delivery of notice thereof by the Company to the Investor, this
Agreement may be amended by the Company from time to time to reduce the Total Commitment by a specified dollar amount as shall be determined by the Company in its sole discretion; provided, however, that any such amendment of this
Agreement (and any such purported amendment) shall be void and of no force and effect if the effect thereof would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under this
Agreement, including, without limitation, the obligation of the Company to deliver the Shares to the Investor in respect of a previously delivered Fixed Request Notice or Optional Amount on the applicable Settlement Date. In the event the Company
shall have elected to reduce the Total Commitment as provided in the immediately preceding sentence, at the Company’s sole discretion, and effective automatically upon delivery of notice thereof by the Company to the Investor, the Company may
subsequently amend this Agreement to increase the Total Commitment up to $45,000,000; provided, however, that in no event shall the Company be entitled to issue Fixed Request Notices and grant Optional

  
 9 

 
Amounts during the remainder of the Investment Period for an aggregate amount greater than the amount obtained by subtracting (x) the aggregate of all Fixed Request Amounts and Optional
Amount Dollar Amounts (including any amounts paid as partial damages pursuant to Section 9.1(ii) hereunder) covered by all Fixed Request Notices and Optional Amounts theretofore issued or granted by the Company in respect of which a settlement
has occurred pursuant to Section 2.7 from (y) $45,000,000, subject, in all cases, to the Exchange Cap (except to the extent the Exchange Cap shall be inapplicable as expressly provided in Sections 2.12 and 2.13). 

Section 2.13 Trading Market Regulation. Notwithstanding anything in this Agreement to the contrary,
neither the Exchange Cap nor the Single Fixed Request Limit shall be applicable for any purposes of this Agreement or the transactions contemplated hereby, solely to the extent (and only for so long as) the Average Discount Price shall equal or
exceed the Base Price (it being hereby acknowledged and agreed that each of the Exchange Cap and the Single Fixed Request Limit shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all other times during
the term of this Agreement); provided, however, that the Company shall not issue any shares of Common Stock under this Agreement if such issuance would otherwise breach the Company’s obligations under the rules and regulations of
NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted. “Base Price” shall mean a price per Share equal to $3.89, representing the consolidated closing bid price of the Common Stock as reported on
NASDAQ on the Effective Date, subject to (a) upward
adjustment (by such amount to be mutually agreed by the Company and the Investor consistent with the rules and regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted) in the event any shares of Common
Stock are issued by the Company as partial damages pursuant to Section 9.1(ii) and (b) adjustment for any stock splits, stock combinations, stock dividends, recapitalizations and other similar transactions that occur on or after the date
of this Agreement. The Company hereby represents and warrants to the Investor that the book value per share of Common Stock on the Effective Date is less than the Base Price. “Average Discount Price” shall mean a price per Share (rounded to the nearest tenth of a cent) equal to
the quotient obtained by dividing (i) the total aggregate gross purchase price paid by the Investor for all Shares purchased pursuant to all Fixed Requests and Optional Amounts under this Agreement, by (ii) the total aggregate number of
Shares issued pursuant to all Fixed Requests and Optional Amounts under this Agreement. The provisions of this Section 2.13 shall be implemented in a manner otherwise than in strict conformity with the terms of this Section 2.13, only if
necessary to ensure compliance with the rules and regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted. 
 Section 2.14 Blackout Periods. The Company shall advise the Investor in writing of any changes to its policy on insider trading. Notwithstanding any other provision of this Agreement, the
Company shall not deliver any Fixed Request Notice or grant any Optional Amount or otherwise offer, sell or deliver Shares to the Investor, and the Investor shall not be obligated to purchase any Shares pursuant to this Agreement, (i) during
any period in which the Company is, or may be deemed to be, in possession of material non-public information, (ii) during any period (other than the period referred to in clause (iii) of this Section 2.14) in which the Company’s
insider trading policy, as it exists from time to time, would prohibit purchases or sales of Common Stock by its officers or directors (each such period, a “Blackout Period”), except with respect to this clause (ii) as
expressly provided in the immediately following

  
 10 

 
sentence, or (iii) except as expressly provided in this Section 2.14, at any time from and including the date (each, an “Announcement Date”) on which the Company shall
issue a press release containing, or shall otherwise publicly announce, its earnings, revenues or other results of operations (each, an “Earnings Announcement”) through and including the time that is 24 hours after the time that the
Company files (a “Filing Time”) a Quarterly Report on Form 10-Q or an Annual Report on Form 10-K that includes consolidated financial statements as of and for the same period or periods, as the case may be, covered by such Earnings
Announcement. If the Company wishes to deliver any Fixed Request Notice or grant any Optional Amount or otherwise offer, sell or deliver Shares to the Investor during any Blackout Period, the Company shall, as conditions thereto, (A) provide
the Investor with the compliance certificate substantially in the form attached hereto as Exhibit D, dated the date of such Fixed Request Notice or Optional Amount grant, as applicable, which certificate shall be deemed to remain in effect
during the applicable Pricing Period through and including the applicable Settlement Date, and the “bring down” opinions in the form mutually agreed to by the parties hereto, dated the date of such Fixed Request Notice or Optional Amount
grant, as applicable, and (B) afford the Investor the opportunity to conduct a due diligence review in accordance with Section 5.4 hereof. If the Company wishes to deliver any Fixed Request Notice or grant any Optional Amount or otherwise
offer, sell or deliver Shares to the Investor at any time during the period from and including an Announcement Date through and including the time that is 24 hours after the corresponding Filing Time, the Company shall, as conditions thereto,
(1) prepare and deliver to the Investor (with a copy to counsel to the Investor) a report on Form 8-K which shall include substantially the same financial and related information as was set forth in the relevant Earnings Announcement (other
than any earnings or other projections, similar forward-looking data and officers’ quotations) (each, an “Earnings 8-K”), in form and substance reasonably satisfactory to the Investor and its counsel, (2) provide the
Investor with the compliance certificate substantially in the form attached hereto as Exhibit D, dated the date of such Fixed Request Notice or Optional Amount grant, as applicable, which certificate shall be deemed to remain in effect during
the applicable Pricing Period through and including the applicable Settlement Date, and the “bring down” opinions in the form mutually agreed to by the parties hereto, dated the date of such Fixed Request Notice or Optional Amount grant,
as applicable, (3) afford the Investor the opportunity to conduct a due diligence review in accordance with Section 5.4 hereof and (4) file such Earnings 8-K with the Commission (so that it is deemed “filed” for purposes of
Section 18 of the Exchange Act) on or prior to the date of such Fixed Request Notice or Optional Amount grant, as applicable. The provisions of clause (iii) of this Section 2.14 shall not be applicable for the period from and after
the time at which all of the conditions set forth in the immediately preceding sentence shall have been satisfied (or, if later, the time that is 24 hours after the time that the relevant Earnings Announcement was first publicly released) through
and including the time that is 24 hours after the Filing Time of the relevant Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as the case may be. For purposes of clarity, the parties agree that the delivery of the compliance certificate
and the “bring down” opinions pursuant to this Section 2.14 shall not relieve the Company from any of its obligations under this Agreement with respect to the delivery of the compliance certificate called for by Section 6.3(v)
and the “bring down” opinions called for by Section 6.3(xii) on the applicable Settlement Date, which Sections shall have independent application. 

  
 11 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR 
 The Investor hereby makes
the following representations and warranties to the Company: 
 Section 3.1 Organization and Standing of the
Investor. The Investor is a limited partnership duly organized, validly existing and in good standing under the laws of the British Virgin Islands. 
 Section 3.2 Authorization and Power. The Investor has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and to purchase the Shares in
accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Investor and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action, and no
further consent or authorization of the Investor, its Board of Directors or stockholders is required. This Agreement has been duly executed and delivered by the Investor. This Agreement constitutes a valid and binding obligation of the Investor
enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership, or similar laws relating to, or affecting
generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

Section 3.3 No Conflicts. The execution, delivery and performance by the Investor of this Agreement and the consummation by
the Investor of the transactions contemplated herein do not and shall not (i) result in a violation of such Investor’s charter documents, bylaws or other applicable organizational instruments, (ii) conflict with, constitute a default
(or an event which, with notice or lapse of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond,
license, lease agreement, instrument or obligation to which the Investor is a party or is bound, (iii) create or impose any lien, charge or encumbrance on any property of the Investor under any agreement or any commitment to which the Investor
is party or under which the Investor is bound or under which any of its properties or assets are bound, or (iv) result in a violation of any federal, state, local or foreign statute, rule, or regulation, or any order, judgment or decree of any
court or governmental agency applicable to the Investor or by which any of its properties or assets are bound or affected, except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults, terminations, amendments,
acceleration, cancellations and violations as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Investor to enter into and perform its obligations under this Agreement in any material respect. The
Investor is not required under federal, state, local or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver
or perform any of its obligations under this Agreement or to purchase the Shares in accordance with the terms hereof. 

Section 3.4 Information. All materials relating to the business, financial condition, management and operations of the
Company and materials relating to the offer and sale of the Shares which have been requested by the Investor have been furnished or otherwise made available to the Investor or its advisors (subject to Section 5.12 of this Agreement). The
Investor 

  
 12 

 
and its advisors have been afforded the opportunity to ask questions of representatives of the Company. The Investor has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the Shares. The Investor understands that it (and not the Company) shall be responsible for its own tax liabilities that may arise as a result of this investment or
the transactions contemplated by this Agreement. The Investor is aware of all of its obligations under U.S. federal and applicable state securities laws and all rules and regulations promulgated thereunder in connection with this Agreement and the
transactions contemplated hereby and the purchase and sale of the Shares. 
 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
 Except as set forth in the Commission Documents or the disclosure schedule delivered by the Company to the Investor (which is hereby incorporated by reference in, and constitutes an integral part of, this
Agreement) (the “Disclosure Schedule”), the Company hereby makes the following representations and warranties to the Investor: 
 Section 4.1 Organization, Good Standing and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the
requisite corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in
every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except to the extent that the failure to be so qualified would not have a Material Adverse Effect. 

Section 4.2 Authorization, Enforcement. The Company has the requisite corporate power and authority to enter into and
perform this Agreement and to issue and sell the Shares in accordance with the terms hereof. Except for approvals of the Company’s Board of Directors or a committee thereof as may be required in connection with any issuance and sale of Shares
to the Investor hereunder (which approvals shall be obtained prior to the delivery of any Fixed Request Notice), the execution, delivery and performance by the Company of this Agreement and the consummation by it of the transactions contemplated
hereby have been duly and validly authorized by all necessary corporate action and no further consent or authorization of the Company or its Board of Directors or stockholders is required. This Agreement has been duly executed and delivered by the
Company and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

Section 4.3 Capitalization. The authorized capital stock of the Company and the shares thereof issued and outstanding were
as set forth in the Commission Documents as of the dates reflected therein. All of the outstanding shares of Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable. No shares of Common Stock are entitled to
preemptive rights and there are no outstanding debt securities and no contracts, 

  
 13 

 
commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares of the capital stock of the Company or options, warrants, scrip, rights to
subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exchangeable for, any shares of capital stock of the Company other than those issued or granted in the ordinary course of
business pursuant to the Company’s equity incentive and/or compensatory plans or arrangements. Except for customary transfer restrictions contained in agreements entered into by the Company to sell restricted securities, the Company is not a
party to, and it has no Knowledge of, any agreement restricting the voting or transfer of any shares of the capital stock of the Company. The offer and sale of all capital stock, convertible or exchangeable securities, rights, warrants or options of
the Company issued prior to the Effective Date complied, in all material respects, with all applicable federal and state securities laws, and no stockholder has any right of rescission or damages or any “put” or similar right with respect
thereto that would have a Material Adverse Effect. The Company has made available via the Commission’s Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”) true and correct copies of the Company’s Certificate
of Incorporation as in effect on the Effective Date (the “Charter”), and the Company’s Bylaws as in effect on the Effective Date (the “Bylaws”). 

Section 4.4 Issuance of Shares. The Shares to be issued under this Agreement have been or will be (prior to the delivery of
any Fixed Request Notice to the Investor hereunder), duly authorized by all necessary corporate action on the part of the Company. The Shares, when paid for in accordance with the terms of this Agreement, shall be validly issued and outstanding,
fully paid and nonassessable and free from all liens, charges, taxes, security interests, encumbrances, rights of first refusal, preemptive or similar rights and other encumbrances with respect to the issue thereof. 

Section 4.5 No Conflicts. The execution, delivery and performance by the Company of this Agreement and the consummation by
the Company of the transactions contemplated hereby do not and shall not (i) result in a violation of any provision of the Company’s Charter or Bylaws, (ii) conflict with, constitute a default (or an event which, with notice or lapse
of time or both, would become a default) under, or give rise to any rights of termination, amendment, acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or
obligation to which the Company is a party or is bound, (iii) create or impose a lien, charge or encumbrance on any property or assets of the Company under any agreement or any commitment to which the Company is a party or by which the Company
is bound or to which any of its properties or assets is subject, or (iv) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree applicable to the Company or by which any property or
asset of the Company is bound or affected (including federal and state securities laws and regulations and the rules and regulations of the Trading Market), except, in the case of clauses (ii), (iii) and (iv), for such conflicts, defaults,
terminations, amendments, acceleration, cancellations, liens, charges, encumbrances and violations as would not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under any applicable federal, state, local
or foreign law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under this
Agreement, or to issue and sell the Shares to the Investor in accordance 

  
 14 

 
with the terms hereof (other than any filings which may be required to be made by the Company with the Commission, the Financial Industry Regulatory Authority (“FINRA”) or the
Trading Market subsequent to the Effective Date, including, but not limited to, a Prospectus Supplement under Section 1.4 of this Agreement). 
 Section 4.6 Commission Documents, Financial Statements. (a) The Company has timely filed (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act)
all Commission Documents. The Company has made available via EDGAR true and complete copies of the Commission Documents filed with or furnished to the Commission prior to the Effective Date (including, without limitation, the 2011 Form 10-K) and has
made available via EDGAR true and complete copies of all of the Commission Documents heretofore incorporated by reference in the Registration Statement and the Prospectus. The Company has not provided to the Investor any information which, according
to applicable law, rule or regulation, was required to have been disclosed publicly by the Company but which has not been so disclosed, other than with respect to the transactions contemplated by this Agreement. As of its filing date, each
Commission Document filed with or furnished to the Commission and incorporated by reference in the Registration Statement and the Prospectus (including, without limitation, the 2011 Form 10-K) complied in all material respects with the requirements
of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and regulations applicable to it, and, as of its filing date (or, if amended or superseded by a filing prior to the Effective Date, on the date
of such amended or superseded filing), such Commission Document did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. Each Commission Document to be filed with or furnished to the Commission after the Effective Date and incorporated by reference in the Registration Statement, the Prospectus and any
Prospectus Supplement required to be filed pursuant to Section 1.4 hereof during the Investment Period (including, without limitation, the Current Report), when such document becomes effective or is filed with or furnished to the Commission
and, if applicable, when such document becomes effective, as the case may be, shall comply in all material respects with the requirements of the Securities Act or the Exchange Act, as applicable, and other federal, state and local laws, rules and
regulations applicable to it, and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. There are no outstanding or unresolved comments or undertakings in such comment letters received by the Company from the Commission. The Commission has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the Securities Act or the Exchange Act. 
 (b) The
financial statements, together with the related notes and schedules, of the Company included in the Commission Documents comply as to form in all material respects with all applicable accounting requirements and the published rules and regulations
of the Commission. Such financial statements, together with the related notes and schedules, have been prepared in accordance with GAAP applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such
financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may 

  
 15 

 
be condensed or summary statements), and fairly present in all material respects the financial condition of the Company as of the dates thereof and the results of operations and cash flows for
the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 
 (c) The Company
has timely filed with the Commission and made available via EDGAR all certifications and statements required by (x) Rule 13a-14 or Rule 15d-14 under the Exchange Act or (y) 18 U.S.C. Section 1350 (Section 906 of the Sarbanes-Oxley Act
of 2002 (“SOXA”)) with respect to all relevant Commission Documents. The Company is in compliance in all material respects with the provisions of SOXA applicable to it as of the date hereof. The Company maintains disclosure controls
and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures are effective to ensure that all material information concerning the Company is made known on a timely basis to the individuals responsible
for the timely and accurate preparation of the Company’s Commission filings and other public disclosure documents. As used in this Section 4.6(c), the term “file” shall be broadly construed to include any manner in which a
document or information is furnished, supplied or otherwise made available to the Commission. 
 (d) Deloitte & Touche
LLP, who have expressed their opinions on the audited financial statements and related schedules included or incorporated by reference in the Registration Statement and the Base Prospectus are, with respect to the Company, independent public
accountants as required by the Securities Act and is an independent registered public accounting firm within the meaning of SOXA as required by the rules of the Public Company Accounting Oversight Board. Deloitte & Touche LLP has not been
engaged by the Company to perform any “prohibited activities” (as defined in Section 10A of the Exchange Act). 

Section 4.7 Subsidiary. As of the Effective Date, EnteroMedics Europe SARL, a Swiss corporation, is the only Subsidiary of
the Company. 
 Section 4.8 No Material Adverse Effect. Since December 31, 2011, except for continued losses
from operations, the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would have a Material Adverse Effect. 

Section 4.9 No Undisclosed Liabilities. The Company has no liabilities, obligations, claims or losses (whether liquidated
or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company (including the notes thereto) in conformity with GAAP and are not disclosed in the Commission
Documents, other than those incurred in the ordinary course of the Company’s business since December 31, 2011 and which, individually or in the aggregate, do not or would not have a Material Adverse Effect. 

Section 4.10 No Undisclosed Events or Circumstances. No event or circumstance has occurred or information exists with
respect to the Company or its business, properties, liabilities, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure or announcement by the
Company at or before the Effective Date but which has not been so publicly announced or disclosed, except for events or circumstances which, individually or in the aggregate, do not or would not have a Material Adverse Effect. 

  
 16 

 Section 4.11 Indebtedness. The Company’s Quarterly Report on Form 10-Q
for its fiscal quarter ended June 30, 2012 sets forth, as of June 30, 2012, all outstanding secured and unsecured Indebtedness of the Company, or for which the Company has commitments through such date. For the purposes of this Agreement,
“Indebtedness” shall mean (a) any liabilities for borrowed money or amounts owed in excess of $10,000,000 (other than trade accounts payable incurred in the ordinary course of business), (b) all guaranties, endorsements,
indemnities and other contingent obligations in respect of Indebtedness of others in excess of $10,000,000, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease payments in excess of $10,000,000 due under leases required to be capitalized in
accordance with GAAP. There is no existing or continuing default or event of default in respect of any Indebtedness of the Company. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to
Title 11 of the United States Code or any similar federal or state bankruptcy law or law for the relief of debtors, nor does the Company have any Knowledge that its creditors intend to initiate involuntary bankruptcy, insolvency, reorganization or
liquidation proceedings or other proceedings for relief under Title 11 of the United States Code or any other federal or state bankruptcy law or any law for the relief of debtors. The Company is financially solvent and is generally able to pay its
debts as they become due. 
 Section 4.12 Title To Assets. The Company has good and valid title to, or has valid
rights to lease or otherwise use, all of its real and personal property reflected in the Commission Documents, free of mortgages, pledges, charges, liens, security interests or other encumbrances, except for those that would not have a Material
Adverse Effect. To the Company’s Knowledge, all real property and facilities held under lease by the Company are held by it under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the
use made and proposed to be made of such property and buildings by the Company. 
 Section 4.13 Actions Pending.
There is no action, suit, claim, investigation or proceeding pending, or to the Knowledge of the Company threatened, against the Company which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to
be taken pursuant hereto or thereto. There is no action, suit, claim, investigation or proceeding pending, or to the Knowledge of the Company threatened in writing, against or involving the Company or any of its properties or assets, or involving
any officers or directors of the Company, including, without limitation, any securities class action lawsuit or stockholder derivative lawsuit related to the Company, in each case which, if determined adversely to the Company or any officer or
director of the Company, would have a Material Adverse Effect. Except as set forth in the Commission Documents, no judgment, order, writ, injunction or decree or award has been issued by or, to the Knowledge of the Company, requested of any court,
arbitrator or governmental agency which would be reasonably expected to result in a Material Adverse Effect. 

  
 17 

 Section 4.14 Compliance With Law. The business of the Company has been and is
presently being conducted in compliance with all applicable federal, state, local and foreign governmental laws, rules, regulations and ordinances, except for such non-compliance which, individually or in the aggregate, would not have a Material
Adverse Effect. The Company is not in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company, except in all cases for possible violations which could not, individually or in the aggregate,
have a Material Adverse Effect. Without limiting the generality of the foregoing, the Company has maintained all requirements for the continued listing or quotation of its Common Stock on the Trading Market, and the Company is not in material
violation of any of the rules, regulations or requirements of the Trading Market and has no Knowledge of any facts or circumstances that could reasonably be expected to lead to delisting or suspension of the Common Stock by the Trading Market in the
foreseeable future. 
 Section 4.15 Certain Fees. Except for the placement fee payable by the Company to Financial
West Group, Member FINRA/SIPC (“FWG”), which shall be set forth in a separate engagement letter between the Company and FWG (a true and complete fully executed copy of which has heretofore been provided to the Investor), no brokers,
finders or financial advisory fees or commissions is or shall be payable by the Company (or any of its affiliates) with respect to the transactions contemplated by this Agreement. Except as set forth in this Section 4.15 or as disclosed in
Section 4.15 of the Disclosure Schedule, there are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company, the Investor or the Broker-Dealer for a brokerage
commission, finder’s fee or other like payment in connection with the transactions contemplated by this Agreement or, to the Company’s Knowledge, any arrangements, agreements, understandings, payments or issuance with respect to the
Company or any of its officers, directors, stockholders, partners, employees, Subsidiaries or Affiliates that could reasonably be expected to affect the FINRA’s determination of the amount of compensation to be received by any FINRA member
(including, without limitation, those FINRA members set forth on Schedule 4.15 of the Disclosure Schedule) or person associated with any FINRA member in connection with the transactions contemplated by this Agreement. Except as set forth in this
Section 4.15 or as disclosed in Section 4.15 of the Disclosure Schedule, no “items of value” (within the meaning of FINRA Rule 5110) have been received, and no arrangements have been entered into for the future receipt of any
items of value, from the Company or, to the Company’s Knowledge, any of its officers, directors, stockholders, partners, employees, Subsidiaries or Affiliates by any FINRA member (including, without limitation, those FINRA members set forth on
Schedule 4.15 of the Disclosure Schedule) or person associated with any FINRA member, during the period commencing 180 days immediately preceding the Effective Date and ending on the date this Agreement is terminated in accordance with Article VII,
that could reasonably be expected to affect the FINRA’s determination of the amount of compensation to be received by any FINRA member or person associated with any FINRA member in connection with the transactions contemplated by this
Agreement. 
 Section 4.16 Operation of Business. (a) The Company possesses such permits, licenses,
approvals, consents and other authorizations (including licenses, accreditation and other similar documentation or approvals of any local health departments) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies,
including, without limitation, the 

  
 18 

 
U.S. Food and Drug Administration (“FDA”), as are necessary to conduct the business now operated by it (collectively, “Governmental Licenses”), except where the
failure to possess such Governmental Licenses, individually or in the aggregate, would not have a Material Adverse Effect. The Company is in compliance with the terms and conditions of all such Governmental Licenses and all applicable FDA rules and
regulations, guidelines and policies, and all applicable rules and regulations, guidelines and policies of any governmental authority exercising authority comparable to that of the FDA (including any non-governmental authority whose approval or
authorization is required under foreign law comparable to that administered by the FDA), except where the failure to so comply, individually or in the aggregate, would not have a Material Adverse Effect. All of the Governmental Licenses are valid
and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect, individually or in the aggregate, would not have a Material Adverse Effect. To the
Company’s Knowledge, as to each product that is subject to FDA regulation or similar legal provisions in any foreign jurisdiction that is developed, manufactured, tested, packaged, labeled, marketed, sold, distributed and/or commercialized by
the Company, each such product is being developed, manufactured, tested, packaged, labeled, marketed, sold, distributed and/or commercialized in compliance with all applicable requirements of the FDA (and any non-governmental authority whose
approval or authorization is required under foreign law comparable to that administered by the FDA), including, but not limited to, those relating to investigational use, premarket approval, good clinical practices, good manufacturing practices,
record keeping, filing of reports, and patient privacy and medical record security, except where such non-compliance, individually or in the aggregate, would not have a Material Adverse Effect. As to each product or product candidate of the Company
subject to FDA regulation or similar legal provision in any foreign jurisdiction, all manufacturing facilities of the Company are operated in compliance with the FDA’s Good Manufacturing Practices requirements at 21 C.F.R. Part 210 and 211, as
applicable, except where such non-compliance, individually or in the aggregate, would not have a Material Adverse Effect. The Company has not received any written notice of proceedings relating to the revocation or modification of any such
Governmental Licenses or relating to a potential violation of, failure to comply with, any FDA rules and regulations, guidelines or policies which, if the subject of any unfavorable decision, ruling or finding, individually or in the aggregate,
would have a Material Adverse Effect. The Company has not received any correspondence, notice or request from the FDA, including, without limitation, notice that any one or more products or product candidates of the Company or any of its
Subsidiaries failed to receive approval from the FDA for use for any one or more indications that, individually or in the aggregate, would have a Material Adverse Effect. This Section 4.16 does not relate to environmental matters, such items
being the subject of Section 4.17. 
 (b) To the Company’s Knowledge, the Company owns or possesses adequate patents,
patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, trade dress, logos,
copyrights and other intellectual property, including, without limitation, all of the intellectual property described in the Commission Documents as being owned or licensed by the Company (collectively, “Intellectual Property”),
necessary to carry on the business now operated by it. There are no actions, suits or judicial proceedings pending, or to the Company’s Knowledge threatened in 

  
 19 

 
writing, relating to patents or proprietary information to which the Company is a party or of which any property of the Company is subject, and the Company has not received any notice or is
otherwise aware of any infringement of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which could render any Intellectual Property invalid or inadequate to protect the interest
of the Company therein, and which infringement or conflict (if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, individually or in the aggregate, would have a Material Adverse Effect. 

(c) All pre-clinical and clinical trials conducted by, or on behalf of, the Company, or in which the Company has participated that are
described in the Commission Documents, or the results of which are referred to in the Commission Documents, if any, are the only pre-clinical and clinical trials currently being conducted by or on behalf of the Company. To the Company’s
Knowledge, all such pre-clinical and clinical trials conducted, supervised or monitored by, or on behalf of, the Company have been conducted in compliance with all applicable federal, state, local and foreign laws, and the regulations and
requirements of any applicable governmental entity, including, but not limited to, FDA good clinical practice and good laboratory practice requirements. The Company has not received any notices or correspondence from the FDA or any other
governmental agency requiring the termination, suspension, delay or modification of any pre-clinical or clinical trials conducted by, or on behalf of, the Company or in which the Company has participated that are described in the Commission
Documents, if any, or the results of which are referred to in the Commission Documents. To the Company’s Knowledge, all pre-clinical and clinical trials previously conducted by, or on behalf of, the Company while conducted by or on behalf of
the Company, were conducted in compliance with all applicable federal, state, local and foreign laws, and the regulations and requirements of any applicable governmental entity, including, but not limited to, FDA good clinical practice and good
laboratory practice requirements. 
 Section 4.17 Environmental Compliance. The Company has obtained all material
approvals, authorization, certificates, consents, licenses, orders and permits or other similar authorizations of all governmental authorities, or from any other Person, that are required under any Environmental Laws, except for any approvals,
authorization, certificates, consents, licenses, orders and permits or other similar authorizations the failure of which to obtain does not or would not have a Material Adverse Effect. “Environmental Laws” shall mean all applicable
laws relating to the protection of the environment, including all requirements pertaining to reporting, licensing, permitting, controlling, investigating or remediating emissions, discharges, releases or threatened releases of hazardous substances,
chemical substances, pollutants, contaminants or toxic substances, materials or wastes, whether solid, liquid or gaseous in nature, into the air, surface water, groundwater or land, or relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of hazardous substances, chemical substances, pollutants, contaminants or toxic substances, material or wastes, whether solid, liquid or gaseous in nature. Except for such instances as would not,
individually or in the aggregate, have a Material Adverse Effect, to the Company’s Knowledge, there are no past or present events, conditions, circumstances, incidents, actions or omissions relating to or in any way affecting the Company that
violate or would reasonably be expected to violate any Environmental Law after the Effective Date or that would reasonably be expected to give rise to any environmental liability, or otherwise form the basis of any claim, action, demand, suit,

  
 20 

 
proceeding, hearing, study or investigation (i) under any Environmental Law, or (ii) based on or related to the manufacture, processing, distribution, use, treatment, storage (including
without limitation underground storage tanks), disposal, transport or handling, or the emission, discharge, release or threatened release of any hazardous substance. 
 Section 4.18 Material Agreements. The Company is not a party to any written or oral contract, instrument, agreement commitment, obligation, plan or arrangement, a copy of which would be
required to be filed with the Commission as an exhibit to an annual report on Form 10-K (collectively, “Material Agreements”). The Company has performed in all material respects all the obligations required to be performed by it
under the Material Agreements, has received no notice of default or an event of default by the Company thereunder and is not aware of any basis for the assertion thereof, and neither the Company nor, to the Knowledge of the Company, any other
contracting party thereto are in default under any Material Agreement now in effect, except in each case, the result of which would not have a Material Adverse Effect. Each of the Material Agreements is in full force and effect, and constitutes a
legal, valid and binding obligation enforceable in accordance with its terms against the Company and, to the Knowledge of the Company, each other contracting party thereto, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application.

 Section 4.19 Transactions With Affiliates. There are no loans, leases, agreements, contracts, royalty
agreements, management contracts, service arrangements or other continuing transactions exceeding $120,000 between (a) the Company, on the one hand, and (b) any Person who would be covered by Item 404(a) of Regulation S-K, on the
other hand. There are no outstanding amounts payable to or receivable from, or advances by the Company to, and the Company is not otherwise a creditor of or debtor to, any beneficial owner of more than 5% of the outstanding shares of Common Stock,
or any director, employee or Affiliate of the Company, other than (i) reimbursement for reasonable expenses incurred on behalf of the Company or (ii) as part of the normal and customary terms of such Persons’ employment or service as
a director with the Company. 
 Section 4.20 Securities Act. The Company has complied with all applicable federal
and state securities laws in connection with the offer, issuance and sale of the Shares contemplated by this Agreement. 
 (i)
The Company has prepared and filed with the Commission, in accordance with the provisions of the Securities Act, the Registration Statement, including a base prospectus relating to the Shares. The Registration Statement was declared effective by
order of the Commission on August 29, 2012. As of the date hereof, no stop order suspending the effectiveness of the Registration Statement has been issued by the Commission or is continuing in effect under the Securities Act and no proceedings
therefor are pending before or, to the Company’s Knowledge, threatened by the Commission. No order preventing or suspending the use of the Prospectus or any Permitted Free Writing Prospectus has been issued by the Commission. 

  
 21 

 (ii) As of the Effective Date, the Company satisfies all of the requirements for the use of
Form S-3 under the Securities Act for the offering and sale of the Shares contemplated by this Agreement (without reliance on General Instruction I.B.6. of Form S-3). If, during the term of this Agreement, the Company becomes subject to General
Instruction I.B.6. of Form S-3, the Company hereby confirms that for as long as the Company is subject to General Instruction I.B.6. of Form S-3 during the term of this Agreement, the Company shall not offer or sell any securities pursuant to this
Agreement that would exceed the limitations set forth in General Instruction I.B.6. of Form S-3 (as applicable). The Company is not, and has not previously been at any time, a “shell company” (as such term is defined in Rule 405 under the
Securities Act). 
 (iii) The Commission has not notified the Company of any objection to the use of the form of the
Registration Statement pursuant to Rule 401(g)(1) under the Securities Act. The Registration Statement complied in all material respects on the date on which it was declared effective by the Commission, and will comply in all material respects at
each deemed effective date with respect to the Investor pursuant to Rule 430B(f)(2) of the Securities Act, with the requirements of the Securities Act, and the Registration Statement (including the documents incorporated by reference therein) did
not on the date it was declared effective by the Commission, and shall not at each deemed effective date with respect to the Investor pursuant to Rule 430B(f)(2) of the Securities Act, contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading; provided that this representation and warranty does not apply to statements in or omissions from the Registration Statement made in
reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. The Registration Statement, as of the Effective Date, meets the requirements set
forth in Rule 415(a)(1)(x) under the Securities Act. The Base Prospectus complied in all material respects on its date and on the Effective Date, and will comply in all material respects on each applicable Fixed Request Exercise Date and, when taken
together with the applicable Prospectus Supplement and any applicable Permitted Free Writing Prospectus, on each applicable Settlement Date, with the requirements of the Securities Act and did not on its date and on the Effective Date and shall not
on each applicable Fixed Request Exercise Date and, when taken together with the applicable Prospectus Supplement and any applicable Permitted Free Writing Prospectus, on each applicable Settlement Date contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that this representation and warranty does not
apply to statements in or omissions from the Base Prospectus made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. 

(iv) Each Prospectus Supplement required to be filed pursuant to Section 1.4 hereof, when taken together with the Base Prospectus and
any applicable Permitted Free Writing Prospectus, on its date and on the applicable Settlement Date, shall comply in all material respects with the provisions of the Securities Act and shall not on its date and on the applicable Settlement Date
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading, except that this
representation and 

  
 22 

 
warranty does not apply to statements in or omissions from any Prospectus Supplement made in reliance upon and in conformity with information relating to the Investor furnished to the Company in
writing by or on behalf of the Investor expressly for use therein. 
 (v) At the earliest time after the filing of the
Registration Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) relating to the Shares, the Company was not and is not an “ineligible issuer”
(as defined in Rule 405 under the Securities Act). Each Permitted Free Writing Prospectus (a) shall conform in all material respects to the requirements of the Securities Act on the date of its first use, (b) when considered together with
the Prospectus on each applicable Fixed Request Exercise Date and on each applicable Settlement Date, shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they are made, not misleading, and (c) shall not include any information that conflicts with the information contained in the Registration Statement, including any document
incorporated by reference therein and any Prospectus Supplement deemed to be a part thereof that has not been superseded or modified. The immediately preceding sentence does not apply to statements in or omissions from any Permitted Free Writing
Prospectus made in reliance upon and in conformity with information relating to the Investor furnished to the Company in writing by or on behalf of the Investor expressly for use therein. 

(vi) Prior to the Effective Date, the Company has not distributed any offering material in connection with the offering and sale of the
Shares. From and after the Effective Date and prior to the completion of the distribution of the Shares, the Company shall not distribute any offering material in connection with the offering and sale of the Shares, other than the Registration
Statement, the Base Prospectus as supplemented by any Prospectus Supplement or a Permitted Free Writing Prospectus. 

Section 4.21 Employees. The Company does not have any collective bargaining arrangements or agreements covering any of its
employees. No officer, consultant or key employee of the Company whose termination, either individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, has terminated or, to the Knowledge of the Company, has any
present intention of terminating his or her employment or engagement with the Company. 
 Section 4.22 Use of
Proceeds. The proceeds from the sale of the Shares shall be used by the Company as set forth in the Base Prospectus and any Prospectus Supplement filed pursuant to Section 1.4. 

Section 4.23 Investment Company Act Status. The Company is not, and as a result of the consummation of the transactions
contemplated by this Agreement and the application of the proceeds from the sale of the Shares as set forth in the Base Prospectus and any Prospectus Supplement shall not be, an “investment company” or a company “controlled” by
an “investment company,” within the meaning of the Investment Company Act of 1940, as amended. 
 Section 4.24
ERISA. No liability to the Pension Benefit Guaranty Corporation has been incurred with respect to any Plan by the Company which has had or would have a Material 

  
 23 

 
Adverse Effect. No “prohibited transaction” (as defined in Section 406 of ERISA or Section 4975 of the Code) or “accumulated funding deficiency” (as defined in
Section 302 of ERISA) or any of the events set forth in Section 4043(b) of ERISA has occurred with respect to any Plan which has had or would have a Material Adverse Effect, and the execution and delivery of this Agreement and the issuance
and sale of the Shares hereunder shall not result in any of the foregoing events. Each Plan is in compliance in all material respects with applicable law, including ERISA and the Code; the Company has not incurred and does not expect to incur
liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any Plan; and each Plan for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified
in all material respects and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualifications. As used in this Section 4.22, the term “Plan” shall mean an “employee pension
benefit plan” (as defined in Section 3 of ERISA) which is or has been established or maintained, or to which contributions are or have been made, by the Company by any trade or business, whether or not incorporated, which, together with
the Company, is under common control, as described in Section 414(b) or (c) of the Code. 
 Section 4.25
Taxes. The Company (i) has filed all necessary federal, state and foreign income and franchise tax returns or has duly requested extensions thereof, except for those the failure of which to file would not have a Material Adverse
Effect, (ii) has paid all federal, state, local and foreign taxes due and payable for which it is liable, except to the extent that any such taxes are being contested in good faith and by appropriate proceedings, except for such taxes the
failure of which to pay would not have a Material Adverse Effect, and (iii) does not have any tax deficiency or claims outstanding or assessed or, to the Company’s Knowledge, proposed against it which would have a Material Adverse Effect.
There are no unpaid taxes of the Company in any material amount claimed to be due by the taxing authority of any jurisdiction, and the Company has no Knowledge of any reasonable basis for any such claim. The Company is not operated in such a manner
as to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended. 
 Section 4.26 Insurance. The Company is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to
be prudent and customary in the businesses in which the Company is engaged. 
 Section 4.27 U.S. Real Property Holding
Corporation. The Company is not and has never been, and so long as any of the Shares are held by the Investor, shall not become a U.S. real property holding corporation within the meaning of Section 897 of the Code. 

Section 4.28 Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to
Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its Knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company
received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the Effective Date, received notice from any Trading Market on which the Common Stock is or has been listed
or quoted to the effect that the Company is not in compliance in any material respect with the listing or maintenance requirements of such Trading Market. As of the Effective Date, the Company is in compliance with all such listing and maintenance
requirements. 

  
 24 

 Section 4.29 Foreign Corrupt Practices Act. None of the Company or, to the
Knowledge of the Company, any director, officer, agent, employee, affiliate or other Person acting on behalf of the Company, is aware of or has taken any action, directly or indirectly, that would result in a violation by such Persons of the Foreign
Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly
in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is
defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA. The Company has conducted its business in compliance with the FCPA and has instituted and maintained
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. 
 Section 4.30 Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of
the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or
enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect
to the Money Laundering Laws is pending or, to the Knowledge of the Company, threatened. 
 Section 4.31 OFAC.
None of the Company or, to the Knowledge of the Company, any director, officer, agent, employee, affiliate or Person acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of
the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other
Person, for the purpose of financing the activities of any Person currently subject to any U.S. sanctions administered by OFAC. 

Section 4.32 Manipulation of Price. Neither the Company nor any of its officers, directors or Affiliates has, and, to the
Knowledge of the Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or to result in the stabilization or manipulation of the price of any security of the Company, or which
caused or resulted in, or which would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale of any of the Shares, or
(ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Shares. 
 Section 4.33
Acknowledgement Regarding Investor’s Acquisition of Shares. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions
contemplated hereby. The 

  
 25 

 
Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement or the transactions
contemplated hereby, and any advice given by the Investor or any of its representatives or agents in connection with this Agreement or the transactions contemplated hereby is merely incidental to the Investor’s acquisition of the Shares. The
Company further represents to the Investor that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. The Company
acknowledges and agrees that the Investor has not made and does not make any representations or warranties with respect to the transactions contemplated by this Agreement other than those specifically set forth in Article III of this Agreement.

 ARTICLE V 
 COVENANTS 
 The Company covenants with the Investor, and the Investor
covenants with the Company, as follows, which covenants of one party are for the benefit of the other party, during the Investment Period: 
 Section 5.1 Securities Compliance; FINRA Filing. 
 (i) The Company
shall notify the Trading Market, as required, in accordance with its rules and regulations, of the transactions contemplated by this Agreement, and shall take all necessary action, undertake all proceedings and obtain all registrations, permits,
consents and approvals for the legal and valid issuance of the Shares to the Investor in accordance with the terms of this Agreement. Without limiting the generality of the foregoing, the Company shall take all necessary action, undertake all
proceedings and obtain all registrations, permits, consents and approvals in order to (i) qualify the Shares for offering and sale to the Investor, or to obtain an exemption for the Shares to be offered and sold to the Investor and
(ii) qualify the Shares for offer and resale by the Investor, or to obtain an exemption for the Shares to be offered and resold by the Investor, in each case under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Investor may designate, and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Shares (but in no event for less than one year from the date of this Agreement);
provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to
subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Shares have been so qualified or exempt, the Company will file such statements and reports as may
be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Shares (but in no event for less than one year from the date of this
Agreement). 
 (ii) The Company shall (with the Investor’s assistance) assist FWG with the preparation and filing with
FINRA’s Corporate Financing Department via the Public Offering System (not later than 24 hours after the Effective Date) of all documents and information required to be filed with FINRA pursuant to FINRA Rule 5110 with regard to the
transactions contemplated by this Agreement (the “FINRA Filing”). In connection therewith, on the Effective 

  
 26 

 
Date, the Company shall pay to FINRA by wire transfer of immediately available funds the applicable filing fee with respect to the FINRA Filing, and the Company shall be solely responsible for
payment of such fee. The parties hereby agree to provide each other and FWG all requisite information and otherwise to assist each other and FWG in a timely fashion in order for FWG to complete the preparation and submission of the FINRA Filing in
accordance with this Section 5.1(ii) and to assist FWG in promptly responding to any inquiries or requests from FINRA or its staff. Each party hereto shall (A) promptly notify the other party and FWG of any communication to that party or
its affiliates from FINRA, including, without limitation, any request from FINRA or its staff for amendments or supplements to or additional information in respect of the FINRA Filing and permit the other party and FWG to review in advance any
proposed written communication to FINRA and (B) furnish the other party and FWG with copies of all written correspondence, filings and communications between them and their affiliates and their respective representatives and advisors, on the
one hand, and FINRA or members of its staff, on the other hand, with respect to this Agreement or the transactions contemplated hereby. Each of the parties hereto agrees to use its commercially reasonable efforts to take, or cause to be taken, all
actions, and to do, or cause to be done, and to assist and cooperate with the other party and FWG in doing, all things necessary, proper or advisable to obtain as promptly as practicable (but in no event later than 60 days after the Effective Date)
written confirmation from FINRA to the effect that FINRA’s Corporate Financing Department has determined not to raise any objection with respect to the fairness and reasonableness of the terms of the transactions contemplated by this Agreement;
provided, however, that the Investor shall have no responsibility for the compliance or non-compliance of any Broker-Dealer with FINRA Rule 5110 and shall not be required to (x) disclose to FINRA or to any other governmental
agency, person or entity any business, financial or other information that the Investor deems, in its sole and absolute discretion, to be proprietary, confidential or otherwise sensitive information, (y) amend, modify or change any of the terms
or conditions of this Agreement or (z) otherwise take any other action, including, without limitation, modifying the Discount Price thresholds referred to in Section 2.2 or the amount of fees and commissions to be paid to the Broker-Dealer
in connection with the transactions contemplated by this Agreement, in each case, in such a manner that would, in the Investor’s sole and absolute discretion, render the terms and conditions of this Agreement or the transactions contemplated
hereby to be no longer advisable to the Investor. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not pay any fees to FWG in connection with any of the transactions contemplated by this Agreement, unless and
until the parties hereto and FWG shall have received written confirmation from FINRA to the effect that FINRA’s Corporate Financing Department has determined not to raise any objection with respect to the fairness and reasonableness of the
terms of the transactions contemplated by this Agreement. 
 Section 5.2 Registration and Listing. The Company
shall take all action necessary to cause the Common Stock to continue to be registered as a class of securities under Sections 12(b) or 12(g) of the Exchange Act, shall comply in all material respects with its reporting and filing obligations under
the Exchange Act, and shall not take any action or file any document (whether or not permitted by the Securities Act or the Exchange Act) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under
the Exchange Act or Securities Act, except as permitted herein. Without limiting the generality of the foregoing, the Company shall file all reports, schedules, registrations, forms, statements,

  
 27 

 
information and other documents required to be filed by the Company with the Commission pursuant to the Exchange Act, including all material required to be filed pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act, in each case within the time periods required by the Exchange Act (giving effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act). The Company shall use its reasonable best
efforts to continue the listing and trading of its Common Stock and the listing of the Shares purchased by the Investor hereunder on the Trading Market, and shall comply with the Company’s reporting, filing and other obligations under the
bylaws, listed securities maintenance standards and other rules and regulations of FINRA and the Trading Market. The Company shall not take any action which could reasonably be expected to result in the delisting or suspension of the Common Stock on
the Trading Market. 
 Section 5.3 Compliance with Laws. 

(i) The Company shall comply (a) with all laws, rules, regulations, permits and orders applicable to the business and operations of
the Company, except as would not have a Material Adverse Effect and (b) with all applicable provisions of the Securities Act, the Exchange Act, the rules and regulations of the FINRA and the listing standards of the Trading Market. Without
limiting the foregoing: (A) neither the Company nor any of its officers or directors (1) will take, directly or indirectly, any action designed or intended to cause or to result in, or which would in the future reasonably be expected to
cause or result in, the stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale of any of the Shares, or (2) sell, bid for, purchase, or pay any compensation for soliciting
purchases of, any of the Shares, other than, in the case of clause (2), compensation paid to FWG in connection with the settlement of each Fixed Request pursuant to this Agreement; and (B) neither the Company nor to the Knowledge of the
Company, any of its directors, officers, agents, employees or any other Persons acting on its behalf shall, in connection with the operation of the Company’s business, (a) use any corporate funds for unlawful contributions, payments, gifts
or entertainment or to make any unlawful expenditures relating to political activity to government officials, candidates or members of political parties or organizations, (b) pay, accept or receive any unlawful contributions, payments,
expenditures or gifts, or (c) violate or operate in noncompliance with any export restrictions, anti-boycott regulations, embargo regulations or other applicable domestic or foreign laws and regulations, including, without limitation, the FCPA
and the Money Laundering Laws. 
 (ii) The Investor shall comply with all laws, rules, regulations and orders applicable to the
performance by it of its obligations under this Agreement and its investment in the Shares, except as would not, individually or in the aggregate, prohibit or otherwise interfere with the ability of the Investor to enter into and perform its
obligations under this Agreement in any material respect. Without limiting the foregoing, the Investor shall comply with all applicable provisions of the Securities Act and the Exchange Act, including Regulation M thereunder, and any applicable
securities laws of any non-U.S. jurisdictions. Neither the Investor nor any of its officers or directors will take, directly or indirectly, any action designed or intended to cause or to result in, or which would in the future reasonably be expected
to cause or result in, the stabilization or manipulation of the price of any security of the Company, in each case to facilitate the sale or resale of any of the Shares. 

  
 28 

 Section 5.4 Due Diligence. Subject to the requirements of
Section 5.12 of this Agreement, from time to time from and after the period beginning with the third Trading Day immediately preceding each Fixed Request Exercise Date through and including the applicable Settlement Date, the Company shall make
available for inspection and review by the Investor, customary documentation allowing the Investor and/or its appointed counsel or advisors to conduct due diligence. 
 Section 5.5 Limitations on Holdings and Issuances. Notwithstanding any other provision of this Agreement, the Company shall not issue and the Investor shall not purchase any shares of Common
Stock which, when aggregated with all other shares of Common Stock then beneficially owned (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder) by the Investor and its Affiliates, would result in
the beneficial ownership by the Investor of more than 9.9% of the then issued and outstanding shares of Common Stock. Upon the written or oral request of the Investor, the Company shall promptly (but not later than the next Trading Day) confirm
orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor’s written
certification to the Company of the applicability of this beneficial ownership limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.

 Section 5.6 Other Agreements and Other Financings. 

(i) The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of
which the terms thereof would restrict, materially delay, conflict with or impair the ability or right of the Company or any Subsidiary to perform its obligations under this Agreement, including, without limitation, the obligation of the Company to
deliver the Shares to the Investor in respect of a previously provided Fixed Request Notice or Optional Amount on the applicable Settlement Date. 
 (ii) If the Company enters into any agreement, plan, arrangement or transaction with a third party or seeks to utilize any existing agreement, plan or arrangement with a third party, in each case the
principal purpose of which is to implement, effect or consummate, at any time during the period beginning on the first Trading Day of any Pricing Period and ending on the second Trading Day next following the applicable Settlement Date (the
“Reference Period”), an Other Financing that does not constitute an Acceptable Financing, the Company shall provide prompt notice thereof (an “Other Financing Notice”) to the Investor; provided,
however, that such Other Financing Notice must be received by the Investor not later than the earlier of (a) 48 hours after the Company’s execution of any agreement, plan, arrangement or transaction relating to such Other
Financing (or, with respect to any existing agreement, plan or arrangement, 48 hours after the Company has determined to utilize any such existing agreement, plan or arrangement to implement, effect or consummate such Other Financing) and
(b) the second Trading Day immediately preceding the applicable Settlement Date with respect to the applicable Fixed Request Notice; provided, further, that the Company shall notify the Investor within 24 hours (an
“Integration Notice”) if it enters into any agreement, plan, arrangement or transaction with a third party, the principal purpose of which is to obtain at any time during the 

  
 29 

 
Investment Period an Other Financing that may be aggregated with the transactions contemplated by this Agreement for purposes of determining whether approval of the Company’s stockholders is
required under any bylaw, listed securities maintenance standards or other rules of the Trading Market and, if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules
and regulations of the Trading Market, the Company shall publicly disclose such information in accordance with Regulation FD and the applicable rules and regulations of the Trading Market. For purposes of this Section 5.6(ii), any press release
issued by, or Commission Document filed by, the Company shall constitute sufficient notice, provided that it is issued or filed, as the case may be, within the time requirements set forth in the first sentence of this Section 5.6(ii) for an
Other Financing Notice or an Integration Notice, as applicable. With respect to any Pricing Period for which the Company is required to provide an Other Financing Notice pursuant to the first sentence (including the provisos thereto) of this
Section 5.6(ii), the Investor shall have the option to purchase the Shares subject to the Fixed Request at (i) the price therefor in accordance with the terms of this Agreement or (ii) the third party’s per share purchase price
in connection with the Other Financing, net of such third party’s discounts, Warrant Value and fees. An “Other Financing” shall mean (w) the issuance for cash of Common Stock for a purchase price less than, or the issuance
for cash of securities convertible into or exchangeable for Common Stock at an exercise or conversion price (as the case may be) less than, the then Current Market Price of the Common Stock (including, without limitation, pursuant to any
“equity line” or other financing that is substantially similar to the financing provided for under this Agreement, or pursuant to any other transaction in which the purchase, conversion or exchange price for such Common Stock is determined
using a floating discount or other post-issuance adjustable discount to the then Current Market Price (any such transaction, a “Similar Financing”)), in each case, after all fees, discounts, Warrant Value and commissions associated
with the transaction (a “Below Market Offering”); (x) an “at-the-market” offering for cash of Common Stock or securities convertible into or exchangeable for Common Stock pursuant to Rule 415(a)(4) under the
Securities Act (an “ATM”); (y) the implementation by the Company of any mechanism in respect of any securities convertible into or exchangeable for Common Stock for the reset of the purchase price of the Common Stock to below
the then Current Market Price of the Common Stock (including, without limitation, any antidilution or similar adjustment provisions in respect of any Company securities, but specifically excluding customary adjustments for stock splits, stock
dividends, stock combinations and similar events) (a “Price Reset Provision”); or (z) the issuance of options, warrants or similar rights of subscription, in the case of each of clause (w) and (z) not constituting an
Acceptable Financing (it being acknowledged and agreed that notwithstanding anything herein to the contrary, any Similar Financing, ATM or Price Reset Provision shall not constitute an Acceptable Financing). “Acceptable Financing”
shall mean the issuance by the Company of: (1) debt securities or any class or series of preferred stock of the Company, in each case that are not convertible into or exchangeable for Common Stock or securities convertible into or exchangeable
for Common Stock; (2) shares of Common Stock or securities convertible into or exchangeable for Common Stock (including, without limitation, convertible debt securities) other than in connection with a Below Market Offering or an ATM, and the
issuance of shares of Common Stock upon conversion, exercise or exchange thereof; (3) shares of Common Stock or securities convertible into or exchangeable for Common Stock (including, without limitation, convertible debt securities) in
connection with an underwritten public offering (or offering under Rule 144A under the Securities Act) of securities of the Company or a 

  
 30 

 
registered direct public offering of securities of the Company, in each case where the price per share of such Common Stock (or the conversion or exercise price of such securities, as applicable)
is fixed concurrently with the execution of definitive documentation relating to such offering, and the issuance of shares of Common Stock upon the conversion, exercise or exchange thereof; (4) shares of Common Stock or securities convertible
into or exchangeable for Common Stock in connection with awards under the Company’s benefit and equity plans and arrangements or shareholder rights plan (as applicable) and the issuance of shares of Common Stock upon the conversion, exercise or
exchange thereof; (5) shares of Common Stock issuable upon the conversion or exchange of equity awards or convertible, exercisable or exchangeable securities (including, without limitation, convertible debt securities) outstanding as of the
Effective Date; (6) shares of Common Stock in connection with stock splits, stock dividends, stock combinations, recapitalizations, reclassifications and similar events; (7) shares of Common Stock or securities convertible into or
exchangeable for Common Stock (including, without limitation, convertible debt securities) issued in connection with the acquisition, license or sale of one or more other companies, equipment, technologies, other assets or lines of business, and the
issuance of shares of Common Stock upon the conversion, exercise or exchange thereof; (8) shares of Common Stock or securities convertible into or exchangeable for Common Stock (including, without limitation, convertible debt securities) or
similar rights to subscribe for the purchase of shares of Common Stock in connection with technology sharing, collaboration, partnering, licensing, research and joint development agreements (or amendments thereto) with third parties, and the
issuance of shares of Common Stock upon the conversion, exercise or exchange thereof; (9) shares of Common Stock or securities convertible into or exchangeable for Common Stock to employees, consultants and/or advisors as consideration for
services rendered or to be rendered, and the issuance of shares of Common Stock upon conversion, exercise or exchange thereof; and (10) shares of Common Stock or securities convertible into or exchangeable for Common Stock issued in connection
with capital or equipment financings and/or real property lease arrangements, and the issuance of shares of Common Stock upon the conversion, exercise or exchange thereof. 
 Section 5.7 Stop Orders. The Company shall advise the Investor promptly (but in no event later than 24 hours) and shall confirm such advice in writing: (i) of the Company’s receipt
of notice of any request by the Commission for amendment of or a supplement to the Registration Statement, the Prospectus, any Permitted Free Writing Prospectus or for any additional information; (ii) of the Company’s receipt of notice of
the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement, or of the suspension of qualification of the Shares for
offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in
the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus untrue or which requires the making of any additions to or changes to the statements then made in the Registration Statement, the Prospectus or any Permitted Free
Writing Prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of the Prospectus, in light of the circumstances under which they
were made) not misleading, or of the necessity to amend the Registration Statement or supplement the Prospectus or any Permitted Free Writing Prospectus 

  
 31 

 
to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investor the substance or specific reasons of any of the events set forth in clauses
(i) through (iii) of the immediately preceding sentence, but rather, shall only be required to disclose that the event has occurred. The Company shall not issue any Fixed Request during the continuation of any of the foregoing events. If
at any time the Commission shall issue any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the Prospectus or any Prospectus Supplement, the Company shall use reasonable best efforts to
obtain the withdrawal of such order at the earliest possible time. The Company shall also advise the Investor promptly (but in no event later than 24 hours) and shall confirm such advice in writing of the Company becoming aware of the happening of
any event, which makes any statement made in the FINRA Filing untrue or which requires the making of any additions to or changes to the statements then made in the FINRA Filing in order to comply with FINRA Rule 5110. 

Section 5.8 Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses. 

(i) Except as provided in this Agreement and other than periodic and current reports required to be filed pursuant to the Exchange Act,
the Company shall not file with the Commission any amendment to the Registration Statement that relates to the Investor, this Agreement or the transactions contemplated hereby or file with the Commission any Prospectus Supplement that relates to the
Investor, this Agreement or the transactions contemplated hereby with respect to which (a) the Investor shall not previously have been advised, (b) the Company shall not have given the Investor and its counsel a reasonable opportunity to
comment on a draft thereof prior to filing with the Commission, (c) the Company shall not have given due consideration to any comments thereon received from the Investor or its counsel prior to filing with the Commission, or (d) the
Investor shall reasonably object after being so advised or after having completed its review (provided, however, that the failure of the Investor to make such objection shall not relieve the Company of any obligation or
liability under this Agreement or affect the Investor’s right to rely on the representations and warranties made by the Company in this Agreement), unless the Company reasonably has determined that it is necessary to amend the Registration
Statement or make any supplement to the Prospectus to comply with the Securities Act or any other applicable law or regulation, in which case the Company shall promptly (but in no event later than 24 hours) so inform the Investor, the Investor shall
be provided with a reasonable opportunity to review and comment upon any disclosure relating to the Investor and the Company shall expeditiously furnish to the Investor an electronic copy thereof (it being acknowledged and agreed that the provisions
of Section 1.4, and not this Section 5.8, shall apply with respect to the Initial Prospectus Supplement). In addition, for so long as, in the reasonable opinion of counsel for the Investor, the Prospectus (or in lieu thereof, the notice
referred to in Rule 173(a) under the Securities Act) is required to be delivered in connection with any acquisition or sale of Shares by the Investor, the Company shall not file any (1) Prospectus Supplement with respect to the Shares, without
delivering or making available a copy of such Prospectus Supplement (in the form filed with the Commission), together with the Base Prospectus, to the Investor promptly after the filing thereof with the Commission, or (2) any amendment to the
Registration Statement, without promptly delivering or making available a copy of such amendment to the Registration Statement (in the form filed with the Commission) 

  
 32 

 
to the Investor promptly after the filing thereof with the Commission, in each case via e-mail in “.pdf” format to an e-mail account designated by the Investor. 

(ii) The Company has not made, and agrees that unless it obtains the prior written consent of the Investor it will not make, an offer
relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company or the Investor with the Commission or retained by the Company or the
Investor under Rule 433 under the Securities Act. The Investor has not made, and agrees that unless it obtains the prior written consent of the Company it will not make, an offer relating to the Shares that would constitute a Free Writing Prospectus
required to be filed by the Company or the Investor with the Commission or retained by the Company or the Investor under Rule 433 under the Securities Act. Any such Issuer Free Writing Prospectus or other Free Writing Prospectus consented to by the
Investor or the Company is referred to in this Agreement as a “Permitted Free Writing Prospectus.” The Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an
Issuer Free Writing Prospectus and (y) it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 under the Securities Act applicable to any Permitted Free Writing Prospectus, including in respect of timely
filing with the Commission, legending and record keeping. 
 Section 5.9 Prospectus Delivery. For so long as, in
the reasonable opinion of counsel for the Investor, the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required to be delivered in connection with any acquisition or sale of Shares by the Investor,
the Company will furnish to the Investor and its counsel (at the expense of the Company) copies of the Base Prospectus and all Prospectus Supplements that are filed with the Commission, in each case, in the form filed with the Commission, as soon as
reasonably practicable via e-mail in “.pdf” format to an e-mail account designated by the Investor and, at the Investor’s request, will also furnish copies of the Base Prospectus and all Prospectus Supplements, in each case, in the
form filed with the Commission, to each exchange or market on which sales of the Shares may be made and to each Broker-Dealer or other Person designated by the Investor. The Company consents to the use of the Prospectus (and of any Prospectus
Supplement thereto) in accordance with the provisions of the Securities Act and with the securities or “Blue Sky” laws of the jurisdictions in which the Shares may be sold by the Investor, in connection with the offering and sale of the
Shares and for such period of time thereafter as the Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required by the Securities Act to be delivered in connection with sales of the Shares. If during
such period of time any event shall occur that in the judgment of the Company and its counsel is required to be set forth in the Registration Statement or the Prospectus or any Permitted Free Writing Prospectus or should be set forth therein in
order to make the statements made therein (in the case of the Prospectus, in light of the circumstances under which they were made) not misleading, or if it is necessary to amend the Registration Statement or supplement or amend the Prospectus or
any Permitted Free Writing Prospectus to comply with the Securities Act or any other applicable law or regulation, the Company shall forthwith prepare and, subject to Section 5.8 above, file with the Commission an appropriate amendment to the
Registration Statement or Prospectus Supplement to the Prospectus (or supplement to the Permitted Free Writing Prospectus) and shall expeditiously furnish or make available to the Investor a copy

  
 33 

 
thereof in accordance with this Section 5.9. The Investor shall comply with any Prospectus delivery requirements under the Securities Act applicable to it. The Investor acknowledges and
agrees that it is not authorized to give any information or to make any representation not contained in the Prospectus or the documents incorporated by reference or specifically referred to therein in connection with the offer and sale of the
Shares. 
 Section 5.10 Selling Restrictions. 

(i) Except as expressly set forth below, the Investor covenants that from and after the date hereof through and including the 90th day
next following the termination of this Agreement (the “Restricted Period”), neither the Investor nor any of its Affiliates nor any entity managed or controlled by the Investor (collectively, the “Restricted Persons”
and each of the foregoing is referred to herein as a “Restricted Person”) shall, directly or indirectly, (x) engage in any Short Sales involving the Company’s securities or (y) grant any option to purchase, or acquire
any right to dispose of or otherwise dispose for value of, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for any shares of Common Stock, or enter into any swap, hedge or other similar agreement that
transfers, in whole or in part, the economic risk of ownership of the Common Stock. Notwithstanding the foregoing, it is expressly understood and agreed that nothing contained herein shall (without implication that the contrary would otherwise be
true) prohibit any Restricted Person during the Restricted Period from: (1) selling “long” (as defined under Rule 200 promulgated under Regulation SHO) any shares of Common Stock (including the Shares); or (2) selling a number of
shares of Common Stock equal to (x) the number of Shares that such Restricted Person is or may be obligated to purchase under a pending Fixed Request Notice and/or (y) the number of Shares that such Restricted Person may purchase under a
pending Optional Amount, but, in each case, has not yet taken possession of so long as such Restricted Person (or the Broker-Dealer, as applicable) delivers the Shares purchased pursuant to such Fixed Request Notice and/or Optional Amount to the
purchaser thereof or the applicable Broker-Dealer; provided, however, such Restricted Person (or the applicable Broker-Dealer, as applicable) shall not be required to so deliver any such Shares subject to such Fixed Request Notice or
Optional Amount, as the case may be, if (a) such Fixed Request or Optional Amount, as the case may be, is terminated by mutual agreement of the Company and the Investor and, as a result of such termination, no such Shares are delivered to the
Investor under this Agreement or (b) the Company otherwise fails to deliver such Shares to the Investor on the applicable Settlement Date upon the terms and subject to the provisions of this Agreement. 

(ii) In addition to the foregoing, in connection with any sale of Shares (including any sale permitted by paragraph (i) above), the
Investor shall comply in all respects with all applicable laws, rules, regulations and orders, including, without limitation, the requirements of the Securities Act and the Exchange Act. 

Section 5.11 Effective Registration Statement. The Company shall use its reasonable best efforts to keep the Registration
Statement effective pursuant to Rule 415 promulgated under the Securities Act, and to keep the Registration Statement and the Prospectus current and available for issuances and sales of Shares by the Company to the Investor, and for the resale of
Shares by the Investor, at all times during the term of this Agreement and, to the 

  
 34 

 
extent the Investor owns any Shares upon the termination of this Agreement, until the 180th day next following the termination of this Agreement (the “Registration Period”).
Without limiting the generality of the foregoing, during the Registration Period, the Company shall prepare and, subject to Section 5.8 above, file with the Commission, at the Company’s expense, such amendments (including, without
limitation, post-effective amendments) to the Registration Statement and such Prospectus Supplements pursuant to Rule 424(b) under the Securities Act, in each case, as may be necessary to keep the Registration Statement effective pursuant to Rule
415 promulgated under the Securities Act, and to keep the Registration Statement and the Prospectus current and available for issuances and sales of Shares by the Company to the Investor, and for the resale of Shares by the Investor, at all times
during the Registration Period. Without limiting the generality of the foregoing, if, immediately prior to the third (3rd) anniversary of the initial effective date of the Registration Statement (the “Renewal Date”), any of the
Shares that have been or may be issued pursuant to this Agreement have not been issued by the Company or resold by the Investor and the Registration Period has not expired, the Company will, prior to the Renewal Date, file a new Registration
Statement relating to the Shares, in a form satisfactory to the Investor and its counsel, and, if such Registration Statement is not an automatic shelf registration statement on Form S-3ASR, will use its reasonable best efforts to cause such
Registration Statement to be declared effective within 180 days after the Renewal Date. The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale of the Shares (and the resale thereof by the
Investor) to continue as contemplated in the expired Registration Statement relating to the Shares. From and after the effective date thereof, references herein to the “Registration Statement” shall include such new Registration Statement.

 Section 5.12 Non-Public Information. Neither the Company, nor any of its directors, officers, employees or
agents shall disclose any material non-public information about the Company to the Investor, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the
foregoing covenant by the Company, or any of its directors, officers, employees and agents (as determined in the reasonable good faith judgment of the Investor), the Investor shall give prompt written notice of such breach to the Company requesting
that the Company make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information. If the Company does not make such public disclosure of such material, non-public information
promptly, and in any case within 24 hours following receipt of such written notice, in addition to any other remedy provided in this Agreement, the Investor shall have the right to make a public disclosure, in the form of a press release, public
advertisement or otherwise, of such material, non-public information without the prior approval by the Company or any of its directors, officers, employees or agents. The Investor shall not have any liability to the Company or any of its directors,
officers, employees, stockholders or agents, for any such disclosure. 
 Section 5.13 Broker/Dealer. The Investor
shall use one or more broker-dealers to effectuate all sales, if any, of the Shares that it may acquire or purchase from the Company pursuant to this Agreement which (or whom) shall be unaffiliated with the Investor and FWG and not then currently
engaged or used by the Company (collectively, the “Broker-Dealer”). The Investor shall provide the Company with all information regarding the Broker-Dealer reasonably requested by the Company. The Investor shall be solely
responsible for all fees and commissions of the Broker-Dealer, which shall not exceed customary brokerage fees and commissions. 

  
 35 

 Section 5.14 Earnings Statement. The Company will make generally available to
its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a)
of and Rule 158 under the Securities Act. The terms “earnings statement” and “make generally available to its security holders” shall have the meanings set forth in Rule 158 under the Securities Act. 

Section 5.15 Disclosure Schedule. 
 (i) From time to time during the Investment Period, the Company shall be permitted to update the Disclosure Schedule as may be required to satisfy the condition set forth in Section 6.3(i). For
purposes of this Section 5.15, any disclosure made in a schedule to the Compliance Certificate substantially in the form attached hereto as Exhibit D shall be deemed to be an update of the Disclosure Schedule. Notwithstanding anything in
this Agreement to the contrary, no update to the Disclosure Schedule pursuant to this Section 5.15 shall cure any breach of a representation or warranty of the Company contained in this Agreement and shall not affect any of the Investor’s
rights or remedies with respect thereto. 
 (ii) Notwithstanding anything to the contrary contained in the Disclosure Schedule or
in this Agreement, the information and disclosure contained in any Schedule of the Disclosure Schedule shall be deemed to be disclosed and incorporated by reference in any other Schedule of the Disclosure Schedule as though fully set forth in such
Schedule for which applicability of such information and disclosure is readily apparent on its face. The fact that any item of information is disclosed in the Disclosure Schedule shall not be construed to mean that such information is required to be
disclosed by this Agreement. Except as expressly set forth in this Agreement, such information and the thresholds (whether based on quantity, qualitative characterization, dollar amounts or otherwise) set forth herein shall not be used as a basis
for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this Agreement. 

ARTICLE VI 

OPINION OF COUNSEL AND CERTIFICATE; 
 CONDITIONS TO THE SALE AND PURCHASE OF THE SHARES 
 Section 6.1
Opinion of Counsel; Certificate. Simultaneously with the execution and delivery of this Agreement on the Effective Date, the Company shall deliver to the Investor (a) an opinion of outside counsel to the Company, dated the Effective
Date, in the form mutually agreed to by the parties hereto and (b) a certificate from the Company, dated the Effective Date, in the form of Exhibit C hereto. On or prior to the Effective Date, the Company shall have paid by wire transfer
of immediately available funds to an account designated by the Investor’s counsel, the fees and expenses of the Investor’s counsel in accordance with the proviso to the first sentence of Section 9.1(i) of this Agreement. 

  
 36 

 Section 6.2 Conditions Precedent to the Obligation of the Company. The
obligation hereunder of the Company to issue and sell the Shares to the Investor under any Fixed Request or Optional Amount is subject to the satisfaction or (to the extent permitted by applicable law) waiver of each of the conditions set forth
below. These conditions are for the Company’s sole benefit and (to the extent permitted by applicable law) may be waived by the Company at any time in its sole discretion. 
 (i) Accuracy of the Investor’s Representations and Warranties. The representations and warranties of the Investor contained in this Agreement (a) that are not qualified by
“materiality” shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the applicable Fixed Request Exercise Date and the applicable Settlement Date with the same
force and effect as if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such other date
and (b) that are qualified by “materiality” shall have been true and correct when made and shall be true and correct as of the applicable Fixed Request Exercise Date and the applicable Settlement Date with the same force and effect as
if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other date. 

(ii) Registration Statement. The Registration Statement is effective and neither the Company nor the Investor shall have
received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement. The Company shall have a maximum dollar amount certain of Common Stock registered under the Registration Statement which
(A) as of the Effective Date, is sufficient to issue to the Investor not less than the Total Commitment worth of Common Stock and (B) as of the applicable Fixed Request Exercise Date and the applicable Settlement Date, is sufficient to
issue to the Investor not less than the maximum dollar amount worth of Shares issuable pursuant to the applicable Fixed Request Notice and applicable Optional Amount, if any. 
 (iii) Other Commission Filings. The Current Report shall have been filed with the Commission as required pursuant to Section 1.4, and all Prospectus Supplements required to have been
filed with the Commission pursuant to Section 1.4 shall have been filed with the Commission in accordance with Section 1.4. All reports, schedules, registrations, forms, statements, information and other documents required to have been
filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have been filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, shall have been filed with
the Commission and such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act. All other material required to be filed by the Company or any other offering participant pursuant to Rule
433(d) under the Securities Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433 under the Securities Act. 
 (iv) Performance by the Investor. The Investor shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions

  
 37 

 
required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to the applicable Fixed Request Exercise Date and the applicable Settlement Date. 

(v) No Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered,
promulgated, threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by this Agreement. 

(vi) No Suspension, Etc. Trading in the Common Stock shall not have been suspended by the Commission or the Trading Market
(except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Fixed Request Exercise Date and applicable Settlement Date), and, at any time prior to the applicable
Fixed Request Exercise Date and applicable Settlement Date, none of the events described in clauses (i), (ii) and (iii) of Section 5.7 shall have occurred, trading in securities generally as reported on the Trading Market shall not
have been suspended or limited, nor shall a banking moratorium have been declared either by the United States or New York State authorities, nor shall there have occurred any material outbreak or escalation of hostilities or other national or
international calamity or crisis of such magnitude in its effect on, or any material adverse change in, any financial, credit or securities market which, in each case, in the reasonable judgment of the Company, makes it impracticable or inadvisable
to issue the Shares. 
 (vii) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or
any court or governmental authority shall have been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been commenced or threatened, against the Company, or any of the officers, directors or Affiliates
of the Company, seeking to restrain, prevent or change the transactions contemplated by this Agreement, or seeking damages in connection with such transactions. 
 (viii) Aggregate Limit. The issuance and sale of the Shares issuable pursuant to such Fixed Request or Optional Amount shall not violate Sections 1.1, 2.2, 2.12, 2.13, 4.20(ii) and 5.5
hereof. 
 (ix) No Unresolved FINRA Objection. There shall not exist any unresolved objection raised by
FINRA’s Corporate Financing Department with respect to the fairness and reasonableness of the terms of the transactions contemplated by this Agreement. 
 Section 6.3 Conditions Precedent to the Obligation of the Investor. The obligation hereunder of the Investor to accept a Fixed Request Notice or Optional Amount grant and to acquire
and pay for the Shares is subject to the satisfaction or (to the extent permitted by applicable law) waiver, at or before each Fixed Request Exercise Date and each Settlement Date, of each of the conditions set forth below. These conditions are for
the Investor’s sole benefit and (to the extent permitted by applicable law) may be waived by the Investor at any time in its sole discretion. 
 (i) Accuracy of the Company’s Representations and Warranties. The representations and warranties of the Company contained in this Agreement, as modified by the Disclosure Schedule
(a) that are not qualified by “materiality” or “Material Adverse Effect” shall 

  
 38 

 
have been true and correct in all material respects when made and shall be true and correct in all material respects as of the applicable Fixed Request Exercise Date and the applicable Settlement
Date with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as
of such other date and (b) that are qualified by “materiality” or “Material Adverse Effect” shall have been true and correct when made and shall be true and correct as of the applicable Fixed Request Exercise Date and the
applicable Settlement Date with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of
such other date. 
 (ii) Registration Statement. The Registration Statement is effective and neither the Company
nor the Investor shall have received notice that the Commission has issued or intends to issue a stop order with respect to the Registration Statement. The Company shall have a maximum dollar amount certain of Common Stock registered under the
Registration Statement which (A) as of the Effective Date, is sufficient to issue to the Investor not less than the Total Commitment worth of Common Stock and (B) as of the applicable Fixed Request Exercise Date and the applicable
Settlement Date, is sufficient to issue to the Investor not less than the maximum dollar amount worth of Shares issuable pursuant to the applicable Fixed Request Notice and applicable Optional Amount, if any. As of the Effective Date, the applicable
Fixed Request Exercise Date and the applicable Settlement Date, the Investor shall be permitted to utilize the Prospectus to resell all of the Shares it then owns or has the right to acquire pursuant to all Fixed Request Notices issued pursuant to
this Agreement. 
 (iii) Other Commission Filings. The Current Report shall have been filed with the Commission as
required pursuant to Section 1.4, and all Prospectus Supplements required to have been filed with the Commission pursuant to Section 1.4 shall have been filed with the Commission in accordance with Section 1.4. All reports, schedules,
registrations, forms, statements, information and other documents required to have been filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required to have been filed pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, shall have been filed with the Commission and such filings shall have been made within the applicable time period prescribed for such filing under the Exchange Act. All other material
required to be filed by the Company or any other offering participant pursuant to Rule 433(d) under the Securities Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433 under the
Securities Act. 
 (iv) No Suspension. Trading in the Common Stock shall not have been suspended by the Commission
or the Trading Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Fixed Request Exercise Date and applicable Settlement Date), and the Company shall
not have received any notice that the listing or quotation of the Common Stock on the Trading Market shall be terminated on a date certain (which termination shall be final and non-appealable). At any time prior to the applicable Fixed Request
Exercise Date and applicable Settlement Date, none of the events described in clauses (i), (ii) and (iii) of Section 5.7 shall have occurred, trading in securities generally as reported on the Trading Market shall not have been

  
 39 

 
suspended or limited, nor shall a banking moratorium have been declared either by the United States or New York State authorities, nor shall there have occurred any material outbreak or
escalation of hostilities or other national or international calamity or crisis of such magnitude in its effect on, or any material adverse change in, any financial, credit or securities market which, in each case, in the reasonable judgment of the
Investor, makes it impracticable or inadvisable to purchase the Shares. 
 (v) Performance of the Company. The
Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the applicable Fixed
Request Exercise Date and the applicable Settlement Date. The Company shall have delivered to the Investor on the applicable Settlement Date the Compliance Certificate substantially in the form attached hereto as Exhibit D. 

(vi) No Injunction. No statute, rule, regulation, order, decree, writ, ruling or injunction shall have been enacted,
entered, promulgated, threatened or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by this Agreement.

 (vii) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or
governmental authority shall have been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been commenced or threatened, against the Company, or any of the officers, directors or Affiliates of the
Company, seeking to restrain, prevent or change the transactions contemplated by this Agreement, or seeking damages in connection with such transactions. 
 (viii) Aggregate Limit. The issuance and sale of the Shares issuable pursuant to such Fixed Request Notice or Optional Amount shall not violate Sections 1.1, 2.2, 2.12, 2.13, 4.20(ii) and
5.5 hereof. 
 (ix) Shares Authorized and Delivered. The Shares issuable pursuant to such Fixed Request Notice or
Optional Amount shall have been duly authorized by all necessary corporate action of the Company. The Company shall have delivered all Shares relating to all prior Fixed Request Notices and Optional Amounts, as applicable. 

(x) Listing of Shares. All of the Shares that may be issued pursuant to this Agreement shall have been approved for listing
or quotation on the Trading Market as of the Effective Date, subject only to notice of issuance. 
 (xi) No Termination
Event. There shall not have occurred any event that would permit the Investor to terminate this Agreement pursuant to Section 7.2. 
 (xii) Opinions of Counsel; Bring-Down. Subsequent to the filing of the Current Report pursuant to Section 1.4 and prior to the first Fixed Request Exercise Date, the Investor shall have
received an opinion from outside counsel to the Company in the form mutually agreed to by the parties hereto. On each Settlement Date, the Investor shall have 

  
 40 

 
received an opinion “bring down” from outside counsel to the Company in the form mutually agreed to by the parties hereto. 

(xiii) No Unresolved FINRA Objection. There shall not exist any unresolved objection raised by FINRA’s Corporate
Financing Department with respect to the fairness and reasonableness of the terms of the transactions contemplated by this Agreement. 
 ARTICLE VII 
 TERMINATION 

Section 7.1 Term, Termination by Mutual Consent. Unless earlier terminated as provided hereunder, this Agreement shall
terminate automatically on the earliest of (i) the first day of the month next following the 24-month anniversary of the Effective Date (the “Investment Period”), (ii) the date that the entire dollar amount of
Common Stock registered under the Registration Statement has been issued and sold and (iii) the date the Investor shall have purchased or acquired shares of Common Stock pursuant to this Agreement equal to the Aggregate Limit. Subject to
Section 7.3, this Agreement may be terminated at any time (A) by the mutual written consent of the parties, effective as of the date of such mutual written consent unless otherwise provided in such written consent, it being hereby
acknowledged and agreed that the Investor may not consent to such termination during a Pricing Period or prior to a Settlement Date in the event the Investor has instructed the Broker-Dealer to effect an open-market sale of Shares which are subject
to a pending Fixed Request or Optional Amount but which have not yet been physically delivered by the Company (and/or credited by book-entry) to the Investor in accordance with the terms and subject to the conditions of this Agreement, or
(B) by either the Company or the Investor effective upon written notice to the other party under Section 9.4, if FINRA’s Corporate Financing Department has raised any objection with respect to the fairness and reasonableness of the
terms of the transactions contemplated by this Agreement, or has otherwise failed to confirm in writing that it has determined not to raise any such objection, and such objection shall not have been resolved, or such confirmation of no objection
shall not have been obtained, prior to (1) the 60th day immediately following the Effective Date, in the case of an objection raised or confirmation failure occurring prior to the first Fixed Request Exercise Date, or (2) prior to the 60th
day immediately following the receipt by the Company or the Investor of notice of such objection, in the case of an objection raised after the first Fixed Request Exercise Date; provided however, that (x) the party seeking to
terminate this Agreement pursuant to this clause (B) of Section 7.1 shall have used its commercially reasonable efforts to resolve such objection and/or to obtain such confirmation of no objection in accordance with and subject to the
provisions of Section 5.1(ii) of this Agreement and (y) the right to terminate this Agreement pursuant to this clause (B) of Section 7.1 shall not be available to any party whose action or failure to act has been a principal
cause of, or has resulted in, such objection or confirmation failure and such action or failure to act constitutes a breach of this Agreement. Subject to Section 7.3, the Company may terminate this Agreement effective upon three Trading
Days’ prior written notice to the Investor delivered in accordance with Section 9.4; provided, however, that (i) such termination shall not occur during any Pricing Period with respect to a pending Fixed Request or
Optional Amount or prior to the Settlement Date related to such pending Fixed Request or Optional Amount, and (ii) prior to issuing any press release, or making any public statement or announcement, with respect to such termination, the Company
shall consult 

  
 41 

 
with the Investor and shall obtain the Investor’s consent to the form and substance of such press release or other disclosure, which consent shall not be unreasonably delayed or withheld.

 Section 7.2 Other Termination. If the Company provides the Investor with an Other Financing Notice or an
Integration Notice, in each case pursuant to Section 5.6(ii) of this Agreement, or if the Company otherwise enters into any agreement, plan, arrangement or transaction with a third party or determines to utilize any existing agreement, plan or
arrangement with a third party, in each case the principal purpose of which is to implement, effect or consummate outside a Pricing Period, but otherwise during the Investment Period, a Similar Financing, an ATM or a Price Reset Provision (in which
case the Company shall so notify the Investor within 48 hours thereof), then in all such cases, subject to Section 7.3, the Investor shall have the right to terminate this Agreement within the subsequent 30-day period (the “Event
Period”), effective upon one Trading Day’s prior written notice delivered to the Company in accordance with Section 9.4 at any time during the Event Period. The Company shall promptly (but in no event later than 24 hours) notify
the Investor (and, if required under applicable law, including, without limitation, Regulation FD promulgated by the Commission, or under the applicable rules and regulations of the Trading Market, the Company shall publicly disclose such
information in accordance with Regulation FD and the applicable rules and regulations of the Trading Market), and, subject to Section 7.3, the Investor shall have the right to terminate this Agreement at any time after receipt of such
notification, upon one Trading Day’s prior written notice delivered to the Company in accordance with Section 9.4 hereof, if: (i) any condition, occurrence, state of facts or event constituting a Material Adverse Effect has occurred;
(ii) a Fundamental Transaction has occurred or the Company enters into a definitive agreement providing for a Fundamental Transaction; (iii) the effectiveness of the Registration 
 Statement lapses for any reason (including, without limitation, the issuance of a stop order) or the Registration Statement or the Prospectus is otherwise unavailable to the Company for the sale of Shares
or to the Investor for the resale of Shares, and such lapse or unavailability continues for a period of 20 consecutive Trading Days or for more than an aggregate of 60 Trading Days in any 365-day period, other than due to acts of the Investor;
(iv) trading in the Common Stock on the Trading Market shall have been suspended or the Common Stock shall have failed to be listed or quoted on the Trading Market, and such suspension or failure continues for a period of 20 consecutive Trading
Days or for more than an aggregate of 60 Trading Days in any 365-day period; (v) the Company has filed for and/or is subject to any bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for relief under any
bankruptcy law or any law for the relief of debtors instituted by or against the Company; or (vi) the Company is in material breach or default of this Agreement, and, if such breach or default is capable of being cured, such breach or default
is not cured within 10 Trading Days after notice of such breach or default is delivered to the Company pursuant to Section 9.4. 
 Section 7.3 Effect of Termination. In the event of termination by the Company or the Investor pursuant to Section 7.1 or 7.2, as applicable, written notice thereof shall forthwith be
given to the other party as provided in Section 9.4 and the transactions contemplated by this Agreement shall be terminated without further action by either party. If this Agreement is terminated as provided in Section 7.1 or 7.2 herein,
this Agreement shall become void and of no further force and effect, except that (i) the provisions of Article VIII (Indemnification), Section

  
 42 

 
9.1 (Fees and Expenses), Section 9.2 (Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.9
(Survival), Section 9.11 (Publicity), Section 9.12 (Severability) and this Article VII (Termination) shall remain in full force and effect notwithstanding such termination, (ii) if the Investor owns any Shares at the time of such
termination, the covenants and agreements of the Company and the Investor, as applicable, contained in Section 5.1(i) (Securities Compliance; FINRA Filing), Section 5.3 (Compliance with Laws), Section 5.7 (Stop Orders),
Section 5.8 (Amendments to the Registration Statement; Prospectus Supplements; Free Writing Prospectuses), Section 5.9 (Prospectus Delivery), Section 5.11 (Effective Registration Statement), Section 5.12 (Non-Public Information)
and Section 5.13 (Broker/Dealer) shall remain in full force and effect notwithstanding such termination for a period of six months following such termination, (iii) the covenants and agreements of the Investor contained in
Section 5.10 (Selling Restrictions) shall remain in full force and effect notwithstanding such termination for a period of 90 days following such termination, and (iv) if the Investor owns any Shares at the time of such termination, the
covenants and agreements of the Company contained in Section 5.2 (Registration and Listing) shall remain in full force and effect notwithstanding such termination for a period of 30 days following such termination. Notwithstanding anything in
this Agreement to the contrary, no termination of this Agreement by any party shall affect any cash fees paid to the Investor’s counsel pursuant to Section 9.1, all of which fees shall be non-refundable, regardless of whether any Fixed
Requests are issued by the Company or settled hereunder. Nothing in this Section 7.3 shall be deemed to release the Company or the Investor from any liability for any breach under this Agreement or to impair the rights of the Company and the
Investor to compel specific performance by the other party of its obligations under this Agreement. 
 ARTICLE VIII

 INDEMNIFICATION 
 Section 8.1 General Indemnity. 
 (i) Indemnification by
the Company. The Company shall indemnify and hold harmless the Investor, each of its directors, officers, partners, employees and Affiliates, and each Person, if any, who controls the Investor within the meaning of Section 15 of the
Securities Act or Section 20(a) of the Exchange Act from and against all losses, claims, damages, liabilities and expenses (including reasonable costs of defense and investigation and all reasonable attorneys’ fees) to which the Investor
and each such other Person may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities and expenses arise out of or are based upon (a) any violation of United States federal or state
securities laws or the rules and regulations of the Trading Market in connection with the transactions contemplated by this Agreement by the Company or any of its affiliates, officers, directors or employees, (b) any untrue statement or alleged
untrue statement of a material fact contained, or incorporated by reference, in the Registration Statement or any amendment thereto or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a
material fact required to be stated therein or necessary to make the statements therein not misleading, or (c) any untrue statement or alleged untrue statement of a material fact contained, or incorporated by reference, in the Prospectus, any
Issuer Free Writing Prospectus, or in any amendment thereof or 

  
 43 

 
supplement thereto, or in any “issuer information” (as defined in Rule 433 under the Securities Act) of the Company, which “issuer information” is required to be, or is, filed
with the Commission or otherwise contained in any Free Writing Prospectus, or any amendment or supplement thereto, or any omission or alleged omission to state therein, or in any document incorporated by reference therein, a material fact required
to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that (A) the Company shall not be liable under this Section 8.1(i) to the
extent that a court of competent jurisdiction shall have determined by a final judgment (from which no further appeals are available) that such loss, claim, damage, liability or expense resulted directly and solely from any such acts or failures to
act, undertaken or omitted to be taken by the Investor or such Person through its bad faith or willful misconduct, (B) the foregoing indemnity shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the
extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Investor expressly
for use in the Current Report or any Prospectus Supplement or Permitted Free Writing Prospectus, or any amendment thereof or supplement thereto, and (C) with respect to the Prospectus, the foregoing indemnity shall not inure to the benefit of
the Investor or any such Person from whom the Person asserting any loss, claim, damage, liability or expense purchased Common Stock, if copies of all Prospectus Supplements required to be filed pursuant to Section 1.4, together with the Base
Prospectus, were timely delivered or made available to the Investor pursuant hereto and a copy of the Base Prospectus, together with a Prospectus Supplement (as applicable), was not sent or given by or on behalf of the Investor or any such Person to
such Person, if required by law to have been delivered, at or prior to the written confirmation of the sale of the Common Stock to such Person, and if delivery of the Base Prospectus, together with a Prospectus Supplement (as applicable), would have
cured the defect giving rise to such loss, claim, damage, liability or expense. 
 The Company shall reimburse the Investor and
each such controlling Person promptly upon demand (with accompanying presentation of documentary evidence) for all legal and other costs and expenses reasonably incurred by the Investor or such indemnified Persons in investigating, defending
against, or preparing to defend against any such claim, action, suit or proceeding with respect to which it is entitled to indemnification. 
 (ii) Indemnification by the Investor. The Investor shall indemnify and hold harmless the Company, each of its directors, officers, employees and Affiliates, and each Person, if any, who
controls the Company within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act from and against all losses, claims, damages, liabilities and expenses (including reasonable costs of defense and
investigation and all reasonable attorneys fees) to which the Company and each such other Person may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages, liabilities and expenses arise out of or are based
upon any untrue statement or alleged untrue statement of a material fact contained in the Current Report, the Registration Statement or any Prospectus Supplement or Permitted Free Writing Prospectus, or in any amendment thereof or supplement
thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were

  
 44 

 
made, not misleading, in each case, to the extent, but only to the extent, the untrue statement, alleged untrue statement, omission or alleged omission was made in reliance upon, and in
conformity with, written information furnished by the Investor to the Company expressly for inclusion in the Current Report, the Registration Statement or such Prospectus Supplement or Permitted Free Writing Prospectus, or any amendment thereof or
supplement thereto. 
 The Investor shall reimburse the Company and each such director, officer or controlling Person promptly
upon demand for all legal and other costs and expenses reasonably incurred by the Company or such indemnified Persons in investigating, defending against, or preparing to defend against any such claim, action, suit or proceeding with respect to
which it is entitled to indemnification. 
 Section 8.2 Indemnification Procedures . Promptly after a Person
receives notice of a claim or the commencement of an action for which the Person intends to seek indemnification under Section 8.1, the Person will notify the indemnifying party in writing of the claim or commencement of the action, suit or
proceeding; provided, however, that failure to notify the indemnifying party will not relieve the indemnifying party from liability under Section 8.1, except to the extent it has been materially prejudiced by the failure to give
notice. The indemnifying party will be entitled to participate in the defense of any claim, action, suit or proceeding as to which indemnification is being sought, and if the indemnifying party acknowledges in writing the obligation to indemnify the
party against whom the claim or action is brought, the indemnifying party may (but will not be required to) assume the defense against the claim, action, suit or proceeding with counsel satisfactory to it. After an indemnifying party notifies an
indemnified party that the indemnifying party wishes to assume the defense of a claim, action, suit or proceeding, the indemnifying party will not be liable for any legal or other expenses incurred by the indemnified party in connection with the
defense against the claim, action, suit or proceeding except that if, in the opinion of counsel to the indemnifying party, one or more of the indemnified parties should be separately represented in connection with a claim, action, suit or
proceeding, the indemnifying party will pay the reasonable fees and expenses of one separate counsel for the indemnified parties. Each indemnified party, as a condition to receiving indemnification as provided in Section 8.1, will cooperate in
all reasonable respects with the indemnifying party in the defense of any action or claim as to which indemnification is sought. No indemnifying party will be liable for any settlement of any action effected without its prior written consent.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested (by written notice provided in accordance with Section 9.4) an indemnifying party to reimburse the indemnified party for fees and expenses of
counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated hereby effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such
indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received written notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party will, without the prior written consent of the indemnified party, effect any settlement of a pending or
threatened action with respect to which an indemnified party is, or is informed that it may be, made a party and for which it would be entitled to indemnification, 

  
 45 

 
unless the settlement includes an unconditional release of the indemnified party from all liability and claims which are the subject matter of the pending or threatened action. 

If for any reason the indemnification provided for in this Agreement is not available to, or is not sufficient to hold harmless, an
indemnified party in respect of any loss or liability referred to in Section 8.1 as to which such indemnified party is entitled to indemnification thereunder, each indemnifying party shall, in lieu of indemnifying the indemnified party,
contribute to the amount paid or payable by the indemnified party as a result of such loss or liability, (i) in the proportion which is appropriate to reflect the relative benefits received by the indemnifying party, on the one hand, and by the
indemnified party, on the other hand, from the sale of Shares which is the subject of the claim, action, suit or proceeding which resulted in the loss or liability or (ii) if the allocation provided by clause (i) is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above, but also the relative fault of the indemnifying party, on the one hand, and the indemnified party, on the other
hand, with respect to the statements or omissions which are the subject of the claim, action, suit or proceeding that resulted in the loss or liability, as well as any other relevant equitable considerations. 

The remedies provided for in Section 8.1 and this Section 8.2 are not exclusive and shall not limit any rights or remedies
which may otherwise be available to any indemnified Person at law or in equity. 
 ARTICLE IX 

MISCELLANEOUS 
 Section 9.1 Fees and Expenses. 
 (i) Each party shall bear its
own fees and expenses related to the transactions contemplated by this Agreement; provided, however, that the Company shall pay, on or prior to the Effective Date, by wire transfer of immediately available funds (A) to FINRA, the
applicable filing fee with respect to the FINRA Filing and (B) to an account designated by the Investor’s counsel, promptly following the receipt of an invoice therefor, all reasonable attorneys’ fees and expenses (exclusive of
disbursements and out-of-pocket expenses) incurred by the Investor, up to $35,000, in connection with the preparation, negotiation, execution and delivery of this Agreement, legal due diligence of the Company and review of the Registration
Statement, the Base Prospectus, the Current Report, any Permitted Free Writing Prospectus and all other related transaction documentation. The Company shall pay all U.S. federal, state and local stamp and other similar transfer and other taxes and
duties levied in connection with issuance of the Shares pursuant hereto. For the avoidance of doubt, all of the fees payable to the Investor or its counsel pursuant to this Section 9.1 shall be non-refundable, regardless of whether any Fixed
Requests are issued by the Company or settled hereunder. 
 (ii) If the Company issues a Fixed Request Notice and fails to
deliver the Shares (which have been approved for listing or quotation on the Trading Market, if such an approval is required for the listing or quotation thereof on the Trading Market) to the Investor on the applicable Settlement Date and such
failure continues for 10 Trading Days, the Company shall pay the Investor, in cash (or, at the option of the Investor, in shares of Common Stock 

  
 46 

 
which have not been registered under the Securities Act valued at the applicable Discount Price of the Shares failed to be delivered; provided that the issuance thereof by the Company would not
violate the Securities Act or any applicable U.S. federal or state securities laws), as partial damages for such failure and not as a penalty, an amount equal to 2.0% of the payment required to be paid by the Investor on such Settlement Date (i.e.,
the sum of the Fixed Amount Requested and the Optional Amount Dollar Amount) for the initial 30 days following such Settlement Date until the Shares (which have been approved for listing or quotation on the Trading Market, if such an approval is
required for the listing or quotation thereof on the Trading Market) have been delivered, and an additional 2.0% for each additional 30-day period thereafter until the Shares (which have been approved for listing or quotation on the Trading Market,
if such an approval is required for the listing or quotation thereof on the Trading Market) have been delivered, which amount shall be prorated for such periods less than 30 days, subject in all cases to the Exchange Cap (except to the extent the
Exchange Cap shall be inapplicable as expressly provided in Sections 2.12 and 2.13). Nothing in this Section 9.1(ii) shall be deemed to release the Company from any liability for any breach under this Agreement, or to impair the rights of the
Investor to compel specific performance by the Company of its obligations under this Agreement. 
 Section 9.2
Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial. 
 (i) The Company and the Investor acknowledge
and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that either party shall be
entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by the other party and to enforce specifically the terms and provisions hereof (without the necessity of showing economic loss and without any
bond or other security being required), this being in addition to any other remedy to which either party may be entitled by law or equity. 
 (ii) Each of the Company and the Investor (a) hereby irrevocably submits to the jurisdiction of the U.S. District Court and other courts of the United States sitting in the City and State of New
York, Borough of Manhattan, for the purposes of any suit, action or proceeding arising out of or relating to this Agreement, and (b) hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Each of the Company and the Investor consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing in this Section 9.2 shall affect or limit any right to serve process in any other manner permitted by law. 
 (iii) EACH OF THE COMPANY AND THE INVESTOR HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR DISPUTES RELATING HERETO. EACH OF THE COMPANY AND THE INVESTOR (A) CERTIFIES 

  
 47 

 
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.2. 

Section 9.3 Entire Agreement; Amendment. This Agreement, together with the exhibits referred to herein and the Disclosure
Schedule, represents the entire agreement of the parties with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by either party relative to subject matter hereof not expressly set forth
herein. Except as expressly provided in Section 2.12, no provision of this Agreement may be amended other than by a written instrument signed by both parties hereto. The Disclosure Schedule and all exhibits to this Agreement are hereby
incorporated by reference in, and made a part of, this Agreement as if set forth in full herein. 
 Section 9.4
Notices. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing and shall be effective (a) upon hand delivery or facsimile (with facsimile machine confirmation of
delivery received) at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business
day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur. The address for such communications shall be: 
  

			
	If to the Company:	  	EnteroMedics Inc.
		  	2800 Patton Road
		  	St. Paul, Minnesota 55113
		  	Telephone Number: (651) 634-3003
		  	Fax:
		  	Attention: Greg S. Lea

  

			
	With a copy (which shall	  	
	not constitute notice) to:	  	Dorsey & Whitney LLP
		  	50 South Sixth Street, Suite 1500
		  	Minneapolis, Minnesota 55402
		  	Telephone Number: (612) 340-2600
		  	Fax:
		  	 Attention:   Kenneth L. Cutler
 Timothy S. Hearn

  

			
	If to the Investor:            	  	Terrapin Opportunity, L.P.
		  	4th Floor, Rodus Building
		  	P.O. Box 765
		  	Road Town, Tortola

  
 48 

			
		  	British Virgin Islands
		  	Telephone Number: (284) 494-8086
		  	Fax: (284) 494-9474
		  	Attention: Peter W. Poole

  

			
	With a copy (which shall	  	
	not constitute notice) to:	  	Greenberg Traurig, LLP
		  	The MetLife Building
		  	200 Park Avenue
		  	New York, NY 10166
		  	Telephone Number: (212) 801-9200
		  	Fax: (212) 801-6400
		  	Attention: Anthony J. Marsico

 Either party hereto may from time to time change its address for notices by giving at least 10 days advance written
notice of such changed address to the other party hereto. 
 Section 9.5 Waivers. No waiver by either party of any
default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provisions, condition or requirement hereof nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it thereafter. No provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such
waiver is sought. 
 Section 9.6 Headings; Construction. The article, section and subsection headings in this
Agreement are for convenience only and shall not constitute a part of this Agreement for any other purpose and shall not be deemed to limit or affect any of the provisions hereof. Unless the context clearly indicates otherwise, each pronoun herein
shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words
“without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found. The parties agree that each of
them and their respective counsel has reviewed and had an opportunity to revise this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in
the interpretation of this Agreement. In addition, each and every reference to share prices and shares of Common Stock in this Agreement shall be subject to adjustment for any stock splits, stock combinations, stock dividends, recapitalizations and
other similar transactions that occur on or after the date of this Agreement. Any reference in this Agreement to “Dollars” or “$” shall mean the lawful currency of the United States of America. 

Section 9.7 Successors and Assigns. The Investor may not assign this Agreement to any Person without the prior consent of
the Company, in the Company’s sole discretion. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. The assignment by a party to this Agreement of any rights hereunder shall not affect
the obligations of such party under this Agreement. 

  
 49 

 Section 9.8 Governing Law. This Agreement shall be governed by and construed
in accordance with the internal procedural and substantive laws of the State of New York, without giving effect to the choice of law provisions of such state that would cause the application of the laws of any other jurisdiction. 

Section 9.9 Survival. The representations, warranties, covenants and agreements of the Company and the Investor contained
in this Agreement shall survive the execution and delivery hereof until the termination of this Agreement; provided, however, that (i) the provisions of Article VII (Termination), Article VIII (Indemnification), Section 9.1 (Fees and
Expenses), Section 9.2 (Specific Enforcement, Consent to Jurisdiction, Waiver of Jury Trial), Section 9.4 (Notices), Section 9.8 (Governing Law), Section 9.11 (Publicity), Section 9.12 (Severability) and this
Section 9.9 (Survival) shall remain in full force and effect notwithstanding such termination, (ii) if the Investor owns any Shares at the time of such termination, the covenants and agreements of the Company and the Investor, as
applicable, contained in Section 5.1(i) (Securities Compliance; FINRA Filing), Section 5.3 (Compliance with Laws), Section 5.7 (Stop Orders), Section 5.8 (Amendments to the Registration Statement; Prospectus Supplements; Free
Writing Prospectuses), Section 5.9 (Prospectus Delivery), Section 5.11 (Effective Registration Statement), Section 5.12 (Non-Public Information) and Section 5.13 (Broker/Dealer) shall remain in full force and effect
notwithstanding such termination for a period of six months following such termination, (iii) the covenants and agreements of the Investor contained in Section 5.10 (Selling Restrictions) shall remain in full force and effect
notwithstanding such termination for a period of 90 days following such termination, and (iv) if the Investor owns any Shares at the time of such termination, the covenants and agreements of the Company contained in Section 5.2
(Registration and Listing) shall remain in full force and effect notwithstanding such termination for a period of 30 days following such termination. 
 Section 9.10 Counterparts. This Agreement may be executed in counterparts, all of which taken together shall constitute one and the same original and binding instrument and shall become
effective when all counterparts have been signed by each party and delivered to the other parties hereto, it being understood that all parties hereto need not sign the same counterpart. In the event any signature is delivered by facsimile, digital
or electronic transmission, such transmission shall constitute delivery of the manually executed original and the party using such means of delivery shall thereafter cause four additional executed signature pages to be physically delivered to the
other parties within five days of the execution and delivery hereof. Failure to provide or delay in the delivery of such additional executed signature pages shall not adversely affect the efficacy of the original delivery. 

Section 9.11 Publicity. The Investor shall have the right to approve, prior to issuance or filing, any press release,
Commission filing or any other public disclosure made by or on behalf of the Company relating to the Investor, its purchases hereunder or any aspect of this Agreement or the transactions contemplated hereby (unless the same disclosure has been
previously reviewed and approved by the Investor); provided, however, that except as otherwise provided in this Agreement, the Company shall be entitled, without the prior approval of the 

  
 50 

 
Investor, to make any press release or other public disclosure (including any filings with the Commission) with respect thereto as is required by applicable law and regulations (including the
regulations of the Trading Market), so long as prior to making any such press release or other public disclosure, if reasonably practicable, the Company and its counsel shall have provided the Investor and its counsel with a reasonable opportunity
to review and comment upon, and shall have consulted with the Investor and its counsel on the form and substance of, such press release or other disclosure. 
 Section 9.12 Severability. The provisions of this Agreement are severable and, in the event that any court of competent jurisdiction shall determine that any one or more of the provisions or
part of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part of a provision of
this Agreement, and this Agreement shall be reformed and construed as if such invalid or illegal or unenforceable provision, or part of such provision, had never been contained herein, so that such provisions would be valid, legal and enforceable to
the maximum extent possible. 
 Section 9.13 No Third Party Beneficiaries. Except as expressly provided in Article
VIII, this Agreement is intended only for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 

Section 9.14 Further Assurances. From and after the date of this Agreement, upon the request of the Investor or the
Company, each of the Company and the Investor shall execute and deliver such instrument, documents and other writings as may be reasonably necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this
Agreement. 
 [Signature Page Follows] 

  
 51 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed
by their respective authorized officer as of the date first above written. 
  

			
	 ENTEROMEDICS INC.:

		
	 By:
	 	 /s/ Mark B. Knudson

		 	 Name: Mark B. Knudson

		 	 Title: Chief Executive Officer

	
	 TERRAPIN OPPORTUNITY, L.P.:

		
	 By: 
	 	 /s/ Peter Poole

		 	 Name: Peter Poole

		 	 Title: Director

 ANNEX A TO THE 
 COMMON STOCK PURCHASE AGREEMENT 
 DEFINITIONS 

“Acceptable Financing” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 

“Affiliate” shall have the meaning assigned to such term in Rule 12b-2 under the Exchange Act. 

“Aggregate Limit” shall have the meaning assigned to such term in Section 1.1 hereof. 

“Agreement” shall have the meaning assigned to such term in the Preamble. 

“Announcement Date” shall have the meaning assigned to such term in Section 2.14 hereof. 

“ATM” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 

“Average Discount Price” shall have the meaning assigned to such term in Section 2.13 hereof. 

“Base Price” shall have the meaning assigned to such term in Section 2.13 hereof. 

“Base Prospectus” shall mean the Company’s prospectus, dated August 29, 2012, a preliminary form of which is
included in the Registration Statement, including the documents incorporated by reference therein. 
 “Below Market
Offering” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 
 “Blackout
Period” shall have the meaning assigned to such term in Section 2.14 hereof. 
 “Broker-Dealer”
shall have the meaning assigned to such term in Section 5.13 hereof. 
 “Bylaws” shall have the meaning
assigned to such term in Section 4.3 hereof. 
 “Charter” shall have the meaning assigned to such term in
Section 4.3 hereof. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended. 

“Commission” shall mean the Securities and Exchange Commission or any successor entity. 

“Commission Documents” shall mean (1) all reports, schedules, registrations, forms, statements, information and
other documents filed with or furnished to the Commission by the Company pursuant to the reporting requirements of the Exchange Act, including all material filed or furnished pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act,
since 

 
December 31, 2011, including, without limitation, the Annual Report on Form 10-K filed by the Company for its fiscal year ended December 31, 2011 (the “2011 Form
10-K”), and which hereafter shall be filed with or furnished to the Commission by the Company during the Investment Period, including, without limitation, the Current Report, (2) the Registration Statement, as the same may be amended
from time to time, the Prospectus and each Prospectus Supplement, and each Permitted Free Writing Prospectus and (3) all information contained in such filings and all documents and disclosures that have been and heretofore shall be incorporated
by reference therein. 
 “Common Stock” shall have the meaning assigned to such term in the Recitals.

 “Company” shall have the meaning assigned to such term in the Preamble. For all purposes of this Agreement,
all references to the “Company” include EnteroMedics, Inc., a Delaware corporation, and its wholly owned subsidiary, EnteroMedics Europe SARL, a Swiss corporation, unless the context otherwise requires. 

“Current Market Price” means, with respect to any particular measurement date, the closing price of a share of Common
Stock as reported on the Trading Market for the Trading Day immediately preceding such measurement date. 
 “Current
Report” shall have the meaning assigned to such term in Section 1.4 hereof. 
 “Disclosure
Schedule” shall have the meaning assigned to such term in Article IV hereof. 
 “Discount Price” shall
have the meaning assigned to such term in Section 2.2 hereof. 
 “Earnings Announcement” shall have the
meaning assigned to such term in Section 2.14 hereof. 
 “Earnings 8-K” shall have the meaning assigned to
such term in Section 2.14 hereof. 
 “EDGAR” shall have the meaning assigned to such term in
Section 4.3 hereof. 
 “Effective Date” shall mean the date of this Agreement. 

“Environmental Laws” shall have the meaning assigned to such term in Section 4.17 hereof. 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended. 

“Event Period” shall have the meaning assigned to such term in Section 7.2 hereof. 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the
Commission thereunder. 

 “Exchange Cap” means, at any time, 8,312,122 shares of duly authorized,
validly issued, fully paid and non-assessable shares of Common Stock (as adjusted for any stock splits, stock combinations, stock dividends, recapitalizations and other similar transactions that occur on or after the date of this Agreement);
provided, however, that the Exchange Cap shall not exceed under any circumstances that number of shares of Common Stock that the Company may issue pursuant to this Agreement and the transactions contemplated hereby without
(a) breaching the Company’s obligations under the rules and regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted or (b) obtaining stockholder approval under the applicable rules and
regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted. 
 “FCPA”
shall have the meaning assigned to such term in Section 4.29 hereof. 
 “FDA” shall have the meaning
assigned to such term in Section 4.16(a) hereof. 
 “Filing Time” shall have the meaning assigned to such
term in Section 2.14 hereof. 
 “FINRA” shall have the meaning assigned to such term in Section 4.5
hereof. 
 “FINRA Filing” shall have the meaning assigned to such term in Section 5.1(ii) hereof.

 “Fixed Amount Requested” shall mean the amount of a Fixed Request requested by the Company in a Fixed
Request Notice delivered pursuant to Section 2.1 hereof. 
 “Fixed Request” means the transactions
contemplated under Sections 2.1 through 2.8 of this Agreement. 
 “Fixed Request Amount” means the actual
amount of proceeds received by the Company pursuant to a Fixed Request under this Agreement. 
 “Fixed Request Exercise
Date” shall have the meaning assigned to such term in Section 2.2 hereof. 
 “Fixed Request
Notice” shall have the meaning assigned to such term in Section 2.1 hereof. 
 “Free Writing
Prospectus” shall mean a “free writing prospectus” as defined in Rule 405 promulgated under the Securities Act. 
 “Fundamental Transaction” means any one or more of the following: (i) the Company shall, directly or indirectly, in one or more related transactions, (1) consolidate or merge
with or into (whether or not the Company is the surviving corporation) another Person, with the result that the holders of the Company’s capital stock immediately prior to such consolidation or merger together beneficially own less than 50% of
the outstanding voting power of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or
(3) take action to facilitate a purchase, tender or exchange offer by another Person that is accepted by the holders of more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or
Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4)

 
consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination), or (5) reorganize, recapitalize or reclassify its Common Stock, or (ii) any “person” or “group” (as these
terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock. 
 “FWG” shall have the meaning assigned to
such term in Section 4.15 hereof. 
 “GAAP” shall mean generally accepted accounting principles in the
United States of America as applied by the Company. 
 “Governmental Licenses” shall have the meaning assigned
to such term in Section 4.16(a) hereof. 
 “Indebtedness” shall have the meaning assigned to such term in
Section 4.11 hereof. 
 “Initial Prospectus Supplement” shall have the meaning assigned to such term in
Section 1.4 hereof. 
 “Integration Notice” shall have the meaning assigned to such term in
Section 5.6(ii) hereof. 
 “Intellectual Property” shall have the meaning assigned to such term in
Section 4.16(b) hereof. 
 “Investment Period” shall have the meaning assigned to such term in
Section 7.1 hereof. 
 “Investor” shall have the meaning assigned to such term in the Preamble.

 “Issuer Free Writing Prospectus” shall mean an “issuer free writing prospectus,” as defined in
Rule 433 promulgated under the Securities Act, relating to the Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i) under the Securities Act, in each case,
in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act. 

“Knowledge” means the actual knowledge of the Company’s Chief Executive Officer or Chief Financial Officer, after
reasonable inquiry of all officers, directors and employees of the Company who could reasonably be expected to have knowledge or information with respect to the matter in question. 

 “Market Capitalization” shall be calculated on the Trading Day immediately
preceding the applicable Pricing Period and shall be the product of (x) the number of shares of Common Stock outstanding on such Trading Day and (y) the closing bid price of the Common Stock on such Trading Day, both as determined by
Bloomberg Financial LP using the DES and HP functions. 
 “Material Adverse Effect” shall mean any condition,
occurrence, state of facts or event having, or insofar as reasonably can be foreseen would reasonably be expected to have, any effect on the business, operations, properties or condition (financial or otherwise) of the Company that is material and
adverse to the Company, taken as a whole, and/or any condition, occurrence, state of facts or event that would prohibit or otherwise materially interfere with or delay the ability of the Company to perform any of its obligations under this
Agreement; provided, however, that none of the following, individually or in the aggregate, shall be taken into account in determining whether a Material Adverse Effect has occurred or insofar as reasonably can be foreseen would
reasonably be expected to occur: (i) changes in conditions in the U.S. or global capital, credit or financial markets generally, including changes in the availability of capital or currency exchange rates, provided such changes shall not have
affected the Company in a materially disproportionate manner as compared to other similarly situated companies; (ii) the effect of any changes arising in connection with acts of war (whether or not declared), terrorism, military actions or the
escalation thereof or other force majeure events occurring after the Effective Date, provided such changes shall not have affected the Company in a materially disproportionate manner as compared to other similarly situated companies; (iii) the
effect of any changes in applicable legal requirements or GAAP; (iv) changes generally affecting the medical device or healthcare industries, provided such changes shall not have affected the Company in a materially disproportionate manner as
compared to other similarly situated companies; and (v) any effect of the announcement of this Agreement or the consummation of the transactions contemplated by this Agreement on the Company’s relationships, contractual or otherwise, with
customers, suppliers, vendors, bank or commercial lenders, lessors, collaboration partners, employees or consultants. 

“Material Agreements” shall have the meaning assigned to such term in Section 4.18 hereof. 

“Money Laundering Laws” shall have the meaning assigned to such term in Section 4.30 hereof. 

“Multiplier” shall have the meaning assigned to such term in Section 2.3 hereof. 

“NASDAQ” means the NASDAQ Capital Market or any successor thereto. 

“OFAC” shall have the meaning assigned to such term in Section 4.31 hereof. 

“Optional Amount” means the transactions contemplated under Sections 2.9 through 2.11 of this Agreement. 

“Optional Amount Dollar Amount” shall mean the actual amount of proceeds received by the Company pursuant to the
exercise of an Optional Amount under this Agreement. 

 “Optional Amount Notice” shall mean a notice sent to the Company with
regard to the Investor’s election to exercise all or any portion of an Optional Amount, as provided in Section 2.11 hereof and substantially in the form attached hereto as Exhibit B. 

“Optional Amount Threshold Price” shall have the meaning assigned to such term in Section 2.1 hereof. 

“Other Financing” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 

“Other Financing Notice” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 

“Permitted Free Writing Prospectus” shall have the meaning assigned to such term in Section 5.8(ii) hereof.

 “Person” means any person or entity, whether a natural person, trustee, corporation, partnership, limited
partnership, limited liability company, trust, unincorporated organization, business association, firm, joint venture, governmental agency or authority. 
 “Plan” shall have the meaning assigned to such term in Section 4.24 hereof. 
 “Price Reset Provision” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 
 “Pricing Period” shall mean a period of 10 consecutive Trading Days commencing on the first Trading Day of the Pricing Period set forth in the Fixed Request Notice, or such other period
mutually agreed upon by the Investor and the Company. 
 “Prospectus” shall mean the Base Prospectus, as
supplemented by any Prospectus Supplement, including the documents incorporated by reference therein, together with any Permitted Free Writing Prospectus. 
 “Prospectus Supplement” shall mean any prospectus supplement to the Base Prospectus (including the Initial Prospectus Supplement) filed with the Commission pursuant to Rule 424(b) under
the Securities Act, including the documents incorporated by reference therein. 
 “Reduction Notice” shall have
the meaning assigned to such term in Section 2.8 hereof. 
 “Reference Period” shall have the meaning
assigned to such term in Section 5.6(ii) hereof. 
 “Registration Period” shall have the meaning assigned
to such term in Section 5.11 hereof. 
 “Registration Statement” shall mean the registration statement on
Form S 3, Commission File Number 333-183313, filed by the Company with the Commission under the Securities Act for the registration of the Shares, as such Registration Statement may be amended and supplemented from time to time (including any
related abbreviated registration statement to 

 
register additional shares of Common Stock filed by the Company pursuant to Rule 462(b) under the Securities Act), including all documents filed as part thereof or incorporated by reference
therein, and including all information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B under the Securities Act, including any comparable successor registration statement filed by the Company with the Commission under
the Securities Act for the registration of shares of its Common Stock, including the Shares. 
 “Renewal Date”
shall have the meaning assigned to such term in Section 5.11. 
 “Restricted Period” shall have the
meaning assigned to such term in Section 5.10(i) hereof. 
 “Restricted Person” shall have the meaning
assigned to such term in Section 5.10(i) hereof. 
 “Restricted Persons” shall have the meaning assigned
to such term in Section 5.10(i) hereof. 
 “Securities Act” shall mean the Securities Act of 1933, as
amended, and the rules and regulations of the Commission thereunder. 
 “Settlement Date” shall have the
meaning assigned to such term in Section 2.7 hereof. 
 “Shares” shall mean shares of Common Stock
issuable to the Investor upon exercise of a Fixed Request and shares of Common Stock issuable to the Investor upon exercise of an Optional Amount. 
 “Short Sales” means “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act. 

“Similar Financing” shall have the meaning assigned to such term in Section 5.6(ii) hereof. 

“Single Fixed Request Limit” means, with respect to any single Fixed Request Notice or Optional Amount, such number of
shares of duly authorized, validly issued, fully paid and non-assessable shares of Common Stock which, when aggregated with all other shares of Common Stock issued or sold pursuant to any transaction or series of transactions that may be aggregated
with the transactions contemplated by such Fixed Request Notice and Optional Amount under applicable rules of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted, is equal to one less than 20.0% of the issued and
outstanding shares of Common Stock on the date immediately prior to the earliest of such issuance or sale (as adjusted for any stock splits, stock combinations, stock dividends, recapitalizations and other similar transactions that occur on or after
the date of this Agreement); provided, however, that the Single Fixed Request Limit shall not exceed under any circumstances that number of shares of Common Stock that the Company may issue pursuant to such Fixed Request Notice and
Optional Amount without (a) breaching the Company’s obligations under the rules and regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted or (b) obtaining stockholder approval under the
applicable rules and regulations of NASDAQ or any other Trading Market on which the Common Stock may be listed or quoted. 

 “SOXA” shall have the meaning assigned to such term in Section 4.6(c)
hereof. 
 “Subsidiary” shall mean any corporation or other entity of which at least a majority of the
securities or other ownership interest having ordinary voting power (absolutely or contingently) for the election of directors or other Persons performing similar functions are at the time owned directly or indirectly by the Company and/or any of
its other Subsidiaries. 
 “Threshold Price” is the lowest price (except to the extent otherwise provided in
Section 2.6) at which the Company may sell Shares during the applicable Pricing Period as set forth in a Fixed Request Notice (not taking into account the applicable percentage discount during such Pricing Period determined in accordance with
Section 2.2); provided, however, that at no time shall the Threshold Price be lower than $1.25 per share unless the Company and the Investor shall mutually agree. 

“Total Commitment” shall have the meaning assigned to such term in Section 1.1 hereof. 

“Trading Day” shall mean a full trading day (beginning at 9:30 a.m., New York City time, and ending at 4:00 p.m., New
York City time) on NASDAQ. 
 “Trading Market” means the following markets or exchanges on which the Common
Stock is listed or quoted for trading on the date in question: the New York Stock Exchange, the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market or the NASDAQ Global Select Market (or any successors to any of the foregoing), whichever
is at the time the principal trading exchange or market for the Common Stock. 
 “VWAP” shall mean the daily
volume weighted average price (based on a Trading Day from 9:30 a.m. to 4:00 p.m. (New York time)) of the Common Stock on NASDAQ as reported by Bloomberg Financial L.P. using the AQR function. 

“Warrant Value” shall mean the fair value of all warrants, options and other similar rights issued to a third party in
connection with an Other Financing, determined by using a standard Black-Scholes option-pricing model using an expected volatility percentage as shall be mutually agreed by the Investor and the Company. In the case of a dispute relating to such
expected volatility assumption, the Investor shall obtain applicable volatility data from three investment banking firms of nationally recognized reputation, and the parties hereto shall use the average thereof for purposes of determining the
expected volatility percentage in connection with the Black-Scholes calculation referred to in the immediately preceding sentence. 

 EXHIBIT A TO THE 

COMMON STOCK PURCHASE AGREEMENT 
 FORM OF FIXED REQUEST NOTICE 
  

					
	 To:
	 	 	 	
	 Fax#:    
	 	 	 	

 Reference is made to the Common Stock Purchase Agreement dated as of October 4, 2012, (the
“Purchase Agreement”) between EnteroMedics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Terrapin Opportunity, L.P., a limited partnership organized under
the laws of the British Virgin Islands. Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement. 
 In accordance with and pursuant to Section 2.1 of the Purchase Agreement, the Company hereby issues this Fixed Request Notice to exercise a Fixed Request for the Fixed Amount Requested indicated
below. 
  

					
	 Fixed Amount Requested:
	  	 	  	 
			
	 Optional Amount Dollar Amount:
	  	 	  	 
			
	 Pricing Period start date:
	  	 	  	 
			
	 Pricing Period end date:
	  	 	  	 
			
	 Settlement Date:
	  	 	  	 
			
	 Fixed Request Threshold Price:
	  	 	  	 
			
	 Optional Amount Threshold Price:
	  	 	  	 
			
	 Dollar Amount of Common Stock Currently Unissued under the Registration Statement;
	  	 	  	 
			
	 Dollar Amount of Common Stock Currently Available under the Aggregate Limit:
	  	 	  	 
			
	 Dated:
                                        

	  	By:  	  	 
		  	Name:
 Title:

 
 Address:
 Facsimile No.

 AGREED AND ACCEPTED 

			
	    By: 	 	 
		 	Name:
		 	Title

 EXHIBIT B TO THE 

COMMON STOCK PURCHASE AGREEMENT 
 FORM OF OPTIONAL AMOUNT NOTICE 
  

					
	 To:
	 	 	 	
	 Fax#:    
	 	 	 	

 Reference is made to the Common Stock Purchase Agreement dated as of October 4, 2012 (the
“Purchase Agreement”) between EnteroMedics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Terrapin Opportunity, L.P., a limited partnership organized under
the laws of the British Virgin Islands (the “Investor”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Purchase Agreement. 

In accordance with and pursuant to Section 2.11 of the Purchase Agreement, the Investor hereby issues this Optional Amount Notice to
exercise an Optional Amount for the Optional Amount Dollar Amount indicated below. 
  

					
	Optional Amount Dollar Amount Exercised	  	 	  	 
			
	Number of Shares to be purchased	  	 	  	 
			
	VWAP on the date hereof:	  	 	  	 
			
	Discount Price:	  	 	  	 
			
	Settlement Date:	  	 	  	 
			
	Threshold Price:	  	 	  	 
			
	    Dated:                        
                            	  	By:  	  	 
		  	Name
 Title:

 
 Address:
 Facsimile No.

 EXHIBIT C TO THE 

COMMON STOCK PURCHASE AGREEMENT 
 CERTIFICATE OF THE COMPANY 
 CLOSING CERTIFICATE 

            , 201     

The undersigned, the [            ] of EnteroMedics Inc., a corporation
organized and existing under the laws of the State of Delaware (the “Company”), delivers this certificate in connection with the Common Stock Purchase Agreement, dated as of October 4, 2012 (the “Agreement”),
by and between the Company and Terrapin Opportunity, L.P., a limited partnership organized under the laws of the British Virgin Islands (the “Investor”), and hereby certifies on the date hereof that (capitalized terms used herein
without definition have the meanings assigned to them in the Agreement): 
 1. Attached hereto as Exhibit A is a true,
complete and correct copy of the Certificate of Incorporation of the Company as filed with the Secretary of State of the State of Delaware. The Certificate of Incorporation of the Company has not been further amended or restated, and no document
with respect to any amendment to the Certificate of Incorporation of the Company has been filed in the office of the Secretary of State of the State of Delaware since the date shown on the face of the state certification relating to the
Company’s Certificate of Incorporation, which is in full force and effect on the date hereof, and no action has been taken by the Company in contemplation of any such amendment or the dissolution, merger or consolidation of the Company.

 2. Attached hereto as Exhibit B is a true and complete copy of the Bylaws of the Company, as amended and restated
through, and as in full force and effect on, the date hereof, and no proposal for any amendment, repeal or other modification to the Bylaws of the Company has been taken or is currently pending before the Board of Directors or stockholders of the
Company. 
 3. The Board of Directors of the Company has approved the transactions contemplated by the Agreement; said approval
has not been amended, rescinded or modified and remains in full force and effect as of the date hereof. 
 4. Each person who, as
an officer of the Company, or as attorney-in-fact of an officer of the Company, signed (i) the Agreement and (ii) any other document delivered prior hereto or on the date hereof in connection with the transactions contemplated by the
Agreement, was duly elected, qualified and acting as such officer or duly appointed and acting as such attorney-in-fact, and the signature of each such person appearing on any such document is his genuine signature. 

IN WITNESS WHEREOF, I have signed my name as of the date first above written. 

 

	
	 
	
	 Print
Name:                                        
                                       

	
	
Title:                       
                                         
                            

 EXHIBIT D TO THE 

COMMON STOCK PURCHASE AGREEMENT 
 COMPLIANCE CERTIFICATE 
 In connection with the issuance of shares of
common stock of EnteroMedics Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), pursuant to the Fixed Request Notice, dated
[            ], delivered by the Company to Terrapin Opportunity, L.P. (the “Investor”) pursuant to Article II of the Common Stock Purchase Agreement, dated as of
October 4, 2012, by and between the Company and the Investor (the “Agreement”), the undersigned hereby certifies as follows: 
 1. The undersigned is the duly elected [            ] of the Company. 
 2. Except as set forth in the attached Disclosure Schedule, the representations and warranties of the Company set forth in Article IV of the Agreement (i) that are not qualified by
“materiality” or “Material Adverse Effect” are true and correct in all material respects as of [insert Fixed Request Exercise Date] and as of the date hereof with the same force and effect as if made on such dates, except to the
extent such representations and warranties are as of another date, in which case, such representations and warranties are true and correct in all material respects as of such other date and (ii) that are qualified by “materiality” or
“Material Adverse Effect” are true and correct as of [insert Fixed Request Exercise Date] and as of the date hereof with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of
another date, in which case, such representations and warranties are true and correct as of such other date. 
 3. The Company
has performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Agreement to be performed, satisfied or complied with by the Company at or prior to [insert Fixed Request Exercise Date] and
the date hereof. 
 4. As of [insert Fixed Request Exercise Date] and the date hereof, (i) the Registration Statement did
not and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading, (ii) the Prospectus did not and does not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and
(iii) no event has occurred as a result of which it is necessary to amend or supplement the Registration Statement or the Prospectus in order to make the statements therein not untrue or misleading for clauses (i) and (ii) above,
respectively, to be true and correct. 
 5. As of [insert Fixed Request Exercise Date] and the date hereof, the Company did not
and does not possess any material non-public information. 
 Capitalized terms used but not otherwise defined herein shall have
the meanings assigned to them in the Agreement. 
 The undersigned has executed this Certificate this
[            ] day of [            ], 20[        ]. 

 

	
	 
	
	 Print
Name:                                        
                                       

	
	
Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]